#sen2geneID	pmid	senID	geneID	hgncID	approvedSymbol	matchString	actualString	startPos	score	flankingText	matchCodeID	tag	SciMinerVersion	SciMinerMethod	inExClude	inExCludeCond	phenotypeOnly	conflictCode	hgncIDbyNR	NRText	editTag	editUser	oldGeneID	oldHgncID	oldApprovedSymbol	oldInExClude	oldInExCludeCond
302977	1853774	437050	20996	11179	SOD1	ALS	ALS	2	0.0	Autoimmunity and ALS a comparison of animal models of immune-mediated motor neuron destruction	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00105796358040523<>ScoreDetail__5468|IGFALS|0__11179|SOD1|0.00105796358040523__	0	0	0	0		0
302978	1853774	437050	20996	11179	SOD1	ALS	ALS	15	0.0	of animal models of immune-mediated motor neuron destruction and human ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00105796358040523<>ScoreDetail__5468|IGFALS|0__11179|SOD1|0.00105796358040523__	0	0	0	0		0
303408	2263315	438324	20996	11179	SOD1	ALS	ALS	20	0.0	a role in the pathogenesis of amyotrophic lateral sclerosis (ALS), ALS the cellular composition of the spinal cord inflammatory infiltrate was	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000967484540195492<>ScoreDetail__5468|IGFALS|0.00016220600162206__11179|SOD1|0.000967484540195492__	0	0	0	0		0
303409	2263315	438324	20996	11179	SOD1	ALS	ALS	37	0.0	cord inflammatory infiltrate was analysed in eight cases of sporadic ALS by a panel of monoclonal antibodies	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000967484540195492<>ScoreDetail__5468|IGFALS|0.00016220600162206__11179|SOD1|0.000967484540195492__	0	0	0	0		0
303411	2263315	438327	20996	11179	SOD1	ALS	ALS	3	0.0	Compared to controls ALS specimens exhibited an increase in major histocompatibility complex (MHC) MHC	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000967484540195492<>ScoreDetail__5468|IGFALS|0.00016220600162206__11179|SOD1|0.000967484540195492__	0	0	0	0		0
303412	2263315	438330	20996	11179	SOD1	ALS	ALS	15	0.0	autoimmune process or infectious agent may play a role in ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000967484540195492<>ScoreDetail__5468|IGFALS|0.00016220600162206__11179|SOD1|0.000967484540195492__	0	0	0	0		0
305218	3719465	443416	20996	11179	SOD1	ALS	ALS	15	0.0	with clinical and pathological resemblance to amyotrophic lateral sclerosis (ALS) ALS in a woman who was severely bitten on the ankle	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000712567808872135<>ScoreDetail__5468|IGFALS|0.000413166230546757__11179|SOD1|0.000712567808872135__	0	0	0	0		0
305219	3719465	443418	20996	11179	SOD1	ALS	ALS	9	0.0	A number of unusual features that are uncharacteristic of ALS were found that included a markedly elevated antinuclear antibody titre	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000712567808872135<>ScoreDetail__5468|IGFALS|0.000413166230546757__11179|SOD1|0.000712567808872135__	0	0	0	0		0
305220	3719465	443419	20996	11179	SOD1	ALS	ALS	16	0.0	anterior horn cells and pyramidal degeneration that are characteristic of ALS but an extraordinary finding was the presence of transmural granulomatous	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000712567808872135<>ScoreDetail__5468|IGFALS|0.000413166230546757__11179|SOD1|0.000712567808872135__	0	0	0	0		0
305242	3772394	443573	3893	1682	CD47	IAP	IAP	6	0.0	Significant increase in immunosuppressive acidic protein (IAP) IAP in serum of patients with multiple sclerosis and other inflammatory	1		JUMiner_v2.2	1	0		0	2	5329	TotalCon:4<>1682|CD47|961|Complete__5329|IAPP|3375|Complete__28880|MAGT1|84061|Complete__437|ALPI|248|Complete__<>AvaiableGeneRif=4<>BEST:5329|IAPP|0.000490780818649671<>ScoreDetail__437|ALPI|0.000436800436800437__1682|CD47|0.000449349104605828__5329|IAPP|0.000490780818649671__28880|MAGT1|0.000235017626321974__	0	0	0	0		0
305243	3772394	443574	3893	1682	CD47	IAP	IAP	0	0.0	IAP a type of alpha 1-acid glycoprotein is mainly produced by	1		JUMiner_v2.2	1	0		0	2	5329	TotalCon:4<>1682|CD47|961|Complete__5329|IAPP|3375|Complete__28880|MAGT1|84061|Complete__437|ALPI|248|Complete__<>AvaiableGeneRif=4<>BEST:5329|IAPP|0.000490780818649671<>ScoreDetail__437|ALPI|0.000436800436800437__1682|CD47|0.000449349104605828__5329|IAPP|0.000490780818649671__28880|MAGT1|0.000235017626321974__	0	0	0	0		0
305244	3772394	443575	3893	1682	CD47	IAP	IAP	6	0.0	We assayed the serum levels of IAP by a single radial immunodiffusion method	1		JUMiner_v2.2	1	0		0	2	5329	TotalCon:4<>1682|CD47|961|Complete__5329|IAPP|3375|Complete__28880|MAGT1|84061|Complete__437|ALPI|248|Complete__<>AvaiableGeneRif=4<>BEST:5329|IAPP|0.000490780818649671<>ScoreDetail__437|ALPI|0.000436800436800437__1682|CD47|0.000449349104605828__5329|IAPP|0.000490780818649671__28880|MAGT1|0.000235017626321974__	0	0	0	0		0
305245	3772394	443576	3893	1682	CD47	IAP	IAP	4	0.0	The normal level of IAP is below 500 micrograms/ml micrograms ml (385 385 -73 .	1		JUMiner_v2.2	1	0		0	2	5329	TotalCon:4<>1682|CD47|961|Complete__5329|IAPP|3375|Complete__28880|MAGT1|84061|Complete__437|ALPI|248|Complete__<>AvaiableGeneRif=4<>BEST:5329|IAPP|0.000490780818649671<>ScoreDetail__437|ALPI|0.000436800436800437__1682|CD47|0.000449349104605828__5329|IAPP|0.000490780818649671__28880|MAGT1|0.000235017626321974__	0	0	0	0		0
305246	3772394	443577	3893	1682	CD47	IAP	IAP	5	0.0	In multiple sclerosis patients however IAP increased during exacerbation (630 630 -191 and decreased during the	1		JUMiner_v2.2	1	0		0	2	5329	TotalCon:4<>1682|CD47|961|Complete__5329|IAPP|3375|Complete__28880|MAGT1|84061|Complete__437|ALPI|248|Complete__<>AvaiableGeneRif=4<>BEST:5329|IAPP|0.000490780818649671<>ScoreDetail__437|ALPI|0.000436800436800437__1682|CD47|0.000449349104605828__5329|IAPP|0.000490780818649671__28880|MAGT1|0.000235017626321974__	0	0	0	0		0
305247	3772394	443578	3893	1682	CD47	IAP	IAP	12	0.0	of patients with neuro-Behcet's disease also had high levels of IAP correlating well with disease activity	1		JUMiner_v2.2	1	0		0	2	5329	TotalCon:4<>1682|CD47|961|Complete__5329|IAPP|3375|Complete__28880|MAGT1|84061|Complete__437|ALPI|248|Complete__<>AvaiableGeneRif=4<>BEST:5329|IAPP|0.000490780818649671<>ScoreDetail__437|ALPI|0.000436800436800437__1682|CD47|0.000449349104605828__5329|IAPP|0.000490780818649671__28880|MAGT1|0.000235017626321974__	0	0	0	0		0
305248	3772394	443579	3893	1682	CD47	IAP	IAP	10	0.0	In some patients with Guillain-Barre syndrome or Miller Fisher syndrome IAP increased during the acute phase	1		JUMiner_v2.2	1	0		0	2	5329	TotalCon:4<>1682|CD47|961|Complete__5329|IAPP|3375|Complete__28880|MAGT1|84061|Complete__437|ALPI|248|Complete__<>AvaiableGeneRif=4<>BEST:5329|IAPP|0.000490780818649671<>ScoreDetail__437|ALPI|0.000436800436800437__1682|CD47|0.000449349104605828__5329|IAPP|0.000490780818649671__28880|MAGT1|0.000235017626321974__	0	0	0	0		0
305249	3772394	443580	3893	1682	CD47	IAP	IAP	6	0.0	In patients with herpes simplex encephalitis IAP levels remained abnormally high for more than 60 days after	1		JUMiner_v2.2	1	0		0	2	5329	TotalCon:4<>1682|CD47|961|Complete__5329|IAPP|3375|Complete__28880|MAGT1|84061|Complete__437|ALPI|248|Complete__<>AvaiableGeneRif=4<>BEST:5329|IAPP|0.000490780818649671<>ScoreDetail__437|ALPI|0.000436800436800437__1682|CD47|0.000449349104605828__5329|IAPP|0.000490780818649671__28880|MAGT1|0.000235017626321974__	0	0	0	0		0
305250	3772394	443581	3893	1682	CD47	IAP	IAP	4	0.0	The mean value of IAP in patients with amyotrophic lateral sclerosis did not differ from	1		JUMiner_v2.2	1	0		0	2	5329	TotalCon:4<>1682|CD47|961|Complete__5329|IAPP|3375|Complete__28880|MAGT1|84061|Complete__437|ALPI|248|Complete__<>AvaiableGeneRif=4<>BEST:5329|IAPP|0.000490780818649671<>ScoreDetail__437|ALPI|0.000436800436800437__1682|CD47|0.000449349104605828__5329|IAPP|0.000490780818649671__28880|MAGT1|0.000235017626321974__	0	0	0	0		0
305251	3772394	443582	3893	1682	CD47	IAP	IAP	3	0.0	An increase in IAP in the serum of patients seems to reflect the activity	1		JUMiner_v2.2	1	0		0	2	5329	TotalCon:4<>1682|CD47|961|Complete__5329|IAPP|3375|Complete__28880|MAGT1|84061|Complete__437|ALPI|248|Complete__<>AvaiableGeneRif=4<>BEST:5329|IAPP|0.000490780818649671<>ScoreDetail__437|ALPI|0.000436800436800437__1682|CD47|0.000449349104605828__5329|IAPP|0.000490780818649671__28880|MAGT1|0.000235017626321974__	0	0	0	0		0
298691	7783760	427455	3930	7203	CD200	MRC	MRC	12	0.0	side of these patients 26 movements were graded by the MRC scale and 20 muscles were assessed by CT imaging	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
299695	7836946	429576	11629	6493	LAMC2	CSF	CSF	14	0.0	(IL-10) IL-10 was investigated in 120 paired cerebrospinal fluid (CSF) CSF and serum specimens from patients with various inflammatory and non-inflammatory	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
299698	7836946	429577	11629	6493	LAMC2	CSF	CSF	14	0.0	in the sera but detectable levels were found in the CSF from patients with acute viral ("aseptic") aseptic meningitis but only	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
299699	7836946	429577	11629	6493	LAMC2	CSF	CSF	66	0.0	encephalomeningeal sarcoidosis (in in whom IL-10 was demonstrated in all CSF collected over a period of 6-months	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
299701	7836946	429578	11629	6493	LAMC2	CSF	CSF	12	0.0	infections inflammations IL-10 seems to be continuously produced within the CSF	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
297548	8737921	424888	20996	11179	SOD1	ALS	ALS	3	0.0	Amyotrophic lateral sclerosis (ALS) ALS resembles the spongiform encephalopathies in its dual pattern of inherited	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000975314771371629<>ScoreDetail__5468|IGFALS|0.000301346012187772__11179|SOD1|0.000975314771371629__	0	0	0	0		0
297549	8737921	424890	20996	11179	SOD1	ALS	ALS	22	0.0	fresh-frozen within three hours of death from a case of ALS or a control case	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000975314771371629<>ScoreDetail__5468|IGFALS|0.000301346012187772__11179|SOD1|0.000975314771371629__	0	0	0	0		0
297550	8737921	424896	20996	11179	SOD1	ALS	ALS	12	0.0	of our carefully-controlled experiment suggest that it is unlikely that ALS is caused by a scrapie-like agent capable of transmission to	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000975314771371629<>ScoreDetail__5468|IGFALS|0.000301346012187772__11179|SOD1|0.000975314771371629__	0	0	0	0		0
296747	9086508	423597	9947	5468	IGFALS	ALS	ALS	36	0.3	range of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) ALS and Alzheimer's disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0005967342053518<>ScoreDetail__5468|IGFALS|0.000510948905109489__11179|SOD1|0.0005967342053518__	0	0	0	0		0
292700	9270568	415805	20996	11179	SOD1	ALS	ALS	8	0.0	Chamorros suffer from two neurologic syndromes known as ALS and the parkinsonism-dementia complex (PDC) PDC of Guam	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00053555337403539<>ScoreDetail__5468|IGFALS|0.000279665520038035__11179|SOD1|0.00053555337403539__	0	0	0	0		0
292701	9270568	415805	16271	8759	PDC	PDC	PDC	13	0.0	neurologic syndromes known as ALS and the parkinsonism-dementia complex (PDC) PDC of Guam	1		JUMiner_v2.2	1	0		0	2	9153	TotalCon:2<>8759|PDC|5132|Complete__9153|PNKD|25953|Complete__<>AvaiableGeneRif=2<>BEST:9153|PNKD|0.00106923282544774<>ScoreDetail__8759|PDC|0__9153|PNKD|0.00106923282544774__	0	0	0	0		0
292702	9270568	415810	16271	8759	PDC	PDC	PDC	5	0.0	Twelve cases were diagnosed as PDC known locally as bodig and three as ALS known locally	1		JUMiner_v2.2	1	0		0	2	9153	TotalCon:2<>8759|PDC|5132|Complete__9153|PNKD|25953|Complete__<>AvaiableGeneRif=2<>BEST:9153|PNKD|0.00106923282544774<>ScoreDetail__8759|PDC|0__9153|PNKD|0.00106923282544774__	0	0	0	0		0
292703	9270568	415810	20996	11179	SOD1	ALS	ALS	13	0.0	diagnosed as PDC known locally as bodig and three as ALS known locally as lytico.	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00053555337403539<>ScoreDetail__5468|IGFALS|0.000279665520038035__11179|SOD1|0.00053555337403539__	0	0	0	0		0
288340	9562310	408233	11629	6493	LAMC2	CSF	CSF	7	1.0	We assayed IL-6 in 105 cerebrospinal fluid (CSF) CSF samples from patients with ALS MS HTLV-1 associated myelopathy (HAM),	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288341	9562310	408233	9947	5468	IGFALS	ALS	ALS	12	0.3	in 105 cerebrospinal fluid (CSF) CSF samples from patients with ALS MS HTLV-1 associated myelopathy (HAM), HAM and controls	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288344	9562310	408235	9947	5468	IGFALS	ALS	ALS	7	0.3	The mean IL-6 in 27 patients with ALS was significantly higher than in 21 patients in the other	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288345	9562310	408237	11629	6493	LAMC2	CSF	CSF	1	1.0	Overall CSF IL-6 correlated with protein concentration but not with percentage IgG	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288347	9562310	408238	11629	6493	LAMC2	CSF	CSF	2	1.0	Patients with CSF oligoclonal bands were no more likely to have detectable IL-6	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288351	9562310	408240	9947	5468	IGFALS	ALS	ALS	4	0.3	The elevated IL-6 in ALS may reflect an ongoing humoral immune response or IL-6 may	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288354	9562310	408246	11629	6493	LAMC2	CSF	CSF	2	1.0	Cerebrospinal fluid (CSF) CSF levels of IL-6 are consistently elevated in herpes simplex virus	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288357	9562310	408248	11629	6493	LAMC2	CSF	CSF	7	1.0	IL-6 was detected in experimental allergic encephalomyelitis CSF ( Gijbels et al. 1990 and systemic lupus erythematosus with	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288360	9562310	408249	11629	6493	LAMC2	CSF	CSF	12	1.0	IL-6 in non-inflammatory CNS disease prompted the present study of CSF in patients with amyotrophic lateral sclerosis (ALS) ALS	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288361	9562310	408249	9947	5468	IGFALS	ALS	ALS	19	0.3	study of CSF in patients with amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288363	9562310	408250	9947	5468	IGFALS	ALS	ALS	13	0.3	higher frequency of detection and higher levels of IL-6 in ALS than in the other neurological disease control group	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288364	9562310	408251	11629	6493	LAMC2	CSF	CSF	8	1.0	In contrast there was no significant difference in CSF IL-6 in either MS or HAM patients compared to other	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288366	9562310	408251	11629	6493	LAMC2	CSF	CSF	28	1.0	other neurological disease controls and there was no correlation of CSF immune parameters and IL-6 levels	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288368	9562310	408252	11629	6493	LAMC2	CSF	CSF	8	1.0	These results are consistent with the hypothesis that CSF IL-6 in ALS has an non-immune origin occurring as a	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288370	9562310	408252	9947	5468	IGFALS	ALS	ALS	11	0.3	results are consistent with the hypothesis that CSF IL-6 in ALS has an non-immune origin occurring as a neurotrophic response to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288371	9562310	408257	9947	5468	IGFALS	ALS	ALS	5	0.3	Diagnostic criteria used were for ALS ( Mulder 1982 MS ( Poser et al. 1983 and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288372	9562310	408258	9947	5468	IGFALS	ALS	ALS	2	0.3	All 19 ALS patients from Japan had progressive weakness without significant sensory disturbance	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288373	9562310	408259	11629	6493	LAMC2	CSF	CSF	1	1.0	Eight CSF ALS samples and two non-neurological disease controls were obtained from	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288374	9562310	408259	9947	5468	IGFALS	ALS	ALS	2	0.3	Eight CSF ALS samples and two non-neurological disease controls were obtained from the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288375	9562310	408260	11629	6493	LAMC2	CSF	CSF	28	1.0	HTLV-1 fluorescein antibody titers in serum (1:160-2560) 1 160-2560 and CSF (1:2-64) 1 2-64	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288376	9562310	408261	11629	6493	LAMC2	CSF	CSF	1	1.0	Eleven CSF samples were from patients previously reported ( Ohbo et al.	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288377	9562310	408264	11629	6493	LAMC2	CSF	CSF	0	1.0	CSF assays	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288382	9562310	408272	11629	6493	LAMC2	CSF	CSF	31	1.0	assayed with MH6OBSF2 cells under the same conditions as the CSF samples	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288383	9562310	408273	11629	6493	LAMC2	CSF	CSF	0	1.0	CSF samples were coded and assayed in a blinded fashion	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288384	9562310	408274	11629	6493	LAMC2	CSF	CSF	0	1.0	CSF IL-6 values were expressed as log 1 0 pg/ml pg	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288391	9562310	408277	11629	6493	LAMC2	CSF	CSF	6	1.0	IgG and albumin in sera and CSF were measured by electro-immunoassay ( Tibbling et al. 1977	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288392	9562310	408278	11629	6493	LAMC2	CSF	CSF	7	1.0	IgG index was determined by the quotient CSF IgG/serum IgG serum IgG divided by the quotient CSF albumin/serum	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288393	9562310	408278	11629	6493	LAMC2	CSF	CSF	14	1.0	quotient CSF IgG/serum IgG serum IgG divided by the quotient CSF albumin/serum albumin serum albumin	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288394	9562310	408283	11629	6493	LAMC2	CSF	CSF	9	1.0	The Student t -test was used for comparison of CSF white blood cell count protein IgG %IgG and IgG index	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288397	9562310	408289	11629	6493	LAMC2	CSF	CSF	3	1.0	Table 1 shows CSF of patients in the ALS MS HAM and OND groups	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288398	9562310	408289	9947	5468	IGFALS	ALS	ALS	8	0.3	Table 1 shows CSF of patients in the ALS MS HAM and OND groups	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288401	9562310	408294	9947	5468	IGFALS	ALS	ALS	11	0.3	2 shows IL-6 detection in 78% of 27 patients with ALS (median median log 1 0 IL-6 of 1.01 55% of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288403	9562310	408295	11629	6493	LAMC2	CSF	CSF	12	1.0	the non-parametric Wilcoxon rank-sum test showed a significant difference in CSF IL-6 between the ALS and OND group ( P =0.0075	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288405	9562310	408295	9947	5468	IGFALS	ALS	ALS	16	0.3	test showed a significant difference in CSF IL-6 between the ALS and OND group ( P =0.0075 but no significant difference	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288406	9562310	408296	9947	5468	IGFALS	ALS	ALS	1	0.3	The ALS MS and HAM groups all had statistically significant higher mean	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288408	9562310	408296	9947	5468	IGFALS	ALS	ALS	23	0.3	than the non-neurological disease control P _amp_#x3c 0.0001 for the ALS group P =0.03 for the MS group and P =0.03	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288409	9562310	408297	11629	6493	LAMC2	CSF	CSF	2	1.0	The greatest CSF IL-6 level in the ALS group (log log 1 0	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288411	9562310	408297	9947	5468	IGFALS	ALS	ALS	7	0.3	The greatest CSF IL-6 level in the ALS group (log log 1 0 IL-6 of 2.55 was a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288413	9562310	408298	9947	5468	IGFALS	ALS	ALS	14	0.3	is arbitrarily omitted the Wilcoxon rank-sum test P value for ALS vs OND changes very little from P =0.0075 to 0.0118	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288416	9562310	408301	11629	6493	LAMC2	CSF	CSF	10	1.0	The results in Fig 2 show no significant difference in CSF IL-6 levels with 7 of 12 patients in relapse having	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288419	9562310	408303	11629	6493	LAMC2	CSF	CSF	4	1.0	Fig 3 summarizes the CSF results	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288420	9562310	408304	11629	6493	LAMC2	CSF	CSF	6	1.0	Oligoclonal bands were present in the CSF only during the relapses and there was an increase in	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288421	9562310	408305	11629	6493	LAMC2	CSF	CSF	2	1.0	Despite these CSF changes consistent with fluctuating immune-mediated activity in the CNS the	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288422	9562310	408305	11629	6493	LAMC2	CSF	CSF	13	1.0	changes consistent with fluctuating immune-mediated activity in the CNS the CSF IL-6 levels remained at undetectable levels in all four spinal	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288424	9562310	408306	11629	6493	LAMC2	CSF	CSF	6	1.0	To evaluate further any correlation of CSF IL-6 with the extent of immune-mediated activity in the CNS	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288426	9562310	408306	11629	6493	LAMC2	CSF	CSF	17	1.0	IL-6 with the extent of immune-mediated activity in the CNS CSF parameters were compared in patients with and without detectable IL-6	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288429	9562310	408308	9947	5468	IGFALS	ALS	ALS	8	0.3	Similarly the percent IgG was higher in the ALS group with detectable IL-6 but not in the combined patient	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288431	9562310	408309	11629	6493	LAMC2	CSF	CSF	6	1.0	Table 3 summarizes correlation studies of CSF parameters combining data from all four neurological disease groups (ALS,	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288432	9562310	408309	9947	5468	IGFALS	ALS	ALS	16	0.3	parameters combining data from all four neurological disease groups (ALS, ALS MS HAM and OND	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288433	9562310	408310	11629	6493	LAMC2	CSF	CSF	2	1.0	Only total CSF protein was significantly higher in patients with detectable IL-6	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288435	9562310	408311	11629	6493	LAMC2	CSF	CSF	7	1.0	As shown in Table 3 mean CSF protein in patients with detectable IL-6 was 49.0_amp_#xb1 3.8 compared	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288438	9562310	408312	11629	6493	LAMC2	CSF	CSF	3	1.0	Fig 4 shows CSF IL-6 levels in 35 patients with MS or HAM who	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288440	9562310	408312	11629	6493	LAMC2	CSF	CSF	20	1.0	MS or HAM who had either oligoclonal bands in the CSF (14 14 patients or did not have oligoclonal bands (21	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288443	9562310	408316	11629	6493	LAMC2	CSF	CSF	9	1.0	We found a modest but statistically significant elevation of CSF IL-6 in ALS patients ( Fig 1	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288445	9562310	408316	9947	5468	IGFALS	ALS	ALS	12	0.3	a modest but statistically significant elevation of CSF IL-6 in ALS patients ( Fig 1	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288446	9562310	408317	9947	5468	IGFALS	ALS	ALS	13	0.3	using this same assay technique found no difference between 15 ALS patient and 20 controls with psychiatric or neurodegenerative disease (	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288447	9562310	408318	9947	5468	IGFALS	ALS	ALS	8	0.3	In comparing these studies a similar percentage of ALS patients had undetectable CSF IL-6 (6/27 6 27 versus 2/15);	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288448	9562310	408318	11629	6493	LAMC2	CSF	CSF	12	1.0	these studies a similar percentage of ALS patients had undetectable CSF IL-6 (6/27 6 27 versus 2/15); 2 15 but 37%	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288452	9562310	408319	9947	5468	IGFALS	ALS	ALS	4	0.3	The IL-6 levels in ALS CSF (less less than 0.96 log 10 pg/ml) pg ml	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288453	9562310	408319	11629	6493	LAMC2	CSF	CSF	5	1.0	The IL-6 levels in ALS CSF (less less than 0.96 log 10 pg/ml) pg ml were	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288454	9562310	408320	3890	11935	CD40LG	IGM	IgM	4	0.3	We did not measure IgM antibodies to GM1 or GDla gangliosides	14		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288455	9562310	408321	9947	5468	IGFALS	ALS	ALS	16	0.3	the serum of up to 78% of patients with classical ALS ( Pestronk et al. 1989	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288456	9562310	408322	9947	5468	IGFALS	ALS	ALS	13	0.3	no data to incriminate antiganglioside antibodies in the pathogenesis of ALS and empiric immunosuppressive treatment of patients with motor neuron syndromes	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288458	9562310	408323	9947	5468	IGFALS	ALS	ALS	20	0.3	to an ongoing humoral immune response in some patients with ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288460	9562310	408324	9947	5468	IGFALS	ALS	ALS	6	0.3	Serum IL-6 was not measured in ALS but prior studies have shown that IL-6 can concentrate in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288462	9562310	408324	11629	6493	LAMC2	CSF	CSF	18	1.0	prior studies have shown that IL-6 can concentrate in the CSF compartment (e.g e.g during active CNS systemic lupus erythematosus (	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288466	9562310	408326	11629	6493	LAMC2	CSF	CSF	17	1.0	not find a statistically significant elevation of IL-6 in MS CSF	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288469	9562310	408330	11629	6493	LAMC2	CSF	CSF	36	1.0	1990 and Maimone et al. 1991 to correlate IL-6 and CSF parameters of immune mediated disease including percentage IgG and elevated	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288472	9562310	408331	11629	6493	LAMC2	CSF	CSF	31	1.0	or (II) II detection of IL-6 is unreliable in the CSF of immune-mediated CNS parenchymal disease (because because of instability or	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288474	9562310	408331	11629	6493	LAMC2	CSF	CSF	52	1.0	IL-6 from brain in these disease does not enter the CSF compartment	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288476	9562310	408332	9947	5468	IGFALS	ALS	ALS	8	0.3	It is possible that the IL-6 elevation in ALS is of non-immune origin	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288480	9562310	408335	9947	5468	IGFALS	ALS	ALS	13	0.3	IL-6 may be produced by astrocytes or microglial cells in ALS as a non-specific response to degeneration of motor neurons or	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288482	9562310	408337	9947	5468	IGFALS	ALS	ALS	7	0.3	Future studies of multiple cytokine expression in ALS and other neurological disease would be helpful to distinguish an	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288484	9562310	408339	11629	6493	LAMC2	CSF	CSF	0	1.0	CSF IL-6 levels in ALS MS (including including relapsing remitting and	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288486	9562310	408339	9947	5468	IGFALS	ALS	ALS	4	0.3	CSF IL-6 levels in ALS MS (including including relapsing remitting and stable disease HAM OND	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288487	9562310	408340	11629	6493	LAMC2	CSF	CSF	1	1.0	Eleven CSF samples were from patients previously reported ( Ohbo et al.	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288488	9562310	408341	9947	5468	IGFALS	ALS	ALS	6	0.3	Statistical test results include the following ALS vs OND P =0.0075 ALS vs control P _amp_#x3c 0.001	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288489	9562310	408341	9947	5468	IGFALS	ALS	ALS	11	0.3	test results include the following ALS vs OND P =0.0075 ALS vs control P _amp_#x3c 0.001 MS vs OND and MS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000688289727488252<>ScoreDetail__5468|IGFALS|0.000688289727488252__11179|SOD1|0.000572368485874859__	0	0	0	0		0
288490	9562310	408343	11629	6493	LAMC2	CSF	CSF	0	1.0	CSF IL-6 levels in MS patients with either relapsing or remitting/stable	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288492	9562310	408346	11629	6493	LAMC2	CSF	CSF	0	1.0	CSF parameters in an MS patient followed for 15 months with	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288493	9562310	408348	11629	6493	LAMC2	CSF	CSF	0	1.0	CSF IL-6 levels in MS or HAM patients that either have	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
288495	9562310	408348	11629	6493	LAMC2	CSF	CSF	21	1.0	or do not have (OCB_amp_#x2212;) OCB_amp_#x2212 oligoclonal bands in the CSF	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
282632	9762518	398387	11629	6493	LAMC2	CSF	CSF	34	0.0	cytokines and their receptors in brain tissue and/or and or CSF (for for review see McGeer and McGeer 1997b	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
282639	9769023	398468	20996	11179	SOD1	ALS	ALS	31	0.0	AD Parkinson's disease (PD), PD and amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000692485252628879<>ScoreDetail__5468|IGFALS|0.000190415741034592__11179|SOD1|0.000692485252628879__	0	0	0	0		0
276178	10225668	387926	11629	6493	LAMC2	CSF	CSF	5	0.0	We determined the cerebrospinal fluid (CSF) CSF levels of adenosine a mediator of cerebral blood flow regulation	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
276179	10225668	387927	20996	11179	SOD1	ALS	ALS	27	0.0	acute meningitis (n=10, n=10 p_lt_0.0001 or amyotrophic lateral sclerosis (ALS, ALS n=12 p_lt_0.05 (Mann-Whitney Mann-Whitney U-test	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000888270961263662<>ScoreDetail__5468|IGFALS|0.000888270961263662__11179|SOD1|0.000716504435406718__	0	0	0	0		0
276180	10225668	387928	22104	11785	THBS1	TSP	TSP	19	0.0	virus type I-associated myelopathy/tropical myelopathy tropical spastic paraparesis (HAM/TSP, HAM TSP p_lt_0.0001 acute meningitis (p_lt_0.0001), p_lt_0.0001 ALS (p_lt_0.05) p_lt_0.05 (Mann-Whitney Mann-Whitney	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
276181	10225668	387928	20996	11179	SOD1	ALS	ALS	24	0.0	spastic paraparesis (HAM/TSP, HAM TSP p_lt_0.0001 acute meningitis (p_lt_0.0001), p_lt_0.0001 ALS (p_lt_0.05) p_lt_0.05 (Mann-Whitney Mann-Whitney U-test or acute-stage cerebral infarction (p_lt_0.005,	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000888270961263662<>ScoreDetail__5468|IGFALS|0.000888270961263662__11179|SOD1|0.000716504435406718__	0	0	0	0		0
276182	10225668	387929	22104	11785	THBS1	TSP	TSP	5	0.0	In the analysis of 41 HAM/TSP HAM TSP patients the neopterin levels were significantly correlated with the cell	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
276183	10225668	387929	11629	6493	LAMC2	CSF	CSF	22	0.0	correlated with the cell number and glucose levels in the CSF and were a sensitive marker of inflammation	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
276184	10225668	387930	22104	11785	THBS1	TSP	TSP	3	0.0	Several of the HAM/TSP HAM TSP patients with increased adenosine levels were probably complicated with other	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
276185	10225668	387931	22104	11785	THBS1	TSP	TSP	6	0.0	The increased neopterin levels in the HAM/TSP HAM TSP group persisted suggesting that the mononuclear cellular infiltration remained for	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
275659	10525172	386981	20996	11179	SOD1	ALS	ALS	29	1.4	(PD), PD multiple sclerosis (MS), MS amyotrophic lateral sclerosis (ALS) ALS and the parkinsonism dementia complex of Guam	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000775018816394618<>ScoreDetail__5468|IGFALS|0.000377891366176734__11179|SOD1|0.000775018816394618__	0	0	0	0		0
275661	10525172	386988	20996	11179	SOD1	ALS	ALS	35	1.4	(PD), PD multiple sclerosis (MS), MS amyotrophic lateral sclerosis (ALS) ALS and the parkinsonism dementia complex of Guam is consistent with	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000775018816394618<>ScoreDetail__5468|IGFALS|0.000377891366176734__11179|SOD1|0.000775018816394618__	0	0	0	0		0
275675	10525172	387024	20996	11179	SOD1	ALS	ALS	20	1.4	neurotransmission 61 and mitochondrial dysfunction including focal trauma epileptic seizure ALS PD and other neurodegenerative diseases the excessive intracellular calcium accumulation	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000775018816394618<>ScoreDetail__5468|IGFALS|0.000377891366176734__11179|SOD1|0.000775018816394618__	0	0	0	0		0
275699	10525172	387073	20996	11179	SOD1	ALS	ALS	14	1.4	suggested to contribute to tissue damage in AD PD MS ALS and the parkinsonism dementia complex of Guam	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000775018816394618<>ScoreDetail__5468|IGFALS|0.000377891366176734__11179|SOD1|0.000775018816394618__	0	0	0	0		0
275701	10525172	387076	20996	11179	SOD1	ALS	ALS	24	1.4	in SOD associated with the autosomal dominant inheritance of familial ALS could both double the steady state concentration of O 2	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000775018816394618<>ScoreDetail__5468|IGFALS|0.000377891366176734__11179|SOD1|0.000775018816394618__	0	0	0	0		0
275704	10525172	387078	20996	11179	SOD1	ALS	ALS-associated	18	1.4	strengthened by the demonstration that the zinc affinity of four ALS-associated SOD mutants was decreased up to 30-fold compared with wild-type	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000775018816394618<>ScoreDetail__5468|IGFALS|0.000377891366176734__11179|SOD1|0.000775018816394618__	0	0	0	0		0
275710	10525172	387080	20996	11179	SOD1	ALS	ALS	26	1.4	al 13 14 detected more nitration in motor neurons of ALS than in controls	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000775018816394618<>ScoreDetail__5468|IGFALS|0.000377891366176734__11179|SOD1|0.000775018816394618__	0	0	0	0		0
275711	10525172	387081	20996	11179	SOD1	ALS	ALS	19	1.4	tyrosine residues in motor neurons of the spinal cord in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000775018816394618<>ScoreDetail__5468|IGFALS|0.000377891366176734__11179|SOD1|0.000775018816394618__	0	0	0	0		0
275713	10525172	387082	20996	11179	SOD1	ALS	ALS	26	1.4	quantitative modifications in the nitrotyrosine-immunoreactivity of NF-L isolated from sporadic ALS cervical spinal cord tissue as compared with age-matched non-ALS controls	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000775018816394618<>ScoreDetail__5468|IGFALS|0.000377891366176734__11179|SOD1|0.000775018816394618__	0	0	0	0		0
275717	10525172	387089	10436	5991	IL1A	IL1	IL1-_amp_#x3b2	16	0.0	et al 71 reported an overexpression of the proinflammatory cytokines IL1-_amp_#x3b2 IL2 IFN_amp_#x3b3 and TNF and a defective production of the	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
275718	10525172	387089	10452	6001	IL2	IL2	IL2	17	0.0	al 71 reported an overexpression of the proinflammatory cytokines IL1-_amp_#x3b2 IL2 IFN_amp_#x3b3 and TNF and a defective production of the anti-inflammatory	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
275719	10525172	387102	6054	2983	DNTT	TDT	TdT	31	0.0	strand breaking (detected detected by the deoxynucleotidyl transferase histochemical technique TdT and tyrosine-nitrated proteins (detected detected by immunocytochemistry using antibodies direct	14		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
275720	10525172	387103	6054	2983	DNTT	TDT	TdT-labeled	6	0.0	They demonstrated that the majority of TdT-labeled nuclei are associated with neurons exhibiting an up-regulation of nitrotyrosine	14		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
275722	10525172	387123	20996	11179	SOD1	ALS	ALS	22	1.4	brain of patients with neurodegenerative disorders such as AD PD ALS and MS has led Mc Geer and Mc Geer 56	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000775018816394618<>ScoreDetail__5468|IGFALS|0.000377891366176734__11179|SOD1|0.000775018816394618__	0	0	0	0		0
275735	10525172	387158	17461	9508	PSEN1	FAD	FAD	28	0.3	substrates -arginine NADPH and O 2 and require five cofactors FAD FMN calmodulin (CaM), CaM tetrahydrobiopterin (BH BH 4 and heme	1		JUMiner_v2.2	1	2	nadph	0	2	3585	TotalCon:3<>1101|BRCA2|675|Complete__3585|FANCD2|2177|Complete__9508|PSEN1|5663|Complete__<>AvaiableGeneRif=3<>BEST:3585|FANCD2|0.000565392205550834<>ScoreDetail__1101|BRCA2|0.000324533567436429__9508|PSEN1|0.000517984626120048__3585|FANCD2|0.000565392205550834__	0	0	0	0		0
252919	11173059	346554	13412	7214	MPHOSPH6	MPP	MPP	11	0.0	converted by monoamino oxidase-B into the methyl phenylpyridinium ion (MPP MPP which is actively taken up by dopaminergic neurons and concentrated	1		JUMiner_v2.2	1	0		0	2	7225	TotalCon:2<>7214|MPHOSPH6|10200|Complete__7225|MPZ|4359|Complete__<>AvaiableGeneRif=2<>BEST:7225|MPZ|0.00108555412199137<>ScoreDetail__7214|MPHOSPH6|0.000567789078700504__7225|MPZ|0.00108555412199137__	0	0	0	0		0
252920	11173059	346555	13412	7214	MPHOSPH6	MPP	MPP	0	0.0	MPP inhibits mitochondrial complex I reductase resulting in a decrease in	1		JUMiner_v2.2	1	0		0	2	7225	TotalCon:2<>7214|MPHOSPH6|10200|Complete__7225|MPZ|4359|Complete__<>AvaiableGeneRif=2<>BEST:7225|MPZ|0.00108555412199137<>ScoreDetail__7214|MPHOSPH6|0.000567789078700504__7225|MPZ|0.00108555412199137__	0	0	0	0		0
252921	11173059	346563	13744	7475	MT-TA	TRNA	tRNA	20	1.0	there to be a significant association between A4336G at the tRNA Glu gene and Parkinson's disease ( Tan et al. 2000	14		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
253416	11220737	347228	20996	11179	SOD1	ALS	ALS	18	1.4	associated with a familial form of amyotrophic lateral sclerosis (ALS), ALS and their expression in transgenic mice produces an ALS-like syndrome	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160441276767528<>ScoreDetail__5468|IGFALS|0.000785571667048542__11179|SOD1|0.00160441276767528__	0	0	0	0		0
253417	11220737	347228	20996	11179	SOD1	ALS	ALS-like	27	1.4	(ALS), ALS and their expression in transgenic mice produces an ALS-like syndrome	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160441276767528<>ScoreDetail__5468|IGFALS|0.000785571667048542__11179|SOD1|0.00160441276767528__	0	0	0	0		0
253418	11220737	347229	20996	11179	SOD1	ALS	ALS	18	1.4	in the progression and propagation of the neurodegenerative process in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160441276767528<>ScoreDetail__5468|IGFALS|0.000785571667048542__11179|SOD1|0.00160441276767528__	0	0	0	0		0
253427	11220737	347234	20996	11179	SOD1	ALS	ALS	16	1.4	is dramatically increased in postmortem spinal cord samples from sporadic ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160441276767528<>ScoreDetail__5468|IGFALS|0.000785571667048542__11179|SOD1|0.00160441276767528__	0	0	0	0		0
253429	11220737	347235	20996	11179	SOD1	ALS	ALS	15	1.4	through its pivotal role in inflammation is instrumental in the ALS neurodegenerative process and that Cox-2 inhibition may be a valuable	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160441276767528<>ScoreDetail__5468|IGFALS|0.000785571667048542__11179|SOD1|0.00160441276767528__	0	0	0	0		0
253431	11220737	347235	20996	11179	SOD1	ALS	ALS	32	1.4	may be a valuable therapeutic avenue for the treatment of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160441276767528<>ScoreDetail__5468|IGFALS|0.000785571667048542__11179|SOD1|0.00160441276767528__	0	0	0	0		0
247362	11458198	336764	20996	11179	SOD1	ALS	ALS	28	0.0	MS rheumatoid arthritis (RA) RA and amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000792414116827246<>ScoreDetail__5468|IGFALS|0.000516457788183446__11179|SOD1|0.000792414116827246__	0	0	0	0		0
247363	11458198	336765	9590	5164	HPSE	HPA	HPA	11	0.0	discuss the role of inflammation-induced changes in the hypothalamus-pituitary-adrenal (HPA) HPA axis as a possible explanation of fatigue depression and other	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
234256	11796754	317535	20996	11179	SOD1	ALS	ALS	1	1.7	Thus ALS has paralleled other neurodegenerative disorders such as Alzheimer's and prion	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00221178824730383<>ScoreDetail__5468|IGFALS|0.0005781600057816__11179|SOD1|0.00221178824730383__	0	0	0	0		0
235273	11847479	319128	20996	11179	SOD1	ALS	ALS	28	0.9	has been reported in patients with amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000729766818348876<>ScoreDetail__5468|IGFALS|0.000714876965911656__11179|SOD1|0.000729766818348876__	0	0	0	0		0
235274	11847479	319129	20996	11179	SOD1	ALS	ALS	31	0.9	patients to ask whether anti-TNF therapy might be beneficial in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000729766818348876<>ScoreDetail__5468|IGFALS|0.000714876965911656__11179|SOD1|0.000729766818348876__	0	0	0	0		0
235277	11847479	319132	20996	11179	SOD1	ALS	ALS	5	0.9	Studies with animal models of ALS are not sufficient to show whether TNF has a pathogenic	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000729766818348876<>ScoreDetail__5468|IGFALS|0.000714876965911656__11179|SOD1|0.000729766818348876__	0	0	0	0		0
226652	12043837	303674	18230	17440	RFWD2	COP1	Cop-1	7	0.0	Candidate vaccines were the safe synthetic copolymer Cop-1 known to cross-react with self-antigens or altered myelin-derived peptides	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
227518	12060810	305721	20996	11179	SOD1	ALS	ALS	18	1.7	of selective motor neuron death during amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
227519	12060810	305722	20996	11179	SOD1	ALS	ALS	23	1.7	this tetracycline derivative in the G93A mice model for familial ALS was tested	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
227520	12060810	305725	20996	11179	SOD1	ALS	ALS	14	1.7	interference with immuno-inflammatory responses has a beneficial effect in the ALS mice model suggesting this to be a potential new strategy	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
227521	12060810	305725	20996	11179	SOD1	ALS	ALS	27	1.7	suggesting this to be a potential new strategy to treat ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
227525	12060810	305732	20996	11179	SOD1	ALS	ALS	24	1.7	in the motor neuron degeneration during amyotrophic lateral sclerosis (ALS) ALS _amp_#91 7 _amp_#93	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
227526	12060810	305734	20996	11179	SOD1	ALS	ALS	1	1.7	Familial ALS accounts for 10_amp_#37 of all cases and mutations of the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
227529	12060810	305735	20996	11179	SOD1	ALS	ALS	12	1.7	over-expressing the human SOD1 gene with a mutation identified in ALS patients develop an adult-onset progressive motor deterioration _amp_#91 8 _amp_#93	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
227530	12060810	305737	20996	11179	SOD1	ALS	ALS	24	1.7	microglia in particular may contribute to the disease progression in ALS _amp_#91 9 10 _amp_#93 we tested the therapeutic efficacy of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
227531	12060810	305737	20996	11179	SOD1	ALS	ALS	41	1.7	therapeutic efficacy of minocycline on the G93A mice model for ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
227533	12060810	305738	22055	11764	TG	TGN	TgN	8	0.1	Transgenic mice with the G93A human SOD1 mutation TgN(SOD1-G93A)G1H, TgN SOD1-G93A G1H were obtained from The Jackson Laboratories (Bar Bar	6		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
227534	12060810	305759	20996	11179	SOD1	ALS	ALS	10	1.7	In order to evaluate the potential benefit of minocycline in ALS G93A transgenic mice were treated from day 70 until death	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
227540	12060810	305781	20996	11179	SOD1	ALS	ALS	18	1.7	microglial activation might actively contribute to the disease progression during ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
227541	12060810	305782	20996	11179	SOD1	ALS	ALS	20	1.7	microglia both in patients _amp_#91 12 _amp_#93 and in mutant ALS mice _amp_#91 9 13 _amp_#93	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
227542	12060810	305793	6869	3518	EXTL3	RPR	RPR	1	0.0	For RPR 119990 _amp_#91 21 _amp_#93 and riluzole _amp_#91 22 _amp_#93 the	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
227543	12060810	305795	20996	11179	SOD1	ALS	ALS	18	1.7	and important protection in the transgenic mice model of familial ALS most likely by inhibition of the microglial activation that coincides	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
227544	12060810	305796	20996	11179	SOD1	ALS	ALS	25	1.7	to test whether it could be an effective treatment for ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00161246018171857<>ScoreDetail__5468|IGFALS|0.000561482313307131__11179|SOD1|0.00161246018171857__	0	0	0	0		0
229347	12124437	309220	18741	10289	RPA1	RPA	RPAs	4	0.0	Multiprobe ribonuclease protection assays (RPAs) RPAs were used to investigate expression of 36 different cytokines and	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
229358	12124437	309225	20996	11179	SOD1	ALS	ALS	43	1.4	TNFalpha and its receptors may link inflammation to apoptosis in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00139476846555297<>ScoreDetail__5468|IGFALS|0.000546761803220427__11179|SOD1|0.00139476846555297__	0	0	0	0		0
229973	12137643	310084	9947	5468	IGFALS	ALS	ALS	16	2.1	was change in disease progression as determined by the Appel ALS Rating Scale total score with 0.1 mg/kg/day mg kg day	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00199497735113948<>ScoreDetail__5468|IGFALS|0.00199497735113948__11179|SOD1|0.00112775227220435__	0	0	0	0		0
223774	12194501	299400	20996	11179	SOD1	ALS	ALS	32	1.4	disorders such as forms of familial amyotrophic lateral sclerosis (ALS) ALS and glutathione peroxidase-linked adolescent seizures Parkinson's disease and Alzheimer's dementia	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00111673933487219<>ScoreDetail__5468|IGFALS|0.000380170316301703__11179|SOD1|0.00111673933487219__	0	0	0	0		0
223778	12194501	299403	20996	11179	SOD1	ALS	ALS	28	1.4	the genetic SOD mutations observed in some familial cases of ALS are also discussed	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00111673933487219<>ScoreDetail__5468|IGFALS|0.000380170316301703__11179|SOD1|0.00111673933487219__	0	0	0	0		0
224941	12270689	301344	20996	11179	SOD1	ALS	ALS	11	1.7	currently no effective pharmacological treatment for amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00203055323719497<>ScoreDetail__5468|IGFALS|0.000443602048634916__11179|SOD1|0.00203055323719497__	0	0	0	0		0
224942	12270689	301345	20996	11179	SOD1	ALS	ALS	15	1.7	secondary inflammation and caspase activation may contribute to neurodegeneration in ALS we tested the effects of minocycline a second-generation tetracycline with	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00203055323719497<>ScoreDetail__5468|IGFALS|0.000443602048634916__11179|SOD1|0.00203055323719497__	0	0	0	0		0
224944	12270689	301345	20996	11179	SOD1	ALS	ALS	39	1.7	a mutant superoxide dismutase (SOD1(G37R)) SOD1 G37R linked to human ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00203055323719497<>ScoreDetail__5468|IGFALS|0.000443602048634916__11179|SOD1|0.00203055323719497__	0	0	0	0		0
224947	12270689	301348	20996	11179	SOD1	ALS	ALS	20	1.7	may represent a novel and effective drug for treatment of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00203055323719497<>ScoreDetail__5468|IGFALS|0.000443602048634916__11179|SOD1|0.00203055323719497__	0	0	0	0		0
226013	12362410	302429	20996	11179	SOD1	ALS	ALS	15	0.0	the brainstem and spinal cord of amyotrophic lateral sclerosis (ALS) ALS cases and in mouse models of the disease	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00103312875457412<>ScoreDetail__5468|IGFALS|0.000205613241492752__11179|SOD1|0.00103312875457412__	0	0	0	0		0
226015	12362410	302432	20996	11179	SOD1	ALS	ALS	10	0.0	Anti-inflammatory agents may have a role to play in treating ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00103312875457412<>ScoreDetail__5468|IGFALS|0.000205613241492752__11179|SOD1|0.00103312875457412__	0	0	0	0		0
226017	12362410	302433	20996	11179	SOD1	ALS	ALS	12	0.0	a particularly attractive target because of its marked increase in ALS spinal cord	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00103312875457412<>ScoreDetail__5468|IGFALS|0.000205613241492752__11179|SOD1|0.00103312875457412__	0	0	0	0		0
220318	12417341	294834	20996	11179	SOD1	ALS	ALS	3	3.9	Amyotrophic lateral sclerosis (ALS) ALS is one of the most common neurodegenerative disorders characterized by	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0012197662335473<>ScoreDetail__5468|IGFALS|0.000411226482985504__11179|SOD1|0.0012197662335473__	0	0	0	0		0
220319	12417341	294835	20996	11179	SOD1	ALS	ALS	3	3.9	Approximately 10% of ALS is familial and 10_amp_#x2013 20% of these familial ALS (FALS)	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0012197662335473<>ScoreDetail__5468|IGFALS|0.000411226482985504__11179|SOD1|0.0012197662335473__	0	0	0	0		0
220320	12417341	294835	20996	11179	SOD1	ALS	ALS	11	3.9	of ALS is familial and 10_amp_#x2013 20% of these familial ALS (FALS) FALS cases are caused by missense mutations in the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0012197662335473<>ScoreDetail__5468|IGFALS|0.000411226482985504__11179|SOD1|0.0012197662335473__	0	0	0	0		0
220322	12417341	294835	20996	11179	SOD1	ALS	ALS	36	3.9	SOD1 gene 1 while others are considered to be sporadic ALS (SALS) SALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0012197662335473<>ScoreDetail__5468|IGFALS|0.000411226482985504__11179|SOD1|0.0012197662335473__	0	0	0	0		0
220323	12417341	294851	20996	11179	SOD1	ALS	ALS	3	3.9	Diagnostic criteria for ALS were based on the El Escorial criteria outlined by the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0012197662335473<>ScoreDetail__5468|IGFALS|0.000411226482985504__11179|SOD1|0.0012197662335473__	0	0	0	0		0
220326	12417341	294867	20996	11179	SOD1	ALS	ALS	28	3.9	cDNA fragments with an apparent difference in peak between the ALS spinal cord and control were chosen as candidate gene fragments	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0012197662335473<>ScoreDetail__5468|IGFALS|0.000411226482985504__11179|SOD1|0.0012197662335473__	0	0	0	0		0
220327	12417341	294875	8278	4250	GGT1	GTG	GTG	31	0.5	ml T7-oligo-dT primer (5_amp_#x2032;-TCT 5_amp_#x2032 -TCT AGT CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG GCG T	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220328	12417341	294875	23798	12612	USP14	TGT	TGT	33	0.6	primer (5_amp_#x2032;-TCT 5_amp_#x2032 -TCT AGT CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG GCG T 21 -3_amp_#x2032	1		JUMiner_v2.2	1	2	35	0	1	0	TotalCon:2<>23797|QTRT1|81890|No_GeneRif__12612|USP14|9097|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
220329	12417341	294875	7572	17371	FHL5	ACT	ACT	36	0.3	-TCT AGT CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG GCG T 21 -3_amp_#x2032 at 42_amp_#xb0 C	1		JUMiner_v2.2	1	2	35	0	2	145	TotalCon:6<>24157|ACOT7|11332|Complete__17371|FHL5|9457|Complete__16|SERPINA3|12|Complete__17780|ACTBL2|345651|No_GeneRif__144|ACTG1|71|Complete__145|ACTG2|72|Complete__<>AvaiableGeneRif=5<>BEST:145|ACTG2|0.000895372811881351<>ScoreDetail__17371|FHL5|0.000809922710232795__145|ACTG2|0.000895372811881351__24157|ACOT7|0.000565426561631495__144|ACTG1|0.000314582224765653__16|SERPINA3|0.000578228402579135__	0	0	0	0		0
220330	12417341	294875	20237	1421	SLC25A20	CAC	CAC	37	0.3	AGT CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG GCG T 21 -3_amp_#x2032 at 42_amp_#xb0 C for	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220331	12417341	294875	452	333	AGT	AGT	AGT	27	0.0	of 0.5 mg/ml mg ml T7-oligo-dT primer (5_amp_#x2032;-TCT 5_amp_#x2032 -TCT AGT CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC	1		JUMiner_v2.2	1	0		0	2	341	TotalCon:2<>333|AGT|183|Complete__341|AGXT|189|Complete__<>AvaiableGeneRif=2<>BEST:341|AGXT|0.000452679490518535<>ScoreDetail__333|AGT|0.000350759529288421__341|AGXT|0.000452679490518535__	0	0	0	0		0
220332	12417341	294875	4265	1885	CGA	CGA	CGA	28	0.0	0.5 mg/ml mg ml T7-oligo-dT primer (5_amp_#x2032;-TCT 5_amp_#x2032 -TCT AGT CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT	1		JUMiner_v2.2	1	0		0	2	1929	TotalCon:2<>1885|CGA|1081|Complete__1929|CHGA|1113|Complete__<>AvaiableGeneRif=2<>BEST:1929|CHGA|0.000418791508538899<>ScoreDetail__1885|CGA|0.00034398566484308__1929|CHGA|0.000418791508538899__	0	0	0	0		0
220333	12417341	294875	7357	3604	FBN2	CCA	CCA	30	0.2	mg ml T7-oligo-dT primer (5_amp_#x2032;-TCT 5_amp_#x2032 -TCT AGT CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG GCG	5		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220334	12417341	294875	19697	8941	SERPINA1	AAT	AAT	32	0.4	T7-oligo-dT primer (5_amp_#x2032;-TCT 5_amp_#x2032 -TCT AGT CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG GCG T 21	5		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220335	12417341	294875	19697	8941	SERPINA1	AAT	AAT	34	0.3	(5_amp_#x2032;-TCT 5_amp_#x2032 -TCT AGT CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG GCG T 21 -3_amp_#x2032 at	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220336	12417341	294875	6069	23483	DOCK11	ACG	ACG	35	0.4	5_amp_#x2032 -TCT AGT CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG GCG T 21 -3_amp_#x2032 at 42_amp_#xb0	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220337	12417341	294875	21790	11573	TAT	TAT	TAT	38	0.3	CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG GCG T 21 -3_amp_#x2032 at 42_amp_#xb0 C for 1	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220338	12417341	294875	8198	4191	GCG	GCG	GCG	40	0.0	CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG GCG T 21 -3_amp_#x2032 at 42_amp_#xb0 C for 1 h in	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220339	12417341	294878	20218	10979	SLC25A1	CTP	CTP	35	0.3	T7 buffer 1.5 _amp_#x3bc l each of 100 mM ATP CTP GTP and UTP 2 _amp_#x3bc l 0.1 M DTT and	1		JUMiner_v2.2	1	2	ctp	0	0	0		0	0	0	0		0
220340	12417341	294878	13812	32159	MTG1	GTP	GTP	36	0.2	buffer 1.5 _amp_#x3bc l each of 100 mM ATP CTP GTP and UTP 2 _amp_#x3bc l 0.1 M DTT and 2	5		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
220341	12417341	294881	19573	10691	SDS	SDS	SDS	26	0.0	solution of 2_amp_#xd7 Denhardt_amp_#x2019 s solution 4_amp_#xd7 SSC and 0.2% SDS	1		JUMiner_v2.2	1	0		0	2	19440	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:19440|SBDS|0.000485519059963831<>ScoreDetail__10691|SDS|0.000263546278726544__19440|SBDS|0.000485519059963831__	0	0	0	0		0
220342	12417341	294882	19573	10691	SDS	SDS	SDS	8	0.0	After hybridization the arrays were washed in 2_amp_#xd7 SSC_amp_#x2013 0.1% SDS and 0.2_amp_#xd7 SSC for 20 min respectively and then rinsed	1		JUMiner_v2.2	1	0		0	2	19440	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:19440|SBDS|0.000485519059963831<>ScoreDetail__10691|SDS|0.000263546278726544__19440|SBDS|0.000485519059963831__	0	0	0	0		0
220347	12417341	294892	8451	13734	GLYAT	CAT	CAT	27	0.5	T-3_amp_#x2032 5_amp_#x2032 -TGA AGT CGC AGG AGA CAA CCT-3_amp_#x2032 5_amp_#x2032 -CAT CAA GAA GGT GGT GAA GCA GGC ATC-3_amp_#x2032 clone 1	11		JUMiner_v2.2	1	2	35	0	1	0	TotalCon:2<>1516|CAT|847|Complete__13734|GLYAT|10249|No_GeneRif__<>AvaiableGeneRif=1<>	0	0	0	0		0
220348	12417341	294892	8278	4250	GGT1	GGT	GGT	30	0.5	AGT CGC AGG AGA CAA CCT-3_amp_#x2032 5_amp_#x2032 -CAT CAA GAA GGT GGT GAA GCA GGC ATC-3_amp_#x2032 clone 1 5_amp_#x2032 -CCG TCA	1		JUMiner_v2.2	1	2	35	0	1	0	TotalCon:6<>4250|GGT1|2678|Complete__4251|GGT2|728441|No_GeneRif__33426|GGTLC3|728226|No_GeneRif__33428|GGTLC4P|729838|No_GeneRif__33427|GGTLC5P|653590|No_GeneRif__4252|GGT3P|2679|No_GeneRif__<>AvaiableGeneRif=1<>	0	0	0	0		0
220349	12417341	294892	8278	4250	GGT1	GGT	GGT	31	0.5	CGC AGG AGA CAA CCT-3_amp_#x2032 5_amp_#x2032 -CAT CAA GAA GGT GGT GAA GCA GGC ATC-3_amp_#x2032 clone 1 5_amp_#x2032 -CCG TCA CTC	1		JUMiner_v2.2	1	2	35	0	1	0	TotalCon:6<>4250|GGT1|2678|Complete__4251|GGT2|728441|No_GeneRif__33426|GGTLC3|728226|No_GeneRif__33428|GGTLC4P|729838|No_GeneRif__33427|GGTLC5P|653590|No_GeneRif__4252|GGT3P|2679|No_GeneRif__<>AvaiableGeneRif=1<>	0	0	0	0		0
220350	12417341	294892	1271	795	ATM	ATC	ATC-3_amp_#x2032	35	0.5	CCT-3_amp_#x2032 5_amp_#x2032 -CAT CAA GAA GGT GGT GAA GCA GGC ATC-3_amp_#x2032 clone 1 5_amp_#x2032 -CCG TCA CTC AAA AGG TTG AA-3_amp_#x2032	11		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220351	12417341	294892	8278	4250	GGT1	GTG	GTG	47	0.5	-CCG TCA CTC AAA AGG TTG AA-3_amp_#x2032 5_amp_#x2032 -TGG CGT GTG AAG TGA CTT TT-3_amp_#x2032 5_amp_#x2032 -AGC ATG AAG AGA CCT	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220353	12417341	294892	1271	795	ATM	ATC	ATC	84	0.5	AGG TGA AGT AG-3_amp_#x2032 5_amp_#x2032 -CTC AGC GAG TAT GGC ATC AAT GTG AAG AAG-3_amp_#x2032 clone 3 5_amp_#x2032 -TAG GAG CCA	11		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220354	12417341	294892	8278	4250	GGT1	GTG	GTG	86	0.5	AGT AG-3_amp_#x2032 5_amp_#x2032 -CTC AGC GAG TAT GGC ATC AAT GTG AAG AAG-3_amp_#x2032 clone 3 5_amp_#x2032 -TAG GAG CCA TCC GAG	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220355	12417341	294892	8451	13734	GLYAT	CAT	CAT	99	0.5	5_amp_#x2032 -TAG GAG CCA TCC GAG ACA AC-3_amp_#x2032 5_amp_#x2032 -TAC CAT GGC ACT TCC TGA CA-3_amp_#x2032 5_amp_#x2032 -CAC TAG CTG GAG	11		JUMiner_v2.2	1	2	35	0	1	0	TotalCon:2<>1516|CAT|847|Complete__13734|GLYAT|10249|No_GeneRif__<>AvaiableGeneRif=1<>	0	0	0	0		0
220356	12417341	294892	7572	17371	FHL5	ACT	ACT	101	0.3	GAG CCA TCC GAG ACA AC-3_amp_#x2032 5_amp_#x2032 -TAC CAT GGC ACT TCC TGA CA-3_amp_#x2032 5_amp_#x2032 -CAC TAG CTG GAG CCA GTA	1		JUMiner_v2.2	1	2	35	0	2	145	TotalCon:6<>24157|ACOT7|11332|Complete__17371|FHL5|9457|Complete__16|SERPINA3|12|Complete__17780|ACTBL2|345651|No_GeneRif__144|ACTG1|71|Complete__145|ACTG2|72|Complete__<>AvaiableGeneRif=5<>BEST:145|ACTG2|0.000895372811881351<>ScoreDetail__17371|FHL5|0.000809922710232795__145|ACTG2|0.000895372811881351__24157|ACOT7|0.000565426561631495__144|ACTG1|0.000314582224765653__16|SERPINA3|0.000578228402579135__	0	0	0	0		0
220357	12417341	294892	20237	1421	SLC25A20	CAC	CAC	105	0.3	AC-3_amp_#x2032 5_amp_#x2032 -TAC CAT GGC ACT TCC TGA CA-3_amp_#x2032 5_amp_#x2032 -CAC TAG CTG GAG CCA GTA TAA CGG GGA-3_amp_#x2032 clone 4	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220359	12417341	294892	23798	12612	USP14	TGT	TGT	143	0.6	AAG CTG GGC TTG CCC AC-3_amp_#x2032 clone 5 5_amp_#x2032 -GCC TGT TCT GTC ACC ATC AA-3_amp_#x2032 5_amp_#x2032 -GCA GAG GCC ACA	1		JUMiner_v2.2	1	2	35	0	1	0	TotalCon:2<>23797|QTRT1|81890|No_GeneRif__12612|USP14|9097|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
220360	12417341	294892	1271	795	ATM	ATC	ATC	147	0.5	CCC AC-3_amp_#x2032 clone 5 5_amp_#x2032 -GCC TGT TCT GTC ACC ATC AA-3_amp_#x2032 5_amp_#x2032 -GCA GAG GCC ACA GGT TTA GA-3_amp_#x2032 5_amp_#x2032	11		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220361	12417341	294892	8278	4250	GGT1	GGT	GGT	153	0.5	TCT GTC ACC ATC AA-3_amp_#x2032 5_amp_#x2032 -GCA GAG GCC ACA GGT TTA GA-3_amp_#x2032 5_amp_#x2032 -CCA TTC AGC AGT CCA TTG AAA	1		JUMiner_v2.2	1	2	35	0	1	0	TotalCon:6<>4250|GGT1|2678|Complete__4251|GGT2|728441|No_GeneRif__33426|GGTLC3|728226|No_GeneRif__33428|GGTLC4P|729838|No_GeneRif__33427|GGTLC5P|653590|No_GeneRif__4252|GGT3P|2679|No_GeneRif__<>AvaiableGeneRif=1<>	0	0	0	0		0
220363	12417341	294892	7572	17371	FHL5	ACT	ACT	185	0.3	GCC ACA GAC AGC ACA GA-3_amp_#x2032 5_amp_#x2032 -AGG GCC CTA ACT ACC TGA CGG CCT GT-3_amp_#x2032 clone 7 5_amp_#x2032 -GTT GAC	1		JUMiner_v2.2	1	2	35	0	2	145	TotalCon:6<>24157|ACOT7|11332|Complete__17371|FHL5|9457|Complete__16|SERPINA3|12|Complete__17780|ACTBL2|345651|No_GeneRif__144|ACTG1|71|Complete__145|ACTG2|72|Complete__<>AvaiableGeneRif=5<>BEST:145|ACTG2|0.000895372811881351<>ScoreDetail__17371|FHL5|0.000809922710232795__145|ACTG2|0.000895372811881351__24157|ACOT7|0.000565426561631495__144|ACTG1|0.000314582224765653__16|SERPINA3|0.000578228402579135__	0	0	0	0		0
220366	12417341	294892	8451	13734	GLYAT	CAT	CAT	207	0.5	AG-3_amp_#x2032 5_amp_#x2032 -CCT GTA GAC GGC ATG GAA AT-3_amp_#x2032 5_amp_#x2032 -CAT CGA CGT CTA CCA CAA GTA CTC CCT GAT-3_amp_#x2032 clone	11		JUMiner_v2.2	1	2	35	0	1	0	TotalCon:2<>1516|CAT|847|Complete__13734|GLYAT|10249|No_GeneRif__<>AvaiableGeneRif=1<>	0	0	0	0		0
220368	12417341	294892	8451	13734	GLYAT	GAT	GAT-3_amp_#x2032	216	0.5	5_amp_#x2032 -CAT CGA CGT CTA CCA CAA GTA CTC CCT GAT-3_amp_#x2032 clone 8 5_amp_#x2032 -AAG TGC GAG GGA TGC AAA T-3_amp_#x2032	11		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220369	12417341	294892	20237	1421	SLC25A20	CAC	CAC	231	0.3	GGA TGC AAA T-3_amp_#x2032 5_amp_#x2032 -ACA CAG TCC TTG GCA CAC TT-3_amp_#x2032 5_amp_#x2032 -ACC TCC TGC AAG AAG AGC TGC TGC	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220370	12417341	294892	8451	13734	GLYAT	GAT	GAT	246	0.5	AAG AGC TGC TGC TC-3_amp_#x2032 clone 9 5_amp_#x2032 -TCC CTT GAT CCC ACA AGT TC-3_amp_#x2032 5_amp_#x2032 -ACA GGC ATA CAC CAC	11		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220371	12417341	294892	1271	795	ATM	ATA	ATA	253	0.5	-TCC CTT GAT CCC ACA AGT TC-3_amp_#x2032 5_amp_#x2032 -ACA GGC ATA CAC CAC CAC AT-3_amp_#x2032 5_amp_#x2032 -AGG CAG CAT AGT GAG	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220372	12417341	294892	20237	1421	SLC25A20	CAC	CAC	254	0.3	CTT GAT CCC ACA AGT TC-3_amp_#x2032 5_amp_#x2032 -ACA GGC ATA CAC CAC CAC AT-3_amp_#x2032 5_amp_#x2032 -AGG CAG CAT AGT GAG ACC	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220373	12417341	294892	20237	1421	SLC25A20	CAC	CAC	255	0.3	GAT CCC ACA AGT TC-3_amp_#x2032 5_amp_#x2032 -ACA GGC ATA CAC CAC CAC AT-3_amp_#x2032 5_amp_#x2032 -AGG CAG CAT AGT GAG ACC CCC	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220374	12417341	294892	20237	1421	SLC25A20	CAC	CAC	256	0.3	CCC ACA AGT TC-3_amp_#x2032 5_amp_#x2032 -ACA GGC ATA CAC CAC CAC AT-3_amp_#x2032 5_amp_#x2032 -AGG CAG CAT AGT GAG ACC CCC ATC	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220375	12417341	294892	8451	13734	GLYAT	CAT	CAT	260	0.5	-ACA GGC ATA CAC CAC CAC AT-3_amp_#x2032 5_amp_#x2032 -AGG CAG CAT AGT GAG ACC CCC ATC TCT ATA-3_amp_#x2032 clone 10 5_amp_#x2032	11		JUMiner_v2.2	1	2	35	0	1	0	TotalCon:2<>1516|CAT|847|Complete__13734|GLYAT|10249|No_GeneRif__<>AvaiableGeneRif=1<>	0	0	0	0		0
220376	12417341	294892	1271	795	ATM	ATC	ATC	265	0.5	CAC AT-3_amp_#x2032 5_amp_#x2032 -AGG CAG CAT AGT GAG ACC CCC ATC TCT ATA-3_amp_#x2032 clone 10 5_amp_#x2032 -AGC TGC AGA ACA AGG	11		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220377	12417341	294892	1271	795	ATM	ATA	ATA-3_amp_#x2032	267	0.5	5_amp_#x2032 -AGG CAG CAT AGT GAG ACC CCC ATC TCT ATA-3_amp_#x2032 clone 10 5_amp_#x2032 -AGC TGC AGA ACA AGG AGC AT-3_amp_#x2032	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220378	12417341	294892	8278	4250	GGT1	GTG	GTG	277	0.5	10 5_amp_#x2032 -AGC TGC AGA ACA AGG AGC AT-3_amp_#x2032 5_amp_#x2032 -GTG AAG CCC CAC TTC TTT GA-3_amp_#x2032 5_amp_#x2032 -AGT TCA AGT	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220379	12417341	294892	20237	1421	SLC25A20	CAC	CAC	280	0.3	TGC AGA ACA AGG AGC AT-3_amp_#x2032 5_amp_#x2032 -GTG AAG CCC CAC TTC TTT GA-3_amp_#x2032 5_amp_#x2032 -AGT TCA AGT TTC CTG GCC	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220380	12417341	294892	7572	17371	FHL5	ACT	ACT	296	0.3	TTC CTG GCC GCC AGA AGA T-3_amp_#x2032 clone 11 5_amp_#x2032 -ACT GGT ACC CGT TGG AAC AA-3_amp_#x2032 5_amp_#x2032 -GTT CAT CCC	1		JUMiner_v2.2	1	2	35	0	2	145	TotalCon:6<>24157|ACOT7|11332|Complete__17371|FHL5|9457|Complete__16|SERPINA3|12|Complete__17780|ACTBL2|345651|No_GeneRif__144|ACTG1|71|Complete__145|ACTG2|72|Complete__<>AvaiableGeneRif=5<>BEST:145|ACTG2|0.000895372811881351<>ScoreDetail__17371|FHL5|0.000809922710232795__145|ACTG2|0.000895372811881351__24157|ACOT7|0.000565426561631495__144|ACTG1|0.000314582224765653__16|SERPINA3|0.000578228402579135__	0	0	0	0		0
220381	12417341	294892	8278	4250	GGT1	GGT	GGT	297	0.5	CTG GCC GCC AGA AGA T-3_amp_#x2032 clone 11 5_amp_#x2032 -ACT GGT ACC CGT TGG AAC AA-3_amp_#x2032 5_amp_#x2032 -GTT CAT CCC ATC	1		JUMiner_v2.2	1	2	35	0	1	0	TotalCon:6<>4250|GGT1|2678|Complete__4251|GGT2|728441|No_GeneRif__33426|GGTLC3|728226|No_GeneRif__33428|GGTLC4P|729838|No_GeneRif__33427|GGTLC5P|653590|No_GeneRif__4252|GGT3P|2679|No_GeneRif__<>AvaiableGeneRif=1<>	0	0	0	0		0
220382	12417341	294892	8451	13734	GLYAT	CAT	CAT	304	0.5	5_amp_#x2032 -ACT GGT ACC CGT TGG AAC AA-3_amp_#x2032 5_amp_#x2032 -GTT CAT CCC ATC GTG GAT TT-3_amp_#x2032 5_amp_#x2032 -TGG TAC ACG ATT	11		JUMiner_v2.2	1	2	35	0	1	0	TotalCon:2<>1516|CAT|847|Complete__13734|GLYAT|10249|No_GeneRif__<>AvaiableGeneRif=1<>	0	0	0	0		0
220383	12417341	294892	1271	795	ATM	ATC	ATC	306	0.5	GGT ACC CGT TGG AAC AA-3_amp_#x2032 5_amp_#x2032 -GTT CAT CCC ATC GTG GAT TT-3_amp_#x2032 5_amp_#x2032 -TGG TAC ACG ATT TTT AAG	11		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220384	12417341	294892	8278	4250	GGT1	GTG	GTG	307	0.5	ACC CGT TGG AAC AA-3_amp_#x2032 5_amp_#x2032 -GTT CAT CCC ATC GTG GAT TT-3_amp_#x2032 5_amp_#x2032 -TGG TAC ACG ATT TTT AAG GAC	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220385	12417341	294892	8451	13734	GLYAT	GAT	GAT	308	0.5	CGT TGG AAC AA-3_amp_#x2032 5_amp_#x2032 -GTT CAT CCC ATC GTG GAT TT-3_amp_#x2032 5_amp_#x2032 -TGG TAC ACG ATT TTT AAG GAC CAC	11		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220386	12417341	294892	20237	1421	SLC25A20	CAC	CAC	317	0.3	GAT TT-3_amp_#x2032 5_amp_#x2032 -TGG TAC ACG ATT TTT AAG GAC CAC GTG TCT-3_amp_#x2032	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220387	12417341	294892	8278	4250	GGT1	GTG	GTG	318	0.5	TT-3_amp_#x2032 5_amp_#x2032 -TGG TAC ACG ATT TTT AAG GAC CAC GTG TCT-3_amp_#x2032	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220388	12417341	294892	8012	4065	GAA	GAA	GAA	14	0.1	primer reverse primer and TaqMan probe GAPDH 5_amp_#x2032 -CCT GGA GAA ACC TGC CAA GTA T-3_amp_#x2032 5_amp_#x2032 -TGA AGT CGC AGG	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220389	12417341	294892	130	84	ACACA	ACC	ACC	15	0.0	reverse primer and TaqMan probe GAPDH 5_amp_#x2032 -CCT GGA GAA ACC TGC CAA GTA T-3_amp_#x2032 5_amp_#x2032 -TGA AGT CGC AGG AGA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220390	12417341	294892	22079	11778	TGM2	TGC	TGC	16	0.0	primer and TaqMan probe GAPDH 5_amp_#x2032 -CCT GGA GAA ACC TGC CAA GTA T-3_amp_#x2032 5_amp_#x2032 -TGA AGT CGC AGG AGA CAA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220391	12417341	294892	10718	6138	ITGA2B	GTA	GTA	18	0.0	TaqMan probe GAPDH 5_amp_#x2032 -CCT GGA GAA ACC TGC CAA GTA T-3_amp_#x2032 5_amp_#x2032 -TGA AGT CGC AGG AGA CAA CCT-3_amp_#x2032 5_amp_#x2032	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220392	12417341	294892	21860	11592	TBX1	TGA	TGA	20	0.0	5_amp_#x2032 -CCT GGA GAA ACC TGC CAA GTA T-3_amp_#x2032 5_amp_#x2032 -TGA AGT CGC AGG AGA CAA CCT-3_amp_#x2032 5_amp_#x2032 -CAT CAA GAA	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220393	12417341	294892	452	333	AGT	AGT	AGT	21	0.0	-CCT GGA GAA ACC TGC CAA GTA T-3_amp_#x2032 5_amp_#x2032 -TGA AGT CGC AGG AGA CAA CCT-3_amp_#x2032 5_amp_#x2032 -CAT CAA GAA GGT	1		JUMiner_v2.2	1	0		0	2	341	TotalCon:2<>333|AGT|183|Complete__341|AGXT|189|Complete__<>AvaiableGeneRif=2<>BEST:341|AGXT|0.000452679490518535<>ScoreDetail__333|AGT|0.000350759529288421__341|AGXT|0.000452679490518535__	0	0	0	0		0
220394	12417341	294892	426	318	AGA	AGA	AGA	24	0.1	ACC TGC CAA GTA T-3_amp_#x2032 5_amp_#x2032 -TGA AGT CGC AGG AGA CAA CCT-3_amp_#x2032 5_amp_#x2032 -CAT CAA GAA GGT GGT GAA GCA	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220395	12417341	294892	8012	4065	GAA	GAA	GAA	29	0.4	-TGA AGT CGC AGG AGA CAA CCT-3_amp_#x2032 5_amp_#x2032 -CAT CAA GAA GGT GGT GAA GCA GGC ATC-3_amp_#x2032 clone 1 5_amp_#x2032 -CCG	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220396	12417341	294892	8012	4065	GAA	GAA	GAA	32	0.3	AGG AGA CAA CCT-3_amp_#x2032 5_amp_#x2032 -CAT CAA GAA GGT GGT GAA GCA GGC ATC-3_amp_#x2032 clone 1 5_amp_#x2032 -CCG TCA CTC AAA	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220397	12417341	294892	8190	15990	GCA	GCA	GCA	33	0.2	AGA CAA CCT-3_amp_#x2032 5_amp_#x2032 -CAT CAA GAA GGT GGT GAA GCA GGC ATC-3_amp_#x2032 clone 1 5_amp_#x2032 -CCG TCA CTC AAA AGG	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220398	12417341	294892	17	13666	AAAS	AAA	AAA	41	0.0	GAA GCA GGC ATC-3_amp_#x2032 clone 1 5_amp_#x2032 -CCG TCA CTC AAA AGG TTG AA-3_amp_#x2032 5_amp_#x2032 -TGG CGT GTG AAG TGA CTT	1		JUMiner_v2.2	1	0		0	2	13666	TotalCon:2<>13666|AAAS|8086|Complete__620|APP|351|Complete__<>AvaiableGeneRif=2<>BEST:13666|AAAS|0.000598571450610142<>ScoreDetail__13666|AAAS|0.000598571450610142__620|APP|0.000379773565387191__	0	0	0	0		0
220399	12417341	294892	23680	12555	UGT8	CGT	CGT	46	0.2	5_amp_#x2032 -CCG TCA CTC AAA AGG TTG AA-3_amp_#x2032 5_amp_#x2032 -TGG CGT GTG AAG TGA CTT TT-3_amp_#x2032 5_amp_#x2032 -AGC ATG AAG AGA	5		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220400	12417341	294892	13410	7211	MPG	AAG	AAG	48	0.2	TCA CTC AAA AGG TTG AA-3_amp_#x2032 5_amp_#x2032 -TGG CGT GTG AAG TGA CTT TT-3_amp_#x2032 5_amp_#x2032 -AGC ATG AAG AGA CCT TTG	5		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220401	12417341	294892	21860	11592	TBX1	TGA	TGA	49	0.1	CTC AAA AGG TTG AA-3_amp_#x2032 5_amp_#x2032 -TGG CGT GTG AAG TGA CTT TT-3_amp_#x2032 5_amp_#x2032 -AGC ATG AAG AGA CCT TTG AGG	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220402	12417341	294892	13410	7211	MPG	AAG	AAG	54	0.1	-TGG CGT GTG AAG TGA CTT TT-3_amp_#x2032 5_amp_#x2032 -AGC ATG AAG AGA CCT TTG AGG AGA AAC TAG TG-3_amp_#x2032 clone 2	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220403	12417341	294892	426	318	AGA	AGA	AGA	55	0.2	CGT GTG AAG TGA CTT TT-3_amp_#x2032 5_amp_#x2032 -AGC ATG AAG AGA CCT TTG AGG AGA AAC TAG TG-3_amp_#x2032 clone 2 5_amp_#x2032	5		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220404	12417341	294892	426	318	AGA	AGA	AGA	59	0.0	CTT TT-3_amp_#x2032 5_amp_#x2032 -AGC ATG AAG AGA CCT TTG AGG AGA AAC TAG TG-3_amp_#x2032 clone 2 5_amp_#x2032 -AAG AGC AAG GAC	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220405	12417341	294892	13410	7211	MPG	AAG	AAG	65	0.0	CCT TTG AGG AGA AAC TAG TG-3_amp_#x2032 clone 2 5_amp_#x2032 -AAG AGC AAG GAC CGC AAG TA-3_amp_#x2032 5_amp_#x2032 -GGG TGG CTC	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220406	12417341	294892	13410	7211	MPG	AAG	AAG	67	0.0	AGG AGA AAC TAG TG-3_amp_#x2032 clone 2 5_amp_#x2032 -AAG AGC AAG GAC CGC AAG TA-3_amp_#x2032 5_amp_#x2032 -GGG TGG CTC AGG TGA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220407	12417341	294892	13410	7211	MPG	AAG	AAG	70	0.0	TAG TG-3_amp_#x2032 clone 2 5_amp_#x2032 -AAG AGC AAG GAC CGC AAG TA-3_amp_#x2032 5_amp_#x2032 -GGG TGG CTC AGG TGA AGT AG-3_amp_#x2032 5_amp_#x2032	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220408	12417341	294892	21860	11592	TBX1	TGA	TGA	76	0.0	AAG GAC CGC AAG TA-3_amp_#x2032 5_amp_#x2032 -GGG TGG CTC AGG TGA AGT AG-3_amp_#x2032 5_amp_#x2032 -CTC AGC GAG TAT GGC ATC AAT	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220409	12417341	294892	452	333	AGT	AGT	AGT	77	0.0	GAC CGC AAG TA-3_amp_#x2032 5_amp_#x2032 -GGG TGG CTC AGG TGA AGT AG-3_amp_#x2032 5_amp_#x2032 -CTC AGC GAG TAT GGC ATC AAT GTG	1		JUMiner_v2.2	1	0		0	2	341	TotalCon:2<>333|AGT|183|Complete__341|AGXT|189|Complete__<>AvaiableGeneRif=2<>BEST:341|AGXT|0.000452679490518535<>ScoreDetail__333|AGT|0.000350759529288421__341|AGXT|0.000452679490518535__	0	0	0	0		0
220410	12417341	294892	21790	11573	TAT	TAT	TAT	82	0.1	TGG CTC AGG TGA AGT AG-3_amp_#x2032 5_amp_#x2032 -CTC AGC GAG TAT GGC ATC AAT GTG AAG AAG-3_amp_#x2032 clone 3 5_amp_#x2032 -TAG	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220411	12417341	294892	19697	8941	SERPINA1	AAT	AAT	85	0.4	TGA AGT AG-3_amp_#x2032 5_amp_#x2032 -CTC AGC GAG TAT GGC ATC AAT GTG AAG AAG-3_amp_#x2032 clone 3 5_amp_#x2032 -TAG GAG CCA TCC	5		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220412	12417341	294892	13410	7211	MPG	AAG	AAG	87	0.2	AG-3_amp_#x2032 5_amp_#x2032 -CTC AGC GAG TAT GGC ATC AAT GTG AAG AAG-3_amp_#x2032 clone 3 5_amp_#x2032 -TAG GAG CCA TCC GAG ACA	5		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220413	12417341	294892	13410	7211	MPG	AAG	AAG-3_amp_#x2032	88	0.1	5_amp_#x2032 -CTC AGC GAG TAT GGC ATC AAT GTG AAG AAG-3_amp_#x2032 clone 3 5_amp_#x2032 -TAG GAG CCA TCC GAG ACA AC-3_amp_#x2032	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220414	12417341	294892	7357	3604	FBN2	CCA	CCA	93	0.0	ATC AAT GTG AAG AAG-3_amp_#x2032 clone 3 5_amp_#x2032 -TAG GAG CCA TCC GAG ACA AC-3_amp_#x2032 5_amp_#x2032 -TAC CAT GGC ACT TCC	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220415	12417341	294892	21860	11592	TBX1	TGA	TGA	103	0.2	TCC GAG ACA AC-3_amp_#x2032 5_amp_#x2032 -TAC CAT GGC ACT TCC TGA CA-3_amp_#x2032 5_amp_#x2032 -CAC TAG CTG GAG CCA GTA TAA CGG	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220416	12417341	294892	7357	3604	FBN2	CCA	CCA	109	0.0	GGC ACT TCC TGA CA-3_amp_#x2032 5_amp_#x2032 -CAC TAG CTG GAG CCA GTA TAA CGG GGA-3_amp_#x2032 clone 4 5_amp_#x2032 -GAA GCT GAA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220417	12417341	294892	10718	6138	ITGA2B	GTA	GTA	110	0.0	ACT TCC TGA CA-3_amp_#x2032 5_amp_#x2032 -CAC TAG CTG GAG CCA GTA TAA CGG GGA-3_amp_#x2032 clone 4 5_amp_#x2032 -GAA GCT GAA GCA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220418	12417341	294892	8012	4065	GAA	GAA	GAA	116	0.0	CTG GAG CCA GTA TAA CGG GGA-3_amp_#x2032 clone 4 5_amp_#x2032 -GAA GCT GAA GCA GGA TCA AA-3_amp_#x2032 5_amp_#x2032 -AGG GAG CAG	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220419	12417341	294892	17756	9753	QPCT	GCT	GCT	117	0.0	GAG CCA GTA TAA CGG GGA-3_amp_#x2032 clone 4 5_amp_#x2032 -GAA GCT GAA GCA GGA TCA AA-3_amp_#x2032 5_amp_#x2032 -AGG GAG CAG CTT	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220420	12417341	294892	8012	4065	GAA	GAA	GAA	118	0.0	CCA GTA TAA CGG GGA-3_amp_#x2032 clone 4 5_amp_#x2032 -GAA GCT GAA GCA GGA TCA AA-3_amp_#x2032 5_amp_#x2032 -AGG GAG CAG CTT TCA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220421	12417341	294892	8190	15990	GCA	GCA	GCA	119	0.0	GTA TAA CGG GGA-3_amp_#x2032 clone 4 5_amp_#x2032 -GAA GCT GAA GCA GGA TCA AA-3_amp_#x2032 5_amp_#x2032 -AGG GAG CAG CTT TCA CCT	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220422	12417341	294892	13410	7211	MPG	AAG	AAG	130	0.1	AA-3_amp_#x2032 5_amp_#x2032 -AGG GAG CAG CTT TCA CCT AT-3_amp_#x2032 5_amp_#x2032 -AAG TCC TTA AGA AAG CTG GGC TTG CCC AC-3_amp_#x2032 clone	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220423	12417341	294892	426	318	AGA	AGA	AGA	133	0.0	GAG CAG CTT TCA CCT AT-3_amp_#x2032 5_amp_#x2032 -AAG TCC TTA AGA AAG CTG GGC TTG CCC AC-3_amp_#x2032 clone 5 5_amp_#x2032 -GCC	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220424	12417341	294892	13410	7211	MPG	AAG	AAG	134	0.0	CAG CTT TCA CCT AT-3_amp_#x2032 5_amp_#x2032 -AAG TCC TTA AGA AAG CTG GGC TTG CCC AC-3_amp_#x2032 clone 5 5_amp_#x2032 -GCC TGT	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220425	12417341	294892	130	84	ACACA	ACC	ACC	146	0.2	TTG CCC AC-3_amp_#x2032 clone 5 5_amp_#x2032 -GCC TGT TCT GTC ACC ATC AA-3_amp_#x2032 5_amp_#x2032 -GCA GAG GCC ACA GGT TTA GA-3_amp_#x2032	5		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220426	12417341	294892	8190	15990	GCA	GCA	GCA	149	0.1	5 5_amp_#x2032 -GCC TGT TCT GTC ACC ATC AA-3_amp_#x2032 5_amp_#x2032 -GCA GAG GCC ACA GGT TTA GA-3_amp_#x2032 5_amp_#x2032 -CCA TTC AGC	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220427	12417341	294892	7357	3604	FBN2	CCA	CCA	156	0.0	AA-3_amp_#x2032 5_amp_#x2032 -GCA GAG GCC ACA GGT TTA GA-3_amp_#x2032 5_amp_#x2032 -CCA TTC AGC AGT CCA TTG AAA GGC TCT TAG-3_amp_#x2032 clone	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220428	12417341	294892	452	333	AGT	AGT	AGT	159	0.0	GAG GCC ACA GGT TTA GA-3_amp_#x2032 5_amp_#x2032 -CCA TTC AGC AGT CCA TTG AAA GGC TCT TAG-3_amp_#x2032 clone 6 5_amp_#x2032 -CCT	1		JUMiner_v2.2	1	0		0	2	341	TotalCon:2<>333|AGT|183|Complete__341|AGXT|189|Complete__<>AvaiableGeneRif=2<>BEST:341|AGXT|0.000452679490518535<>ScoreDetail__333|AGT|0.000350759529288421__341|AGXT|0.000452679490518535__	0	0	0	0		0
220429	12417341	294892	7357	3604	FBN2	CCA	CCA	160	0.0	GCC ACA GGT TTA GA-3_amp_#x2032 5_amp_#x2032 -CCA TTC AGC AGT CCA TTG AAA GGC TCT TAG-3_amp_#x2032 clone 6 5_amp_#x2032 -CCT GTT	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220430	12417341	294892	17	13666	AAAS	AAA	AAA	162	0.0	GGT TTA GA-3_amp_#x2032 5_amp_#x2032 -CCA TTC AGC AGT CCA TTG AAA GGC TCT TAG-3_amp_#x2032 clone 6 5_amp_#x2032 -CCT GTT GGA GGA	1		JUMiner_v2.2	1	0		0	2	13666	TotalCon:2<>13666|AAAS|8086|Complete__620|APP|351|Complete__<>AvaiableGeneRif=2<>BEST:13666|AAAS|0.000598571450610142<>ScoreDetail__13666|AAAS|0.000598571450610142__620|APP|0.000379773565387191__	0	0	0	0		0
220431	12417341	294892	8190	15990	GCA	GCA	GCA	172	0.0	GGC TCT TAG-3_amp_#x2032 clone 6 5_amp_#x2032 -CCT GTT GGA GGA GCA GAA CT-3_amp_#x2032 5_amp_#x2032 -GAA GCC ACA GAC AGC ACA GA-3_amp_#x2032	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220432	12417341	294892	8012	4065	GAA	GAA	GAA	173	0.0	TCT TAG-3_amp_#x2032 clone 6 5_amp_#x2032 -CCT GTT GGA GGA GCA GAA CT-3_amp_#x2032 5_amp_#x2032 -GAA GCC ACA GAC AGC ACA GA-3_amp_#x2032 5_amp_#x2032	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220433	12417341	294892	8012	4065	GAA	GAA	GAA	175	0.0	6 5_amp_#x2032 -CCT GTT GGA GGA GCA GAA CT-3_amp_#x2032 5_amp_#x2032 -GAA GCC ACA GAC AGC ACA GA-3_amp_#x2032 5_amp_#x2032 -AGG GCC CTA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220434	12417341	294892	130	84	ACACA	ACC	ACC	186	0.2	ACA GAC AGC ACA GA-3_amp_#x2032 5_amp_#x2032 -AGG GCC CTA ACT ACC TGA CGG CCT GT-3_amp_#x2032 clone 7 5_amp_#x2032 -GTT GAC CGA	5		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220435	12417341	294892	21860	11592	TBX1	TGA	TGA	187	0.2	GAC AGC ACA GA-3_amp_#x2032 5_amp_#x2032 -AGG GCC CTA ACT ACC TGA CGG CCT GT-3_amp_#x2032 clone 7 5_amp_#x2032 -GTT GAC CGA GCT	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220436	12417341	294892	4265	1885	CGA	CGA	CGA	195	0.0	ACC TGA CGG CCT GT-3_amp_#x2032 clone 7 5_amp_#x2032 -GTT GAC CGA GCT GGA GAA AG-3_amp_#x2032 5_amp_#x2032 -CCT GTA GAC GGC ATG	1		JUMiner_v2.2	1	0		0	2	1929	TotalCon:2<>1885|CGA|1081|Complete__1929|CHGA|1113|Complete__<>AvaiableGeneRif=2<>BEST:1929|CHGA|0.000418791508538899<>ScoreDetail__1885|CGA|0.00034398566484308__1929|CHGA|0.000418791508538899__	0	0	0	0		0
220437	12417341	294892	17756	9753	QPCT	GCT	GCT	196	0.0	TGA CGG CCT GT-3_amp_#x2032 clone 7 5_amp_#x2032 -GTT GAC CGA GCT GGA GAA AG-3_amp_#x2032 5_amp_#x2032 -CCT GTA GAC GGC ATG GAA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220438	12417341	294892	8012	4065	GAA	GAA	GAA	198	0.1	CCT GT-3_amp_#x2032 clone 7 5_amp_#x2032 -GTT GAC CGA GCT GGA GAA AG-3_amp_#x2032 5_amp_#x2032 -CCT GTA GAC GGC ATG GAA AT-3_amp_#x2032 5_amp_#x2032	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220439	12417341	294892	10718	6138	ITGA2B	GTA	GTA	201	0.2	5_amp_#x2032 -GTT GAC CGA GCT GGA GAA AG-3_amp_#x2032 5_amp_#x2032 -CCT GTA GAC GGC ATG GAA AT-3_amp_#x2032 5_amp_#x2032 -CAT CGA CGT CTA	5		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220440	12417341	294892	8012	4065	GAA	GAA	GAA	205	0.1	GCT GGA GAA AG-3_amp_#x2032 5_amp_#x2032 -CCT GTA GAC GGC ATG GAA AT-3_amp_#x2032 5_amp_#x2032 -CAT CGA CGT CTA CCA CAA GTA CTC	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220441	12417341	294892	4265	1885	CGA	CGA	CGA	208	0.2	5_amp_#x2032 -CCT GTA GAC GGC ATG GAA AT-3_amp_#x2032 5_amp_#x2032 -CAT CGA CGT CTA CCA CAA GTA CTC CCT GAT-3_amp_#x2032 clone 8	5		JUMiner_v2.2	1	2	35	0	2	1929	TotalCon:2<>1885|CGA|1081|Complete__1929|CHGA|1113|Complete__<>AvaiableGeneRif=2<>BEST:1929|CHGA|0.000418791508538899<>ScoreDetail__1885|CGA|0.00034398566484308__1929|CHGA|0.000418791508538899__	0	0	0	0		0
220442	12417341	294892	23680	12555	UGT8	CGT	CGT	209	0.1	-CCT GTA GAC GGC ATG GAA AT-3_amp_#x2032 5_amp_#x2032 -CAT CGA CGT CTA CCA CAA GTA CTC CCT GAT-3_amp_#x2032 clone 8 5_amp_#x2032	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220443	12417341	294892	7357	3604	FBN2	CCA	CCA	211	0.0	GAC GGC ATG GAA AT-3_amp_#x2032 5_amp_#x2032 -CAT CGA CGT CTA CCA CAA GTA CTC CCT GAT-3_amp_#x2032 clone 8 5_amp_#x2032 -AAG TGC	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220444	12417341	294892	10718	6138	ITGA2B	GTA	GTA	213	0.1	ATG GAA AT-3_amp_#x2032 5_amp_#x2032 -CAT CGA CGT CTA CCA CAA GTA CTC CCT GAT-3_amp_#x2032 clone 8 5_amp_#x2032 -AAG TGC GAG GGA	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220445	12417341	294892	13410	7211	MPG	AAG	AAG	219	0.0	CTA CCA CAA GTA CTC CCT GAT-3_amp_#x2032 clone 8 5_amp_#x2032 -AAG TGC GAG GGA TGC AAA T-3_amp_#x2032 5_amp_#x2032 -ACA CAG TCC	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220446	12417341	294892	22079	11778	TGM2	TGC	TGC	220	0.0	CCA CAA GTA CTC CCT GAT-3_amp_#x2032 clone 8 5_amp_#x2032 -AAG TGC GAG GGA TGC AAA T-3_amp_#x2032 5_amp_#x2032 -ACA CAG TCC TTG	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220447	12417341	294892	22079	11778	TGM2	TGC	TGC	223	0.0	CTC CCT GAT-3_amp_#x2032 clone 8 5_amp_#x2032 -AAG TGC GAG GGA TGC AAA T-3_amp_#x2032 5_amp_#x2032 -ACA CAG TCC TTG GCA CAC TT-3_amp_#x2032	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220448	12417341	294892	17	13666	AAAS	AAA	AAA	224	0.0	CCT GAT-3_amp_#x2032 clone 8 5_amp_#x2032 -AAG TGC GAG GGA TGC AAA T-3_amp_#x2032 5_amp_#x2032 -ACA CAG TCC TTG GCA CAC TT-3_amp_#x2032 5_amp_#x2032	1		JUMiner_v2.2	1	0		0	2	13666	TotalCon:2<>13666|AAAS|8086|Complete__620|APP|351|Complete__<>AvaiableGeneRif=2<>BEST:13666|AAAS|0.000598571450610142<>ScoreDetail__13666|AAAS|0.000598571450610142__620|APP|0.000379773565387191__	0	0	0	0		0
220449	12417341	294892	8190	15990	GCA	GCA	GCA	230	0.2	GAG GGA TGC AAA T-3_amp_#x2032 5_amp_#x2032 -ACA CAG TCC TTG GCA CAC TT-3_amp_#x2032 5_amp_#x2032 -ACC TCC TGC AAG AAG AGC TGC	5		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220450	12417341	294892	130	84	ACACA	ACC	ACC	233	0.1	T-3_amp_#x2032 5_amp_#x2032 -ACA CAG TCC TTG GCA CAC TT-3_amp_#x2032 5_amp_#x2032 -ACC TCC TGC AAG AAG AGC TGC TGC TC-3_amp_#x2032 clone 9	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220451	12417341	294892	22079	11778	TGM2	TGC	TGC	235	0.0	-ACA CAG TCC TTG GCA CAC TT-3_amp_#x2032 5_amp_#x2032 -ACC TCC TGC AAG AAG AGC TGC TGC TC-3_amp_#x2032 clone 9 5_amp_#x2032 -TCC	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220452	12417341	294892	13410	7211	MPG	AAG	AAG	236	0.0	CAG TCC TTG GCA CAC TT-3_amp_#x2032 5_amp_#x2032 -ACC TCC TGC AAG AAG AGC TGC TGC TC-3_amp_#x2032 clone 9 5_amp_#x2032 -TCC CTT	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220453	12417341	294892	13410	7211	MPG	AAG	AAG	237	0.0	TCC TTG GCA CAC TT-3_amp_#x2032 5_amp_#x2032 -ACC TCC TGC AAG AAG AGC TGC TGC TC-3_amp_#x2032 clone 9 5_amp_#x2032 -TCC CTT GAT	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220454	12417341	294892	22079	11778	TGM2	TGC	TGC	239	0.0	GCA CAC TT-3_amp_#x2032 5_amp_#x2032 -ACC TCC TGC AAG AAG AGC TGC TGC TC-3_amp_#x2032 clone 9 5_amp_#x2032 -TCC CTT GAT CCC ACA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220455	12417341	294892	22079	11778	TGM2	TGC	TGC	240	0.0	CAC TT-3_amp_#x2032 5_amp_#x2032 -ACC TCC TGC AAG AAG AGC TGC TGC TC-3_amp_#x2032 clone 9 5_amp_#x2032 -TCC CTT GAT CCC ACA AGT	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220456	12417341	294892	452	333	AGT	AGT	AGT	249	0.0	TGC TC-3_amp_#x2032 clone 9 5_amp_#x2032 -TCC CTT GAT CCC ACA AGT TC-3_amp_#x2032 5_amp_#x2032 -ACA GGC ATA CAC CAC CAC AT-3_amp_#x2032 5_amp_#x2032	1		JUMiner_v2.2	1	0		0	2	341	TotalCon:2<>333|AGT|183|Complete__341|AGXT|189|Complete__<>AvaiableGeneRif=2<>BEST:341|AGXT|0.000452679490518535<>ScoreDetail__333|AGT|0.000350759529288421__341|AGXT|0.000452679490518535__	0	0	0	0		0
220457	12417341	294892	452	333	AGT	AGT	AGT	261	0.2	GGC ATA CAC CAC CAC AT-3_amp_#x2032 5_amp_#x2032 -AGG CAG CAT AGT GAG ACC CCC ATC TCT ATA-3_amp_#x2032 clone 10 5_amp_#x2032 -AGC	5		JUMiner_v2.2	1	2	35	0	2	341	TotalCon:2<>333|AGT|183|Complete__341|AGXT|189|Complete__<>AvaiableGeneRif=2<>BEST:341|AGXT|0.000452679490518535<>ScoreDetail__333|AGT|0.000350759529288421__341|AGXT|0.000452679490518535__	0	0	0	0		0
220458	12417341	294892	130	84	ACACA	ACC	ACC	263	0.1	CAC CAC CAC AT-3_amp_#x2032 5_amp_#x2032 -AGG CAG CAT AGT GAG ACC CCC ATC TCT ATA-3_amp_#x2032 clone 10 5_amp_#x2032 -AGC TGC AGA	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220459	12417341	294892	22079	11778	TGM2	TGC	TGC	271	0.0	GAG ACC CCC ATC TCT ATA-3_amp_#x2032 clone 10 5_amp_#x2032 -AGC TGC AGA ACA AGG AGC AT-3_amp_#x2032 5_amp_#x2032 -GTG AAG CCC CAC	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220460	12417341	294892	426	318	AGA	AGA	AGA	272	0.0	ACC CCC ATC TCT ATA-3_amp_#x2032 clone 10 5_amp_#x2032 -AGC TGC AGA ACA AGG AGC AT-3_amp_#x2032 5_amp_#x2032 -GTG AAG CCC CAC TTC	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220461	12417341	294892	13410	7211	MPG	AAG	AAG	278	0.3	5_amp_#x2032 -AGC TGC AGA ACA AGG AGC AT-3_amp_#x2032 5_amp_#x2032 -GTG AAG CCC CAC TTC TTT GA-3_amp_#x2032 5_amp_#x2032 -AGT TCA AGT TTC	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220462	12417341	294892	452	333	AGT	AGT	AGT	284	0.0	AT-3_amp_#x2032 5_amp_#x2032 -GTG AAG CCC CAC TTC TTT GA-3_amp_#x2032 5_amp_#x2032 -AGT TCA AGT TTC CTG GCC GCC AGA AGA T-3_amp_#x2032 clone	1		JUMiner_v2.2	1	0		0	2	341	TotalCon:2<>333|AGT|183|Complete__341|AGXT|189|Complete__<>AvaiableGeneRif=2<>BEST:341|AGXT|0.000452679490518535<>ScoreDetail__333|AGT|0.000350759529288421__341|AGXT|0.000452679490518535__	0	0	0	0		0
220463	12417341	294892	452	333	AGT	AGT	AGT	286	0.0	-GTG AAG CCC CAC TTC TTT GA-3_amp_#x2032 5_amp_#x2032 -AGT TCA AGT TTC CTG GCC GCC AGA AGA T-3_amp_#x2032 clone 11 5_amp_#x2032	1		JUMiner_v2.2	1	0		0	2	341	TotalCon:2<>333|AGT|183|Complete__341|AGXT|189|Complete__<>AvaiableGeneRif=2<>BEST:341|AGXT|0.000452679490518535<>ScoreDetail__333|AGT|0.000350759529288421__341|AGXT|0.000452679490518535__	0	0	0	0		0
220464	12417341	294892	426	318	AGA	AGA	AGA	291	0.0	TTT GA-3_amp_#x2032 5_amp_#x2032 -AGT TCA AGT TTC CTG GCC GCC AGA AGA T-3_amp_#x2032 clone 11 5_amp_#x2032 -ACT GGT ACC CGT TGG	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220465	12417341	294892	426	318	AGA	AGA	AGA	292	0.0	GA-3_amp_#x2032 5_amp_#x2032 -AGT TCA AGT TTC CTG GCC GCC AGA AGA T-3_amp_#x2032 clone 11 5_amp_#x2032 -ACT GGT ACC CGT TGG AAC	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220466	12417341	294892	130	84	ACACA	ACC	ACC	298	0.3	GCC GCC AGA AGA T-3_amp_#x2032 clone 11 5_amp_#x2032 -ACT GGT ACC CGT TGG AAC AA-3_amp_#x2032 5_amp_#x2032 -GTT CAT CCC ATC GTG	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220467	12417341	294892	23680	12555	UGT8	CGT	CGT	299	0.1	GCC AGA AGA T-3_amp_#x2032 clone 11 5_amp_#x2032 -ACT GGT ACC CGT TGG AAC AA-3_amp_#x2032 5_amp_#x2032 -GTT CAT CCC ATC GTG GAT	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220468	12417341	294892	6069	23483	DOCK11	ACG	ACG	312	0.0	-GTT CAT CCC ATC GTG GAT TT-3_amp_#x2032 5_amp_#x2032 -TGG TAC ACG ATT TTT AAG GAC CAC GTG TCT-3_amp_#x2032	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
220469	12417341	294892	13410	7211	MPG	AAG	AAG	315	0.1	ATC GTG GAT TT-3_amp_#x2032 5_amp_#x2032 -TGG TAC ACG ATT TTT AAG GAC CAC GTG TCT-3_amp_#x2032	6		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
220474	12417341	294924	641	451	AMACR	RACE	RACE	7	1.3	We cloned these two unknown genes using RACE methods and named them dorfin and neugrin in previous reports	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
220490	12417341	294936	20996	11179	SOD1	ALS	ALS	28	3.9	Huntington disease Alzheimer disease Parkinson disease familial spinocerebellar degeneration and ALS 16 dorfin may possibly work to eliminate proteins which are	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0012197662335473<>ScoreDetail__5468|IGFALS|0.000411226482985504__11179|SOD1|0.0012197662335473__	0	0	0	0		0
220494	12417341	294943	20996	11179	SOD1	ALS	ALS	11	3.9	is paradoxical because gliosis is one of the hallmarks in ALS pathology	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0012197662335473<>ScoreDetail__5468|IGFALS|0.000411226482985504__11179|SOD1|0.0012197662335473__	0	0	0	0		0
220505	12417341	294956	20996	11179	SOD1	ALS	ALS	26	3.9	and if they are key molecules to explore treatments for ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0012197662335473<>ScoreDetail__5468|IGFALS|0.000411226482985504__11179|SOD1|0.0012197662335473__	0	0	0	0		0
215952	12528305	289111	20996	11179	SOD1	ALS	ALS	3	1.2	Amyotrophic lateral sclerosis (ALS) ALS is a rapidly progressive neuromuscular disease that destroys both upper	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00140420620671967<>ScoreDetail__5468|IGFALS|0.000182481751824818__11179|SOD1|0.00140420620671967__	0	0	0	0		0
215953	12528305	289112	20996	11179	SOD1	ALS	ALS	10	1.2	It is presumed that in the vast majority of cases ALS is acquired and occurs sporadically although the exact etiology is	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00140420620671967<>ScoreDetail__5468|IGFALS|0.000182481751824818__11179|SOD1|0.00140420620671967__	0	0	0	0		0
199189	12843244	266717	20996	11179	SOD1	ALS	ALS	29	3.2	transgenic mice a mouse model of amyotrophic lateral sclerosis (ALS), ALS before the onset of motor dysfunction and remains at the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199193	12843244	266720	20996	11179	SOD1	ALS	ALS	15	3.2	to certain aspects of pathology in this mouse model of ALS their inhibition is not sufficient to prevent neurodegeneration	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199194	12843244	266722	20996	11179	SOD1	ALS	ALS	2	3.2	Key words ALS motor neuron degeneration neurodegeneration SOD1 caspase apoptosis	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199196	12843244	266723	20996	11179	SOD1	ALS	ALS	3	3.2	Amyotrophic lateral sclerosis (ALS) ALS is a fatal neurological disorder characterized by selective degeneration of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199198	12843244	266723	20996	11179	SOD1	ALS	ALS	62	3.2	(SOD1) SOD1 are causally responsible for a subset of familial ALS (FALS) FALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199201	12843244	266724	20996	11179	SOD1	ALS	ALS	31	3.2	degeneration with cellular pathological features similar to that of human ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199202	12843244	266725	20996	11179	SOD1	ALS	ALS	14	3.2	apoptosis as a possible mechanism for motor neuron degeneration in ALS (Friedlander Friedlander et al. 1997 Kostic et al. 1997 Li	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199204	12843244	266727	20996	11179	SOD1	ALS	ALS	14	3.2	caspase-3 in the spinal cords of mutant SOD1 mice and ALS patients has been reported previously (Martin, Martin 1999 Li et	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199206	12843244	266729	20996	11179	SOD1	ALS	ALS	48	3.2	al. 2000 suggesting the importance of caspase-mediated apoptosis in the ALS pathology	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199207	12843244	266730	20996	11179	SOD1	ALS	ALS	12	3.2	involvement of both caspase-1 and caspase-3 in the pathogenesis of ALS strongly suggested the involvement of caspase-11 in this process because	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199211	12843244	266733	20996	11179	SOD1	ALS	ALS	20	3.2	beneficial effect of general caspase inhibition in mouse models of ALS a critical role of individual caspases in mutant SOD1-mediated neurodegeneration	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199213	12843244	266734	20996	11179	SOD1	ALS	ALS	23	3.2	resulting apoptosis play an indispensable role in mediating neurodegeneration in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199218	12843244	266749	19573	10691	SDS	SDS	SDS	34	0.0	buffer (150 150 m M NaCl 1% Triton X-100 0.1% SDS and 1% sodium deoxycholate in 50 m M Tris-HCl pH	1		JUMiner_v2.2	1	0		0	2	10691	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:10691|SDS|0.000327439423706614<>ScoreDetail__10691|SDS|0.000327439423706614__19440|SBDS|0.000304380309361078__	0	0	0	0		0
199220	12843244	266765	20996	11179	SOD1	ALS	ALS	31	3.2	the disease onset and progression of this mouse model of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199221	12843244	266767	20996	11179	SOD1	ALS	ALS	33	3.2	is not crucial for neurodegeneration in this mouse model of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199226	12843244	266770	20996	11179	SOD1	ALS	ALS	21	3.2	targets for the treatment of chronic neurodegenerative diseases such as ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199239	12843244	266779	20996	11179	SOD1	ALS	ALS	6	3.2	It has been well documented that ALS motor neurons undergo vacuolarization of the rough endoplasmic reticulum and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199241	12843244	266782	20996	11179	SOD1	ALS	ALS	12	3.2	weak protection by Bcl-2 overexpression in a mouse model of ALS (Kostic Kostic et al. 1997 suggests an involvement of alternative	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199243	12843244	266789	20996	11179	SOD1	ALS	ALS	10	3.2	The exact parallels between SOD1 mutant transgenic mice and human ALS are not clear because of the difference in the temporal	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199244	12843244	266790	20996	11179	SOD1	ALS	ALS	12	3.2	activation of caspases and apoptosis in this mouse model of ALS may reflect a secondary degenerative response it remains to be	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199245	12843244	266790	20996	11179	SOD1	ALS	ALS	35	3.2	inhibition of selective caspases may be beneficial for treatment of ALS in human	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199246	12843244	266791	20996	11179	SOD1	ALS	ALS	8	3.2	In particular considering that onset and progression of ALS in humans occur over a much longer period of time	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199247	12843244	266792	20996	11179	SOD1	ALS	ALS	18	3.2	considering caspases as a direct therapeutic target for treatment of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014804281480155<>ScoreDetail__5468|IGFALS|0.00041031399818598__11179|SOD1|0.0014804281480155__	0	0	0	0		0
199248	12843244	266801	536	387	AKR1C4	C11	C11	18	0.0	cord lysates were prepared from caspase-11+/-; caspase-11 - G93A (C11+/-G93A), C11 -G93A caspase-11-/-; caspase-11- - G93A (C11-/-G93A), C11- -G93A and caspase-11	1		JUMiner_v2.2	1	0		0	2	387	TotalCon:2<>387|AKR1C4|1109|Complete__14121|POLR3K|51728|Complete__<>AvaiableGeneRif=2<>BEST:387|AKR1C4|0.000418929850918756<>ScoreDetail__14121|POLR3K|0.000417485265225933__387|AKR1C4|0.000418929850918756__	0	0	0	0		0
199249	12843244	266801	536	387	AKR1C4	C11	C11-	21	0.0	- G93A (C11+/-G93A), C11 -G93A caspase-11-/-; caspase-11- - G93A (C11-/-G93A), C11- -G93A and caspase-11 - C11 - mice	1		JUMiner_v2.2	1	0		0	2	387	TotalCon:2<>387|AKR1C4|1109|Complete__14121|POLR3K|51728|Complete__<>AvaiableGeneRif=2<>BEST:387|AKR1C4|0.000418929850918756<>ScoreDetail__14121|POLR3K|0.000417485265225933__387|AKR1C4|0.000418929850918756__	0	0	0	0		0
199250	12843244	266801	536	387	AKR1C4	C11	C11	23	0.0	caspase-11-/-; caspase-11- - G93A (C11-/-G93A), C11- -G93A and caspase-11 - C11 - mice	1		JUMiner_v2.2	1	0		0	2	387	TotalCon:2<>387|AKR1C4|1109|Complete__14121|POLR3K|51728|Complete__<>AvaiableGeneRif=2<>BEST:387|AKR1C4|0.000418929850918756<>ScoreDetail__14121|POLR3K|0.000417485265225933__387|AKR1C4|0.000418929850918756__	0	0	0	0		0
193304	14511332	258337	20996	11179	SOD1	ALS	ALS	20	3.2	motor neurons in a model of amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193306	14511332	258338	20996	11179	SOD1	ALS	ALS-like	15	2.9	shown to be increased in transgenic mice that produce an ALS-like syndrome	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193310	14511332	258339	20996	11179	SOD1	ALS	ALS	17	3.2	and COX-2 in the spinal cord of seven human sporadic ALS patients by means of immunohistochemistry	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193312	14511332	258341	20996	11179	SOD1	ALS	ALS	12	3.2	was dramatically increased in the spinal cord of patients with ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193314	14511332	258343	20996	11179	SOD1	ALS	ALS	10	3.2	Statistical analysis showed a significantly higher expression of COX-2 in ALS for both neurons and glia	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193316	14511332	258344	20996	11179	SOD1	ALS	ALS	18	3.2	microglia and no apparent difference was detected between controls and ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193318	14511332	258345	20996	11179	SOD1	ALS	ALS	28	3.2	activity in the cerebrospinal fluid of nine patients diagnosed for ALS and compared the results with those from nine patients without	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193319	14511332	258346	20996	11179	SOD1	ALS	ALS	8	3.2	PG E 2 levels were markedly increased in ALS cases (45.8 45.8 _amp_plusmn 35.1 pg/mL) pg mL compared to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193321	14511332	258347	20996	11179	SOD1	ALS	ALS	19	3.2	for COX-2 in the pathogenesis of motor neuron death in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193323	14511332	258348	20996	11179	SOD1	ALS	ALS	14	3.2	therefore offer a new possibility in the treatment of human ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193325	14511332	258349	20996	11179	SOD1	ALS	ALS	10	3.2	However to determine the exact role of COX-2 in human ALS will require further research	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193327	14511332	258352	20996	11179	SOD1	ALS	ALS	18	3.2	superoxide dismutase (SOD1) SOD1 account for a familial form of ALS linked to chromosome 21q ( Rosen et al . 1993	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193342	14511332	258362	20996	11179	SOD1	ALS	ALS	1	3.2	In ALS glutamatergic excitotoxicity was shown to contribute to motoneuron-death ( Fray	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193343	14511332	258363	20996	11179	SOD1	ALS	ALS	9	3.2	Glutamate levels are elevated in the cerebrospinal fluid of ALS patients and inhibition of glial glutamate uptake has been used	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193344	14511332	258363	20996	11179	SOD1	ALS	ALS	26	3.2	uptake has been used as an in vitro model for ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193348	14511332	258366	20996	11179	SOD1	ALS	ALS	17	3.2	(PG PG E 2 level in post mortem samples of ALS cases as a marker for COX-2 activity	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193357	14511332	258371	20996	11179	SOD1	ALS	ALS	24	3.2	E 2 in the cerebrospinal fluid of patients diagnosed with ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193358	14511332	258374	20996	11179	SOD1	ALS	ALS	12	3.2	spinal cord segment was examined in seven patients with sporadic ALS and seven age matched patients without any neurological disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193370	14511332	258400	19381	19440	SBDS	SDS	SDS-polyacrylamide	12	0.3	50 _amp_micro;g/lane) _amp_micro g lane was loaded on a 10% SDS-polyacrylamide gel and electroblotted onto nitrocellulose membranes (Schleicher Schleicher and Schuell	11		JUMiner_v2.2	1	2	sds	0	2	10691	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:10691|SDS|0.00047941921786179<>ScoreDetail__10691|SDS|0.00047941921786179__19440|SBDS|0.000459162067811292__	0	0	0	0		0
193373	14511332	258402	3778	10620	CCL21	ECL	ECL	6	0.0	Blots were developed with enhanced chemiluminescence (ECL) ECL detection reagents (Amersham, Amersham Arlington Heights IL and exposed to	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
193374	14511332	258405	20996	11179	SOD1	ALS	ALS	5	3.2	Nine patients with clinically definite ALS were studied	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193375	14511332	258406	20996	11179	SOD1	ALS	ALS	0	3.2	ALS was diagnosed on the basis of the El Escorial Criteria	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193376	14511332	258406	20996	11179	SOD1	ALS	ALS	16	3.2	the El Escorial Criteria (World World Federation of Neurology of ALS ( Brooks 1994	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193377	14511332	258411	11629	6493	LAMC2	CSF	CSF	3	0.0	The cerebrospinal fluid (CSF) CSF control group ( n = 9 consisted of patients with	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
193378	14511332	258412	11629	6493	LAMC2	CSF	CSF	4	0.0	These specimens had normal CSF parameters i.e absence of pleocytosis intrathecal production of immunoglobulins and	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
193379	14511332	258414	11629	6493	LAMC2	CSF	CSF	0	0.0	CSF was obtained at routine lumbar puncture for diagnostic purposes after	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
193413	14511332	258449	11629	6493	LAMC2	CSF	CSF	21	0.0	sALS cases The individual concentrations of PG E 2 in CSF along with the means and standard deviations are shown for	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
193417	14511332	258458	11629	6493	LAMC2	CSF	CSF	8	0.0	Fourthly higher PG-E 2 levels were found in CSF specimens of sALS patients compared to controls	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
193421	14511332	258461	20996	11179	SOD1	ALS	ALS	1	3.2	Regarding ALS Drachman and Rothstein ( Drachman _amp_ Rothstein 2000 demonstrated a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193427	14511332	258464	20996	11179	SOD1	ALS	ALS	16	3.2	beneficial effect of selective COX-2 inhibition in mouse models of ALS ( Drachman et al . 2002 Pompl et al .	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193436	14511332	258472	11629	6493	LAMC2	CSF	CSF	16	0.0	interplay with glutamate levels of which are elevated in the CSF of sALS patients ( Plaitakis et al . 1988	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
193443	14511332	258477	20996	11179	SOD1	ALS	ALS	16	3.2	expression and their concentrations are elevated in the CSF of ALS cases ( Sekizawa et al . 1998 Vane et al	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193444	14511332	258477	11629	6493	LAMC2	CSF	CSF	14	0.1	of COX-2 expression and their concentrations are elevated in the CSF of ALS cases ( Sekizawa et al . 1998 Vane	6		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
193449	14511332	258480	20996	11179	SOD1	ALS	ALS	7	3.2	Gliosis is a common histological hallmark of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193457	14511332	258487	20996	11179	SOD1	ALS	ALS	30	3.2	and an active involvement of interneurons in the pathology of ALS ( Rowland _amp_ Shneider 2001	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193463	14511332	258491	20996	11179	SOD1	ALS	ALS	17	3.2	tissues and that previously obtained in an experimental model of ALS in the mouse are in excellent agreement	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193464	14511332	258497	20996	11179	SOD1	ALS	ALS	10	3.2	Despite a significant reduction in the number of neurons in ALS specimens the proportion of motoneurons and interneurons was virtually the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193473	14511332	258503	20996	11179	SOD1	ALS	ALS	17	3.2	situ expression of both COX-1 and COX-2 proteins in human ALS spinal cords	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193475	14511332	258505	20996	11179	SOD1	ALS	ALS	14	3.2	necessary data regarding the expression of COX isoforms in human ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193476	14511332	258506	20996	11179	SOD1	ALS	ALS	19	3.2	of PG-E 2 in the CSF of patients diagnosed for ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193477	14511332	258506	11629	6493	LAMC2	CSF	CSF	14	0.0	were confirmed by the measurement of PG-E 2 in the CSF of patients diagnosed for ALS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
193478	14511332	258507	20996	11179	SOD1	ALS	ALS	8	3.2	PG-E 2 levels were significantly increased in the ALS group	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193483	14511332	258513	20996	11179	SOD1	ALS	ALS	8	3.2	What is the significance of COX-2 overexpression in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193485	14511332	258514	20996	11179	SOD1	ALS	ALS	16	3.2	that COX-2 might play a role in the pathogenesis of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193487	14511332	258515	20996	11179	SOD1	ALS	ALS	14	3.2	selective COX-2 inhibitor in an in vitro organotypic model of ALS protected against the loss of motor neurons in this system	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193489	14511332	258516	20996	11179	SOD1	ALS	ALS	30	3.2	neuron degeneration and prolonged survival in transgenic mouse models of ALS ( Drachman et al . 2002 Pompl et al .	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193491	14511332	258517	20996	11179	SOD1	ALS	ALS	13	3.2	the action of PGs COX-2 could promote inflammatory processes in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193492	14511332	258518	20996	11179	SOD1	ALS	ALS	7	3.2	Although classical cellular inflammation is absent in ALS there is mounting evidence that inflammatory related processes may be	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193494	14511332	258520	20996	11179	SOD1	ALS	ALS	17	3.2	role in glutamate excitotoxicity which is postulated to occur in ALS ( Rowland _amp_ Shneider 2001	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193503	14511332	258531	20996	11179	SOD1	ALS	ALS	7	3.2	However the specifity of COX-2 expression for ALS has to be questioned	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193506	14511332	258533	20996	11179	SOD1	ALS	ALS	24	3.2	common endpoint in neurodegeneration rather than the actual cause of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193513	14511332	258538	20996	11179	SOD1	ALS	ALS	23	3.2	the exact role of COX-2 in the pathogenesis of human ALS still remains to be elucidated	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193514	14511332	258539	20996	11179	SOD1	ALS	ALS	9	3.2	Clinical trials are underway in the United States (North-east North-east ALS consortium to test a potential benefit of selective COX-2 inhibition	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193516	14511332	258539	20996	11179	SOD1	ALS	ALS	22	3.2	test a potential benefit of selective COX-2 inhibition in human ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193523	14511332	258546	20996	11179	SOD1	ALS	ALS	24	3.2	a minor role for this isoform in the pathogenesis of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193529	14511332	258552	20996	11179	SOD1	ALS	ALS	12	3.2	the beneficial effects of selective COX-2 inhibition in models of ALS the results of this and other studies might give a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193531	14511332	258556	20996	11179	SOD1	ALS	ALS	0	3.2	ALS amyotrophic lateral sclerosis COX cyclooxygenase CSF cerebrospinal fluid GFAP glial	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000844058375623846<>ScoreDetail__5468|IGFALS|0.000553428263731004__11179|SOD1|0.000844058375623846__	0	0	0	0		0
193535	14511332	258556	11629	6493	LAMC2	CSF	CSF	6	0.1	ALS amyotrophic lateral sclerosis COX cyclooxygenase CSF cerebrospinal fluid GFAP glial fibrillary acidic protein IR immunoreactivity PG	6		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
195581	14556941	260922	20996	11179	SOD1	ALS	ALS	12	0.0	that riluzole a drug used in amyotrophic lateral sclerosis (ALS), ALS might be beneficial for the treatment of MS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00106563979929848<>ScoreDetail__5468|IGFALS|0.000359823172612316__11179|SOD1|0.00106563979929848__	0	0	0	0		0
195582	14556941	260934	11629	6493	LAMC2	CSF	CSF	11	0.3	Moreover Stover et al 46 demonstrated an increase in CSF glutamate levels in MS patients which correlated with the severity	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
195583	14556941	260936	20996	11179	SOD1	ALS	ALS	11	0.0	hypothesis in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) ALS suggests that anti-glutamatergic agents might be neuroprotective	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00106563979929848<>ScoreDetail__5468|IGFALS|0.000359823172612316__11179|SOD1|0.00106563979929848__	0	0	0	0		0
195584	14556941	260937	20996	11179	SOD1	ALS	ALS	20	0.0	to be protective in several models of neurodegenerative diseases including ALS 19 and 20 Parkinson_amp_#x2019 s 1 3 5 9 and	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00106563979929848<>ScoreDetail__5468|IGFALS|0.000359823172612316__11179|SOD1|0.00106563979929848__	0	0	0	0		0
195585	14556941	260941	20996	11179	SOD1	ALS	ALS	18	0.0	was approved by the US Food and Drug Administration for ALS therapy 8	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00106563979929848<>ScoreDetail__5468|IGFALS|0.000359823172612316__11179|SOD1|0.00106563979929848__	0	0	0	0		0
195590	14556941	260993	4863	2311	CPM	CPM	CPM	16	0.0	H -thymidine incorporation expressed as mean counts per minute (CPM) CPM of triplicate wells	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
195616	14556941	261053	20996	11179	SOD1	ALS	ALS	42	0.0	Parkinson_amp_#x2019 s disease 1 3 5 9 and 10 and ALS 19 and 20	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00106563979929848<>ScoreDetail__5468|IGFALS|0.000359823172612316__11179|SOD1|0.00106563979929848__	0	0	0	0		0
195617	14556941	261055	11629	6493	LAMC2	CSF	CSF	9	0.3	However based on several previous studies showing that the CSF glutamate levels are increased in MS patients 2 and that	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
196768	14597108	262716	20996	11179	SOD1	ALS	ALS	17	1.4	inflammation contributes to the pathogenesis of amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196771	14597108	262718	20996	11179	SOD1	ALS	ALS	11	1.4	studied MCP-1 levels in sera and cerebrospinal fluid of 29 ALS patients and compared the results with 11 control patients with	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196774	14597108	262720	20996	11179	SOD1	ALS	ALS	18	1.4	but not serum level was seen in the patients with ALS compared to the control subjects	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196776	14597108	262721	20996	11179	SOD1	ALS	ALS	16	1.4	MCP-1 activity may be a sensitive marker for neuroinflammation in ALS useful for monitoring treatment trials in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196777	14597108	262721	20996	11179	SOD1	ALS	ALS	23	1.4	for neuroinflammation in ALS useful for monitoring treatment trials in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196778	14597108	262725	20996	11179	SOD1	ALS	ALS	3	1.4	Amyotrophic lateral sclerosis (ALS) ALS is a progressive fatal neurodegenerative disorder that primarily affects motor	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196779	14597108	262726	20996	11179	SOD1	ALS	ALS	3	1.4	The cause of ALS is not completely understood but accumulating evidence indicates that inflammatory	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196781	14597108	262727	20996	11179	SOD1	ALS	ALS	43	1.4	the superoxide dismutase gene (SOD1), SOD1 an animal model of ALS Alexianu et al. 2001	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196782	14597108	262728	20996	11179	SOD1	ALS	ALS	17	1.4	mortem in cerebral cortex and spinal cord of patients with ALS Kawamata et al. 1992 and Troost et al. 1990	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196783	14597108	262729	20996	11179	SOD1	ALS	ALS	58	1.4	been demonstrated in the cerebrospinal fluid and spinal cord of ALS patients (for for review see McGeer and McGeer 2002	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196784	14597108	262730	20996	11179	SOD1	ALS	ALS	31	1.4	is neuroprotective in mutant superoxide dismutase transgenic mouse models of ALS Kriz et al. 2002 Van Den Bosch et al. 2002	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196788	14597108	262735	20996	11179	SOD1	ALS	ALS	7	1.4	Changes in MCP-1 in living patients with ALS have not been studied however its evaluation might aid in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196789	14597108	262736	20996	11179	SOD1	ALS	ALS	18	1.4	might furthermore offer a possible treatment option for patients with ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196791	14597108	262737	20996	11179	SOD1	ALS	ALS	15	1.4	the MCP-1 level in CSF and serum of patients with ALS with that in controls 2	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196792	14597108	262737	11629	6493	LAMC2	CSF	CSF	9	0.0	Therefore the present study compares the MCP-1 level in CSF and serum of patients with ALS with that in controls	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196793	14597108	262740	20996	11179	SOD1	ALS	ALS	9	1.4	Experimental and control groups were matched for age 29 ALS patients (mean mean age 61.6_amp_#xb1 12.5 years and 11 individuals	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196794	14597108	262741	20996	11179	SOD1	ALS	ALS	1	1.4	All ALS patients had been diagnosed with definite or probable ALS in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196795	14597108	262741	20996	11179	SOD1	ALS	ALS	10	1.4	All ALS patients had been diagnosed with definite or probable ALS in accordance with the revised El Escorial criteria Brooks et	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196796	14597108	262742	20996	11179	SOD1	ALS	ALS	3	1.4	Seven of the ALS patients had predominant bulbar signs and 22 had only spinal	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196797	14597108	262744	11629	6493	LAMC2	CSF	CSF	17	0.0	been given to patients with tension headaches before blood and CSF sampling	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196798	14597108	262746	11629	6493	LAMC2	CSF	CSF	0	0.0	CSF/serum CSF serum preparation	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196799	14597108	262747	11629	6493	LAMC2	CSF	CSF	0	0.0	CSF and serum samples of patients and controls were obtained with	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196800	14597108	262747	11629	6493	LAMC2	CSF	CSF	23	0.0	as part of the diagnostic evaluation and stored in the CSF banks of the Department of Neurology MHH Hannover and the	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196801	14597108	262748	20996	11179	SOD1	ALS	ALS	17	1.4	the CSF were within normal range in both patients with ALS and controls	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196802	14597108	262748	11629	6493	LAMC2	CSF	CSF	8	0.0	Cells counts and the protein concentration in the CSF were within normal range in both patients with ALS and	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196803	14597108	262749	11629	6493	LAMC2	CSF	CSF	0	0.0	CSF samples were centrifuged immediately after lumbar puncture at 250_amp_#xd7 g	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196805	14597108	262751	11629	6493	LAMC2	CSF	CSF	5	0.0	MCP-1 levels in serum and CSF samples were quantified by ELISA (Quantikine Quantikine R_amp_#x26 D Systems	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196806	14597108	262751	12473	20867	MCHR2	SLT	SLT	33	0.0	of 450 nm (reference reference wavelength 550 nm with a SLT Reader 340 ATTC	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196808	14597108	262756	20996	11179	SOD1	ALS	ALS	15	1.4	used to compare MCP-1 levels in CSF and serum in ALS patients with controls	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196809	14597108	262756	11629	6493	LAMC2	CSF	CSF	11	0.0	Whitney U -test was used to compare MCP-1 levels in CSF and serum in ALS patients with controls	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196812	14597108	262761	20996	11179	SOD1	ALS	ALS	12	1.4	of MCP-1 was significantly ( p _amp_#x3c 0.001 higher in ALS patients (570.5_amp_#xb1;199.9 570.5_amp_#xb1 199.9 pg/ml) pg ml as compared to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196813	14597108	262761	11629	6493	LAMC2	CSF	CSF	1	0.0	The CSF concentration of MCP-1 was significantly ( p _amp_#x3c 0.001 higher	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196814	14597108	262762	20996	11179	SOD1	ALS	ALS	9	1.4	Although an overlap of values was seen among the ALS group MCP-1 values of only 8 patients of 29 were	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196817	14597108	262763	20996	11179	SOD1	ALS	ALS	4	1.4	Furthermore MCP-1 levels in ALS patients (570.5_amp_#xb1;199.9 570.5_amp_#xb1 199.9 pg/ml) pg ml were substantially higher	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196818	14597108	262763	11629	6493	LAMC2	CSF	CSF	13	0.0	570.5_amp_#xb1 199.9 pg/ml) pg ml were substantially higher in the CSF ( p _amp_#x3c 0.001 than in the serum (191.6_amp_#xb1;104.9 191.6_amp_#xb1	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196819	14597108	262764	20996	11179	SOD1	ALS	ALS	17	1.4	expression in the serum or CSF of patients with definite ALS compared with patients with probable ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196820	14597108	262764	20996	11179	SOD1	ALS	ALS	23	1.4	of patients with definite ALS compared with patients with probable ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196821	14597108	262764	11629	6493	LAMC2	CSF	CSF	12	0.0	no differential pattern of chemokine expression in the serum or CSF of patients with definite ALS compared with patients with probable	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196824	14597108	262766	20996	11179	SOD1	ALS	ALS	20	1.4	at time of lumbar puncture and intrathecal MCP-1 level in ALS patients ( r =0.045 Fig 1a or control patients (	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196825	14597108	262768	20996	11179	SOD1	ALS	ALS	24	1.4	as well as in the spinal cord of patients with ALS Kawamata et al. 1992	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196826	14597108	262770	20996	11179	SOD1	ALS	ALS	16	1.4	the recruitment of microglial cells into the spinal cord of ALS patients have remained elusive so far	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196828	14597108	262771	20996	11179	SOD1	ALS	ALS	21	1.4	mediate recruitment of myelomonocytic cells to areas of neurodegeneration in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196830	14597108	262772	20996	11179	SOD1	ALS	ALS	15	1.4	vivo evidence for elevated cerebrospinal fluid levels of MCP-1 in ALS patients providing further evidence for the hypothesis that inflammatory processes	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196831	14597108	262772	20996	11179	SOD1	ALS	ALS	30	1.4	for the hypothesis that inflammatory processes contribute to neurodegeneration in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196833	14597108	262773	20996	11179	SOD1	ALS	ALS	16	1.4	the CSF than in paired serum samples in patients with ALS provide evidence for intrathecal synthesis of this chemokine	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196834	14597108	262773	11629	6493	LAMC2	CSF	CSF	7	0.0	The higher levels of MCP-1 in the CSF than in paired serum samples in patients with ALS provide	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196837	14597108	262776	20996	11179	SOD1	ALS	ALS	8	1.4	Neuropathological studies show that in animal models of ALS glial reactions even precede neuronal loss in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196838	14597108	262776	20996	11179	SOD1	ALS	ALS	16	1.4	models of ALS glial reactions even precede neuronal loss in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196840	14597108	262777	20996	11179	SOD1	ALS	ALS	13	1.4	speculate that MCP-1 might further increase during the course of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196843	14597108	262779	11629	6493	LAMC2	CSF	CSF	13	0.2	correlation between clinical impairment/progression impairment progression of the disease and CSF MCP-1 levels a larger sample size may be needed to	5		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
196844	14597108	262780	20996	11179	SOD1	ALS	ALS	19	1.4	explore the potential of immunotherapies specifically targeting MCP-1-dependant mechanisms in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196845	14597108	262780	3892	6953	CD46	MCP	MCP-1-dependant	16	0.0	be interesting to explore the potential of immunotherapies specifically targeting MCP-1-dependant mechanisms in ALS	11		JUMiner_v2.2	1	0		0	2	6953	TotalCon:3<>6953|CD46|4179|Complete__1474|CAPG|822|Complete__32018|C1orf132|388732|No_GeneRif__<>AvaiableGeneRif=2<>BEST:6953|CD46|0.000506737674493666<>ScoreDetail__6953|CD46|0.000506737674493666__1474|CAPG|0.000485731633272617__	0	0	0	0		0
196849	14597108	262784	20996	11179	SOD1	ALS	ALS	24	1.4	marker in the diagnosis or in treatment of patients with ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196850	14597108	262784	11629	6493	LAMC2	CSF	CSF	8	0.0	The present data suggest that MCP-1 levels in CSF may be an appropriate surrogate marker in the diagnosis or	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
196852	14597108	262785	20996	11179	SOD1	ALS	ALS	15	1.4	the prognostic value of CSF/plasma CSF plasma MCP-1 ratios in ALS patients who are followed longitudinally which should be done in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
196853	14597108	262785	11629	6493	LAMC2	CSF	CSF	11	0.2	would be worthwhile to examine the prognostic value of CSF/plasma CSF plasma MCP-1 ratios in ALS patients who are followed longitudinally	5		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
196855	14597108	262787	20996	11179	SOD1	ALS	ALS	14	1.4	the time of lumbar puncture and intrathecal MCP-1 levels in ALS patients (a) a and control patients (b) b	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00087402263009945<>ScoreDetail__5468|IGFALS|0.00087402263009945__11179|SOD1|0.000743974127739445__	0	0	0	0		0
186758	14642384	249791	22000	11730	TERT	TERT	tert	8	0.0	FDNB GSH GSSG iodoacetic acid (IA), IA N-ethylmaleimide (NEM), NEM tert -butyl hydroperoxide (t-BOOH), t-BOOH and trichloroacetic acid (TCA) TCA were	14		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
186759	14642384	249798	22000	11730	TERT	TERT	tert	3	0.0	Then 1 mM tert -butyl hydroperoxide (t-BOOH) t-BOOH treatment was performed on heparinized blood	14		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
186761	14642384	249888	16561	8947	PI3	ESI	ESI-MS_amp_#x2014	10	0.0	disulfide HPLC_amp_#x2014 high-pressure liquid chromatography IA_amp_#x2014 iodoacetic acid LC/ESI-MS_amp_#x2014;liquid LC ESI-MS_amp_#x2014 liquid chromatography/electron chromatography electron spray ionization-mass spectrometry NEM_amp_#x2014 N-ethylmaleimide t-BOOH_amp_#x2014	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
186762	14642384	249888	22000	11730	TERT	TERT	tert	17	0.0	liquid chromatography/electron chromatography electron spray ionization-mass spectrometry NEM_amp_#x2014 N-ethylmaleimide t-BOOH_amp_#x2014 tert -butylhydroperoxide TCA_amp_#x2014 trichloroacetic acid	14		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
187086	14645737	250134	9947	5468	IGFALS	ALS	ALS	5	0.3	Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00132105505278114<>ScoreDetail__5468|IGFALS|0.000868960722975322__11179|SOD1|0.00132105505278114__	0	0	0	0		0
187087	14645737	250135	9947	5468	IGFALS	ALS	ALS	16	0.3	patterns in the human neurodegenerative disease amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00132105505278114<>ScoreDetail__5468|IGFALS|0.000868960722975322__11179|SOD1|0.00132105505278114__	0	0	0	0		0
187088	14645737	250136	9947	5468	IGFALS	ALS	ALS	27	0.3	in postmortem spinal cord gray matter obtained from individuals with ALS as well as normal individuals	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00132105505278114<>ScoreDetail__5468|IGFALS|0.000868960722975322__11179|SOD1|0.00132105505278114__	0	0	0	0		0
187089	14645737	250137	9947	5468	IGFALS	ALS	ALS-specific	12	0.3	(FDA) FDA and leave-one-out cross-validation (LOOCV), LOOCV we discerned an ALS-specific signature	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00132105505278114<>ScoreDetail__5468|IGFALS|0.000868960722975322__11179|SOD1|0.00132105505278114__	0	0	0	0		0
187090	14645737	250138	9947	5468	IGFALS	ALS	ALS	7	0.3	Moreover it was possible to distinguish familial ALS (FALS) FALS from sporadic ALS (SALS) SALS gene expression profiles	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00132105505278114<>ScoreDetail__5468|IGFALS|0.000868960722975322__11179|SOD1|0.00132105505278114__	0	0	0	0		0
187091	14645737	250138	9947	5468	IGFALS	ALS	ALS	11	0.3	was possible to distinguish familial ALS (FALS) FALS from sporadic ALS (SALS) SALS gene expression profiles	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00132105505278114<>ScoreDetail__5468|IGFALS|0.000868960722975322__11179|SOD1|0.00132105505278114__	0	0	0	0		0
187092	14645737	250139	9947	5468	IGFALS	ALS	ALS	8	0.3	Characterization of the specific genes significantly altered in ALS uncovered a pro-inflammatory terminal state	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00132105505278114<>ScoreDetail__5468|IGFALS|0.000868960722975322__11179|SOD1|0.00132105505278114__	0	0	0	0		0
187093	14645737	250141	9947	5468	IGFALS	ALS	ALS	26	0.3	phenotypic changes that underlie the terminal stages of neurodegeneration in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00132105505278114<>ScoreDetail__5468|IGFALS|0.000868960722975322__11179|SOD1|0.00132105505278114__	0	0	0	0		0
188367	14661102	251394	16315	30012	PDF	PDF	PDF	2	0.5	Contribution in PDF	3		JUMiner_v2.2	1	2	UserEdit	0	2	30142	TotalCon:3<>30012|PDF|64146|Complete__30142|GDF15|9518|Complete__8866|PFDN1|5201|Complete__<>AvaiableGeneRif=3<>BEST:30142|GDF15|0.000422092041646415<>ScoreDetail__8866|PFDN1|0__30142|GDF15|0.000422092041646415__30012|PDF|0.000368188512518409__	1	1	0	0		0
190248	14720207	253624	20996	11179	SOD1	ALS	ALS	14	1.4	both inflammation and mitochondrial dysfunction in amyotrophic lateral sclerosis (ALS) ALS pathogenesis	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011702678254673<>ScoreDetail__5468|IGFALS|0.000437082040298964__11179|SOD1|0.0011702678254673__	0	0	0	0		0
190250	14720207	253625	20996	11179	SOD1	ALS	ALS	24	1.4	combination with creatine in the G93A transgenic mouse model of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011702678254673<>ScoreDetail__5468|IGFALS|0.000437082040298964__11179|SOD1|0.0011702678254673__	0	0	0	0		0
190256	14720207	253630	20996	11179	SOD1	ALS	ALS	20	1.4	mechanisms may be a useful strategy in the treatment of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011702678254673<>ScoreDetail__5468|IGFALS|0.000437082040298964__11179|SOD1|0.0011702678254673__	0	0	0	0		0
190795	14739060	254283	6981	22140	FAM20C	RNS	RNS	19	0.3	reactive oxygen species (ROS) ROS and reactive nitrogen species (RNS) RNS	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
190796	14739060	254283	18723	10261	ROS1	ROS	ROS	14	0.0	as accountable for redox regulation involving reactive oxygen species (ROS) ROS and reactive nitrogen species (RNS) RNS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
190797	14739060	254289	18723	10261	ROS1	ROS	ROS	7	0.0	ATP synthesis is responsible for most of ROS and notably the first produced superoxide anion (	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
190798	14739060	254290	20996	11179	SOD1	ALS	ALS	35	1.3	Parkinson_amp_#x2019 s disease (PD) PD and amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160093311530149<>ScoreDetail__5468|IGFALS|0.000534659909805198__11179|SOD1|0.00160093311530149__	0	0	0	0		0
190799	14739060	254290	18723	10261	ROS1	ROS	ROS	10	0.0	Mitochondrial dysfunction i.e cell energy impairment apoptosis and overproduction of ROS is a final common pathogenic mechanism in aging and in	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
190800	14739060	254291	6981	22140	FAM20C	RNS	RNS	5	0.3	Nitric oxide (NO NO an RNS which can be produced by three isoforms of NO-synthase in	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
190801	14739060	254292	20996	11179	SOD1	ALS	ALS	9	1.3	The research on the genetics of inherited forms notably ALS AD PD has improved our understanding of the pathobiology of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160093311530149<>ScoreDetail__5468|IGFALS|0.000534659909805198__11179|SOD1|0.00160093311530149__	0	0	0	0		0
190802	14739060	254293	6981	22140	FAM20C	RNS	RNS	2	0.3	ROS and RNS i.e oxidative stress are not the origin of neuronal death	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
190803	14739060	254293	18723	10261	ROS1	ROS	ROS	0	0.1	ROS and RNS i.e oxidative stress are not the origin of	6		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
190804	14739060	254311	18723	10261	ROS1	ROS	ROS	14	0.0	is responsible for most of the reactive oxygen species (ROS) ROS and notably the first produced superoxide anion ( in human	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
190805	14739060	254312	18723	10261	ROS1	ROS	ROS	14	0.0	1_amp_#x2013 2% of the O 2 consumed is converted to ROS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
190806	14739060	254313	6981	22140	FAM20C	RNS	RNS	11	0.3	is nitric oxide (NO NO a reactive nitrogen species (RNS) RNS	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
190811	14739060	254315	6981	22140	FAM20C	RNS	RNS	15	0.3	peroxynitrite (ONOO ONOO _amp_#x2013 _amp_#x2013 which is the most reactive RNS	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
190812	14739060	254316	6981	22140	FAM20C	RNS	RNS	2	0.3	ROS and RNS are the cause of oxidative stress in nervous system	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
190813	14739060	254316	18723	10261	ROS1	ROS	ROS	0	0.1	ROS and RNS are the cause of oxidative stress in nervous	6		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
190816	14739060	254318	18723	10261	ROS1	ROS	ROS	4	0.0	The main sources of ROS in inflammatory process are both damaged mitochondria and activated microglia	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
190817	14739060	254319	6981	22140	FAM20C	RNS	RNS	15	0.3	as an imbalance between generation and elimination of ROS and RNS	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
190818	14739060	254319	18723	10261	ROS1	ROS	ROS	13	0.1	is described as an imbalance between generation and elimination of ROS and RNS	6		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
190820	14739060	254321	18723	10261	ROS1	ROS	ROS	8	0.0	It is now recognized that redox regulation involving ROS is key to the modulation of critical cellular functions notably	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
190821	14739060	254330	6981	22140	FAM20C	RNS	RNS	2	0.3	ROS and RNS are involved in both apoptosis and excitotoxicity 27 and 28	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
190822	14739060	254330	18723	10261	ROS1	ROS	ROS	0	0.1	ROS and RNS are involved in both apoptosis and excitotoxicity 27	6		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
190824	14739060	254346	6981	22140	FAM20C	RNS	RNS	10	0.3	The last three (phospholipase phospholipase A 2 produce ROS and RNS by triggering acide arachidonic cascade	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
190825	14739060	254346	18723	10261	ROS1	ROS	ROS	8	0.1	The last three (phospholipase phospholipase A 2 produce ROS and RNS by triggering acide arachidonic cascade	6		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
190826	14739060	254361	6981	22140	FAM20C	RNS	RNS	13	0.3	result in overproduction of proteolytic enzymes lipid peroxidation ROS and RNS formation 33 and in triggering programmed cell death i.e apoptosis	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
190827	14739060	254361	18723	10261	ROS1	ROS	ROS	11	0.1	intracellular responses result in overproduction of proteolytic enzymes lipid peroxidation ROS and RNS formation 33 and in triggering programmed cell death	6		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
190828	14739060	254366	6981	22140	FAM20C	RNS	RNS	32	0.3	as that triggered by excitotoxicity _amp_#x2022 elevated levels of ROS_amp_#x2013 RNS	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
190831	14739060	254369	18723	10261	ROS1	ROS	ROS	4	0.0	When the level of ROS exceeds the capacity of the mitochondria and cell to detoxify	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
190833	14739060	254378	20996	11179	SOD1	ALS	ALS	46	1.3	neurons obtained by cyclooxygenase 2_amp_#xa0 in transgenic mouse model of ALS 15	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160093311530149<>ScoreDetail__5468|IGFALS|0.000534659909805198__11179|SOD1|0.00160093311530149__	0	0	0	0		0
190834	14739060	254380	20996	11179	SOD1	ALS	ALS	36	1.3	heterozygote gene diseases for example familial amyotrophic lateral sclerosis (ALS), ALS familial Parkinson_amp_#x2019 s disease (PD), PD familial Alzheimer_amp_#x2019 s disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160093311530149<>ScoreDetail__5468|IGFALS|0.000534659909805198__11179|SOD1|0.00160093311530149__	0	0	0	0		0
190835	14739060	254383	20996	11179	SOD1	ALS	ALS	0	1.3	ALS a neurodegenerative disease characterized by the degeneration of motor neurons	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160093311530149<>ScoreDetail__5468|IGFALS|0.000534659909805198__11179|SOD1|0.00160093311530149__	0	0	0	0		0
190839	14739060	254384	20996	11179	SOD1	ALS	ALS	15	1.3	human mutant SOD1 gene syndrome develops with many features of ALS including specific cell death of motor neurons progressive weakness and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160093311530149<>ScoreDetail__5468|IGFALS|0.000534659909805198__11179|SOD1|0.00160093311530149__	0	0	0	0		0
190846	14739060	254392	20996	11179	SOD1	ALS	ALS	13	1.3	peripherin is found in neuronal inclusions in patients with sporadic ALS and in transgenic mice with SOD1 mutations	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160093311530149<>ScoreDetail__5468|IGFALS|0.000534659909805198__11179|SOD1|0.00160093311530149__	0	0	0	0		0
190850	14739060	254398	20996	11179	SOD1	ALS	ALS	12	1.3	of other neurodegenerative diseases with familial and sporadic forms like ALS display numerous similitudes	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160093311530149<>ScoreDetail__5468|IGFALS|0.000534659909805198__11179|SOD1|0.00160093311530149__	0	0	0	0		0
190865	14739060	254464	6981	22140	FAM20C	RNS	RNS	15	0.3	of aging i.e progressive damage to mtDNA by ROS/RNS ROS RNS 42 and induced changes in redox state of the cell	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
190866	14739060	254464	18723	10261	ROS1	ROS	ROS	15	0.3	theory of aging i.e progressive damage to mtDNA by ROS/RNS ROS RNS 42 and induced changes in redox state of the	4		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
190867	14739060	254468	18723	10261	ROS1	ROS	ROS	44	0.0	reflect either decreased mitochondrial biogenesis or turnover secondary to cumulative ROS inflicted mitochondrial damage 11	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
190869	14739060	254479	6981	22140	FAM20C	RNS	RNS	32	0.3	neurotoxins such as cytokine (TNF, TNF IL1 eicosanoides ROS and RNS 9 and 13	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
190871	14739060	254479	18723	10261	ROS1	ROS	ROS	30	0.1	production of neurotoxins such as cytokine (TNF, TNF IL1 eicosanoides ROS and RNS 9 and 13	6		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
190873	14739060	254490	20996	11179	SOD1	ALS	ALS	3	1.3	Animal models for ALS 17 and 19 AD PD 5 and aging brain 35	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00160093311530149<>ScoreDetail__5468|IGFALS|0.000534659909805198__11179|SOD1|0.00160093311530149__	0	0	0	0		0
180857	14960605	241507	10676	6121	IRF6	LPS	LPS	15	0.3	the effects of acute and chronic administration of lipopolysaccharide (LPS), LPS a Gram-negative bacterial wall component in a genetic model of	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180859	14960605	241508	10676	6121	IRF6	LPS	LPS	30	0.3	challenged intraperitoneally with a single nontoxic or repeated injections of LPS (1 1 mg/kg) mg kg	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180861	14960605	241510	10676	6121	IRF6	LPS	LPS	6	0.3	Remarkably only a chronic challenge with LPS in presymptomatic 6-month-old SOD1 mice exacerbated disease progression by 3	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180863	14960605	241511	10676	6121	IRF6	LPS	LPS-treated	42	0.3	cord and efferent fiber tracts of the brain from the LPS-treated SOD1 mice	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180866	14960605	241519	20996	11179	SOD1	ALS	ALS	27	1.7	dismutase 1 (SOD1 SOD1 linked to amyotrophic lateral sclerosis (ALS), ALS the most common form of human motor neuron disease (Nguyen	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180867	14960605	241519	20996	11179	SOD1	ALS	ALS	45	1.7	disease (Nguyen Nguyen et al. 2001b ~20% cases of familial ALS (Rosen Rosen et al. 1993 Cudkowicz et al. 1997	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180870	14960605	241521	20996	11179	SOD1	ALS	ALS	10	1.7	Transgenic mice expressing mutant SOD1 develop motor neuron disease resembling ALS through a gain of unidentified deleterious properties (Wong Wong et	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180875	14960605	241523	20996	11179	SOD1	ALS	ALS	11	1.7	these findings the toxicity of SOD1 mutants linked to human ALS remains poorly understood	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180877	14960605	241524	20996	11179	SOD1	ALS	ALS	21	1.7	that cells other than motor neurons play a role in ALS (Clement Clement et al. 2003	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180880	14960605	241527	20996	11179	SOD1	ALS	ALS	24	1.7	processes and activation of microglia and other immune cells in ALS patients and mice (Bruijn Bruijn et al. 1997 Nguyen et	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180881	14960605	241528	20996	11179	SOD1	ALS	ALS	14	1.7	compounds has recently conferred protection in models of neurodegeneration including ALS (Drachman Drachman and Rothstein 2000 Kriz et al. 2002 Schenk	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180883	14960605	241531	10676	6121	IRF6	LPS	LPS	17	0.3	immunity of SOD1 mice with systemic administration of lipopolysaccharide (LPS), LPS a potent activator of microglia	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180884	14960605	241532	10676	6121	IRF6	LPS	LPS	11	0.3	results demonstrate that chronic activation of innate immunity by systemic LPS is noxious to motor neurons bearing SOD1 linked to ALS	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180886	14960605	241532	20996	11179	SOD1	ALS	ALS	21	1.7	LPS is noxious to motor neurons bearing SOD1 linked to ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180888	14960605	241534	10676	6121	IRF6	LPS	LPS	7	0.3	Generation of SOD1 mice and protocol for LPS injection	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180892	14960605	241539	10676	6121	IRF6	LPS	LPS	9	0.3	To avoid any potential interference with the effects of LPS mice were kept in a pathogen-free facility	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180894	14960605	241540	10676	6121	IRF6	LPS	LPS	23	0.3	and 9-month-old SOD1 mice received a single intraperitoneal injection of LPS (1 1 mg/kg mg kg of body weight from Escherichia	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180896	14960605	241545	10676	6121	IRF6	LPS	LPS	9	0.3	Another group of presymptomatic 6-month-old SOD1 mice received intraperitoneal LPS or vehicle injections once every 2 weeks for a duration	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180897	14960605	241546	10676	6121	IRF6	LPS	LPS-treated	9	0.3	Around month 9 (42-43 42-43 weeks of age the chronically LPS-treated SOD1 mice exhibited the first signs of paralysis and the	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180902	14960605	241561	20996	11179	SOD1	ALS	ALS	26	1.7	or necrosis is the dominant form of cell death in ALS (Migheli Migheli et al. 1999 Pasinelli et al. 2000 Vukosavic	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180904	14960605	241562	10676	6121	IRF6	LPS	LPS	12	0.3	exhibited a normal innate immune response after an acute systemic LPS injection	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180905	14960605	241563	10676	6121	IRF6	LPS	LPS	3	0.3	A single systemic LPS injection caused a robust increase in the expression of Toll-like	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180911	14960605	241566	10676	6121	IRF6	LPS	LPS	26	0.3	control of the innate immune response in the CNS after LPS administration	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180914	14960605	241567	20996	11179	SOD1	ALS	ALS	24	1.7	genes takes place in transgenic mice expressing SOD1 linked to ALS (Nguyen Nguyen et al. 2001b	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180915	14960605	241568	10676	6121	IRF6	LPS	LPS	7	0.3	The results presented here demonstrate that repeated LPS injections exacerbated the pathogenesis and neuronal death processes of ALS	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180916	14960605	241568	20996	11179	SOD1	ALS	ALS	17	1.7	LPS injections exacerbated the pathogenesis and neuronal death processes of ALS caused by SOD1 mutation	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180919	14960605	241569	10676	6121	IRF6	LPS	LPS	11	0.3	SOD1 mice responded normally to an acute systemic injection of LPS chronic stimulation of innate immune response with the bacterial cell	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180924	14960605	241572	10676	6121	IRF6	LPS	LPS-treated	5	0.3	As a consequence the chronically LPS-treated SOD1 mice exhibited accelerated disease progression motor axon degeneration and	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180926	14960605	241573	10676	6121	IRF6	LPS	LPS-treated	2	0.3	Interestingly chronically LPS-treated SOD1 mice exhibited a more important loss of astrocytes than	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180929	14960605	241575	20996	11179	SOD1	ALS	ALS	13	1.7	compatible with a non-cell-autonomous mechanism of motor neuron death in ALS mice (Clement Clement et al. 2003	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180930	14960605	241576	10676	6121	IRF6	LPS	LPS	2	0.3	The endotoxin LPS is able to activate microglia because these cells are of	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180933	14960605	241578	20996	11179	SOD1	ALS	ALS	14	1.7	supported by studies on human patients with neurodegenerative disorders including ALS reporting the expression of molecules of adaptive immunity such as	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180936	14960605	241578	11629	6493	LAMC2	CSF	CSF	43	0.3	II and human histocompatibility leukocyte antigen in brains spinal cords CSF and sera (Kriz Kriz et al. 2002 Nguyen et al.	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
180937	14960605	241579	10676	6121	IRF6	LPS	LPS	15	0.3	the gene encoding IL-12 was found in the CNS of LPS treated-SOD1 mice the cerebral tissue of these animals did not	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180941	14960605	241580	10676	6121	IRF6	LPS	LPS	24	0.3	spinal cord of SOD1 mice treated chronically with vehicle or LPS	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180942	14960605	241580	3870	1706	CD8A	CD8	CD8	6	0.3	Immunohistochemistry also failed to detect infiltrating CD4 and CD8 cells in the brain and spinal cord of	4		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
180943	14960605	241580	3870	1706	CD8A	CD8	CD8	8	0.1	Immunohistochemistry also failed to detect infiltrating CD4 and CD8 cells in the brain and spinal cord of SOD1 mice	6		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
180944	14960605	241581	20996	11179	SOD1	ALS	ALS	24	1.7	with a specific transfer to an adaptive immune response in ALS mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180945	14960605	241582	10676	6121	IRF6	LPS	LPS-treated	28	0.3	adaptive response may be toxic for the CNS of the LPS-treated SOD1 and SOD1 mice	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180951	14960605	241586	10676	6121	IRF6	LPS	LPS	2	0.3	The endotoxin LPS is able to trigger transcriptional activation of the gene encoding	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180955	14960605	241586	11629	6493	LAMC2	CSF	CSF	46	0.3	and Rivest 2000 alpha levels are also found in the CSF of ALS patients (Poloni Poloni et al. 2000 kappaB pathway	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
180956	14960605	241586	20996	11179	SOD1	ALS	ALS	48	1.7	2000 alpha levels are also found in the CSF of ALS patients (Poloni Poloni et al. 2000 kappaB pathway which is	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180959	14960605	241592	20996	11179	SOD1	ALS	ALS	7	1.7	Indeed the mechanisms that underlie 90% of ALS cases sporadic Parkinson's disease and Alzheimer's disease remain elusive (Nguyen	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180960	14960605	241593	20996	11179	SOD1	ALS	ALS	2	1.7	Actually sporadic ALS may result from gene-environment interactions	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180961	14960605	241594	20996	11179	SOD1	ALS	ALS	17	1.7	dietary glutamate-fat intake have been proposed as etiological causes for ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180962	14960605	241597	20996	11179	SOD1	ALS	ALS	20	1.7	infiltration of peripheral immune cells in the CNS of sporadic ALS cases have been reported (Nguyen Nguyen et al. 2002	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180963	14960605	241599	10676	6121	IRF6	LPS	LPS	7	0.3	Beyond the toxicity of chronic administration of LPS in the mutant SOD1 mice our study constitutes a simple	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180965	14960605	241600	20996	11179	SOD1	ALS	ALS	17	1.7	bacterial infections in a wide diversity of neurodegenerative disorder including ALS we provide evidence here that environmental factors and innate immunity	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
180966	14960605	241604	10676	6121	IRF6	LPS	LPS	6	0.3	Effect of a single bolus of LPS on TLR2 gene expression in the brains and spinal cords	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180970	14960605	241605	10676	6121	IRF6	LPS	LPS	24	0.3	after a single intraperitoneal injection of vehicle (Veh) Veh or LPS (1 1 mg/kg mg kg of body weight	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180973	14960605	241610	10676	6121	IRF6	LPS	LPS	25	0.3	WT and SOD1 mice that received an intraperitoneal bolus of LPS	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180974	14960605	241614	10676	6121	IRF6	LPS	LPS-treated	22	0.3	main effect ( p _lt_ 0.0001 between the vehicle- and LPS-treated groups	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180975	14960605	241619	10676	6121	IRF6	LPS	LPS	5	0.3	Chronic treatment with the endotoxin LPS increases the innate immune response and neurodegeneration in SOD1 mice	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180983	14960605	241630	10676	6121	IRF6	LPS	LPS-treated	7	0.3	Exacerbation of motor axon degeneration in chronically LPS-treated SOD1 mice accelerates disease progression	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180986	14960605	241631	10676	6121	IRF6	LPS	LPS	12	0.3	Survival curves of transgenic mice expressing SOD1 challenged systemically with LPS or vehicle every 2 weeks	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180987	14960605	241632	10676	6121	IRF6	LPS	LPS-treated	4	0.3	Disease progression of chronically LPS-treated mice is exacerbated by ~3 weeks	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180988	14960605	241633	10676	6121	IRF6	LPS	LPS	15	0.3	of wild-type mice is unaffected by the same dose of LPS (see see Materials and Methods	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180989	14960605	241635	10676	6121	IRF6	LPS	LPS	17	0.3	from normal mice treated chronically with vehicle (WT-Veh) WT-Veh or LPS (WT-LPS) WT-LPS and from SOD1 mice challenged chronically with vehicle	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180991	14960605	241635	10676	6121	IRF6	LPS	LPS	29	0.3	from SOD1 mice challenged chronically with vehicle (G37R-Veh) G37R-Veh or LPS (G37R-LPS) G37R-LPS	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
180992	14960605	241641	10676	6121	IRF6	LPS	LPS-treated	9	0.3	Robust inflammatory response in ventral spinal horn of chronically LPS-treated SOD1 mice associated with massive degeneration of astrocytes	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181000	14960605	241651	10676	6121	IRF6	LPS	LPS	25	0.3	wild-type littermates that received chronic systemic injections of the endotoxin LPS or sterile saline solution (Veh) Veh	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181001	14960605	241658	10676	6121	IRF6	LPS	LPS-treated	10	0.3	reported as mean values (_amp_#177;SEM) _amp_#177 SEM for vehicle- and LPS-treated animals of both mouse stains	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181002	14960605	241664	10676	6121	IRF6	LPS	LPS	5	0.3	Acute and chronic administration of LPS in SOD1 failed to alter expression of endogenous and transgene	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181007	14960605	241664	10676	6121	IRF6	LPS	LPS	34	0.3	analyzed for SOD1 levels 24 hr after acute injection of LPS (1 1 mg/kg mg kg of body weight	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181011	14960605	241665	10676	6121	IRF6	LPS	LPS	33	0.3	of SOD1 animals in response to saline (Veh) Veh or LPS injection as detected by means of an antibody recognizing both	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181016	14960605	241667	10676	6121	IRF6	LPS	LPS	15	0.3	were found in WT and SOD1 mice 48 hr after LPS or Veh administration (data data not shown	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181018	14960605	241668	10676	6121	IRF6	LPS	LPS	8	0.3	In SOD1 mice that were chronically treated with LPS expression of mutant SOD1 (detected detected with an antibody directed	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181021	14960605	241670	10676	6121	IRF6	LPS	LPS	7	0.3	Thus neither acute nor chronic administration of LPS in SOD1 mice affected expression of endogenous and transgene SOD1	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181024	14960605	241689	19573	10691	SDS	SDS	SDS	14	0.0	spinal cord were obtained by homogenization in SDS-urea beta-mercaptoethanol 0.5% SDS 8 M urea in phosphate buffer pH 7.4 with a	1		JUMiner_v2.2	1	0		0	2	19440	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:19440|SBDS|0.000304534248390088<>ScoreDetail__10691|SDS|0.000200734113328745__19440|SBDS|0.000304534248390088__	0	0	0	0		0
181028	14960605	241697	10676	6121	IRF6	LPS	LPS	28	0.3	both WT and SOD1 groups of mice challenged acutely with LPS ( Fig 1 D E	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181029	14960605	241698	10676	6121	IRF6	LPS	LPS-treated	9	0.3	The area postrema (AP) AP and spinal L5 segment of LPS-treated SOD1 mice did not exhibit a different hybridization signal when	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181032	14960605	241700	10676	6121	IRF6	LPS	LPS	4	0.3	Chronic systemic injections of LPS exacerbate disease progression and motor axon degeneration in SOD1 mice	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181034	14960605	241701	10676	6121	IRF6	LPS	LPS	10	0.3	Remarkably a chronic systemic injection of an equal dose of LPS in presymptomatic 6-month-old SOD1 mice had a significant effect on	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181037	14960605	241702	10676	6121	IRF6	LPS	LPS	17	0.3	SOD1 mice (line line 29 treated chronically with Veh or LPS	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181041	14960605	241705	10676	6121	IRF6	LPS	LPS	5	0.3	SOD1 mice treated chronically with LPS ( n = 13 exhibited an average life span of	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181042	14960605	241706	10676	6121	IRF6	LPS	LPS	12	0.3	demonstrate that repeated intraperitoneal injections of a nontoxic dose of LPS in presymptomatic 6-month-old SOD1 mice exacerbated disease progression by 3	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181045	14960605	241707	10676	6121	IRF6	LPS	LPS	39	0.3	in L5 ventral roots of SOD1 mice treated chronically with LPS or vehicle and killed at 10 months of age	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181046	14960605	241708	10676	6121	IRF6	LPS	LPS-treated	8	0.3	At this age the L5 ventral roots of LPS-treated SOD1 mice were smaller when compared with those dissected from	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181048	14960605	241709	10676	6121	IRF6	LPS	LPS-treated	1	0.3	Furthermore LPS-treated SOD1 mice ( n = 5 had 358 _amp_#177 48	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181052	14960605	241712	10676	6121	IRF6	LPS	LPS	8	0.3	It is noteworthy that the chronic injection of LPS in WT mice did not cause neurodegeneration (1033 1033 _amp_#177	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181056	14960605	241714	10676	6121	IRF6	LPS	LPS	26	0.3	proapoptotic cytokine TNF-alpha in the SOD1 mice challenged chronically with LPS	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181060	14960605	241719	10676	6121	IRF6	LPS	LPS-treated	10	0.3	The innate immune response was much more pronounced in chronically LPS-treated SOD1 mice than in Veh-treated SOD1 mice (Figs Figs 3	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181065	14960605	241724	10676	6121	IRF6	LPS	LPS-treated	16	0.3	FJB-positive astrocytes were found in the spinal cord of chronically LPS-treated mutant SOD1 mice ( Fig 4 B	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181067	14960605	241725	20996	11179	SOD1	ALS	ALS	19	1.7	first pathological changes observed in patients and rodent models with ALS (Rothstein Rothstein et al. 1995 Bristol and Rothstein 1996 Bruijn	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
181068	14960605	241726	10676	6121	IRF6	LPS	LPS-treated	8	0.3	Absence of adaptive immunity in the CNS of LPS-treated SOD1 mice	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181071	14960605	241728	10676	6121	IRF6	LPS	LPS-treated	21	0.3	upregulation of IL-12 in degenerating CNS regions of the chronically LPS-treated SOD1 mice when compared with chronically Veh-treated SOD1 mice	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181077	14960605	241730	10676	6121	IRF6	LPS	LPS-treated	25	0.3	infiltrating T cells in the CNS of both vehicle- and LPS-treated SOD1 mice (data data not shown	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181080	14960605	241732	10676	6121	IRF6	LPS	LPS-treated	4	0.3	Accelerated neurodegeneration in chronically LPS-treated SOD1 mice is not attributable to an upregulation in levels	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181082	14960605	241733	10676	6121	IRF6	LPS	LPS	4	0.3	Emerging evidence indicates that LPS can induce SOD1 which subsequently might play an important role	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181084	14960605	241734	10676	6121	IRF6	LPS	LPS-treated	11	0.3	to the understanding of mechanisms causing accelerated neurodegeneration in chronically LPS-treated SOD1 mice is whether LPS upregulates expression of the transgene	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181086	14960605	241734	10676	6121	IRF6	LPS	LPS	16	0.3	causing accelerated neurodegeneration in chronically LPS-treated SOD1 mice is whether LPS upregulates expression of the transgene SOD1	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181094	14960605	241736	10676	6121	IRF6	LPS	LPS	30	0.3	SOD1 mice in response to acute or chronic injection of LPS	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181097	14960605	241737	10676	6121	IRF6	LPS	LPS	23	0.3	and spleen were unchanged 24 hr after acute injection of LPS when compared with animals treated with vehicle solution (Veh) Veh	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181099	14960605	241739	10676	6121	IRF6	LPS	LPS	7	0.3	In addition SOD1 mice chronically challenged with LPS did not display increased levels of both enzymes	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181100	14960605	241740	10676	6121	IRF6	LPS	LPS	9	0.3	These results clearly indicate that toxicity caused by chronic LPS treatment is not caused by enhanced SOD1 expression	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
181102	14960605	241742	20996	11179	SOD1	ALS	ALS	18	1.7	Health Research (CIHR) CIHR and the Robert Packard Center for ALS Research at Johns Hopkins	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00127141958380738<>ScoreDetail__5468|IGFALS|0.000363923721587955__11179|SOD1|0.00127141958380738__	0	0	0	0		0
176355	15081582	235151	20996	11179	SOD1	ALS	ALS	25	1.4	in these types of disease including amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176357	15081582	235153	20996	11179	SOD1	ALS	ALS	23	1.4	potential target sites for treatments to halt the progression of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176361	15081582	235158	20996	11179	SOD1	ALS	ALS	16	1.4	duality may affect future treatments for neurodegenerative diseases such as ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176362	15081582	235161	20996	11179	SOD1	ALS	ALS	8	1.4	In neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), ALS neuroinflammation is a key event although the cause and significance	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176363	15081582	235168	20996	11179	SOD1	ALS	ALS	18	1.4	leukocytes marginating along postcapillary venules around areas of neuroinflammation in ALS ( Engelhardt et al. 1989 and Engelhardt et al. 1993	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176365	15081582	235176	20996	11179	SOD1	ALS	ALS	13	1.4	represent potential sites for treatments to curb the progression of ALS ( McGeer and McGeer 2002	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176368	15081582	235178	20996	11179	SOD1	ALS	ALS	31	1.4	its impact upon the design of future treatment strategies for ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176380	15081582	235189	10676	6121	IRF6	LPS	LPS	19	0.3	cytokines interleukin (IL)-1_amp_#x3b2; IL -1_amp_#x3b2 tumor necrosis factor-TNF lipopolysaccharide (LPS), LPS phorbol ester and elevated intracellular calcium concentration	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176396	15081582	235198	16459	8893	PGF	PGF	PGF	19	0.3	prostaglandin D 2 (PGD PGD 2 prostaglandin F 2 (PGF PGF 2 prostaglandin (PGI PGI 2 also known as prostacyclin and	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
176397	15081582	235198	16457	8891	PGD	PGD	PGD	13	0.0	prostaglandin E 2 (PGE PGE 2 prostaglandin D 2 (PGD PGD 2 prostaglandin F 2 (PGF PGF 2 prostaglandin (PGI PGI	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176398	15081582	235198	1647	1044	BGN	PGI	PGI	23	0.0	PGD 2 prostaglandin F 2 (PGF PGF 2 prostaglandin (PGI PGI 2 also known as prostacyclin and thromboxane A 2 (	1		JUMiner_v2.2	1	0		0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.00055137110031907<>ScoreDetail__1044|BGN|0.00055137110031907__4458|GPI|0.000443515174554901__	0	0	0	0		0
176400	15081582	235200	20996	11179	SOD1	ALS	ALS	20	1.4	free radical superoxide which may cause damage to cells in ALS and other neurodegenerative diseases ( Kaufmann et al. 1996	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176407	15081582	235205	20996	11179	SOD1	ALS	ALS	8	1.4	Analysis of the expression of COX isoforms in ALS models is expected to not only determine the role of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176408	15081582	235205	20996	11179	SOD1	ALS	ALS	33	1.4	disease but also provide clues toward understanding the pathology of ALS itself	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176410	15081582	235206	20996	11179	SOD1	ALS	ALS	26	1.4	understand the pathogenic and protective implications of COX activity in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176449	15081582	235244	10676	6121	IRF6	LPS	LPS	6	0.3	Astrocytic COX-2 is also induced by LPS TNF basic fibroblast growth factor (bFGF), bFGF and phorbol ester	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176455	15081582	235248	8254	4235	GFAP	GFAP	GFAP-positive	20	0.0	a COX-2 riboprobe revealed signal in a small proportion of GFAP-positive astrocytes ( Chang et al. 1996	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
176457	15081582	235249	8254	4235	GFAP	GFAP	GFAP	5	0.0	In addition COX-2 colocalizes with GFAP in infarcted human brains ( Sairanen et al. 1998	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
176466	15081582	235259	10676	6121	IRF6	LPS	LPS	18	0.3	to release PGE 2 and PGD 2 in response to LPS stimulation ( Gebicke-Haerter et al. 1989	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176467	15081582	235259	16457	8891	PGD	PGD	PGD	13	0.0	in culture acquire the capacity to release PGE 2 and PGD 2 in response to LPS stimulation ( Gebicke-Haerter et al.	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176468	15081582	235260	10676	6121	IRF6	LPS	LPS	6	0.3	In cultures of neonatal rat microglia LPS induces equivalent levels of PGD 2 and TXA 2 over	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176469	15081582	235260	16457	8891	PGD	PGD	PGD	11	0.0	cultures of neonatal rat microglia LPS induces equivalent levels of PGD 2 and TXA 2 over the initial 8 h	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176474	15081582	235266	10676	6121	IRF6	LPS	LPS	5	0.3	In cultured rat brain microglia LPS induces COX-2 expression that is prevented in the presence of	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176477	15081582	235267	10676	6121	IRF6	LPS	LPS-stimulated	5	0.3	Thus NF-_amp_#x3ba B is involved in LPS-stimulated microglial COX-2 expression ( Bauer et al. 1997	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176483	15081582	235276	1647	1044	BGN	PGI	PGI	16	0.0	by thromboxane A 2 (TXA TXA 2 but inhibited by PGI 2 ( Wu and Thiagarajan 1996	1		JUMiner_v2.2	1	0		0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.00055137110031907<>ScoreDetail__1044|BGN|0.00055137110031907__4458|GPI|0.000443515174554901__	0	0	0	0		0
176484	15081582	235278	16457	8891	PGD	PGD	PGD	0	0.0	PGD 2 produces sleep but wakefulness is promoted by PGE 2	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176487	15081582	235280	16457	8891	PGD	PGD	PGD	14	0.0	COX-2 increases again but this time with increased levels of PGD 2 and PGJ 2 and decreased inflammation	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176490	15081582	235288	16440	8884	PGA	PGA	PGA	2	0.6	For example PGA 1 that is derived from PGE 2 blunts NMDA receptor	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
176491	15081582	235288	7708	3811	FOXG1	QIN	Qin	32	0.0	heat shock proteins and inhibition of NF-_amp_#x3ba B activity ( Qin et al. 2001	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
176495	15081582	235291	1647	1044	BGN	PGI	PGI	2	0.0	Analogs of PGI 2 also are neuroprotective ( Watanabe et al. 1999	1		JUMiner_v2.2	1	0		0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.00055137110031907<>ScoreDetail__1044|BGN|0.00055137110031907__4458|GPI|0.000443515174554901__	0	0	0	0		0
176496	15081582	235294	20996	11179	SOD1	ALS	ALS	9	1.4	In both in vitro and in vivo models of ALS strong evidence is obtained for prostaglandins mediating apoptosis	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176503	15081582	235303	16457	8891	PGD	PGD	PGD	15	0.0	PGJ 2 a natural peroxisome proliferator-activated receptor-gamma ligand formed from PGD 2 induces apoptosis in both human astrocytes ( Chattopadhyay et	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176504	15081582	235304	16457	8891	PGD	PGD	PGD	2	0.0	Exposure to PGD 2 synthase induces apoptosis in PC12 neuronal cells via caspase-3	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176505	15081582	235305	16457	8891	PGD	PGD	PGD	16	0.0	with anti-PGD 2 synthase antibody or selenium that both inhibit PGD 2 synthase activity	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176506	15081582	235307	16459	8893	PGF	PGF	PGF	9	0.3	In addition PGE 1 PGE 2 and PGF 2 all inhibit PGD 2 synthase-induced apoptosis while PGH 2	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
176507	15081582	235307	16457	8891	PGD	PGD	PGD	13	0.0	addition PGE 1 PGE 2 and PGF 2 all inhibit PGD 2 synthase-induced apoptosis while PGH 2 has no effect (	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
176509	15081582	235316	16459	8893	PGF	PGF	PGF	4	0.3	Both PGE 2 and PGF 2 at micromolar concentrations prevent NMDA-induced death in cultured cortical	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
176511	15081582	235318	16459	8893	PGF	PGF	PGF	19	0.3	PGE 2 abrogates APHS neuroprotection but coapplication of APHS with PGF 2 maintains the APHS neuroprotective effect ( Carlson 2003	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
176516	15081582	235324	16440	8884	PGA	PGA	PGA	1	0.6	Prostaglandins PGA 1 PGA 2 and PGJ 2 all can suppress NF-_amp_#x3ba	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
176517	15081582	235324	16440	8884	PGA	PGA	PGA	4	0.6	Prostaglandins PGA 1 PGA 2 and PGJ 2 all can suppress NF-_amp_#x3ba B activation	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
176524	15081582	235337	20996	11179	SOD1	ALS	ALS	0	1.4	ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176525	15081582	235338	20996	11179	SOD1	ALS	ALS	0	1.4	ALS is the most common motor neuron disease in adults	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176526	15081582	235344	20996	11179	SOD1	ALS	ALS	5	1.4	The pathogenic mechanisms underlying idiopathic ALS remain unknown	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176527	15081582	235345	20996	11179	SOD1	ALS	ALS	1	1.4	Although ALS is described as a motor neuron disease it is likely	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176528	15081582	235347	20996	11179	SOD1	ALS	ALS	10	1.4	The familial disorder is clinically and pathologically indistinguishable from sporadic ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176533	15081582	235351	20996	11179	SOD1	ALS	ALS	9	1.4	However SOD1 mutations account for only 20% of familial ALS ( Feldman 1999	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176535	15081582	235352	20996	11179	SOD1	ALS	ALS	10	1.4	Because mutant SOD1 explains only a very small subset of ALS pathology it is very likely that ALS is a disorder	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176536	15081582	235352	20996	11179	SOD1	ALS	ALS	17	1.4	small subset of ALS pathology it is very likely that ALS is a disorder with heterogeneous causes	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176537	15081582	235354	20996	11179	SOD1	ALS	ALS	9	1.4	Common theories to explain the pathogenic mechanism of idiopathic ALS include (1) 1 excitotoxic damage secondary to excessive glutamate (2)	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176538	15081582	235356	20996	11179	SOD1	ALS	ALS	7	1.4	Although the root cause or causes of ALS remain unclear there is new interest in the role of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176539	15081582	235357	20996	11179	SOD1	ALS	ALS	0	1.4	ALS spinal cord tissue is characterized by neuroinflammatory changes consistent with	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176540	15081582	235359	20996	11179	SOD1	ALS	ALS	18	1.4	major relevance to developing new clinical therapies for treatment of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176542	15081582	235360	20996	11179	SOD1	ALS	ALS	3	1.4	COX prostaglandins and ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176544	15081582	235361	20996	11179	SOD1	ALS	ALS	9	1.4	COX-2 activity appears to play an important role in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176546	15081582	235362	20996	11179	SOD1	ALS	ALS	9	1.4	In many different models COX-2 upregulation occurs concurrently with ALS disease events	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176548	15081582	235363	20996	11179	SOD1	ALS	ALS	18	1.4	of sevenfold in postmortem spinal cords of patients with sporadic ALS ( Almer et al. 2001 and Yasojima et al. 2001	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176556	15081582	235366	20996	11179	SOD1	ALS	ALS	14	1.4	glutamate-induced motor neuron loss this prominent prostaglandin is implicated in ALS pathogenesis	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176560	15081582	235369	20996	11179	SOD1	ALS	ALS	16	1.4	protects motor neurons in an organotypic cell culture model of ALS ( Drachman and Rothstein 2000	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176569	15081582	235375	20996	11179	SOD1	ALS	ALS	17	1.4	inhibitor also prolongs survival in the mSOD1 mouse model of ALS ( Drachman et al. 2002	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176575	15081582	235380	18723	10261	ROS1	ROS	ROS	3	0.0	Reactive oxygen species (ROS) ROS that are produced downstream of exposure to NMDA can cause	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
176577	15081582	235381	18723	10261	ROS1	ROS	ROS	2	0.0	Yet NMDA-induced ROS are produced from multiple sources and it is not known	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
176578	15081582	235381	18723	10261	ROS1	ROS	ROS	17	0.0	sources and it is not known whether the amount of ROS produced by the COX enzyme is sufficient to cause neuronal	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
176581	15081582	235384	20996	11179	SOD1	ALS	ALS	20	1.4	production plays a significant role in neurodegenerative disorders such as ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176582	15081582	235385	20996	11179	SOD1	ALS	ALS	1	1.4	In ALS however the link between the pathology of the disease and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176584	15081582	235387	20996	11179	SOD1	ALS	ALS	7	1.4	Although treatment of neurodegenerative diseases such as ALS with COX-2 inhibitors is likely to produce some symptomatic benefit	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
176592	15081582	235396	20996	11179	SOD1	ALS	ALS	22	1.4	also stop the progressive loss of motor neurons in the ALS patient	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000767671373411518<>ScoreDetail__5468|IGFALS|0.00028997100289971__11179|SOD1|0.000767671373411518__	0	0	0	0		0
169750	15210305	227134	20996	11179	SOD1	ALS	ALS	6	4.1	Research efforts in amyotrophic lateral sclerosis (ALS) ALS have not yet provided a comprehensive explanation of the disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169751	15210305	227136	20996	11179	SOD1	ALS	ALS	14	4.1	significantly improved our understanding of the molecular changes occurring in ALS although its limitations in the detection of low-abundance transcripts in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169752	15210305	227137	20996	11179	SOD1	ALS	ALS	16	4.1	on an expression study in post-mortem spinal cord from sporadic ALS individuals will be discussed in light of recently published data	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169753	15210305	227139	20996	11179	SOD1	ALS	ALS	8	4.1	Through the analysis of the information arising from ALS post-mortem and animal model tissues studies we have identified a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169754	15210305	227141	20996	11179	SOD1	ALS	ALS	4	4.1	Introduction molecular studies on ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169755	15210305	227142	20996	11179	SOD1	ALS	ALS	19	4.1	shed light on the pathogenesis of amyotrophic lateral sclerosis (ALS) ALS which include the significant findings that have arisen in the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169756	15210305	227143	20996	11179	SOD1	ALS	ALS	0	4.1	ALS can be inherited as an autosomal dominant trait in a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169757	15210305	227144	20996	11179	SOD1	ALS	ALS	1	4.1	Familial ALS (FALS) FALS is a heterogeneous entity	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169758	15210305	227146	20996	11179	SOD1	ALS	ALS	2	4.1	The first ALS locus (ALS1) ALS1 to be identified on chromosome 21 contains	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169761	15210305	227147	20996	11179	SOD1	ALS	ALS	15	4.1	been identified for the classical form of adult-onset autosomal dominant ALS but two new loci have been reported the first of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169763	15210305	227150	20996	11179	SOD1	ALS	ALS	28	4.1	been found in a juvenile onset rare recessive form of ALS characterized by a predominant spastic paraparesis 33 and 112	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169765	15210305	227152	20996	11179	SOD1	ALS	ALS	15	4.1	gene (VEGF) VEGF as a risk/causitive risk causitive factor in ALS has been recently evaluated through extensive genotyping in patients and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169766	15210305	227152	20996	11179	SOD1	ALS	ALS	37	4.1	populations and using expression analysis in an animal model of ALS and post-mortem tissue from affected individuals 31 50 and 74	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169769	15210305	227154	20996	11179	SOD1	ALS	ALS	10	4.1	VEGF coding region analysis has failed to identify mutations in ALS patients but further genotyping of Swedish Belgian and English patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169771	15210305	227154	20996	11179	SOD1	ALS	ALS	41	4.1	which is associated with a 1.8 times greater risk of ALS and with lowered circulating VEGF levels in vivo 31 and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169773	15210305	227155	20996	11179	SOD1	ALS	ALS	13	4.1	have emerged from the analysis of potential risk factors in ALS such as the neurofilament heavy subunit 25 the apolipoprotein E	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169774	15210305	227155	20478	11117	SMN1	SMN	SMN	35	0.6	apolipoprotein E allele 4 71 the gene-survival motor neuron (SMN) SMN and neuronal apoptosis inhibitory protein (NAIP) NAIP 79	1		JUMiner_v2.2	1	2	UserEdit	0	2	6510	TotalCon:3<>6510|STMN1|3925|Complete__11117|SMN1|6606|Complete__11164|SNRPN|6638|Complete__<>AvaiableGeneRif=3<>BEST:6510|STMN1|0.00124258466838137<>ScoreDetail__11117|SMN1|0.000835550050902403__11164|SNRPN|0.000636246962125556__6510|STMN1|0.00124258466838137__	1	1	0	0		0
169780	15210305	227158	20996	11179	SOD1	ALS	ALS	17	4.1	by the disease has represented an alternative research strategy in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169781	15210305	227159	20996	11179	SOD1	ALS	ALS	26	4.1	proteins and enzyme activity in spinal cord and cortex from ALS individuals	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169782	15210305	227163	20996	11179	SOD1	ALS	ALS	18	4.1	the main findings obtained through traditional gene expression studies in ALS affected tissues and describe the results of large-scale gene expression	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169783	15210305	227163	20996	11179	SOD1	ALS	ALS	42	4.1	spinal cord from individuals affected by the sporadic form of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169784	15210305	227166	20996	11179	SOD1	ALS	ALS	12	4.1	is to extrapolate significant information about molecular pathways involved in ALS pathogenesis and their importance in different phases of disease progression	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169785	15210305	227182	19327	30369	SAGE1	SAGE	SAGE	12	1.0	hybridization (SH) SH and serial analysis of gene expression (SAGE) SAGE allow the comparison of a large number of mRNAs at	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
169786	15210305	227192	19327	30369	SAGE1	SAGE	SAGE	17	1.0	rat hippocampus comparing the results to baseline data obtained from SAGE expression analysis on the same tissue estimates that Affymetrix arrays	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
169787	15210305	227198	20233	10986	SLC25A16	GDA	GDA	9	0.6	A traditional membrane-based array technology the Gene Discovery Array (GDA) GDA filter is the array format utilized in a study of	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>4212|GDA|9615|Complete__10986|SLC25A16|8034|No_GeneRif__<>AvaiableGeneRif=1<>	1	1	0	0		0
169788	15210305	227198	20996	11179	SOD1	ALS	ALS	23	4.1	array format utilized in a study of gene expression in ALS spinal cord study discussed in this paper 60	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169789	15210305	227200	20233	10986	SLC25A16	GDA	GDA	1	0.6	The GDA filter is a low-cost alternative to the recently developed microarrays	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>4212|GDA|9615|Complete__10986|SLC25A16|8034|No_GeneRif__<>AvaiableGeneRif=1<>	1	1	0	0		0
169790	15210305	227202	20996	11179	SOD1	ALS	ALS	25	4.1	expression studies undertaken in spinal cord tissue from individuals with ALS compared to normal controls	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169791	15210305	227204	20996	11179	SOD1	ALS	ALS	3	4.1	Transcriptional analysis in ALS spinal cord single mRNA studies and gene array screening	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169792	15210305	227205	20996	11179	SOD1	ALS	ALS	4	4.1	Gene expression studies in ALS have targeted tissues known to be functionally involved and those	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169793	15210305	227206	20996	11179	SOD1	ALS	ALS	1	4.1	Both ALS post-mortem tissue and tissues taken from animal models (G93 G93	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169795	15210305	227206	20996	11179	SOD1	ALS	ALS	15	4.1	taken from animal models (G93 G93 SOD1 transgenic mouse of ALS have been investigated	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169796	15210305	227209	20996	11179	SOD1	ALS	ALS	18	4.1	under five main headings which cover pathogenic mechanisms implicated in ALS pathogenesis	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169797	15210305	227212	20996	11179	SOD1	ALS	ALS	39	4.1	analysis of spinal cord tissues from both sporadic and familial ALS individuals and from healthy controls	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169799	15210305	227215	20996	11179	SOD1	ALS	ALS	17	4.1	oxidative stress has gained momentum as a major factor in ALS pathogenesis 90	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169803	15210305	227222	20996	11179	SOD1	ALS	ALS	1	4.1	In ALS prolonged synaptic activation by glutamate could trigger neuronal cell damage	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169805	15210305	227224	20996	11179	SOD1	ALS	ALS	4	4.1	The array-based analysis of ALS spinal cord using a GDA filter format has also confirmed	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169806	15210305	227224	20233	10986	SLC25A16	GDA	GDA	9	0.6	The array-based analysis of ALS spinal cord using a GDA filter format has also confirmed a pattern of marked differential	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>4212|GDA|9615|Complete__10986|SLC25A16|8034|No_GeneRif__<>AvaiableGeneRif=1<>	1	1	0	0		0
169809	15210305	227226	20996	11179	SOD1	ALS	ALS	16	4.1	powerful antioxidant function counteracting the copper-catalysed oxidation of proteins in ALS tissue	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169811	15210305	227230	20996	11179	SOD1	ALS	ALS	9	4.1	Flavin-containing monooxygenase (FMO) FMO found to be significantly down-regulated in ALS spinal cord exerts a powerful intrinsic protective action against oxidative	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169812	15210305	227231	20996	11179	SOD1	ALS	ALS	23	4.1	to be markedly up-regulated in spinal cord from individuals with ALS 59	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169813	15210305	227234	22710	12017	TPR	TPR	TPR	8	0.6	A transcript identical to the ubiquitous tetratricopeptide repeat (TPR) TPR motif (Y Y isoform showed the highest level of differential	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
169814	15210305	227234	20233	10986	SLC25A16	GDA	GDA	22	0.6	showed the highest level of differential gene expression in the GDA array study	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>4212|GDA|9615|Complete__10986|SLC25A16|8034|No_GeneRif__<>AvaiableGeneRif=1<>	1	1	0	0		0
169815	15210305	227235	22710	12017	TPR	TPR	TPR	1	0.6	The TPR motif facilitates protein_amp_#x2013 protein interaction and the assembly of multiprotein	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
169816	15210305	227236	22710	12017	TPR	TPR	TPR-containing	0	1.1	TPR-containing mRNAs share common structural and functional properties with 14-3-3 proteins	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
169817	15210305	227237	22710	12017	TPR	TPR	TPR	0	0.6	TPR motifs are also involved in processes such as transcription control	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
169818	15210305	227239	20996	11179	SOD1	ALS	ALS	10	4.1	Altered patterns of NF phosphorylation have also been documented in ALS 47 and 104	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169820	15210305	227241	20996	11179	SOD1	ALS	ALS	7	4.1	Indirect evidence of nitration of neurofilaments in ALS spinal cord is indicated by elevated levels of 3-nitrotyrosine and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169822	15210305	227243	20996	11179	SOD1	ALS	ALS	23	4.1	the degeneration of the motor neurones in spinal cord from ALS individuals	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169823	15210305	227245	20996	11179	SOD1	ALS	ALS-related	0	2.9	ALS-related differential expression has been identified in tissues other than those	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169824	15210305	227247	20996	11179	SOD1	ALS	ALS	31	4.1	procollagen (PIIIP) PIIIP in serum and skin of patients with ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169825	15210305	227248	20996	11179	SOD1	ALS	ALS	7	4.1	The PIIIP immunoreactivity in these tissues from ALS individuals was significantly higher than in controls and was markedly	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169827	15210305	227249	20996	11179	SOD1	ALS	ALS	16	4.1	of collagen taking place in the skin and serum of ALS patients and the neurodegenerative changes targeting the motor neurones population	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169829	15210305	227250	20996	11179	SOD1	ALS	ALS	16	4.1	serum but not in homogenates of spinal cord from sporadic ALS patients indicates that hypoxia may play a part during the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169831	15210305	227256	20996	11179	SOD1	ALS	ALS	14	4.1	in human neuroblastoma cell lines by anti-Fas antibody-containing sera from ALS patients whereas this was less convincingly obtained using sera from	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169832	15210305	227257	20996	11179	SOD1	ALS	ALS	10	4.1	Other authors have failed to demonstrate evidence of apoptosis in ALS 36	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169833	15210305	227258	20996	11179	SOD1	ALS	ALS	38	4.1	in dorsal and ventral horns of autopsied spinal cord from ALS cases 108	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169839	15210305	227260	20996	11179	SOD1	ALS	ALS	13	4.1	SAPK-c-Jun pathway was found to be markedly up-regulated 67 in ALS spinal cord astrocytes together with NF-kappa B whereas motor neurones	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169840	15210305	227261	20996	11179	SOD1	ALS	ALS	14	4.1	idea that astrocytes are key players in the pathogenesis of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169841	15210305	227262	20996	11179	SOD1	ALS	ALS	22	4.1	to be differentially regulated using large-scale gene expression studies in ALS spinal cord	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169842	15210305	227265	20996	11179	SOD1	ALS	ALS	12	4.1	selective pro-apoptotic activity targeting the glial and neuronal cells in ALS spinal cord may be suggested in light of these expression	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169848	15210305	227271	20996	11179	SOD1	ALS	ALS	8	4.1	The importance of this anti-apoptotic agent over-expressed in ALS spinal cord and down-regulated in a hereditary form of epilepsy	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169850	15210305	227272	20996	11179	SOD1	ALS	ALS	35	4.1	segmental myoclonus in EPM1 and paralysis with muscle wasting in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169851	15210305	227276	20996	11179	SOD1	ALS	ALS	4	4.1	Gene expression analysis in ALS spinal cord has revealed the differential regulation of transcripts contributing	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169852	15210305	227276	20996	11179	SOD1	ALS	ALS	40	4.1	silenced_amp_#x201d in spinal cord from post-mortem and animal model of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169855	15210305	227278	20996	11179	SOD1	ALS	ALS	13	4.1	down-regulated in the lateral corticospinal tracts of spinal cord from ALS patients compared to control particularly in those patients exhibiting a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169858	15210305	227279	20996	11179	SOD1	ALS	ALS	23	4.1	significant association between allelic variants of this gene and familial ALS (FALS) FALS 44	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169859	15210305	227280	20996	11179	SOD1	ALS	ALS	10	4.1	A marked increase in CNTFR-alpha mRNA expression was found in ALS spinal cord whereas the same transcript showed little or no	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169860	15210305	227280	20996	11179	SOD1	ALS	ALS	23	4.1	whereas the same transcript showed little or no expression in ALS motor cortex with no differences seen between ALS and control	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169861	15210305	227280	20996	11179	SOD1	ALS	ALS	31	4.1	expression in ALS motor cortex with no differences seen between ALS and control tissues 22	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169863	15210305	227281	20996	11179	SOD1	ALS	ALS	16	4.1	been investigated in anterior horn cells of spinal cord from ALS patients using reverse transcription polymerase chain reaction (RT-PCR) RT-PCR and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169865	15210305	227282	20996	11179	SOD1	ALS	ALS	35	4.1	spinal cord but it became detectable in motor neurones of ALS patients with a further up-regulation during disease progression 70	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169866	15210305	227283	20996	11179	SOD1	ALS	ALS	9	4.1	The same pattern of up-regulation in motor neurones from ALS spinal cord applies to growth-associated protein 43 (GAP43), GAP43 a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169868	15210305	227284	20996	11179	SOD1	ALS	ALS	39	4.1	androgens and steroids were seen in post-mortem spinal cord from ALS individuals and from animal models of the disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169870	15210305	227285	20996	11179	SOD1	ALS	ALS	32	4.1	in which a clinical picture of motor neurone degeneration resembling ALS and clinical signs of androgen partial insensitivity (gynecomastia) gynecomastia coexist	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169871	15210305	227287	20996	11179	SOD1	ALS	ALS	11	4.1	was found to be over-expressed in spinal cord tissues from ALS individuals	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169873	15210305	227290	20996	11179	SOD1	ALS	ALS	18	4.1	rat H-REV107-like protein was found to be significantly up-regulated in ALS spinal cord	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169876	15210305	227292	20996	11179	SOD1	ALS	ALS	9	4.1	Cellular retinol-binding protein1 (CRBP1) CRBP1 showed a marked up-regulation in ALS spinal cord 60	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169878	15210305	227297	18723	10261	ROS1	ROS	ROS	8	0.3	Retinoid acid (RA) RA reduces neuronal reactive oxygen species (ROS) ROS content and enhances SOD1 protein levels during staurosporine-induced apoptosis in	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
169882	15210305	227300	20996	11179	SOD1	ALS	ALS	7	4.1	The marked up-regulation of the CRBP1 in ALS spinal cord and of the retinoid receptor subunit in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169883	15210305	227300	20996	11179	SOD1	ALS	ALS	17	4.1	ALS spinal cord and of the retinoid receptor subunit in ALS transgenic mice may be a response to a _amp_#x201c loss	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169884	15210305	227302	20996	11179	SOD1	ALS	ALS	13	4.1	an involvement of these molecular pathways in the pathogenesis of ALS may find some support in the study by Yoshihara et	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169886	15210305	227304	20996	11179	SOD1	ALS	ALS	8	4.1	In addition the over-expression of hormone-sensitive transcripts in ALS spinal cord such as granulin may be related to the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169887	15210305	227306	20996	11179	SOD1	ALS	ALS	34	4.1	us to reveal further important clues in the pathogenesis of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169888	15210305	227309	20996	11179	SOD1	ALS	ALS	9	4.1	The role of tissue inflammation in the development of ALS pathology has been widely debated	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169889	15210305	227310	20996	11179	SOD1	ALS	ALS	12	4.1	of any consistent response to immunosuppressive and immuno-modulatory treatments in ALS is not consistent with autoimmunity playing a major role in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169890	15210305	227311	20996	11179	SOD1	ALS	ALS	21	4.1	of glutamate-mediated excitotoxicity may trigger a tissue inflammatory response in ALS 12	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169893	15210305	227315	18723	10261	ROS1	ROS	ROS	11	0.3	stimulates microglia to secrete cytokines and reactive oxygen species (ROS), ROS which can induce neuronal damage	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
169894	15210305	227316	20996	11179	SOD1	ALS	ALS	13	4.1	T cells adhering to postcapillary venules are frequently observed in ALS and in mouse models of the disease 63	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169895	15210305	227317	20996	11179	SOD1	ALS	ALS	18	4.1	over-expression of transcripts associated with immune and inflammatory response within ALS spinal cord and in the activation of the complement system	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169898	15210305	227318	20996	11179	SOD1	ALS	ALS	19	4.1	have been found to be markedly up-regulated in areas of ALS spinal cord undergoing degeneration 30 and 80 whereas a study	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169899	15210305	227318	20996	11179	SOD1	ALS	ALS	43	4.1	kinase-5 (cdk-5) cdk-5 regional expression identified a significant up-regulation in ALS affected motor neurones 6	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169902	15210305	227319	20996	11179	SOD1	ALS	ALS	16	4.1	of microglia activation have been reported to be up-regulated in ALS spinal cord tissue 113	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169904	15210305	227320	20996	11179	SOD1	ALS	ALS	6	4.1	The significant up-regulation of COX-2 in ALS spinal cord compared to control tissues including patients affected by	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169905	15210305	227320	20996	11179	SOD1	ALS	ALS	42	4.1	observation of a central role of an inflammatory response in ALS pathogenesis 113	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169908	15210305	227322	20233	10986	SLC25A16	GDA	GDA	1	0.6	The GDA array study has further contributed to the identification of differentially	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>4212|GDA|9615|Complete__10986|SLC25A16|8034|No_GeneRif__<>AvaiableGeneRif=1<>	1	1	0	0		0
169910	15210305	227323	20996	11179	SOD1	ALS	ALS	10	4.1	I receptor accessory protein (IL-1RAcP) IL-1RAcP mRNA markedly over-expressed in ALS spinal cord is a trans-membrane protein belonging to a receptor	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169914	15210305	227326	20996	11179	SOD1	ALS	ALS	30	4.1	reaction causing dendritic/axonal dendritic axonal and somatic degeneration closely resembling ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169916	15210305	227327	20233	10986	SLC25A16	GDA	GDA	11	0.6	inducible cytokine (RANTES) RANTES mRNA was also found in the GDA study to be up-regulated in ALS spinal cord	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>4212|GDA|9615|Complete__10986|SLC25A16|8034|No_GeneRif__<>AvaiableGeneRif=1<>	1	1	0	0		0
169917	15210305	227327	20996	11179	SOD1	ALS	ALS	17	4.1	also found in the GDA study to be up-regulated in ALS spinal cord	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169920	15210305	227332	20996	11179	SOD1	ALS	ALS	3	4.1	Studies on post-mortem ALS spinal cord have hinted at a potential role for lipid	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169921	15210305	227332	20996	11179	SOD1	ALS	ALS	21	4.1	role for lipid and oxysterols metabolism in the pathogenesis of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169922	15210305	227333	20996	11179	SOD1	ALS	ALS	12	4.1	up-regulation of cholesterol 25 hydroxylase has been identified in post-mortem ALS spinal cord 60	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169923	15210305	227336	20996	11179	SOD1	ALS	ALS	13	4.1	an abnormal metabolism of cholesterol as a disease-causing factor in ALS has been strengthened further by the report of abnormalities in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169924	15210305	227336	20996	11179	SOD1	ALS	ALS	33	4.1	in sphingolipid and cholesterol metabolism in the spinal cords of ALS patients and animal models of the disease based on the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169930	15210305	227344	78	61	ABCD1	adrenoleukodystrophy	adrenoleukodystrophy	4	1.0	A form of X-linked adrenoleukodystrophy (X-ALD) X-ALD which involves the spinal cord adrenomyeloneuropathy (AMN), AMN	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
169931	15210305	227344	78	61	ABCD1	AMN	AMN	12	1.0	adrenoleukodystrophy (X-ALD) X-ALD which involves the spinal cord adrenomyeloneuropathy (AMN), AMN is another neurodegenerative disease characterized by elevated levels of saturated	1		JUMiner_v2.2	1	2	UserEdit	0	2	61	TotalCon:2<>14604|AMN|81693|Complete__61|ABCD1|215|Complete__<>AvaiableGeneRif=2<>BEST:61|ABCD1|0.000689058035943246<>ScoreDetail__14604|AMN|0.000485149686427642__61|ABCD1|0.000689058035943246__	1	1	0	0		0
169932	15210305	227346	20996	11179	SOD1	ALS	ALS	9	4.1	Spinal cord expression profiles in an animal model of ALS compared to post-mortem findings what can we learn	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169933	15210305	227349	20996	11179	SOD1	ALS	ALS	1	4.1	In ALS the interpretation of the gene expression profile in post-mortem tissue	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169936	15210305	227353	20996	11179	SOD1	ALS	ALS	13	4.1	spinal cord from this transgenic construct is in line with ALS studies yielding a pattern of differential regulation of gene candidates	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169937	15210305	227360	18741	10289	RPA1	RPA	RPAs	38	0.0	apoptosis-related genes were investigated using multiprobe ribonuclease protection assays (RPAs) RPAs in the study by Hensley et al 37 whereas the	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
169938	15210305	227367	20996	11179	SOD1	ALS	ALS	24	4.1	life in spinal cord from the G93A animal model of ALS which undergoes a slight decline towards the 120th day (	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169949	15210305	227373	20996	11179	SOD1	ALS	ALS	37	4.1	be up-regulated in spinal cord of the animal model of ALS 109	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169950	15210305	227375	20996	11179	SOD1	ALS	ALS	5	4.1	In the animal model of ALS LO shows a steady increase at 3 and 4.5 months	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169952	15210305	227376	20996	11179	SOD1	ALS	ALS	8	4.1	The expression data from the animal model of ALS indicates that an inflammatory reaction persists throughout the disease enhanced	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169953	15210305	227379	20996	11179	SOD1	ALS	ALS	25	4.1	regulated in a post-mortem expression study of spinal cord from ALS cases in adult rat motor neurones following hypoglossal nerve injury	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169955	15210305	227380	20996	11179	SOD1	ALS	ALS	11	4.1	the other hand RNAse-I which is also significantly up-regulated in ALS is known to have an anti-proliferative effect and it may	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169958	15210305	227382	20996	11179	SOD1	ALS	ALS	8	4.1	Up-regulation of cystatin B and 14-3-3 proteins in ALS spinal cord may also be seen as an anti-apoptotic mechanism	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169959	15210305	227383	20996	11179	SOD1	ALS	ALS	19	4.1	protective function has been found to be markedly down-regulated in ALS spinal cord	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169963	15210305	227391	20996	11179	SOD1	ALS	ALS	18	4.1	studies gene expression analysis in human post-mortem spinal cord from ALS individuals shows that the majority of differentially regulated transcripts serve	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169965	15210305	227395	20996	11179	SOD1	ALS	ALS	19	4.1	differentially expressed in the expression studies in human tissue from ALS individuals	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169966	15210305	227397	20996	11179	SOD1	ALS	ALS	12	4.1	a recent molecular indexing and cDNA microarray analysis study on ALS spinal cord have also been included which account for a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169967	15210305	227404	20996	11179	SOD1	ALS	ALS	6	4.1	In the G93A animal models of ALS clinical manifestations appear as early as 60_amp_#x2013 90 days of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169969	15210305	227408	20996	11179	SOD1	ALS	ALS	24	4.1	analysis in the spinal cord of the animal model of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169970	15210305	227414	1372	870	ATP7B	ATP7B	ATP7B	0	0.0	ATP7B regulates copper uptake in the trans-Golgi network which is channeled	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
169973	15210305	227417	20996	11179	SOD1	ALS	ALS	36	4.1	early involvement of impaired axonal transport in the development of ALS 111 and LDL-r which is involved in lipid metabolism	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169976	15210305	227421	20996	11179	SOD1	ALS	ALS	6	4.1	The quest for pathogenic clues in ALS makes it a priority to understand these events in the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169977	15210305	227424	20996	11179	SOD1	ALS	ALS	13	4.1	be also identified in more accessible tissue of the living ALS patients such as blood or skin providing a way of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169978	15210305	227429	20996	11179	SOD1	ALS	ALS	21	4.1	candidates functionally related to the gene families highlighted in the ALS expression studies reported above	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169979	15210305	227435	20996	11179	SOD1	ALS	ALS	9	4.1	This molecular picture clearly differs from the findings in ALS spinal cord where remarkable up-regulation of stress-related and cytoskeletal transcripts	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169987	15210305	227442	2163	1325	C4BPA	PrP	PrP	37	1.3	as lipopolysaccharide and IFN-gamma as well as prion protein (PrP) PrP amyloid 5	1		JUMiner_v2.2	1	2	UserEdit	0	2	9353	TotalCon:4<>9353|PRDX2|7001|Complete__9449|PRNP|5621|Complete__47|ABCB6|10058|Complete__1325|C4BPA|722|Complete__<>AvaiableGeneRif=4<>BEST:9353|PRDX2|0.000802889290179192<>ScoreDetail__1325|C4BPA|0.000456412596987677__47|ABCB6|0.000359424920127796__9353|PRDX2|0.000802889290179192__9449|PRNP|0.000643033151108111__	1	1	0	0		0
169989	15210305	227443	2163	1325	C4BPA	PrP	PrP	7	1.3	A microglia-activated phenotype is detectable even before PrP pathology is detectable in brain	1		JUMiner_v2.2	1	2	UserEdit	0	2	9353	TotalCon:4<>9353|PRDX2|7001|Complete__9449|PRNP|5621|Complete__47|ABCB6|10058|Complete__1325|C4BPA|722|Complete__<>AvaiableGeneRif=4<>BEST:9353|PRDX2|0.000802889290179192<>ScoreDetail__1325|C4BPA|0.000456412596987677__47|ABCB6|0.000359424920127796__9353|PRDX2|0.000802889290179192__9449|PRNP|0.000643033151108111__	1	1	0	0		0
169990	15210305	227450	20996	11179	SOD1	ALS	ALS	4	4.1	In contrast in the ALS studies various members of the retinoid pathways seem to be	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169992	15210305	227462	20996	11179	SOD1	ALS	ALS	15	4.1	studies in tissues undergoing degeneration in neurological conditions such as ALS is becoming increasingly evident with the development of molecular studies	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169993	15210305	227463	19327	30369	SAGE1	SAGE	SAGE	14	1.0	applied in a search for new PD molecular abnormalities using SAGE to identify potential candidate genes in substantia nigra (SN) SN	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
169995	15210305	227465	20996	11179	SOD1	ALS	ALS	43	4.1	and the ALS4 locus (9q34) 9q34 for early onset dominant ALS cases 10 in which RXR-alpha is located	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169997	15210305	227468	20996	11179	SOD1	ALS	ALS	4	4.1	As reported above for ALS the two experimental approaches can yield a similar picture with	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169998	15210305	227472	20996	11179	SOD1	ALS	ALS	3	4.1	A model of ALS pathogenesis from healthy motor neurones (MN) MN and glia through	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
169999	15210305	227472	20996	11179	SOD1	ALS	ALS	37	4.1	genes that have been detected in spinal cord tissue from ALS cases 59 and 60	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
170001	15210305	227480	18741	10289	RPA1	RPA	RPAs	38	0.0	apoptosis-related genes were investigated using multiprobe ribonuclease protection assays (RPAs) RPAs in the study by Hensley et al 39 whereas the	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
170002	15210305	227482	20996	11179	SOD1	ALS	ALS	10	4.1	Summary of functional categories of genes that are affected in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
170003	15210305	227483	20996	11179	SOD1	ALS	ALS	28	4.1	transcripts identified in the expression studies in spinal cord from ALS individuals 43 and 60 *This category includes genes involved in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000753659189285332<>ScoreDetail__5468|IGFALS|0.000600572854106994__11179|SOD1|0.000753659189285332__	0	0	0	0		0
164490	15453089	221281	20996	11179	SOD1	ALS	ALS	25	3.4	such as multiple sclerosis (MS), MS amyotrophic lateral sclerosis (ALS), ALS Parkinson disease (PD), PD Creutzfeldt-Jakob disease (CJD), CJD and Alzheimer	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164491	15453089	221281	17345	9449	PRNP	CJD	CJD	31	1.7	sclerosis (ALS), ALS Parkinson disease (PD), PD Creutzfeldt-Jakob disease (CJD), CJD and Alzheimer disease (AD) AD	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
164521	15453089	221301	16457	8891	PGD	PGD	PGD	9	0.0	In agreement with this hypothesis PGE 2 but not PGD 2 reversed the suppression of LTP induced by COX-2-inhibitor in	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
164552	15453089	221329	7438	3613	FCGR1A	CD64	CD64-positive	3	1.0	However not all CD64-positive cells expressed COX-2	1		JUMiner_v2.2	1	2	32	0	2	3613	TotalCon:3<>3613|FCGR1A|2209|Complete__3614|FCGR1B|2210|Complete__3615|FCGR1C|2211|No_GeneRif__<>AvaiableGeneRif=2<>BEST:3613|FCGR1A|0.000638172481034299<>ScoreDetail__3614|FCGR1B|0.000511948995102179__3613|FCGR1A|0.000638172481034299__	0	0	0	0		0
164560	15453089	221336	18723	10261	ROS1	ROS	ROS	19	0.0	PGE 2 analog suggesting that distinct COX-derived products (i.e i.e ROS and PGs may have protective or detrimental effects in EAE	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
164561	15453089	221338	11629	6493	LAMC2	CSF	CSF	3	0.3	Recently cerebrospinal fluid (CSF) CSF levels of PGE 2 and isoprostane 8-epi-PGF 2 a stable	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
164562	15453089	221341	11629	6493	LAMC2	CSF	CSF	12	0.3	of PGE 2 and that of 8-epi-PGF 2 in the CSF of each single subject were not correlated suggesting that PG	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
164563	15453089	221343	20996	11179	SOD1	ALS	ALS	3	3.4	Amyotrophic lateral sclerosis (ALS) ALS is a devastating neurodegenerative disease characterized by the progressive loss	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164565	15453089	221345	20996	11179	SOD1	ALS	ALS	18	3.4	superoxide dismutase (SOD1) SOD1 account for a familial form of ALS linked to chromosome 21q	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164567	15453089	221347	20996	11179	SOD1	ALS	ALS	8	3.4	Spinal cord tissue from patients who died of ALS shows several neuroinflammatory changes that are found in other neurodegenerative	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164568	15453089	221349	11629	6493	LAMC2	CSF	CSF	3	0.3	In addition high CSF levels of glutamate and excitotoxicity have been reported in ALS	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
164569	15453089	221349	20996	11179	SOD1	ALS	ALS	13	3.4	CSF levels of glutamate and excitotoxicity have been reported in ALS ( 41	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164572	15453089	221350	20996	11179	SOD1	ALS	ALS	22	3.4	set the basis for the hypothesis of COX-2 involvement in ALS pathogenesis	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164574	15453089	221351	20996	11179	SOD1	ALS	ALS	11	3.4	mRNA and protein were increased in postmortem spinal cords of ALS patients ( 42 and transgenic mutated SOD1 mice ( 43	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164577	15453089	221353	11629	6493	LAMC2	CSF	CSF	12	0.3	independent studies reported increased levels of PGE 2 in the CSF of ALS patients ( 44 45	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
164578	15453089	221353	20996	11179	SOD1	ALS	ALS	14	3.4	reported increased levels of PGE 2 in the CSF of ALS patients ( 44 45	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164581	15453089	221356	20996	11179	SOD1	ALS	ALS	5	3.4	In postmortem spinal cord of ALS patients COX-2 expression was markedly increased and localized to both	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164586	15453089	221359	20996	11179	SOD1	ALS	ALS	21	3.4	there was no significant difference was detected between control and ALS specimens ( 45	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164590	15453089	221361	20996	11179	SOD1	ALS	ALS	6	3.4	The role of COX-2 activity in ALS was examined by using selective COX-2 inhibitors	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164597	15453089	221365	20996	11179	SOD1	ALS	ALS	24	3.4	cascade of events leading to the progressive neuronal death in ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164606	15453089	221371	20996	11179	SOD1	ALS	ALS	5	3.4	COX-2 could also contribute to ALS by promoting inflammatory processes	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164607	15453089	221373	24402	12856	YY1	DELTA	DELTA	17	1.3	can be generated and influence the course of disease 15-deoxy- DELTA 12-14 -PGJ 2 (15d-PGJ 15d-PGJ 2 immunoreactivity was found in	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>9543|PSMB6|5694|No_GeneRif__12856|YY1|7528|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
164608	15453089	221373	20996	11179	SOD1	ALS	ALS	32	3.4	15d-PGJ 2 immunoreactivity was found in spinal cords of sporadic ALS patients ( 48 15d-PGJ 2 derives from the non-enzymatic dehydration	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131390228980071<>ScoreDetail__5468|IGFALS|0.000611670676507768__11179|SOD1|0.00131390228980071__	0	0	0	0		0
164609	15453089	221373	16457	8891	PGD	PGD	PGD	45	0.0	( 48 15d-PGJ 2 derives from the non-enzymatic dehydration of PGD 2 a major brain PG and activates the nuclear receptor	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
164620	15453089	221394	17345	9449	PRNP	CJD	CJD	2	1.7	Creutzfeldt-Jakob disease (CJD) CJD is the best known human form of transmissible spongiform encephalopathies	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
164624	15453089	221396	17345	9449	PRNP	CJD	CJD	11	1.7	further disease hallmark is the extensive microglial activation observed in CJD patients as well as in experimental prion diseases which supports	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
164631	15453089	221401	17345	9449	PRNP	CJD	CJD	23	1.7	mice were infected with homogenates from 2 cases of genetic CJD and 3 cases of sporadic CJD ( 57 suggesting that	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
164632	15453089	221401	17345	9449	PRNP	CJD	CJD	29	1.7	2 cases of genetic CJD and 3 cases of sporadic CJD ( 57 suggesting that the selective upregulation of COX-2 in	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
164637	15453089	221402	17345	9449	PRNP	CJD	CJD	18	1.7	in which both COX-1 and COX-2 were increased in sporadic CJD cortex ( 58	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
164640	15453089	221403	17345	9449	PRNP	CJD	CJD	28	1.7	isoforms were higher in tissue from temporal lobe of 1 CJD patient when compared to 1 neuropathologically unaltered control case	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
164642	15453089	221404	11629	6493	LAMC2	CSF	CSF	17	0.3	was confirmed by 2 studies ( 55 59 reporting elevated CSF PGE 2 levels in a group of 62 subjects affected	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
164643	15453089	221404	17345	9449	PRNP	CJD	CJD	32	1.7	a group of 62 subjects affected by sporadic and genetic CJD and in 18 cases of variant CJD the novel human	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
164644	15453089	221404	17345	9449	PRNP	CJD	CJD	39	1.7	sporadic and genetic CJD and in 18 cases of variant CJD the novel human form associated with the consumption of contaminated	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
164645	15453089	221405	17345	9449	PRNP	CJD	CJD	2	1.7	In sporadic CJD patients higher CSF levels of PGE 2 were associated with	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
164646	15453089	221405	11629	6493	LAMC2	CSF	CSF	5	0.3	In sporadic CJD patients higher CSF levels of PGE 2 were associated with shorter survival	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
164647	15453089	221406	11629	6493	LAMC2	CSF	CSF	10	0.3	PGE 2 levels were not dependent on the time of CSF sampling during the course of the disease suggesting that PGE	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
164648	15453089	221407	11629	6493	LAMC2	CSF	CSF	8	0.3	The increased levels of PGE 2 in the CSF of CJD patients and the high expression of COX-2 in	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
164649	15453089	221407	17345	9449	PRNP	CJD	CJD	10	1.7	The increased levels of PGE 2 in the CSF of CJD patients and the high expression of COX-2 in microglial cells	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
164651	15453089	221408	17345	9449	PRNP	CJD	CJD	1	1.7	In CJD abundance of apoptotic neurons correlated well with microglial activation (	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
164657	15453089	221411	17345	9449	PRNP	CJD	CJD	10	1.7	At present whether PGE 2 contributes to neuronal death in CJD is a consequence of neuronal apoptosis or is just an	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
164683	15453089	221431	11629	6493	LAMC2	CSF	CSF	0	0.3	CSF levels of PGE 2 were increased in probable AD patients	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
164684	15453089	221432	11629	6493	LAMC2	CSF	CSF	17	0.3	a longitudinal study in which PGE 2 was measured in CSF samples obtained on at least 3 annual visits in 35	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
164685	15453089	221433	11629	6493	LAMC2	CSF	CSF	4	0.3	The study showed that CSF PGE 2 declines with the increasing dementia severity	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
164686	15453089	221434	11629	6493	LAMC2	CSF	CSF	3	0.3	Compared with controls CSF PGE 2 was higher in patients with mild memory impairment	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
168688	15512862	226133	20996	11179	SOD1	ALS	ALS	3	1.2	Amyotrophic lateral sclerosis (ALS) ALS is a fatal paralytic neurodegenerative disorder	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000822418971594751<>ScoreDetail__5468|IGFALS|0.000180973638173373__11179|SOD1|0.000822418971594751__	0	0	0	0		0
168689	15512862	226134	20996	11179	SOD1	ALS	ALS	3	1.2	Experimental models of ALS such as the transgenic rodents expressing mutant superoxide dimutase-1 are	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000822418971594751<>ScoreDetail__5468|IGFALS|0.000180973638173373__11179|SOD1|0.000822418971594751__	0	0	0	0		0
168690	15512862	226134	20996	11179	SOD1	ALS	ALS	22	1.2	dimutase-1 are playing a pivotal role in our understanding of ALS pathogenesis and in our testing of new therapeutic interventions aimed	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000822418971594751<>ScoreDetail__5468|IGFALS|0.000180973638173373__11179|SOD1|0.000822418971594751__	0	0	0	0		0
168691	15512862	226135	20996	11179	SOD1	ALS	ALS	13	1.2	as a significant pathogenic factor in several neurodegenerative diseases including ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000822418971594751<>ScoreDetail__5468|IGFALS|0.000180973638173373__11179|SOD1|0.000822418971594751__	0	0	0	0		0
168692	15512862	226136	20996	11179	SOD1	ALS	ALS	26	1.2	and genetic interventions to be tested in experimental models of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000822418971594751<>ScoreDetail__5468|IGFALS|0.000180973638173373__11179|SOD1|0.000822418971594751__	0	0	0	0		0
168693	15512862	226137	20996	11179	SOD1	ALS	ALS	22	1.2	scientific basis for the development of effective neuroprotective therapies for ALS and Behavior Columbia University New York NY 10032 USA	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000822418971594751<>ScoreDetail__5468|IGFALS|0.000180973638173373__11179|SOD1|0.000822418971594751__	0	0	0	0		0
161097	15571972	216578	20996	11179	SOD1	ALS	ALS	11	1.0	crucial for lethal disorders such as amyotrophic lateral sclerosis (ALS) ALS and Huntington's disease (HD) HD for which no pharmacological or	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000974281109189134<>ScoreDetail__5468|IGFALS|0.000886173363494322__11179|SOD1|0.000974281109189134__	0	0	0	0		0
161103	15571972	216643	20996	11179	SOD1	ALS	ALS	3	1.0	Amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000974281109189134<>ScoreDetail__5468|IGFALS|0.000886173363494322__11179|SOD1|0.000974281109189134__	0	0	0	0		0
161104	15571972	216644	20996	11179	SOD1	ALS	ALS	15	1.0	reported a beneficial effect of minocycline in mouse models of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000974281109189134<>ScoreDetail__5468|IGFALS|0.000886173363494322__11179|SOD1|0.000974281109189134__	0	0	0	0		0
161108	15571972	216647	11629	6493	LAMC2	CSF	CSF	14	0.0	the protective effect that minocycline exerted against the neurotoxicity of CSF coming from patients carrying the SOD D90A mutation ( Tikka	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
161109	15571972	216650	3353	1368	CA1	CA1	CA1	17	0.0	of minocycline increased the number of surviving neurons in the CA1 pyramidal cell layer of gerbils submitted to a global ischemia	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
161116	15571972	216672	20996	11179	SOD1	ALS	ALS	8	1.0	Minocycline is being tested in HD PD and ALS patients ( URL	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000974281109189134<>ScoreDetail__5468|IGFALS|0.000886173363494322__11179|SOD1|0.000974281109189134__	0	0	0	0		0
161117	15571972	216673	20996	11179	SOD1	ALS	ALS	21	1.0	any efficient therapies for devastating disorders such as HD and ALS these therapeutical trials are justified in these circumstances	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000974281109189134<>ScoreDetail__5468|IGFALS|0.000886173363494322__11179|SOD1|0.000974281109189134__	0	0	0	0		0
161118	15571972	216680	20996	11179	SOD1	ALS	ALS	7	1.0	A trial is also in progress for ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000974281109189134<>ScoreDetail__5468|IGFALS|0.000886173363494322__11179|SOD1|0.000974281109189134__	0	0	0	0		0
161119	15571972	216681	20996	11179	SOD1	ALS	ALS	14	1.0	that minocycline is safe and well tolerated by patients with ALS with few side effects	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000974281109189134<>ScoreDetail__5468|IGFALS|0.000886173363494322__11179|SOD1|0.000974281109189134__	0	0	0	0		0
161120	15571972	216687	20996	11179	SOD1	ALS	ALS	29	1.0	these deleterious events have been or are being tested in ALS or HD patients ( Huntington Study Group 2001 Huntington Study	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000974281109189134<>ScoreDetail__5468|IGFALS|0.000886173363494322__11179|SOD1|0.000974281109189134__	0	0	0	0		0
161122	15571972	216690	20996	11179	SOD1	ALS	ALS	25	1.0	be very effective in the SOD1 G37R mouse model of ALS with a major increase of the mice life span of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000974281109189134<>ScoreDetail__5468|IGFALS|0.000886173363494322__11179|SOD1|0.000974281109189134__	0	0	0	0		0
161123	15571972	216692	20996	11179	SOD1	ALS	ALS	13	1.0	with both creatine and minocycline which are clinically tested in ALS patients as a sole therapy significantly delayed disease onset and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000974281109189134<>ScoreDetail__5468|IGFALS|0.000886173363494322__11179|SOD1|0.000974281109189134__	0	0	0	0		0
161126	15571972	216709	20996	11179	SOD1	ALS	ALS	26	1.0	worth to be tested in neurodegenerative disorders such as HD ALS and PD	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000974281109189134<>ScoreDetail__5468|IGFALS|0.000886173363494322__11179|SOD1|0.000974281109189134__	0	0	0	0		0
161141	15572176	216716	20996	11179	SOD1	ALS	ALS	18	1.9	upper and lower motor neurons and degenerating descending tracts of ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161142	15572176	216717	20996	11179	SOD1	ALS	ALS	3	1.9	Reactive astrocytes in ALS contain protein inclusions express inflammatory makers such as the inducible	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161146	15572176	216718	20996	11179	SOD1	ALS	ALS	23	1.9	in the induction and propagation of motor neuron loss in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161149	15572176	216723	20996	11179	SOD1	ALS	ALS	12	1.9	understanding of the interactions between motor neurons and glia in ALS may lead to a more accurate theory of the pathogenesis	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161150	15572176	216727	20996	11179	SOD1	ALS	ALS	3	1.9	Amyotrophic lateral sclerosis (ALS) ALS is a neurodegenerative disease originally described by Charcot in 1869	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161151	15572176	216729	20996	11179	SOD1	ALS	ALS	23	1.9	subtle changes in other cell types that may contribute to ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161152	15572176	216730	20996	11179	SOD1	ALS	ALS	12	1.9	review we will consider the origin of reactive astrogliosis in ALS and how reactive changes in astrocytes may contribute to the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161153	15572176	216730	20996	11179	SOD1	ALS	ALS	26	1.9	changes in astrocytes may contribute to the progressive nature of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161154	15572176	216731	20996	11179	SOD1	ALS	ALS	3	1.9	About 10% of ALS cases show familial inheritance 20% of which are caused by	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161156	15572176	216732	20996	11179	SOD1	ALS	ALS	7	1.9	An important clue to the pathogenesis of ALS was provided by the development of several strains of different	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161160	15572176	216735	20996	11179	SOD1	ALS	ALS-linked	5	1.9	However current evidence indicates that ALS-linked SOD-1 mutations must be expressed in both neuronal and non-neuronal	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161163	15572176	216736	20996	11179	SOD1	ALS	ALS	28	1.9	muscle are required for mutated SOD-1 to initiate neurodegeneration in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161164	15572176	216737	20996	11179	SOD1	ALS	ALS	23	1.9	mice composed of mixtures of normal cells and cells expressing ALS mutant SOD-1 showed that motor neuron degeneration is not necessarily	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161168	15572176	216747	20996	11179	SOD1	ALS	ALS	52	1.9	it is not considered as a primary pathogenic element in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161169	15572176	216749	20996	11179	SOD1	ALS	ALS	10	1.9	Extensive reviews have been recently published about the pathogenesis of ALS 12 25 and 110 the role of microglia and inflammatory	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161170	15572176	216749	20996	11179	SOD1	ALS	ALS	26	1.9	and 110 the role of microglia and inflammatory cells in ALS 83 and the immune function of astrocytes 31	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161171	15572176	216751	20996	11179	SOD1	ALS	ALS	9	1.9	Understanding of the interactions between neurons and glia in ALS may help to explain the progressive nature of ALS 2	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161172	15572176	216751	20996	11179	SOD1	ALS	ALS	18	1.9	in ALS may help to explain the progressive nature of ALS 2	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161173	15572176	216752	20996	11179	SOD1	ALS	ALS	3	1.9	Astrocyte pathology in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161174	15572176	216753	20996	11179	SOD1	ALS	ALS	13	1.9	reaction typically surrounds both upper and lower motor neurons in ALS patients 59 71 87 90 and 120	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161175	15572176	216756	20996	11179	SOD1	ALS	ALS	3	1.9	Reactive astrocytes in ALS show increased immunoreactivity for GFAP and the calcium binding protein	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161180	15572176	216758	20996	11179	SOD1	ALS	ALS	15	1.9	changes has been described in the different animal models of ALS including mice and rats carrying different SOD-1 mutations	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161194	15572176	216770	20996	11179	SOD1	ALS	ALS	16	1.9	pathology of the disease indicate that astrocytic activation occurs in ALS both in humans and animal models of the disease with	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161196	15572176	216776	20996	11179	SOD1	ALS	ALS	5	1.9	The origin of astrocytosis in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161197	15572176	216777	20996	11179	SOD1	ALS	ALS	1	1.9	Symptomatic ALS mice develop a typical _amp_#x201c isomorphic_amp_#x201d gliosis characterized by proliferative	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161198	15572176	216781	20996	11179	SOD1	ALS	ALS	13	1.9	difficult to define the underlying causes of astrocytosis occurring in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161199	15572176	216782	20996	11179	SOD1	ALS	ALS	22	1.9	might illustrate some of the mechanisms causing astrocyte reactivity in ALS 3.1	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161200	15572176	216784	20996	11179	SOD1	ALS	ALS	0	1.9	ALS and related neurodegenerative diseases are closely associated with the aging	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161203	15572176	216792	20996	11179	SOD1	ALS	ALS	24	1.9	neurons may constitute a potential mechanism for astrocyte activation in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161208	15572176	216797	10676	6121	IRF6	LPS	LPS	8	0.6	A similar phenotype was induced by bacterial lipopolysaccharide (LPS), LPS a well-known inflammatory stimulus to glial cells	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
161209	15572176	216798	10676	6121	IRF6	LPS	LPS	0	0.6	LPS stimulated iNOS expression and nitrotyrosine formation suggesting a role for	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
161222	15572176	216816	20996	11179	SOD1	ALS	ALS	28	1.9	elicit a secondary glial response resembling astrocytic changes in presymptomatic ALS mouse and rat models	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161223	15572176	216822	20996	11179	SOD1	ALS	ALS	3	1.9	In this perspective ALS might be caused in part by a defective crosstalk between	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161224	15572176	216823	20996	11179	SOD1	ALS	ALS	6	1.9	Neurotoxic potential of reactive astrocytes in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161225	15572176	216824	20996	11179	SOD1	ALS	ALS	13	1.9	emphasized the involvement of astrocyte dysfunction in the pathogenesis of ALS through different synergistic mechanisms 4.1	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161226	15572176	216826	20996	11179	SOD1	ALS	ALS	1	1.9	Many ALS patients have elevated glutamate levels in cerebrospinal fluid and a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161229	15572176	216828	20996	11179	SOD1	ALS	ALS	3	1.9	In patients with ALS EAAT2 transporters are decreased or defective 108 and 114 which	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161236	15572176	216832	20996	11179	SOD1	ALS	ALS	20	1.9	the significant reduction in the ability to transport glutamate in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161238	15572176	216833	20996	11179	SOD1	ALS	ALS	10	1.9	The presence of aberrant mRNA splice variants for EAAT2 in ALS has been hypothesized as a putative cause of EAAT2 loss	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161240	15572176	216834	20996	11179	SOD1	ALS	ALS	36	1.9	of astrocytosis suggesting that the loss of glutamate transporters in ALS may be secondary to astrocytic activation	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161241	15572176	216841	20996	11179	SOD1	ALS	ALS	5	1.9	For example reactive astrocytes in ALS express COX-2 an enzyme that catalyzes the synthesis of the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161243	15572176	216842	20996	11179	SOD1	ALS	ALS	2	1.9	Treatment of ALS mice with the COX-2 inhibitor Celecoxib delayed the onset of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161245	15572176	216845	20996	11179	SOD1	ALS	ALS	1	1.9	In ALS neuroinflammatory changes can be observed through the entire motor system	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161246	15572176	216846	20996	11179	SOD1	ALS	ALS	14	1.9	activation and its expression of some inflammatory mediators described in ALS the pathophysiological role of relevant cytokines and chemokines has remained	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161248	15572176	216848	20996	11179	SOD1	ALS	ALS	31	1.9	in diverse forms of neurodegeneration which could be relevant in ALS pathophysiology	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161259	15572176	216854	10676	6121	IRF6	LPS	LPS-treated	23	0.6	has been recently reported in the spinal cord of chronically LPS-treated mutant SOD1 mice 88	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
161263	15572176	216857	20996	11179	SOD1	ALS	ALS	27	1.9	a role in initiating and modulating the inflammatory mechanisms in ALS explaining relevant features of the astrocyte pathology 4.3	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161264	15572176	216859	20996	11179	SOD1	ALS	ALS	9	1.9	Free radical damage is a characteristic of pathologically affected ALS tissues	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161266	15572176	216861	10676	6121	IRF6	LPS	LPS	6	0.6	In particular induction of iNOS by LPS or cytokines seems to be required for astrocytes to promote	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
161267	15572176	216864	10676	6121	IRF6	LPS	LPS	22	0.6	monolayers of astrocytes that were first exposed to peroxynitrite or LPS	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
161268	15572176	216866	10676	6121	IRF6	LPS	LPS	14	0.6	the motor neurons plated on astrocytes pretreated with peroxynitrite or LPS undergo apoptosis over the next 24 h	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
161271	15572176	216872	20996	11179	SOD1	ALS	ALS	33	1.9	42 and 116 and in sporadic and familial cases of ALS 1 8 43 and 115	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161273	15572176	216876	20996	11179	SOD1	ALS	ALS	4	1.9	Thus reactive astrocytes in ALS would not only impair neuronal excitability and neurotransmission but they	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161277	15572176	216879	20996	11179	SOD1	ALS	ALS	12	1.9	could play a role in motor neuron loss observed in ALS without the direct involvement of the immune system	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161279	15572176	216881	20996	11179	SOD1	ALS	ALS	29	1.9	44 and 45 little is known about its expression in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161284	15572176	216884	20996	11179	SOD1	ALS	ALS-linked	7	1.9	Furthermore motor neurons from transgenic mice overexpressing ALS-linked SOD mutations G37R G85R or G93A display an increased susceptibility	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161312	15572176	216894	20996	11179	SOD1	ALS	ALS	9	1.9	Moreover p75 NTR is found in motor neurons of ALS patients 80 and 121 suggesting that re-expression of the receptor	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161321	15572176	216898	20996	11179	SOD1	ALS	ALS	10	1.9	However little is known about the expression of NGF in ALS although increased NGF levels were reported in muscle of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161323	15572176	216898	20996	11179	SOD1	ALS	ALS	20	1.9	ALS although increased NGF levels were reported in muscle of ALS patients 72 and 127	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161327	15572176	216899	20996	11179	SOD1	ALS	ALS	24	1.9	neurons may contribute to the induction of neuronal apoptosis in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161332	15572176	216900	20996	11179	SOD1	ALS	ALS	47	1.9	increased NGF production may parallel the development of astrocytosis in ALS and contribute to motor neuron death	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161343	15572176	216904	20996	11179	SOD1	ALS	ALS	14	1.9	role for a NGF/p75 NGF p75 NTR apoptotic pathway in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161357	15572176	216916	20996	11179	SOD1	ALS	ALS	37	1.9	triggers a progressive motor neuron disease with the characteristics of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161358	15572176	216918	20996	11179	SOD1	ALS	ALS	12	1.9	that these mechanisms are somehow critically and irreversibly disrupted in ALS 6	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161359	15572176	216920	20996	11179	SOD1	ALS	ALS	3	1.9	The pathology of ALS is characterized by widespread signs of neuronal and astrocyte dysfunction	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161360	15572176	216923	20996	11179	SOD1	ALS	ALS	5	1.9	Because reactive astrocytes occurring in ALS may spread the phenotypic transformation to astrocytes located in adjacent	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161361	15572176	216927	20996	11179	SOD1	ALS	ALS	9	1.9	Deciphering the interactions between motor neurons and glia in ALS may reveal the basis for the progressive pathogenesis of the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
161362	15572176	216929	20996	11179	SOD1	ALS	ALS	10	1.9	Proposed pathogenic steps involving astrocyte to motor neuron signaling in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000806718321836908<>ScoreDetail__5468|IGFALS|0.000350557049558202__11179|SOD1|0.000806718321836908__	0	0	0	0		0
155370	15649489	206195	20996	11179	SOD1	ALS	ALS	19	1.7	the pathogenesis of motoneuron death in amyotrophic lateral sclerosis (ALS) ALS both in humans and transgenic mouse models	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00150977120752612<>ScoreDetail__5468|IGFALS|0.000376251034690345__11179|SOD1|0.00150977120752612__	0	0	0	0		0
155375	15649489	206198	20996	11179	SOD1	ALS	ALS	21	1.7	PPAR-_amp_#x3b3 agonist in the G93A SOD1 transgenic mouse model of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00150977120752612<>ScoreDetail__5468|IGFALS|0.000376251034690345__11179|SOD1|0.00150977120752612__	0	0	0	0		0
155379	15649489	206202	20996	11179	SOD1	ALS	ALS	11	1.7	results suggest that pioglitazone may have therapeutic potential for human ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00150977120752612<>ScoreDetail__5468|IGFALS|0.000376251034690345__11179|SOD1|0.00150977120752612__	0	0	0	0		0
155380	15649489	206204	20996	11179	SOD1	ALS	ALS	3	1.7	Amyotrophic lateral sclerosis (ALS) ALS is one of the most common adult onset neurodegenerative diseases	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00150977120752612<>ScoreDetail__5468|IGFALS|0.000376251034690345__11179|SOD1|0.00150977120752612__	0	0	0	0		0
155382	15649489	206205	20996	11179	SOD1	ALS	ALS	33	1.7	SOD1 in a subset of patients with autosomal dominant inherited ALS ( Rosen et al. 1993	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00150977120752612<>ScoreDetail__5468|IGFALS|0.000376251034690345__11179|SOD1|0.00150977120752612__	0	0	0	0		0
155383	15649489	206207	20996	11179	SOD1	ALS	ALS	14	1.7	demonstrated that activated microglia occur in transgenic mouse models of ALS ( Hall et al. 1998	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00150977120752612<>ScoreDetail__5468|IGFALS|0.000376251034690345__11179|SOD1|0.00150977120752612__	0	0	0	0		0
155391	15649489	206217	14535	7873	NOS2A	iNOS	iNOS-positive	9	3.2	Pioglitazone treatment reduced activation of microglia reduced induction of iNOS-positive cells and less glial fibrillary acidic protein-positive cells in both	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
155394	15649489	206218	20996	11179	SOD1	ALS	ALS	26	1.7	disease process in the G93A SOD1 transgenic mouse model of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00150977120752612<>ScoreDetail__5468|IGFALS|0.000376251034690345__11179|SOD1|0.00150977120752612__	0	0	0	0		0
155395	15649489	206221	20996	11179	SOD1	ALS	ALS	3	1.7	G93A transgenic familial ALS mice (high high expresser line ( Gurney 1994 were obtained	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00150977120752612<>ScoreDetail__5468|IGFALS|0.000376251034690345__11179|SOD1|0.00150977120752612__	0	0	0	0		0
155398	15649489	206248	11763	6553	LEP	LEP	LEP	17	0.0	of a Nikon Eclipse E600 microscope equipped with a computer-controlled LEP BioPoint motorized stage a DEI-750 video camera a Dell Dimension	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
155409	15649489	206284	20996	11179	SOD1	ALS	ALS	11	1.7	is increasing evidence that inflammatory mechanisms play a role in ALS pathogenesis	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00150977120752612<>ScoreDetail__5468|IGFALS|0.000376251034690345__11179|SOD1|0.00150977120752612__	0	0	0	0		0
155411	15649489	206286	20996	11179	SOD1	ALS	ALS	15	1.7	and iNOS levels are increased in transgenic mouse models of ALS ( Almer et al. 1999 Elliott 2001 Ghezzi et al.	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00150977120752612<>ScoreDetail__5468|IGFALS|0.000376251034690345__11179|SOD1|0.00150977120752612__	0	0	0	0		0
155412	15649489	206287	20996	11179	SOD1	ALS	ALS	13	1.7	activation slowed disease progression in one transgenic mouse model of ALS ( Friedlander et al. 1998	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00150977120752612<>ScoreDetail__5468|IGFALS|0.000376251034690345__11179|SOD1|0.00150977120752612__	0	0	0	0		0
155417	15649489	206291	10444	5993	IL1R1	IL1RA	IL1-RA	3	0.0	IL-_amp_#x3b2 IL-1_amp_#x3b2 and IL1-RA are increased at 80 days and multiple caspase and death	11		JUMiner_v2.2	1	0		0	2	6000	TotalCon:2<>5993|IL1R1|3554|Complete__6000|IL1RN|3557|Complete__<>AvaiableGeneRif=2<>BEST:6000|IL1RN|0.000183493733979586<>ScoreDetail__5993|IL1R1|0.000136263904125759__6000|IL1RN|0.000183493733979586__	0	0	0	0		0
155418	15649489	206299	14535	7873	NOS2A	iNOS	iNOS-positive	4	3.2	It reduced induction of iNOS-positive cells and there was less glial fibrillary acidic protein-positive cells	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
155420	15649489	206300	8569	16769	GORASP1	P65	P65	25	0.0	inhibition of translocation of nuclear factor _amp_#x3ba -_amp_#x3b2 _amp_#xa0 subunit P65 to the nucleus in the dopaminergic neurons and glial cells	1		JUMiner_v2.2	1	0		0	2	16769	TotalCon:2<>16769|GORASP1|64689|Complete__11509|SYT1|6857|Complete__<>AvaiableGeneRif=2<>BEST:16769|GORASP1|0.000327398191754602<>ScoreDetail__16769|GORASP1|0.000327398191754602__11509|SYT1|0.000159201867968584__	0	0	0	0		0
155428	15649489	206311	20996	11179	SOD1	ALS	ALS	20	1.7	may be an effective strategy for ameliorating the progression of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00150977120752612<>ScoreDetail__5468|IGFALS|0.000376251034690345__11179|SOD1|0.00150977120752612__	0	0	0	0		0
155429	15649489	206313	20996	11179	SOD1	ALS	ALS	18	1.7	could readily become an agent worthy of testing in human ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00150977120752612<>ScoreDetail__5468|IGFALS|0.000376251034690345__11179|SOD1|0.00150977120752612__	0	0	0	0		0
156440	15657392	207605	20996	11179	SOD1	ALS	ALS	3	2.2	Amyotrophic lateral sclerosis (ALS) ALS is a progressive neurodegenerative disease characterized by a selective degeneration	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156441	15657392	207606	20996	11179	SOD1	ALS	ALS	6	2.2	Although a significant proportion of familial ALS results from a toxic gain of function associated with dominant	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156447	15657392	207610	20996	11179	SOD1	ALS	ALS	8	2.2	Abbreviations used in this paper AChR acetylcholine receptor ALS amyotrophic lateral sclerosis CnA calcineurin GFAP glial fibrillary acidic protein	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156453	15657392	207612	20996	11179	SOD1	ALS	ALS	3	2.2	Amyotrophic lateral sclerosis (ALS) ALS is a fatal neuromuscular disorder involving the degeneration of motor	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156455	15657392	207613	20996	11179	SOD1	ALS	ALS	12	2.2	ubiquitously overexpressing human SOD1 mutants develop motor neuron disease resembling ALS ( Gurney et al. 1994 and provide useful model to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156457	15657392	207614	20996	11179	SOD1	ALS	ALS-associated	36	2.2	2002 suggesting that other cell types may be involved in ALS-associated neurodegeneration	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156477	15657392	207629	38	22	AAVS1	AAV	AAV	14	0.9	delivered either as an inherited transgene or somatically on an AAV vector induces muscle hypertrophy and strength and preserves regenerative capacity	1		JUMiner_v2.2	1	2	aav vector	0	0	0		0	0	0	0		0
156478	15657392	207630	20996	11179	SOD1	ALS	ALS	16	2.2	skeletal muscle as a primary target in inherited forms of ALS by showing that localized expression of the coinherited MLC/mIgf-1 MLC	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156481	15657392	207630	20996	11179	SOD1	ALS	ALS	39	2.2	the skeletal muscle of SOD1 mice counteracted the symptoms of ALS induced satellite cell activity stabilized neuromuscular junctions and led to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156484	15657392	207631	20996	11179	SOD1	ALS	ALS	25	2.2	importance of Igf-1 isoform selection when designing therapeutic strategies for ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156584	15657392	207697	16100	8621	PAX7	PAX7	Pax-7	9	0.0	In addition markers of satellite cell activity such as Pax-7 and desmin were increased to varying extents in affected SOD	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
156585	15657392	207697	16100	8621	PAX7	PAX7	Pax-7	43	0.0	maturation including centralized nuclei ( Fig 2 a yellow arrows Pax-7 isoforms desmin myogenin and neonatal myosin heavy chain (MyHC) MyHC	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
156592	15657392	207702	20996	11179	SOD1	ALS	ALS	31	2.2	support the hypothesis that delaying the progression and severity of ALS disease may depend on the maintenance of muscle integrity	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156597	15657392	207706	20996	11179	SOD1	ALS	ALS	28	2.2	an alternate therapeutic approach to counteract muscle wasting associated with ALS disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156623	15657392	207726	20996	11179	SOD1	ALS	ALS	47	2.2	mIgf-1 expression preserves the motor neuron during the progression of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156624	15657392	207727	20996	11179	SOD1	ALS	ALS	10	2.2	One of the prominent markers of motor neuron dysfunction in ALS mice is the activation of astrocytes leading to motor weakness	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156645	15657392	207733	20996	11179	SOD1	ALS	ALS	47	2.2	astrocytosis and inflammatory cytokines that normally exacerbate the pathogenesis of ALS disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156646	15657392	207734	20996	11179	SOD1	ALS	ALS	0	2.2	ALS is emerging as a multi-systemic disease in which the alteration	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156652	15657392	207743	20996	11179	SOD1	ALS	ALS	37	2.2	counteract the degeneration of both muscle and motor neuron in ALS disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00171098438242487<>ScoreDetail__5468|IGFALS|0.000488478876777714__11179|SOD1|0.00171098438242487__	0	0	0	0		0
156660	15657392	207760	1759	1102	BRD1	BRL	BRL	8	0.3	RNA was extracted from muscles by RNA-TRIzol-kit (GIBCO GIBCO BRL	1		JUMiner_v2.2	1	2	gibco brl	0	0	0		0	0	0	0		0
156665	15657392	207767	19573	10691	SDS	SDS	SDS	11	0.0	amounts of protein from each muscle lysate were separated in SDS polyacrylamide gel and transferred onto a hybond C extra nitrocellulose	1		JUMiner_v2.2	1	0		0	2	19440	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:19440|SBDS|0.000407140221636958<>ScoreDetail__10691|SDS|0.000301114122252334__19440|SBDS|0.000407140221636958__	0	0	0	0		0
157135	15668976	208352	9947	5468	IGFALS	ALS	ALS	8	0.3	The causative pathomechanism of sporadic amyotrophic lateral sclerosis (ALS) ALS is not clearly understood	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00125566384543045<>ScoreDetail__5468|IGFALS|0.00103406326034063__11179|SOD1|0.00125566384543045__	0	0	0	0		0
157136	15668976	208353	9947	5468	IGFALS	ALS	ALS	21	0.3	degenerating spinal motor neurons isolated from autopsied patients with sporadic ALS were examined	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00125566384543045<>ScoreDetail__5468|IGFALS|0.00103406326034063__11179|SOD1|0.00125566384543045__	0	0	0	0		0
157141	15668976	208362	9947	5468	IGFALS	ALS	ALS	8	0.3	The motor neuron-specific gene expression profile in sporadic ALS can provide direct information on the genes leading to neurodegeneration	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00125566384543045<>ScoreDetail__5468|IGFALS|0.00103406326034063__11179|SOD1|0.00125566384543045__	0	0	0	0		0
157731	15691215	209294	20996	11179	SOD1	ALS	ALS	3	1.4	Amyotrophic lateral sclerosis (ALS) ALS is a progressive neurodegenerative disease for which no cure or	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00128599243576359<>ScoreDetail__5468|IGFALS|0.000890990713135259__11179|SOD1|0.00128599243576359__	0	0	0	0		0
157732	15691215	209296	20996	11179	SOD1	ALS	ALS	7	1.4	The discovery that a small percentage of ALS cases are familial and involve mutation in a superoxide dismutase	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00128599243576359<>ScoreDetail__5468|IGFALS|0.000890990713135259__11179|SOD1|0.00128599243576359__	0	0	0	0		0
150946	15777251	199027	20996	11179	SOD1	ALS	ALS	21	0.0	PD Alzheimer's disease (AD) AD or amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000720315629212073<>ScoreDetail__5468|IGFALS|0.000377165930823331__11179|SOD1|0.000720315629212073__	0	0	0	0		0
150961	15782606	199052	20996	11179	SOD1	ALS	ALS	9	0.0	Primary progressive multiple sclerosis as a differential diagnosis of ALS a case report	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000465747863617697<>ScoreDetail__5468|IGFALS|0.000403027181944382__11179|SOD1|0.000465747863617697__	0	0	0	0		0
150962	15782606	199056	20996	11179	SOD1	ALS	ALS	15	0.0	and decreased number of motor units in the extremities suggesting ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000465747863617697<>ScoreDetail__5468|IGFALS|0.000403027181944382__11179|SOD1|0.000465747863617697__	0	0	0	0		0
150964	15782606	199057	5142	2537	CTSL1	MEP	MEP	15	0.0	head and spinal MRI a prolonged central conduction time of MEP and SEP a delayed P100 latency of VEP and a	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
150965	15782606	199057	13321	14668	MMEL1	SEP	SEP	17	0.0	spinal MRI a prolonged central conduction time of MEP and SEP a delayed P100 latency of VEP and a increased IgG	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>14668|MMEL1|79258|No_GeneRif__9103|PLXNB1|5364|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
150966	15782606	199057	11629	6493	LAMC2	CSF	CSF	31	0.0	latency of VEP and a increased IgG index in the CSF indicated primary progressive type multiple sclerosis	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
150967	15782606	199059	20996	11179	SOD1	ALS	ALS-like	22	0.0	the anterior horn cells/intramedullary cells intramedullary ventral roots explained the ALS-like clinical picture	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000465747863617697<>ScoreDetail__5468|IGFALS|0.000403027181944382__11179|SOD1|0.000465747863617697__	0	0	0	0		0
151001	15799549	199163	20996	11179	SOD1	ALS	ALS	14	0.0	markers in affected neural tissues of amyotrophic lateral sclerosis (ALS) ALS patients	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000936474939593148<>ScoreDetail__5468|IGFALS|0.00019208605455244__11179|SOD1|0.000936474939593148__	0	0	0	0		0
151002	15799549	199164	20996	11179	SOD1	ALS	ALS	10	0.0	We examined immunocytochemically spinal cord tissues of six patients with ALS two with corticospinal tract degeneration secondary to cerebral infarcts and	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000936474939593148<>ScoreDetail__5468|IGFALS|0.00019208605455244__11179|SOD1|0.000936474939593148__	0	0	0	0		0
151003	15799549	199165	20996	11179	SOD1	ALS	ALS	0	0.0	ALS spinal cords had dense macrophage infiltration (one one log greater	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000936474939593148<>ScoreDetail__5468|IGFALS|0.00019208605455244__11179|SOD1|0.000936474939593148__	0	0	0	0		0
151005	15799549	199166	20996	11179	SOD1	ALS	ALS	2	0.0	Macrophages in ALS spinal cord showed strong expression of cyclooxygenase-2 (COX-2) COX-2 (one	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000936474939593148<>ScoreDetail__5468|IGFALS|0.00019208605455244__11179|SOD1|0.000936474939593148__	0	0	0	0		0
151009	15799549	199169	20996	11179	SOD1	ALS	ALS	0	0.0	ALS spinal cords but not control cords were sparsely infiltrated with	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000936474939593148<>ScoreDetail__5468|IGFALS|0.00019208605455244__11179|SOD1|0.000936474939593148__	0	0	0	0		0
151011	15799549	199171	20996	11179	SOD1	ALS	ALS	6	0.0	Our data suggest that inflammation in ALS spinal cord and cortex is based on innate immune responses	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000936474939593148<>ScoreDetail__5468|IGFALS|0.00019208605455244__11179|SOD1|0.000936474939593148__	0	0	0	0		0
151248	15804265	199551	20996	11179	SOD1	ALS	ALS	11	1.7	of intraperitoneal injection of Rofecoxib in a mouse model of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00103560857600355<>ScoreDetail__5468|IGFALS|0.00059183270862103__11179|SOD1|0.00103560857600355__	0	0	0	0		0
151249	15804265	199552	20996	11179	SOD1	ALS	ALS	16	1.7	are involved in the pathogenesis of amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00103560857600355<>ScoreDetail__5468|IGFALS|0.00059183270862103__11179|SOD1|0.00103560857600355__	0	0	0	0		0
151251	15804265	199553	20996	11179	SOD1	ALS	ALS	16	1.7	cyclooxygenase 2 (COX-2), COX-2 represents a promising therapeutic approach in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00103560857600355<>ScoreDetail__5468|IGFALS|0.00059183270862103__11179|SOD1|0.00103560857600355__	0	0	0	0		0
151254	15804265	199554	20996	11179	SOD1	ALS	ALS	28	1.7	SOD1 G93A G1H mouse model of the familial form of ALS (fALS) fALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00103560857600355<>ScoreDetail__5468|IGFALS|0.00059183270862103__11179|SOD1|0.00103560857600355__	0	0	0	0		0
151255	15804265	199555	21239	11280	SQSTM1	P60	P60	7	0.0	Rofecoxib administration commenced at postnatal day 60 (P60), P60 since the hallmarks of inflammation in the spinal cord were	1		JUMiner_v2.2	1	0		0	2	11916	TotalCon:4<>11280|SQSTM1|8878|Complete__11916|TNFRSF1A|7132|Complete__13209|ARHGEF5|7984|Complete__11387|STIP1|10963|Complete__<>AvaiableGeneRif=4<>BEST:11916|TNFRSF1A|0.00038587446428289<>ScoreDetail__11916|TNFRSF1A|0.00038587446428289__11387|STIP1|0__13209|ARHGEF5|0__11280|SQSTM1|0.000321300321300321__	0	0	0	0		0
153856	15846792	203807	20996	11179	SOD1	ALS	ALS	19	0.0	microglia in an adult-onset neurodegenerative disease amyotrophic lateral sclerosis (ALS), ALS and pays particular attention to the possible mechanisms of initiation	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00104727707959306<>ScoreDetail__5468|IGFALS|0.00032441200324412__11179|SOD1|0.00104727707959306__	0	0	0	0		0
153857	15846792	203809	20996	11179	SOD1	ALS	ALS	10	0.0	The neuroinflammatory changes that occur in a mouse model of ALS are summarized	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00104727707959306<>ScoreDetail__5468|IGFALS|0.00032441200324412__11179|SOD1|0.00104727707959306__	0	0	0	0		0
147157	15962273	193995	20996	11179	SOD1	ALS	ALS	13	0.0	microglia in the spinal cord of amyotrophic lateral sclerosis (ALS) ALS patients is usually accompanied by inflammatory biochemical changes but these	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000879667751065275<>ScoreDetail__5468|IGFALS|0.000768344218209758__11179|SOD1|0.000879667751065275__	0	0	0	0		0
147160	15962273	193997	11629	6493	LAMC2	CSF	CSF	13	0.0	by an enzyme-linked immunosorbent assay in the cerebrospinal fluid (CSF) CSF and the serum of 27 patients with ALS and 30	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
147161	15962273	193997	20996	11179	SOD1	ALS	ALS	21	0.0	fluid (CSF) CSF and the serum of 27 patients with ALS and 30 patients with noninflammatory neurological diseases	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000879667751065275<>ScoreDetail__5468|IGFALS|0.000768344218209758__11179|SOD1|0.000879667751065275__	0	0	0	0		0
147163	15962273	193998	20996	11179	SOD1	ALS	ALS	1	0.1	In ALS circulating MCP-1 levels were significantly increased in the serum and	6		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000879667751065275<>ScoreDetail__5468|IGFALS|0.000768344218209758__11179|SOD1|0.000879667751065275__	0	0	0	0		0
147164	15962273	193998	11629	6493	LAMC2	CSF	CSF	15	0.0	were significantly increased in the serum and particularly in the CSF	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
147166	15962273	193999	20996	11179	SOD1	ALS	ALS	4	0.1	Immunoreactivity for MCP-1 in ALS spinal cord was detected mostly in astrocytes but also in	6		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000879667751065275<>ScoreDetail__5468|IGFALS|0.000768344218209758__11179|SOD1|0.000879667751065275__	0	0	0	0		0
147168	15962273	194000	20996	11179	SOD1	ALS	ALS	17	0.0	as an important molecular mediator of the injury response in ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000879667751065275<>ScoreDetail__5468|IGFALS|0.000768344218209758__11179|SOD1|0.000879667751065275__	0	0	0	0		0
135211	16014720	179157	6981	22140	FAM20C	RNS	RNS	15	0.0	degradation product NO 2 to generate reactive nitrogen species (RNS) RNS (van van der Vliet et al. 1997 and studies of	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
135230	16014720	179196	20996	11179	SOD1	ALS	ALS	34	0.3	and the frontal motor cortex for amyotrophic lateral sclerosis (ALS) ALS or motor neuron disease and controls	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00056102382469375<>ScoreDetail__5468|IGFALS|0.000352634551292419__11179|SOD1|0.00056102382469375__	0	0	0	0		0
135231	16014720	179197	20996	11179	SOD1	ALS	ALS	20	0.3	neuropathological diagnoses using the criteria for definite PD HD and ALS outlined in the supplemental material (available available at www.jneurosci.org	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00056102382469375<>ScoreDetail__5468|IGFALS|0.000352634551292419__11179|SOD1|0.00056102382469375__	0	0	0	0		0
135234	16014720	179202	13412	7214	MPHOSPH6	MPP	MPP	2	0.0	Striatal 1-methyl-4-phenylpyridinium (MPP MPP levels were determined by HPLC with UV detection ( =	1		JUMiner_v2.2	1	0		0	2	7214	TotalCon:2<>7214|MPHOSPH6|10200|Complete__7225|MPZ|4359|Complete__<>AvaiableGeneRif=2<>BEST:7214|MPHOSPH6|0.000481293134762078<>ScoreDetail__7214|MPHOSPH6|0.000481293134762078__7225|MPZ|0.000398765781984089__	0	0	0	0		0
135235	16014720	179203	13412	7214	MPHOSPH6	MPP	MPP	6	0.0	Striatal tissue lactate production induced by MPP and synaptosomal uptake of H MPP were performed as described	1		JUMiner_v2.2	1	0		0	2	7214	TotalCon:2<>7214|MPHOSPH6|10200|Complete__7225|MPZ|4359|Complete__<>AvaiableGeneRif=2<>BEST:7214|MPHOSPH6|0.000481293134762078<>ScoreDetail__7214|MPHOSPH6|0.000481293134762078__7225|MPZ|0.000398765781984089__	0	0	0	0		0
135236	16014720	179203	13412	7214	MPHOSPH6	MPP	MPP	12	0.0	lactate production induced by MPP and synaptosomal uptake of H MPP were performed as described previously (Wu Wu et al. 2003	1		JUMiner_v2.2	1	0		0	2	7214	TotalCon:2<>7214|MPHOSPH6|10200|Complete__7225|MPZ|4359|Complete__<>AvaiableGeneRif=2<>BEST:7214|MPHOSPH6|0.000481293134762078<>ScoreDetail__7214|MPHOSPH6|0.000481293134762078__7225|MPZ|0.000398765781984089__	0	0	0	0		0
135237	16014720	179208	1552	30000	BBS9	C18	C-18	7	0.0	The amino acids were isolated using a C-18 solid-phase extraction column and subjected to derivatization and analysis by	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
135258	16014720	179234	20996	11179	SOD1	ALS	ALS	12	0.3	assessments performed in two other neurodegenerative diseases namely HD and ALS it appears that MPO upregulation in the brain is not	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00056102382469375<>ScoreDetail__5468|IGFALS|0.000352634551292419__11179|SOD1|0.00056102382469375__	0	0	0	0		0
135275	16014720	179254	8254	4235	GFAP	GFAP	GFAP-positive	15	2.5	(blue) blue is not detected in control tissues neither in GFAP-positive cells (open open arrow nor in or around neuromelanized dopaminergic	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
135277	16014720	179255	8254	4235	GFAP	GFAP	GFAP-positive	12	2.5	MPO immunoreactivity (blue, blue small black arrow is found in GFAP-positive cells (open open arrow in PD tissue but not in	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
135286	16014720	179272	13419	7218	MPO	MPO	MPO-positive	1	1.0	These MPO-positive cells showed punctate immunoreactivity over both the cell bodies and	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
135303	16014720	179287	20996	11179	SOD1	ALS	ALS	7	0.3	Compared with controls the motor cortex from ALS patients did not exhibit higher GFAP or MPO values (data	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00056102382469375<>ScoreDetail__5468|IGFALS|0.000352634551292419__11179|SOD1|0.00056102382469375__	0	0	0	0		0
135325	16014720	179300	13412	7214	MPHOSPH6	MPP	MPP	12	0.0	controlling MPTP neurotoxicity are its conversion in the brain to MPP followed by MPP entry into dopaminergic neurons and its subsequent	1		JUMiner_v2.2	1	0		0	2	7214	TotalCon:2<>7214|MPHOSPH6|10200|Complete__7225|MPZ|4359|Complete__<>AvaiableGeneRif=2<>BEST:7214|MPHOSPH6|0.000481293134762078<>ScoreDetail__7214|MPHOSPH6|0.000481293134762078__7225|MPZ|0.000398765781984089__	0	0	0	0		0
135326	16014720	179300	13412	7214	MPHOSPH6	MPP	MPP	16	0.0	are its conversion in the brain to MPP followed by MPP entry into dopaminergic neurons and its subsequent blockade of mitochondrial	1		JUMiner_v2.2	1	0		0	2	7214	TotalCon:2<>7214|MPHOSPH6|10200|Complete__7225|MPZ|4359|Complete__<>AvaiableGeneRif=2<>BEST:7214|MPHOSPH6|0.000481293134762078<>ScoreDetail__7214|MPHOSPH6|0.000481293134762078__7225|MPZ|0.000398765781984089__	0	0	0	0		0
135329	16014720	179302	13412	7214	MPHOSPH6	MPP	MPP	6	0.0	Results show that striatal levels of MPP striatal uptake of H MPP and MPP -induced lactate production	1		JUMiner_v2.2	1	0		0	2	7214	TotalCon:2<>7214|MPHOSPH6|10200|Complete__7225|MPZ|4359|Complete__<>AvaiableGeneRif=2<>BEST:7214|MPHOSPH6|0.000481293134762078<>ScoreDetail__7214|MPHOSPH6|0.000481293134762078__7225|MPZ|0.000398765781984089__	0	0	0	0		0
135330	16014720	179302	13412	7214	MPHOSPH6	MPP	MPP	12	0.0	show that striatal levels of MPP striatal uptake of H MPP and MPP -induced lactate production (a a measure of mitochondrial	1		JUMiner_v2.2	1	0		0	2	7214	TotalCon:2<>7214|MPHOSPH6|10200|Complete__7225|MPZ|4359|Complete__<>AvaiableGeneRif=2<>BEST:7214|MPHOSPH6|0.000481293134762078<>ScoreDetail__7214|MPHOSPH6|0.000481293134762078__7225|MPZ|0.000398765781984089__	0	0	0	0		0
135331	16014720	179302	13412	7214	MPHOSPH6	MPP	MPP	15	0.0	striatal levels of MPP striatal uptake of H MPP and MPP -induced lactate production (a a measure of mitochondrial function did	1		JUMiner_v2.2	1	0		0	2	7214	TotalCon:2<>7214|MPHOSPH6|10200|Complete__7225|MPZ|4359|Complete__<>AvaiableGeneRif=2<>BEST:7214|MPHOSPH6|0.000481293134762078<>ScoreDetail__7214|MPHOSPH6|0.000481293134762078__7225|MPZ|0.000398765781984089__	0	0	0	0		0
135354	16014720	179333	6981	22140	FAM20C	RNS	RNS	15	0.0	known for its production of cytotoxic reactive oxygen species and RNS (Harrison Harrison and Schultz 1976 Eiserich et al. 1996 Hampton	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
135355	16014720	179334	13419	7218	MPO	MPO	MPO-containing	7	1.0	Therefore neurons located in the vicinity of MPO-containing cells may have their plasma membrane proteins and lipids subjected	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
140248	16101543	184879	20996	11179	SOD1	ALS	ALS	12	0.0	such as Parkinson's disease Alzheimer's disease amyotrophic lateral sclerosis (ALS), ALS Huntington stroke head trauma and infection are associated with inflammation	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000657028209296694<>ScoreDetail__5468|IGFALS|0.000261726815366272__11179|SOD1|0.000657028209296694__	0	0	0	0		0
140317	16104843	184928	23910	12680	VEGFA	VEGF	VEGF-producing	13	5.8	is known about how VEGF isoform levels are regulated most VEGF-producing cells appear to preferentially express VEGF 121 VEGF 165 and	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
140324	16104843	184931	13346	7178	MMRN1	ECM	ECM	21	0.3	6 binds heparin strongly and is completely sequestered in the ECM (extracellular extracellular matrix and to a lesser extent at the	3		JUMiner_v2.2	1	2	extracellular matrix	0	0	0		0	0	0	0		0
140365	16104843	184952	6559	3312	ELAVL1	HuR	HuR	0	0.6	HuR an AU-rich element binding protein and PAIP2 polyadenylated-binding protein-interacting protein	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
140369	16104843	184954	20149	10919	SLC14A2	UTR	UTR	6	0.3	It has been shown that the 5_amp_#180 -UTR of VEGF mRNA contains two functional internal ribosome entry sites	11		JUMiner_v2.2	1	2	untranslated region	0	2	4468	TotalCon:2<>10919|SLC14A2|8170|Complete__4468|UTS2R|2837|Complete__<>AvaiableGeneRif=2<>BEST:4468|UTS2R|0.000718341656974755<>ScoreDetail__10919|SLC14A2|0.000381768999132343__4468|UTS2R|0.000718341656974755__	0	0	0	0		0
140450	16104843	184990	1860	18380	BZW1	ORF	Orf	13	0.3	have also been identified in the genome of the parapoxvirus Orf virus 54 and have been shown to have VEGF-A-like activities	2		JUMiner_v2.2	1	2	orf	0	2	18380	TotalCon:2<>18380|BZW1|9689|Complete__11866|TMEFF1|8577|Complete__<>AvaiableGeneRif=2<>BEST:18380|BZW1|0.000784719032307457<>ScoreDetail__18380|BZW1|0.000784719032307457__11866|TMEFF1|0.000674666972898484__	0	0	0	0		0
140453	16104843	184991	1860	18380	BZW1	ORF	Orf	16	0.3	group of these proteins including VEGF-E NZ-2 (VEGF VEGF from Orf virus strain NZ-2 55 VEGF-E NZ-7 (VEGF VEGF from Orf	2		JUMiner_v2.2	1	2	orf	0	2	18380	TotalCon:2<>18380|BZW1|9689|Complete__11866|TMEFF1|8577|Complete__<>AvaiableGeneRif=2<>BEST:18380|BZW1|0.000784719032307457<>ScoreDetail__18380|BZW1|0.000784719032307457__11866|TMEFF1|0.000674666972898484__	0	0	0	0		0
140455	16104843	184991	1860	18380	BZW1	ORF	Orf	27	0.3	Orf virus strain NZ-2 55 VEGF-E NZ-7 (VEGF VEGF from Orf virus strain NZ-7 56 VEGF-E NZ-10 (VEGF VEGF from Orf	2		JUMiner_v2.2	1	2	orf	0	2	18380	TotalCon:2<>18380|BZW1|9689|Complete__11866|TMEFF1|8577|Complete__<>AvaiableGeneRif=2<>BEST:18380|BZW1|0.000784719032307457<>ScoreDetail__18380|BZW1|0.000784719032307457__11866|TMEFF1|0.000674666972898484__	0	0	0	0		0
140457	16104843	184991	1860	18380	BZW1	ORF	Orf	38	0.3	Orf virus strain NZ-7 56 VEGF-E NZ-10 (VEGF VEGF from Orf virus strain NZ-10 57 VEGF-E D1701 (VEGF VEGF from Orf	2		JUMiner_v2.2	1	2	orf	0	2	18380	TotalCon:2<>18380|BZW1|9689|Complete__11866|TMEFF1|8577|Complete__<>AvaiableGeneRif=2<>BEST:18380|BZW1|0.000784719032307457<>ScoreDetail__18380|BZW1|0.000784719032307457__11866|TMEFF1|0.000674666972898484__	0	0	0	0		0
140459	16104843	184991	1860	18380	BZW1	ORF	Orf	49	0.3	Orf virus strain NZ-10 57 VEGF-E D1701 (VEGF VEGF from Orf virus strain D1701 58 and VEGF-E VR634 (VEGF VEGF from	2		JUMiner_v2.2	1	2	orf	0	2	18380	TotalCon:2<>18380|BZW1|9689|Complete__11866|TMEFF1|8577|Complete__<>AvaiableGeneRif=2<>BEST:18380|BZW1|0.000784719032307457<>ScoreDetail__18380|BZW1|0.000784719032307457__11866|TMEFF1|0.000674666972898484__	0	0	0	0		0
140467	16104843	184996	11376	6416	KRT14	K14	K14-driven	0	0.0	K14-driven VEGF-E NZ-7 transgenic mice have shown a significant increase in	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
140647	16104843	185086	21242	11283	SRC	SRC	Src	7	0.0	An analysis of mice deficient in specific Src family kinases has demonstrated no decrease in VEGF-dependent neovascularization but	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
140648	16104843	185086	21242	11283	SRC	SRC	Src	25	0.0	VEGF-dependent neovascularization but a complete ablation of vascular permeability in Src or Yes mice whereas Fyn mice show no such defect	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
140649	16104843	185086	24357	12841	YES1	Yes	Yes	27	0.0	but a complete ablation of vascular permeability in Src or Yes mice whereas Fyn mice show no such defect 119	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
140652	16104843	185087	21242	11283	SRC	SRC	Src	4	0.0	In addition blockade of Src prevents the disassociation of a complex comprising VEGFR-2 VE-cadherin and	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
140656	16104843	185088	21242	11283	SRC	SRC	Src	8	0.0	These findings indicate that the activity of specific Src family kinases is essential for the VEGF-induced enhancement of vascular	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
140665	16104843	185092	13812	32159	MTG1	GTP	GTP-binding	2	0.5	The small GTP-binding protein Rac which is also activated by PI3K has been	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
140695	16104843	185108	21242	11283	SRC	SRC	Src	16	0.0	a VE-cadherin/ VE-cadherin b -catenin complex via the activation of Src and facilitates tumour cell extravasation and metastasis 136	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
140728	16104843	185137	21242	11283	SRC	SRC	Src	9	0.0	Paul et al 156 have reported that Src mice are resistant to VEGF-A-induced vascular permeability and show decreased	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
140730	16104843	185138	21242	11283	SRC	SRC	Src	4	0.0	Systemic application of a Src inhibitor suppresses vascular permeability protecting wild-type mice from ischaemia-induced brain	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
140740	16104843	185146	651	460	AMDP1	AMD	AMD	19	0.0	significant and clinically meaningful benefit in the treatment of neovascular AMD (age-related age-related macular degeneration 160 which is the leading cause	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>460|AMDP1|263|No_GeneRif__457|AMD1|262|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
140743	16104843	185147	20996	11179	SOD1	ALS	ALS	34	1.0	cord and causes adult-onset progressive motor neuron degeneration reminiscent of ALS (amyotrophic amyotrophic lateral sclerosis	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00117767640411015<>ScoreDetail__5468|IGFALS|0.000820142704830641__11179|SOD1|0.00117767640411015__	0	0	0	0		0
140748	16104843	185149	20996	11179	SOD1	ALS	ALS	17	1.0	is a modifier associated with motor neuron degeneration in human ALS and in a mouse model of ALS 162	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00117767640411015<>ScoreDetail__5468|IGFALS|0.000820142704830641__11179|SOD1|0.00117767640411015__	0	0	0	0		0
140749	16104843	185149	20996	11179	SOD1	ALS	ALS	24	1.0	degeneration in human ALS and in a mouse model of ALS 162	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00117767640411015<>ScoreDetail__5468|IGFALS|0.000820142704830641__11179|SOD1|0.00117767640411015__	0	0	0	0		0
140751	16104843	185150	20996	11179	SOD1	ALS	ALS	7	1.0	VEGF-A treatment increases the life expectancy of ALS mice without causing toxic side effects 163 164 indicating that	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00117767640411015<>ScoreDetail__5468|IGFALS|0.000820142704830641__11179|SOD1|0.00117767640411015__	0	0	0	0		0
140754	16104843	185150	20996	11179	SOD1	ALS	ALS	41	1.0	VEGF-A could be one of the most effective therapies for ALS reported so far	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00117767640411015<>ScoreDetail__5468|IGFALS|0.000820142704830641__11179|SOD1|0.00117767640411015__	0	0	0	0		0
140761	16104843	185154	4986	2412	CRYGEP1	CCL	CCl	7	0.0	A VEGFR-1 agonist protected the liver from CCl 4 -induced damage in spite of its inability to induce	14		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>2412|CRYGEP1|200575|No_GeneRif__2410|CRYGC|1420|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
140780	16104843	185170	20996	11179	SOD1	ALS	ALS	1	1.0	Abbreviations ALS amyotrophic lateral sclerosis DSCR1 Down syndrome critical region protein 1	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00117767640411015<>ScoreDetail__5468|IGFALS|0.000820142704830641__11179|SOD1|0.00117767640411015__	0	0	0	0		0
140782	16104843	185170	13346	7178	MMRN1	ECM	ECM	12	0.3	amyotrophic lateral sclerosis DSCR1 Down syndrome critical region protein 1 ECM extracellular matrix ERK extracellular signal-regulated kinase FAK focal adhesion kinase	3		JUMiner_v2.2	1	2	extracellular matrix	0	0	0		0	0	0	0		0
140799	16104843	185170	20149	10919	SLC14A2	UTR	UTR	120	0.3	kinase Tag T antigen T H 2 T-helper type 2 UTR untranslated region VEGF vascular endothelial growth factor VEGFR VEGF receptor	11		JUMiner_v2.2	1	2	untranslated region	0	2	4468	TotalCon:2<>10919|SLC14A2|8170|Complete__4468|UTS2R|2837|Complete__<>AvaiableGeneRif=2<>BEST:4468|UTS2R|0.000718341656974755<>ScoreDetail__10919|SLC14A2|0.000381768999132343__4468|UTS2R|0.000718341656974755__	0	0	0	0		0
140824	16104843	185179	20996	11179	SOD1	ALS	ALS	15	1.0	effect on hypoxic motor neurons and is a modifier of ALS (amyotrophic amyotrophic lateral sclerosis	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00117767640411015<>ScoreDetail__5468|IGFALS|0.000820142704830641__11179|SOD1|0.00117767640411015__	0	0	0	0		0
142213	16120782	186870	20996	11179	SOD1	ALS	ALS	3	1.9	Amyotrophic lateral sclerosis (ALS) ALS represents a fatal neurodegenerative disorder characterized by progressive death of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142216	16120782	186872	20996	11179	SOD1	ALS	ALS	25	1.9	dismutase (SOD1)-G93A SOD1 -G93A transgenic mice a mouse model of ALS benefit from oral treatment with the PPAR gamma agonist pioglitazone	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142224	16120782	186881	20996	11179	SOD1	ALS	ALS	13	1.9	as Alzheimer's disease (AD) AD and amyotrophic lateral sclerosis (ALS), ALS are accompanied by an inflammatory component it has been hypothesized	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142225	16120782	186882	20996	11179	SOD1	ALS	ALS	19	1.9	developed and tested in animal models and clinical trials of ALS and AD (Lim Lim et al. 2000 In t'Veld et	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142226	16120782	186882	16343	17468	PDLIM5	LIM	Lim	22	0.8	animal models and clinical trials of ALS and AD (Lim Lim et al. 2000 In t'Veld et al. 2001 Drachman et	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
142227	16120782	186883	20996	11179	SOD1	ALS	ALS	5	1.9	The primary pathological feature of ALS is the loss of motor neurons (Talbot, Talbot 2002 which	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142231	16120782	186884	20996	11179	SOD1	ALS	ALS	32	1.9	superoxide dismutase (SOD1), SOD1 which have been linked to inherited ALS (Gurney Gurney et al. 1994 Hensley et al. 2002 Yoshihara	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142237	16120782	186887	20996	11179	SOD1	ALS	ALS	35	1.9	reduce neuroinflammation protect from motor neuron loss and improve clinical ALS symptoms	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142242	16120782	186918	19305	10489	S100A12	CGRP	CGRP	8	1.3	Sections were then stained for calcitonin gene-related peptide (CGRP) CGRP immunoreactivity essentially as described in detail previously (Schutz Schutz et	1		JUMiner_v2.2	1	2	calcitonin gene-related peptide	0	2	10489	TotalCon:2<>10489|S100A12|6283|Complete__1437|CALCA|796|Complete__<>AvaiableGeneRif=2<>BEST:10489|S100A12|0.000449019781345252<>ScoreDetail__1437|CALCA|0.000385381921135833__10489|S100A12|0.000449019781345252__	0	0	0	0		0
142243	16120782	186919	19305	10489	S100A12	CGRP	CGRP-positive	6	1.3	For the quantification of motor neurons CGRP-positive cell bodies were counted on six sections per animal and	1		JUMiner_v2.2	1	2	calcitonin gene-related peptide	0	2	10489	TotalCon:2<>10489|S100A12|6283|Complete__1437|CALCA|796|Complete__<>AvaiableGeneRif=2<>BEST:10489|S100A12|0.000449019781345252<>ScoreDetail__1437|CALCA|0.000385381921135833__10489|S100A12|0.000449019781345252__	0	0	0	0		0
142246	16120782	186933	19254	10472	RUNX2	CCD	CCD	26	0.3	a Nikon (D_amp_uuml;sseldorf, D_amp_uuml sseldorf Germany H800 microscope with a CCD camera (DXP-9100P DXP-9100P 3CCD color video Sony Tokyo Japan and	1		JUMiner_v2.2	1	2	ccd camera	0	0	0		0	0	0	0		0
142247	16120782	186933	16343	17468	PDLIM5	LIM	LIM	40	0.8	video Sony Tokyo Japan and using Lucia imaging software (LIM LIM Laboratory Imaging distributed by Nikon	1		JUMiner_v2.2	1	2	lim et al	0	0	0		0	0	0	0		0
142248	16120782	186936	19573	10691	SDS	SDS	SDS	23	0.0	radioimmunoprecipitation assay buffer (1% 1% Triton 1% sodium deoxycholate 0.1% SDS 150 m M NaCl 50 m M Tris-HCl pH 7.2	1		JUMiner_v2.2	1	0		0	2	19440	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:19440|SBDS|0.000302519680639415<>ScoreDetail__10691|SDS|6.84041316095492e-05__19440|SBDS|0.000302519680639415__	0	0	0	0		0
142255	16120782	186937	19573	10691	SDS	SDS	SDS	16	0.0	COX-2 100 microg of protein samples was separated in 10% SDS gels transferred onto Immobilon-P polyvinylidene difluoride membranes and stained with	1		JUMiner_v2.2	1	0		0	2	19440	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:19440|SBDS|0.000302519680639415<>ScoreDetail__10691|SDS|6.84041316095492e-05__19440|SBDS|0.000302519680639415__	0	0	0	0		0
142263	16120782	186939	19573	10691	SDS	SDS	SDS	17	0.0	SOD1 2 microg of protein samples was separated in 15% SDS gels transferred onto nitrocellulose membranes and stained with a rabbit	1		JUMiner_v2.2	1	0		0	2	19440	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:19440|SBDS|0.000302519680639415<>ScoreDetail__10691|SDS|6.84041316095492e-05__19440|SBDS|0.000302519680639415__	0	0	0	0		0
142275	16120782	186948	16033	8600	PANX2	PX2	PX2	30	0.0	s and extension at 72degreeC for 45 s using a PX2 thermocycler (ThermoHybaid, ThermoHybaid Ulm Germany	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
142285	16120782	186978	20996	11179	SOD1	ALS	ALS	12	1.9	COX-2 and iNOS were described in several neurodegenerative disorders including ALS as well as in the SOD1-G93A model used in this	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142294	16120782	186983	20996	11179	SOD1	ALS	ALS	0	1.9	ALS is a fatal neurodegenerative disease without curative treatment options to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142295	16120782	186985	20996	11179	SOD1	ALS	ALS	13	1.9	including excitotoxic apoptotic and metabolic mechanisms have been implied in ALS pathogenesis and proposed as therapeutic targets (Talbot, Talbot 2002	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142297	16120782	186988	20996	11179	SOD1	ALS	ALS	35	1.9	radicals may significantly contribute to the development and progression of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142301	16120782	186990	20996	11179	SOD1	ALS	ALS	16	1.9	suppression of inflammation may offer a new therapeutic avenue in ALS treatment as supported by previous findings in animal models of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142307	16120782	187002	19305	10489	S100A12	CGRP	CGRP-positive	14	1.3	treatment on motor neuron degeneration and muscle fiber morphology a CGRP-positive motor neuron numbers in the lumbar spinal cord ( n	1		JUMiner_v2.2	1	2	calcitonin gene-related peptide	0	2	10489	TotalCon:2<>10489|S100A12|6283|Complete__1437|CALCA|796|Complete__<>AvaiableGeneRif=2<>BEST:10489|S100A12|0.000449019781345252<>ScoreDetail__1437|CALCA|0.000385381921135833__10489|S100A12|0.000449019781345252__	0	0	0	0		0
142311	16120782	187003	19305	10489	S100A12	CGRP	CGRP	4	1.3	Error bars represent SEM (CGRP CGRP cells or SD (median median fiber diameter b Evaluation of	1		JUMiner_v2.2	1	2	32	0	2	10489	TotalCon:2<>10489|S100A12|6283|Complete__1437|CALCA|796|Complete__<>AvaiableGeneRif=2<>BEST:10489|S100A12|0.000449019781345252<>ScoreDetail__1437|CALCA|0.000385381921135833__10489|S100A12|0.000449019781345252__	0	0	0	0		0
142312	16120782	187003	19305	10489	S100A12	CGRP	CGRP	22	1.3	b Evaluation of the spinal cord motor neuron area by CGRP immunohistochemistry and muscle fiber morphology by histological HE stain	1		JUMiner_v2.2	1	2	calcitonin gene-related peptide	0	2	10489	TotalCon:2<>10489|S100A12|6283|Complete__1437|CALCA|796|Complete__<>AvaiableGeneRif=2<>BEST:10489|S100A12|0.000449019781345252<>ScoreDetail__1437|CALCA|0.000385381921135833__10489|S100A12|0.000449019781345252__	0	0	0	0		0
142314	16120782	187005	19305	10489	S100A12	CGRP	CGRP	20	1.3	inflammation markers a Immunofluorescence colabeling of CD11b (green) green and CGRP (red) red in the spinal cord motor neuron area at	1		JUMiner_v2.2	1	2	calcitonin gene-related peptide	0	2	10489	TotalCon:2<>10489|S100A12|6283|Complete__1437|CALCA|796|Complete__<>AvaiableGeneRif=2<>BEST:10489|S100A12|0.000449019781345252<>ScoreDetail__1437|CALCA|0.000385381921135833__10489|S100A12|0.000449019781345252__	0	0	0	0		0
142364	16120782	187034	20996	11179	SOD1	ALS	ALS	4	1.9	Antiinflammatory treatment strategies in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142365	16120782	187035	20996	11179	SOD1	ALS	ALS	22	1.9	significantly contributes to the progression of motor neuron death in ALS has been supported by studies on SOD1 transgenic mice reporting	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142367	16120782	187038	20996	11179	SOD1	ALS	ALS	29	1.9	not allow us to conclude that patients suffering from sporadic ALS will benefit from PPAR gamma-agonist treatment if initiated after clinical	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142369	16120782	187039	20996	11179	SOD1	ALS	ALS	10	1.9	However it seems possible that in the case of familiar ALS family members with an inherited ALS risk which can be	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142370	16120782	187039	20996	11179	SOD1	ALS	ALS	16	1.9	the case of familiar ALS family members with an inherited ALS risk which can be diagnosed before the appearance of clinical	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142372	16120782	187040	20996	11179	SOD1	ALS	ALS	29	1.9	they would be available readily for clinical trials in human ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00102919223206476<>ScoreDetail__5468|IGFALS|0.000491297024143739__11179|SOD1|0.00102919223206476__	0	0	0	0		0
142373	16120782	187045	19305	10489	S100A12	CGRP	CGRP	26	1.3	Nyberg (Uppsala, Uppsala Sweden for the generous gift of the CGRP antibody and Dr Albrecht Clement (Mainz, Mainz Germany for donating	1		JUMiner_v2.2	1	2	calcitonin gene-related peptide	0	2	10489	TotalCon:2<>10489|S100A12|6283|Complete__1437|CALCA|796|Complete__<>AvaiableGeneRif=2<>BEST:10489|S100A12|0.000449019781345252<>ScoreDetail__1437|CALCA|0.000385381921135833__10489|S100A12|0.000449019781345252__	0	0	0	0		0
142375	16120782	187045	10290	5825	IGKV3D-20	A11	A11	0	0.0	(SFB400/A11), SFB400 A11 and by Grant DA016768 from the National Institutes of Health	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
131177	16179515	172934	20996	11179	SOD1	ALS	ALS	24	1.7	SOD1 mouse an animal model of amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00139723958710624<>ScoreDetail__5468|IGFALS|0.000612915807655876__11179|SOD1|0.00139723958710624__	0	0	0	0		0
131182	16179515	172942	5200	10672	CXCL12	SDF1	SDF-1	21	0.0	mutation glial fibrillary acidic protein (GFAP), GFAP stroma-derived factor-1 (SDF-1), SDF-1 and excitatory amino acid transporter-2 (EAAT2) EAAT2	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
132373	16197805	174843	20996	11179	SOD1	ALS	ALS	12	0.0	briefly summarize their possible roles in amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000974177821936674<>ScoreDetail__5468|IGFALS|0.000368030423848371__11179|SOD1|0.000974177821936674__	0	0	0	0		0
126503	16326025	166566	9947	5468	IGFALS	ALS	ALS	12	0.3	of SSTT in therapeutic strategies against amyotrophic lateral sclerosis (ALS) ALS or early-stage Alzheimer_amp_#x2019 s disease may offer a reasonable first	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000554703949134244<>ScoreDetail__5468|IGFALS|0.000339500933627567__11179|SOD1|0.000554703949134244__	0	0	0	0		0
126504	16326025	166567	9947	5468	IGFALS	ALS	ALS	10	0.3	In view of the known rapid progressive neurodegeneration associated with ALS minute variations in core body temperature may in fact demonstrate	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000554703949134244<>ScoreDetail__5468|IGFALS|0.000339500933627567__11179|SOD1|0.000554703949134244__	0	0	0	0		0
128657	16380619	169458	11629	6493	LAMC2	CSF	CSF	13	0.0	compared IL-6 and tumor necrosis factor alpha TNF-alpha levels in CSF and sera from 10 hypoxemics and 10 normoxemics patients with	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
128664	16380619	169463	11629	6493	LAMC2	CSF	CSF	12	0.0	excessive production of tumor necrosis factor alpha TNF-alpha with lower CSF levels of interleukin (IL)-6 IL -6 was demonstrated in a	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
128672	16380619	169466	11629	6493	LAMC2	CSF	CSF	34	0.0	controls or elevated levels of IL-6 and IL-1_amp_#223 in the CSF spinal cords and sera of patients with ALS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
128677	16380619	169469	11629	6493	LAMC2	CSF	CSF	27	0.0	cytokines by studying TNF-alpha and IL-6 in the sera and CSF of hypoxemic and normoxemic patients with ALS and neurologic controls	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
128679	16380619	169470	11629	6493	LAMC2	CSF	CSF	2	0.0	Plasma and CSF from patients with ALS and control subjects were obtained with	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
128680	16380619	169475	11629	6493	LAMC2	CSF	CSF	2	0.0	Sera and CSF samples were stored in a refrigerator at -80degreeC	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
128683	16380619	169476	11629	6493	LAMC2	CSF	CSF	6	0.0	IL-6 and TNF-alpha levels in CSF and sera were determined using a chemiluminescent assay (QuantiGlo, QuantiGlo	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
128687	16380619	169477	11629	6493	LAMC2	CSF	CSF	7	0.1	We found higher levels of IL-6 in CSF ( z = -2.7 p = 0.02 in serum (	6		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
128692	16380619	169478	16035	20837	PAOX	PAO	Pao	4	0.0	A correlation exists between Pao 2 and levels of CSF IL-6 ( p = 0.0001	2		JUMiner_v2.2	1	0		0	2	15862	TotalCon:2<>20837|PAOX|196743|Complete__15862|SMOX|54498|Complete__<>AvaiableGeneRif=2<>BEST:15862|SMOX|0.000474608448030375<>ScoreDetail__20837|PAOX|0.000447227191413238__15862|SMOX|0.000474608448030375__	0	0	0	0		0
128693	16380619	169478	11629	6493	LAMC2	CSF	CSF	9	0.2	A correlation exists between Pao 2 and levels of CSF IL-6 ( p = 0.0001 r = -0.7 serum IL-6	5		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
128696	16380619	169479	11629	6493	LAMC2	CSF	CSF	10	0.1	In neurologic controls we found higher levels of IL-6 in CSF ( z = -2.8 p = 0.02 in serum (	6		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
128700	16380619	169480	16035	20837	PAOX	PAO	Pao	4	0.0	There were correlations between Pao 2 and CSF IL-6 ( p = 0.01 r =	2		JUMiner_v2.2	1	0		0	2	15862	TotalCon:2<>20837|PAOX|196743|Complete__15862|SMOX|54498|Complete__<>AvaiableGeneRif=2<>BEST:15862|SMOX|0.000474608448030375<>ScoreDetail__20837|PAOX|0.000447227191413238__15862|SMOX|0.000474608448030375__	0	0	0	0		0
128701	16380619	169480	11629	6493	LAMC2	CSF	CSF	7	0.2	There were correlations between Pao 2 and CSF IL-6 ( p = 0.01 r = 0.5 serum IL-6	5		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
128703	16380619	169481	11629	6493	LAMC2	CSF	CSF	5	0.0	TNF-alpha was undetectable in CSF	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
128706	16380619	169482	11629	6493	LAMC2	CSF	CSF	15	0.0	between IL-6 or TNF-alpha levels in plasma and those in CSF	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
128713	16380619	169484	11629	6493	LAMC2	CSF	CSF	8	0.0	We found an increase in IL-6 levels in CSF and sera and TNF-alpha in sera in hypoxemic patients with	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
128747	16380619	169505	11629	6493	LAMC2	CSF	CSF	0	0.0	CSF and sera interleukin-6 levels and tumor necrosis factor alpha sera	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
128748	16380619	169505	16035	20837	PAOX	PAO	Pao	24	0.0	ALS according to the condition of hypoxemia or normoxemia (Pao Pao 2 *Significant difference (p p _lt_ 0.05 between the hypoxemic	2		JUMiner_v2.2	1	0		0	2	15862	TotalCon:2<>20837|PAOX|196743|Complete__15862|SMOX|54498|Complete__<>AvaiableGeneRif=2<>BEST:15862|SMOX|0.000474608448030375<>ScoreDetail__20837|PAOX|0.000447227191413238__15862|SMOX|0.000474608448030375__	0	0	0	0		0
128749	16380619	169507	11629	6493	LAMC2	CSF	CSF	0	0.0	CSF and sera interleukin-6 levels and tumor necrosis factor alpha sera	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
128750	16380619	169507	16035	20837	PAOX	PAO	Pao	23	0.0	controls according to the condition of hypoxemia or normoxemia (Pao Pao 2 *Significant difference (p p _lt_ 0.05 between the hypoxemic	2		JUMiner_v2.2	1	0		0	2	15862	TotalCon:2<>20837|PAOX|196743|Complete__15862|SMOX|54498|Complete__<>AvaiableGeneRif=2<>BEST:15862|SMOX|0.000474608448030375<>ScoreDetail__20837|PAOX|0.000447227191413238__15862|SMOX|0.000474608448030375__	0	0	0	0		0
128751	16380619	169510	16035	20837	PAOX	PAO	Pao	14	0.0	to be hypoxemic if their oxygen arterial blood pressure (Pao Pao 2 was below the age-dependent minimal reference value each time	2		JUMiner_v2.2	1	0		0	2	15862	TotalCon:2<>20837|PAOX|196743|Complete__15862|SMOX|54498|Complete__<>AvaiableGeneRif=2<>BEST:15862|SMOX|0.000474608448030375<>ScoreDetail__20837|PAOX|0.000447227191413238__15862|SMOX|0.000474608448030375__	0	0	0	0		0
128753	16380619	169515	20006	10902	SLA	SLA	SLA	11	0.2	by grants from the Association pour la Recherche sur la SLA (ARS) ARS	5		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>10902|SLA|6503|Complete__30605|SEPSECS|51091|No_GeneRif__<>AvaiableGeneRif=1<>	1	1	0	0		0
118012	16425674	153703	20996	11179	SOD1	ALS	ALS	28	0.9	as a potential subcutaneous treatment for amyotrophic lateral sclerosis (ALS), ALS stroke spinal cord injury lung inflammation and mucositis	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000793984273108762<>ScoreDetail__5468|IGFALS|0.000310607237148626__11179|SOD1|0.000793984273108762__	0	0	0	0		0
118013	16425674	153704	20996	11179	SOD1	ALS	ALS	11	0.9	compound is currently undergoing a phase I clinical trial for ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000793984273108762<>ScoreDetail__5468|IGFALS|0.000310607237148626__11179|SOD1|0.000793984273108762__	0	0	0	0		0
118580	16436205	154682	20996	11179	SOD1	ALS	ALS	19	1.4	dismutase (G93A-SOD1) G93A-SOD1 associated with familial amyotrophic lateral sclerosis (ALS) ALS demonstrate age-dependent neuroinflammation associated with broad-spectrum cytokine eicosanoid and oxidant	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00115672406106539<>ScoreDetail__5468|IGFALS|0.000514378092392103__11179|SOD1|0.00115672406106539__	0	0	0	0		0
118584	16436205	154686	18741	10289	RPA1	RPA	RPAs	20	0.0	G93A-SOD1 cells as assessed by multiprobe ribonuclease protection assays (RPAs) RPAs for their mRNA transcripts	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
118585	16436205	154688	20996	11179	SOD1	ALS	ALS	10	1.4	These findings support a role for active glial involvement in ALS and may provide a useful cell culture tool for the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00115672406106539<>ScoreDetail__5468|IGFALS|0.000514378092392103__11179|SOD1|0.00115672406106539__	0	0	0	0		0
118586	16436205	154690	20996	11179	SOD1	ALS	ALS	10	1.4	the proximal cause of paralysis in amyotrophic lateral sclerosis (ALS) ALS is the death of motor neurons it is becoming widely	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00115672406106539<>ScoreDetail__5468|IGFALS|0.000514378092392103__11179|SOD1|0.00115672406106539__	0	0	0	0		0
118587	16436205	154690	20996	11179	SOD1	ALS	ALS	27	1.4	it is becoming widely accepted that motor neuron death in ALS is not cell autonomous but depends upon active and passive	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00115672406106539<>ScoreDetail__5468|IGFALS|0.000514378092392103__11179|SOD1|0.00115672406106539__	0	0	0	0		0
118588	16436205	154691	20996	11179	SOD1	ALS	ALS	4	1.4	The neuron-cell autonomy of ALS pathogenesis has been strongly questioned by a number of studies	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00115672406106539<>ScoreDetail__5468|IGFALS|0.000514378092392103__11179|SOD1|0.00115672406106539__	0	0	0	0		0
118596	16436205	154698	20996	11179	SOD1	ALS	ALS	10	1.4	These studies provide strong incentive to consider glial involvement in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00115672406106539<>ScoreDetail__5468|IGFALS|0.000514378092392103__11179|SOD1|0.00115672406106539__	0	0	0	0		0
118597	16436205	154700	20996	11179	SOD1	ALS	ALS	7	1.4	Using the G93A-SOD1 mutant mouse model for ALS Gurney et al reported dramatically increased numbers of MHC-II microglia	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00115672406106539<>ScoreDetail__5468|IGFALS|0.000514378092392103__11179|SOD1|0.00115672406106539__	0	0	0	0		0
118598	16436205	154702	20996	11179	SOD1	ALS	ALS-linked	38	1.4	the application of this cytokine in cell culture studies of ALS-linked glial activation	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00115672406106539<>ScoreDetail__5468|IGFALS|0.000514378092392103__11179|SOD1|0.00115672406106539__	0	0	0	0		0
118599	16436205	154705	20996	11179	SOD1	ALS	ALS	23	1.4	antagonist nordihydroguaiaretic acid (NDGA) NDGA slows disease progression in the ALS mouse 14	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00115672406106539<>ScoreDetail__5468|IGFALS|0.000514378092392103__11179|SOD1|0.00115672406106539__	0	0	0	0		0
118600	16436205	154706	20996	11179	SOD1	ALS	ALS	16	1.4	neuroinflammatory response antagonism of which may slow the progression of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00115672406106539<>ScoreDetail__5468|IGFALS|0.000514378092392103__11179|SOD1|0.00115672406106539__	0	0	0	0		0
118601	16436205	154707	20996	11179	SOD1	ALS	ALS	13	1.4	better understand the contributions of astroglia to neuroinflammation in the ALS context and to create a tool for the study of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00115672406106539<>ScoreDetail__5468|IGFALS|0.000514378092392103__11179|SOD1|0.00115672406106539__	0	0	0	0		0
118608	16436205	154723	6895	3530	F12	F12	F12	17	0.0	of 50% Dulbecco's Modified Essential Medium (DMEM) DMEM and 50% F12 media containing 10% heat-inactivated fetal bovine serum 1% glutamine and	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
118610	16436205	154742	18741	10289	RPA1	RPA	RPAs	10	0.0	and methods Ribonuclease protection assays Multiprobe ribonuclease protection assays (RPAs) RPAs were performed as described 14 7 8	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
118611	16436205	154745	18741	10289	RPA1	RPA	RPA	7	0.0	Panels of mRNA were detected using commercial RPA kits (Riboquant_amp_#x02122;, Riboquant_amp_#x02122 Pharmingen San Diego CA	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
118614	16436205	154763	12519	6983	ME1	MES	MES	7	0.0	were lysed in 20 mM 2-(N-morpholino)-ethanesulfonate 2- N-morpholino -ethanesulfonate (MES) MES buffer pH 5.5 containing 0.1% triton X-100 5 mM biotin-LC-hydrazide	1		JUMiner_v2.2	1	0		0	2	7121	TotalCon:2<>6983|ME1|4199|Complete__7121|MKS1|54903|Complete__<>AvaiableGeneRif=2<>BEST:7121|MKS1|0.000281213582841022<>ScoreDetail__7121|MKS1|0.000281213582841022__6983|ME1|0.000245218244237371__	0	0	0	0		0
118615	16436205	154770	18741	10289	RPA1	RPA	RPAs	66	0.0	immunoblot (not not shown or cytokine expression patterns assessed by RPAs (data data not shown	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
118617	16436205	154778	18741	10289	RPA1	RPA	RPA	10	0.0	Results Specific cytokine expressioin differences occur in G93A-SOD1 astrocytes Multiprobe RPA methods were used to assess genotype-dependent differences in cytokine-stimulated cytokine	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
118635	16436205	154826	20996	11179	SOD1	ALS	ALS	4	1.4	In murine models of ALS neuroinflammation is robust as indicated by broad-spectrum cytokine upregulation plus	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00115672406106539<>ScoreDetail__5468|IGFALS|0.000514378092392103__11179|SOD1|0.00115672406106539__	0	0	0	0		0
118642	16436205	154837	20996	11179	SOD1	ALS	ALS	9	1.4	One of the most important unaccomplished necessities in understanding ALS is to elucidate the toxic gain-of-function(s) gain-of-function s inherent to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00115672406106539<>ScoreDetail__5468|IGFALS|0.000514378092392103__11179|SOD1|0.00115672406106539__	0	0	0	0		0
122173	16510725	160989	20996	11179	SOD1	ALS	ALS	20	1.4	pathogenesis of motor neuron death in amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122178	16510725	160991	20996	11179	SOD1	ALS	ALS	14	1.4	TNF-alpha and FasL immunoreactivity in lumbar spinal cord sections of ALS patients and G93A transgenic mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122189	16510725	160997	20996	11179	SOD1	ALS	ALS	14	1.4	lenalidomide bear promise as therapeutic interventions for the treatment of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122193	16510725	160999	20996	11179	SOD1	ALS	ALS	3	1.4	Amyotrophic lateral sclerosis (ALS) ALS is a fatal disease characterized by an age-related progressive degeneration	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122194	16510725	160999	19891	29546	SH3YL1	Ray	Ray-Chaudhuri	23	0.6	of both upper and lower motor neurons (Leigh Leigh and Ray-Chaudhuri 1994	11		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
122195	16510725	161000	20996	11179	SOD1	ALS	ALS	3	1.4	Approximately 5-10% of ALS cases are familial and exhibit an autosomal-dominant pattern of inheritance	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122196	16510725	161001	20996	11179	SOD1	ALS	ALS	7	1.4	A major discovery in the study of ALS was the finding of missense mutations in the enzyme copper-zinc	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122198	16510725	161001	20996	11179	SOD1	ALS	ALS	28	1.4	dismutase (SOD1), SOD1 which is associated with 15-20% of familial ALS cases (Rosen Rosen et al. 1993	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122199	16510725	161003	20996	11179	SOD1	ALS	ALS	8	1.4	Neuroinflammation is one of the pathological hallmarks in ALS transgenic mice (West West et al. 1991 Almer et al.	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122205	16510725	161004	20996	11179	SOD1	ALS	ALS	107	1.4	soluble TNF receptor are elevated in serum of humans with ALS (Poloni Poloni et al. 2000 alpha is capable of activating	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122217	16510725	161007	20996	11179	SOD1	ALS	ALS	21	1.4	FasL are elevated in both human and mouse models of ALS and play a role in the pathogenesis of ALS we	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122218	16510725	161007	20996	11179	SOD1	ALS	ALS	30	1.4	of ALS and play a role in the pathogenesis of ALS we tested the neuroprotective effects of thalidomide and lenalidomide two	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122221	16510725	161009	20996	11179	SOD1	ALS	ALS	4	1.4	G93A SOD1 transgenic familial ALS mice (high high copy number (Gurney Gurney et al. 1994	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122237	16510725	161065	20996	11179	SOD1	ALS	ALS	5	1.4	Paraffin-embedded spinal cord tissues from ALS patients ( n = 6 four males and two females	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122238	16510725	161066	20996	11179	SOD1	ALS	ALS	3	1.4	One of the ALS patients had an I113T mutation of the SOD1 gene	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122240	16510725	161068	20996	11179	SOD1	ALS	ALS	11	1.4	age at death was 59 years (range, range 27-69 for ALS patients and 65 years (range, range 54-73 for controls	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122243	16510725	161073	18741	10289	RPA1	RPA	RPA	4	0.0	Commercial ribonuclease protection assay (RPA) RPA probe sets (PharMingen, PharMingen San Diego CA were used to	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
122247	16510725	161082	20996	11179	SOD1	ALS	ALS	11	1.4	TNF-alpha and FasL immunoreactivity in G93A SOD1 mouse model of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122255	16510725	161088	20996	11179	SOD1	ALS	ALS	5	1.4	Pro-inflammatory cytokines are implicated in ALS pathogenesis	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122256	16510725	161089	20996	11179	SOD1	ALS	ALS	6	1.4	Previous evidence for inflammatory mechanisms in ALS comes from a number of studies (Almer Almer et al.	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122257	16510725	161089	11629	6493	LAMC2	CSF	CSF	22	0.3	(Almer Almer et al. 2001 beta are increased in the CSF and spinal cord respectively in ALS patients (Almer Almer et	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
122258	16510725	161089	20996	11179	SOD1	ALS	ALS	28	1.4	are increased in the CSF and spinal cord respectively in ALS patients (Almer Almer et al. 1999 beta is also increased	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122259	16510725	161089	20996	11179	SOD1	ALS	ALS	43	1.4	1999 beta is also increased in transgenic mouse models of ALS (Ghezzi Ghezzi et al. 1998 beta activation slowed disease progression	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122260	16510725	161089	20996	11179	SOD1	ALS	ALS	59	1.4	activation slowed disease progression in a transgenic mouse model of ALS (Li Li et al. 2000	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122263	16510725	161091	20996	11179	SOD1	ALS	ALS	6	1.4	Studies performed in mouse models of ALS and patients with ALS show increases in TNF-alpha.	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122264	16510725	161091	20996	11179	SOD1	ALS	ALS	10	1.4	Studies performed in mouse models of ALS and patients with ALS show increases in TNF-alpha.	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122266	16510725	161092	20996	11179	SOD1	ALS	ALS	1	1.4	In ALS patients antigenic TNF-alpha and its soluble receptors measured by ELISA	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122268	16510725	161092	20996	11179	SOD1	ALS	ALS	17	1.4	its soluble receptors measured by ELISA were significantly higher in ALS patients than in healthy controls (Poloni Poloni et al. 2000	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122276	16510725	161092	18741	10289	RPA1	RPA	RPAs	84	0.0	Elliott 2001 alpha receptors was also present A study using RPAs showed increased Fas-associated death domain (FADD) FADD and TNF-alpha receptor	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
122304	16510725	161105	20996	11179	SOD1	ALS	ALS	12	1.4	provide additional evidence for a role of pro-inflammatory cytokines in ALS and suggest that TNF-alpha and FasL and related cytokines have	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122307	16510725	161105	20996	11179	SOD1	ALS	ALS	31	1.4	related cytokines have important triggering roles in the pathogenesis of ALS in initiating a cell death pathway(s) pathway s	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122319	16510725	161109	20996	11179	SOD1	ALS	ALS	18	1.4	and lenalidomide may have therapeutic value for treatment of human ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122323	16510725	161113	20996	11179	SOD1	ALS	ALS	33	1.4	one or several pathways to cause motor neuron degeneration in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122328	16510725	161120	20996	11179	SOD1	ALS	ALS	13	1.4	therefore have promise as therapeutic agents for the treatment of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122359	16510725	161139	20996	11179	SOD1	ALS	ALS	7	1.4	TNF-alpha and FasL immunoreactivity in human ALS and controls	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122362	16510725	161140	20996	11179	SOD1	ALS	ALS	20	1.4	the lumbar ventral horn of the spinal cord of human ALS and control patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122365	16510725	161141	20996	11179	SOD1	ALS	ALS	16	1.4	neurons in the lumbar spinal cord sections of a familial ALS patient with SOD1 mutation (I113T) I113T and sporadic ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122367	16510725	161141	20996	11179	SOD1	ALS	ALS	24	1.4	familial ALS patient with SOD1 mutation (I113T) I113T and sporadic ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122370	16510725	161142	20996	11179	SOD1	ALS	ALS	11	1.4	Intense TNF-alpha and FasL immunoreactivity occurred predominantly in neurons of ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122373	16510725	161143	20996	11179	SOD1	ALS	ALS	15	1.4	FasL occurred in the same neurons in adjacent sections of ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122389	16510725	161168	18741	10289	RPA1	RPA	RPA	8	0.0	Spinal cord total RNA was used against a RPA multiprobe of cytokines a IL-1 alpha RNA was elevated in	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
122390	16510725	161168	22059	11766	TGFB1	TGFB1	TGF-beta1	124	0.0	elevated further in both lenalidomide- and thalidomide-treated G93A mice e TGF-beta1 RNA was not changed significantly in vehicle-treated G93A mice compared	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
122405	16510725	161177	20996	11179	SOD1	ALS	ALS	7	1.4	TNF-alpha and FasL immunoreactivity in human ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122406	16510725	161178	20996	11179	SOD1	ALS	ALS	6	1.4	Consistent with the immunohistochemical findings in ALS transgenic mice intense TNF-alpha and FasL immunoreactivity occurred in the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122409	16510725	161178	20996	11179	SOD1	ALS	ALS	24	1.4	immunoreactivity occurred in the lumbar spinal cord sections from an ALS patient with a SOD1 mutation (I113T) I113T as well as	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122411	16510725	161178	20996	11179	SOD1	ALS	ALS	35	1.4	with a SOD1 mutation (I113T) I113T as well as sporadic ALS patients whereas control tissues showed very little or no TNF-alpha	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
122426	16510725	161202	18741	10289	RPA1	RPA	RPAs	4	0.0	Cytokine levels by multiprobe RPAs	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
122427	16510725	161203	18741	10289	RPA1	RPA	RPA	22	0.0	G93A mice at 110 d of age were subjected to RPA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
122429	16510725	161204	18741	10289	RPA1	RPA	RPA	0	0.0	RPA showed that both thalidomide and lenalidomide downregulated interleukin (IL)-12p40 IL	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
122430	16510725	161204	22059	11766	TGFB1	TGFB1	TGF-beta1	12	0.0	thalidomide and lenalidomide downregulated interleukin (IL)-12p40 IL -12p40 and upregulated TGF-beta1 and IL-1RA in treated G93A mice compared with vehicle-treated G93A	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
122439	16510725	161210	20996	11179	SOD1	ALS	ALS	8	1.4	We thank Dr A Hays for providing human ALS spinal cord samples	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0011541420877148<>ScoreDetail__5468|IGFALS|0.000575879295699621__11179|SOD1|0.0011541420877148__	0	0	0	0		0
109232	16533145	142006	20996	11179	SOD1	ALS	ALS	4	1.9	Although amyotrophic lateral sclerosis (ALS) ALS was described more than 130 years ago the cause(s) cause	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00141825132207281<>ScoreDetail__5468|IGFALS|0.000434480361487661__11179|SOD1|0.00141825132207281__	0	0	0	0		0
109233	16533145	142007	20996	11179	SOD1	ALS	ALS	19	1.9	superoxide dismutase as a primary cause of some forms of ALS model systems have been developed that have helped us begin	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00141825132207281<>ScoreDetail__5468|IGFALS|0.000434480361487661__11179|SOD1|0.00141825132207281__	0	0	0	0		0
113036	16624536	146803	20996	11179	SOD1	ALS	ALS	3	1.7	Amyotrophic lateral sclerosis (ALS) ALS is a fatal neurodegenerative condition in which motor neurons are	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113037	16624536	146805	20996	11179	SOD1	ALS	ALS	14	1.7	motor neuron loss is evident in presymptomatic mouse models of ALS and in human patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113038	16624536	146806	20996	11179	SOD1	ALS	ALS	8	1.7	Efforts aimed at attenuating the inflammatory response in ALS animal models have delayed symptom onset and extended survival	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113039	16624536	146809	20996	11179	SOD1	ALS	ALS	1	1.7	Because ALS is a syndromic disease in which glutamate excitotoxicity altered cytoskeletal	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113040	16624536	146824	20996	11179	SOD1	ALS	ALS	3	1.7	Amyotrophic lateral sclerosis (ALS) ALS is a fatal neurodegenerative disease characterized by the selective loss	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113041	16624536	146828	20996	11179	SOD1	ALS	ALS	6	1.7	While between 5 and 8% of ALS cases are familial (fALS), fALS of which 20% harbour missense	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113043	16624536	146828	20996	11179	SOD1	ALS	ALS	29	1.7	zinc superoxide dismutase (SOD1) SOD1 gene 3 the majority of ALS cases are sporadic (sALS) sALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113044	16624536	146829	20996	11179	SOD1	ALS	ALS	4	1.7	Although the etiology of ALS remains to be defined the contemporary understanding of ALS is	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113045	16624536	146829	20996	11179	SOD1	ALS	ALS	13	1.7	of ALS remains to be defined the contemporary understanding of ALS is that it is likely syndromic as opposed to a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113046	16624536	146830	20996	11179	SOD1	ALS	ALS	7	1.7	Key components of the pathological process of ALS include glutamate excitotoxicity disturbances in cytoskeletal protein metabolism (e.g., e.g.	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113054	16624536	146851	20996	11179	SOD1	ALS	ALS	30	1.7	to understanding the role of the innate immune response in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113057	16624536	146858	20996	11179	SOD1	ALS	ALS	2	1.7	Microglia in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113058	16624536	146859	20996	11179	SOD1	ALS	ALS	15	1.7	neurochemical evidence for the proliferation and activation of microglia in ALS 15 16 17 18 19 20 21 22 23 24	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113060	16624536	146862	20996	11179	SOD1	ALS	ALS	16	1.7	macrophage-colony stimulating factor (M-CSF) M-CSF receptor expression is upregulated in ALS precentral gyrus	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113062	16624536	146863	20996	11179	SOD1	ALS	ALS	16	1.7	domains of its receptors TNFRI and TNFRII are increased in ALS serum 27 and 28	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113064	16624536	146864	20996	11179	SOD1	ALS	ALS	23	1.7	of microglia-mediated protein oxidative pathology 32 is also observed in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113065	16624536	146865	20996	11179	SOD1	ALS	ALS	12	1.7	issue as to when in the course of degeneration in ALS that microglial activation becomes prominent is being addressed through neuroimaging	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113066	16624536	146866	20996	11179	SOD1	ALS	ALS	33	1.7	of microglia microglial activation can be observed in patients with ALS 33	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113067	16624536	146868	20996	11179	SOD1	ALS	ALS	28	1.7	possibility that microglial activation occurs early in the pathogenesis of ALS ( Fig 2	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113074	16624536	146874	20996	11179	SOD1	ALS	ALS	28	1.7	of the macrophage lineage can significantly slow the progression of ALS 38	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113076	16624536	146876	20996	11179	SOD1	ALS	ALS	37	1.7	and the rate of propagation of motor neuron degeneration in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113079	16624536	146880	20996	11179	SOD1	ALS	ALS	20	1.7	between inflammation and the progression of motor neuron disease in ALS arises from the study of murine models of motor neuron	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113085	16624536	146886	10676	6121	IRF6	LPS	LPS	11	0.6	neuron disease is accelerated by chronic stimulation of inflammation using LPS in the SOD1 G37R mouse model of ALS with increasing	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
113087	16624536	146886	20996	11179	SOD1	ALS	ALS	19	1.7	inflammation using LPS in the SOD1 G37R mouse model of ALS with increasing levels of pro-inflammatory cytokines and increased expression of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113093	16624536	146896	6554	3309	ELA2	HNE	HNE	12	0.0	can be triggered by oxidative injury mediated through hydroxynonenal (HNE) HNE formation and the triggering of apoptosis 60 suggesting that another	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
113094	16624536	146897	20996	11179	SOD1	ALS	ALS	31	1.7	neuron cell line an important consideration in the context of ALS is the selective vulnerability of motor neurons in vivo	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113107	16624536	146909	10676	6121	IRF6	LPS	LPS-stimulated	20	0.6	SOD1 transgenic mice show decreased IL-6 production in response to LPS-stimulated activation compared to controls 37	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
113119	16624536	146917	10676	6121	IRF6	LPS	LPS	29	0.6	and suppressed neuronal cell death induced by microglia activated with LPS and interferon-gamma (IFN-_amp_#x3b3;), IFN-_amp_#x3b3 in a dose-dependent manner	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
113122	16624536	146918	20996	11179	SOD1	ALS	ALS	24	1.7	may therefore represent a viable target for pharmacological manipulation in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113130	16624536	146919	14728	8024	NTF4	NT4	NT-4	35	0.0	factors (e.g., e.g. plasminogen TGF-_amp_#x3b2 bFGF BDNF NGF NT-3 and NT-4 80 81 and 82	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
113132	16624536	146920	10676	6121	IRF6	LPS	LPS	18	0.6	that at higher concentrations both mimic the cytotoxic effects of LPS 83	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
113166	16624536	146936	20996	11179	SOD1	ALS	ALS	1	1.7	In ALS neuronal function is compromised	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113167	16624536	146944	10676	6121	IRF6	LPS	LPS-activated	11	0.6	it is an incorrect assumption to extrapolate the behaviour of LPS-activated microglia to that of microglia neighbouring degenerating motor neurons in	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
113168	16624536	146949	20996	11179	SOD1	ALS	ALS	11	1.7	concept is reviewed in the discussion of adaptive immunity in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113169	16624536	146951	20996	11179	SOD1	ALS	ALS	5	1.7	Adaptive and acquired immunity in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113170	16624536	146954	22088	15934	TH1L	TH1	Th1	14	0.0	present antigens to a distinct subset of helper T-cells (Th1 Th1 cells capable of producing additional cytokines in order to amplify	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
113171	16624536	146955	20996	11179	SOD1	ALS	ALS	9	1.7	A study investigating systemic immune system changes in sporadic ALS revealed that increased levels of circulating monocytes and macrophages were	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113173	16624536	146956	11629	6493	LAMC2	CSF	CSF	13	0.3	protein-1 (MCP-1) MCP-1 are seen in the cerebrospinal fluid (CSF) CSF from ALS patients 98 and 99	13		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
113174	16624536	146956	20996	11179	SOD1	ALS	ALS	15	1.7	MCP-1 are seen in the cerebrospinal fluid (CSF) CSF from ALS patients 98 and 99	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113178	16624536	146958	22088	15934	TH1L	TH1	Th1	5	0.0	These cells present antigen to Th1 cells which can in turn produce IL-1 IFN-_amp_#x3b3 TNF-_amp_#x3b2 and	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
113179	16624536	146960	20996	11179	SOD1	ALS	ALS	27	1.7	to disease end stage time points in mouse models of ALS 34	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113180	16624536	146960	22088	15934	TH1L	TH1	Th1	13	0.0	of cells mediating adaptive immunity in the CNS such as Th1 infiltrates is limited to disease end stage time points in	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
113183	16624536	146963	22088	15934	TH1L	TH1	Th1	10	0.0	This efficacy is thought to result from the sensitization of Th1 cells to self-antigens	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
113184	16624536	146964	22088	15934	TH1L	TH1	Th1	7	0.0	This theoretically leads to an increase in Th1 migration to injured sites activation and production of cytokines and	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
113191	16624536	146967	10676	6121	IRF6	LPS	LPS-treated	33	0.6	(an an inhibitor of NF-_amp_#x3ba B by microglia compared to LPS-treated microglia	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
113193	16624536	146968	22088	15934	TH1L	TH1	Th1	16	0.0	antigen-presenting capability and were therefore able to more efficiently recruit Th1 cells and increase glutamate clearance 95	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
113194	16624536	146972	20996	11179	SOD1	ALS	ALS	17	1.7	the role of IgG in inducing altered calcium permeability in ALS motor neurons IgG isolated from ALS patient serum injected intraperitoneally	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113195	16624536	146972	20996	11179	SOD1	ALS	ALS	23	1.7	altered calcium permeability in ALS motor neurons IgG isolated from ALS patient serum injected intraperitoneally into mice has been shown to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113196	16624536	146973	20996	11179	SOD1	ALS	ALS	11	1.7	in vivo studies have demonstrated the ability of passively transferred ALS IgG to cause recruitment of activated microglia 104 and motor	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113197	16624536	146974	20996	11179	SOD1	ALS	ALS	16	1.7	mixed primary spinal cord cultures that IgG from patients with ALS induces apoptosis via the caspase-3 pathway selectively in motor neurons	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113198	16624536	146975	20996	11179	SOD1	ALS	ALS	6	1.7	One experiment demonstrated the ability of ALS IgG to shift the activation curve of calcium current indicating	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113199	16624536	146976	20996	11179	SOD1	ALS	ALS	20	1.7	demonstrate such effects in rat cerebral synaptosomes thus concluding that ALS IgG is ineffective in enhancing presynaptic calcium influx 109	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113200	16624536	146980	20996	11179	SOD1	ALS	ALS	20	1.7	also become reactive in areas of motor neuron degeneration in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113201	16624536	146982	20996	11179	SOD1	ALS	ALS	11	1.7	function as executors of glutamate clearance may be compromised in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113204	16624536	146984	20996	11179	SOD1	ALS	ALS	7	1.7	Although the evidence is controversial astrocytes in ALS have been observed to have decreased expression of the glutamate	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113207	16624536	146985	20996	11179	SOD1	ALS	ALS	21	1.7	EAAT2 has been demonstrated in normal controls in addition to ALS patients 112 and 113	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113209	16624536	146987	20996	11179	SOD1	ALS	ALS	10	1.7	As discussed in relation to adaptive and acquired immunity in ALS MCP-1 concentrations are significantly increased in both serum and cerebrospinal	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113211	16624536	146987	11629	6493	LAMC2	CSF	CSF	22	0.3	are significantly increased in both serum and cerebrospinal fluid (CSF) CSF from ALS patients	13		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
113212	16624536	146987	20996	11179	SOD1	ALS	ALS	24	1.7	increased in both serum and cerebrospinal fluid (CSF) CSF from ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113214	16624536	146988	20996	11179	SOD1	ALS	ALS	7	1.7	MCP-1 immunoreactivity is highest in astrocytes in ALS spinal cord suggesting that astrocytes have an important role in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113215	16624536	146988	20996	11179	SOD1	ALS	ALS	25	1.7	important role in mediating the inflammatory response to injury in ALS 98	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113227	16624536	146995	20996	11179	SOD1	ALS	ALS	8	1.7	Returning to the work of Raoul et al. ALS motor neurons are particularly susceptible to Fas signaling and the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113229	16624536	146999	20996	11179	SOD1	ALS	ALS	3	1.7	Anti-inflammatory treatment of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113230	16624536	147000	20996	11179	SOD1	ALS	ALS	10	1.7	The identification of microglial activation and proliferation as hallmarks of ALS in vivo and as contributors to motor neuron death in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113233	16624536	147006	20996	11179	SOD1	ALS	ALS	10	1.7	led to phase I/II I II studies of minocycline in ALS patients 134	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113239	16624536	147012	20996	11179	SOD1	ALS	ALS	19	1.7	of the COX inhibitors tested have shown efficacy in human ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113240	16624536	147017	20996	11179	SOD1	ALS	ALS	17	1.7	for microglia and their inflammatory products in the pathogenesis of ALS the most significant pieces of information remain elusive	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113241	16624536	147019	20996	11179	SOD1	ALS	ALS	18	1.7	motor neurons and take on a protective role or is ALS a disease with auto-immune characteristics	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113243	16624536	147022	20996	11179	SOD1	ALS	ALS	6	1.7	Other studies suggest however that in ALS microglia can have cytotoxic potential regardless of the health status	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113245	16624536	147026	20996	11179	SOD1	ALS	ALS	3	1.7	As discussed previously ALS is clearly a multi-factorial disease in which complex neuronal_amp_#x2013 glial	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113246	16624536	147028	20996	11179	SOD1	ALS	ALS	12	1.7	also important that the relationships between various pathological features of ALS intrinsic to motor neurons themselves and the glial inflammatory response	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113248	16624536	147031	20996	11179	SOD1	ALS	ALS	10	1.7	Immunity is therefore a process that is potentially altered in ALS and as such is an intriguing candidate for therapeutic intervention	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113249	16624536	147032	20996	11179	SOD1	ALS	ALS	6	1.7	This is not to say that ALS is a disease of cells of the macrophage lineage	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113250	16624536	147033	20996	11179	SOD1	ALS	ALS	5	1.7	Rather the evidence suggests that ALS is a disease in which inflammation remains a theoretically beneficial	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113251	16624536	147034	20996	11179	SOD1	ALS	ALS	21	1.7	creates controversy as to their role in the pathogenesis of ALS but also offers therapeutic potential as a useful tool in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113252	16624536	147034	20996	11179	SOD1	ALS	ALS	41	1.7	in the modulation of factors influencing motor neuron death in ALS such as release of inflammatory mediators with pro-apoptotic effects and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
113253	16624536	147035	20996	11179	SOD1	ALS	ALS	8	1.7	Perhaps inflammation is a key determinant of the ALS disease process but its elimination as a therapeutic objective may	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000788452378603699<>ScoreDetail__5468|IGFALS|0.000436151439801075__11179|SOD1|0.000788452378603699__	0	0	0	0		0
115231	16647138	150270	23681	19683	UHMK1	KIS	Kis	21	0.6	2 COX and LOX under normal or stimulated situations ( Kis et al. 2003 Kis et al. 2004 Kolko et al.	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
115232	16647138	150270	23681	19683	UHMK1	KIS	Kis	26	0.6	under normal or stimulated situations ( Kis et al. 2003 Kis et al. 2004 Kolko et al. 2005 Shaftel et al.	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
115237	16647138	150274	11001	28961	KIAA0101	PAF	PAF	18	0.3	1-alkyl-2-lyso-sn -glycero-3-phosphocholine is the immediate precursor for platelet-activating factor (PAF), PAF a potent inflammatory mediator	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115238	16647138	150275	11001	28961	KIAA0101	PAF	PAF	5	0.3	Besides inflammation in brain tissue PAF modulates transcription factors and gene expression and is involved in	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115244	16647138	150276	18723	10261	ROS1	ROS	ROS	17	0.0	LOX and EPOX-catalyzed reactions also produce reactive oxygen species (ROS) ROS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115245	16647138	150277	18723	10261	ROS1	ROS	ROS	0	0.0	ROS include oxygen free radicals (superoxide superoxide radicals hydroxyl and alkoxyl	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115246	16647138	150278	18723	10261	ROS1	ROS	ROS	3	0.0	At low levels ROS function as signaling intermediates in the regulation of fundamental cell	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115247	16647138	150279	18723	10261	ROS1	ROS	ROS	3	0.0	At higher concentration ROS contribute to neural membrane damage when the balance between reducing	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115248	16647138	150280	18723	10261	ROS1	ROS	ROS	5	0.0	The other biological targets of ROS may be membrane proteins unsaturated lipids and DNA ( Berlett	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115249	16647138	150281	18723	10261	ROS1	ROS	ROS	3	0.0	The reaction between ROS and proteins or unsaturated lipids in the plasma membrane leads	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115250	16647138	150282	19891	29546	SH3YL1	Ray	Ray	24	0.9	decreased activity of membrane-bound enzymes ion channels and receptors ( Ray et al. 1994	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115261	16647138	150313	16457	8891	PGD	PGD	PGD	7	0.3	Among the dilator prostanoids are the prostaglandins (PGD PGD 2 and PGE 2 and prostacyclin (PGI PGI 2 whereas	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115262	16647138	150313	8612	4458	GPI	PGI	PGI	15	0.6	prostaglandins (PGD PGD 2 and PGE 2 and prostacyclin (PGI PGI 2 whereas constrictor prostanoids include thromboxane (TXA TXA 2 and	1		JUMiner_v2.2	1	2	prostacyclin	0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.000317087492660012<>ScoreDetail__1044|BGN|0.000317087492660012__4458|GPI|0.000299625468164794__	0	0	0	0		0
115265	16647138	150315	8612	4458	GPI	PGI	PGI	16	0.6	is the most abundant prostanoid followed by PGE 2 whereas PGI 2 is the principal prostanoid in human CSF ( Abdel-Halim	1		JUMiner_v2.2	1	2	prostacyclin	0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.000317087492660012<>ScoreDetail__1044|BGN|0.000317087492660012__4458|GPI|0.000299625468164794__	0	0	0	0		0
115266	16647138	150315	11629	6493	LAMC2	CSF	CSF	24	0.0	2 whereas PGI 2 is the principal prostanoid in human CSF ( Abdel-Halim et al. 1980b	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115267	16647138	150316	16457	8891	PGD	PGD	PGD	7	0.3	The predominant prostanoid in rodent brains is PGD 2 ( Abdel-Halim et al. 1980a	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115270	16647138	150324	8612	4458	GPI	PGI	PGI	14	0.6	to several prostaglandins thromboxanes (TXA TXA 2 and prostacyclins (PGI PGI 2 ( Fig 2	1		JUMiner_v2.2	1	2	prostacyclin	0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.000317087492660012<>ScoreDetail__1044|BGN|0.000317087492660012__4458|GPI|0.000299625468164794__	0	0	0	0		0
115336	16647138	150357	10676	6121	IRF6	LPS	LPS	15	0.3	increased in microglial cells after intraperitoneal administration of lipopolysaccharide (LPS), LPS whereas neuronal COX-2 remains unchanged ( Elmquist et al. 1997	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
115339	16647138	150358	10676	6121	IRF6	LPS	LPS	21	0.3	PGE 2 TXA 2 and TXB 2 upon stimulation by LPS are several times higher than in astrocytes but lower than	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
115360	16647138	150368	23681	19683	UHMK1	KIS	Kis	21	0.6	relates to the vascular density of a given region ( Kis et al. 2004	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
115364	16647138	150370	23681	19683	UHMK1	KIS	Kis	9	0.6	Cerebral endothelial cells showed the highest COX-3 expression ( Kis et al. 2003	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
115380	16647138	150382	23681	19683	UHMK1	KIS	Kis	18	0.6	variants some with and others without any COX activity ( Kis et al. 2005 Simmons et al. 2005 and Snipes et	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
115401	16647138	150405	12108	6709	LTA	LTA	LTA	14	0.0	reaction generating an unstable epoxide intermediate leukotriene A 4 (LTA LTA 4	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115402	16647138	150406	12108	6709	LTA	LTA	LTA	0	0.0	LTA 4 is metabolized to LTB 4 by LTA 4 hydrolase	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115403	16647138	150406	12110	6711	LTB	LTB	LTB	5	0.0	LTA 4 is metabolized to LTB 4 by LTA 4 hydrolase or to LTC 4 by	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115404	16647138	150406	12108	6709	LTA	LTA	LTA	8	0.0	LTA 4 is metabolized to LTB 4 by LTA 4 hydrolase or to LTC 4 by conjugation of glutathione	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115405	16647138	150407	12108	6709	LTA	LTA	LTA	0	0.0	LTA 4 is the precursor for the family of cysteinyl leukotrienes	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115413	16647138	150412	21242	11283	SRC	SRC	Src	22	0.0	but has no enzymic activity itself 5-LOX also contains an Src homology 3 (SH3) SH3 binding motif which may be involved	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115459	16647138	150453	11001	28961	KIAA0101	PAF	PAF	26	0.3	2 with the generation of PGE 2 LTB 4 and PAF through COX-2 LOX and acetyl-CoA acetyltransferase reactions respectively	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115462	16647138	150453	12110	6711	LTB	LTB	LTB	22	0.0	stimulation of iPLA 2 with the generation of PGE 2 LTB 4 and PAF through COX-2 LOX and acetyl-CoA acetyltransferase reactions	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115463	16647138	150454	11001	28961	KIAA0101	PAF	PAF	22	0.3	as cPLA 2 and is associated with the generation of PAF lipoxins and the pro-resolving prostaglandin PGD 2 ( Gilroy et	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115464	16647138	150454	16457	8891	PGD	PGD	PGD	28	0.3	with the generation of PAF lipoxins and the pro-resolving prostaglandin PGD 2 ( Gilroy et al. 2004	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115469	16647138	150473	832	549	AOC2	RAO	Rao	34	0.3	mitochondrial oxyradical generation and mild calcium overload ( Sastry and Rao 2000	2		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115476	16647138	150477	832	549	AOC2	RAO	Rao	19	0.3	and redox status also dictates this mode ( Sastry and Rao 2000	2		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115479	16647138	150483	18723	10261	ROS1	ROS	ROS	18	0.0	the increased production of free radicals reactive oxygen species (ROS) ROS and hence for lipid peroxidation and oxidative damage to membrane	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115483	16647138	150493	8612	4458	GPI	PGI	PGI	11	0.6	behavior in rats can be produced by peripheral administration of PGI 2 and PGE 2 ( Taiwo and Levine 1990	1		JUMiner_v2.2	1	2	prostacyclin	0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.000317087492660012<>ScoreDetail__1044|BGN|0.000317087492660012__4458|GPI|0.000299625468164794__	0	0	0	0		0
115505	16647138	150510	16457	8891	PGD	PGD	PGD	21	0.3	COX-1/COX-2 COX-1 COX-2 pathways (PGE PGE 2 PGF 2a and PGD 2 are modulators of synaptic activity and efficacy by exerting	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115507	16647138	150512	16457	8891	PGD	PGD	PGD	8	0.3	The addition of PGE 2 but not PGD 2 or PGF 2_amp_#x3b1 reverses COX-2-mediated suppression of LTP	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115514	16647138	150517	11934	6664	LOX	LOX	LOX-generated	0	0.0	LOX-generated AA metabolites are also implicated in the modulation of synaptic	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115523	16647138	150559	11629	6493	LAMC2	CSF	CSF	5	0.0	F4-NPs occur in cerebrospinal fluid (CSF) CSF from normal individuals	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115524	16647138	150560	11629	6493	LAMC2	CSF	CSF	8	0.0	The levels of F4-NP are significantly higher in CSF from patients with Alzheimer's disease ( Reich et al. 2001	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115525	16647138	150564	11001	28961	KIAA0101	PAF	PAF	2	0.3	Platelet-activating factor (PAF) PAF	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115526	16647138	150565	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF is a short-lived biologically active ether lipid with diverse physiological	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115527	16647138	150568	11001	28961	KIAA0101	PAF	PAF	17	0.3	platelets endothelial cells mast cells neutrophils and neural cells release PAF	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115528	16647138	150569	11001	28961	KIAA0101	PAF	PAF	7	0.3	It exerts its biological effects by activating PAF receptors that consequently activate leukocytes stimulate platelet aggregation and induce	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115529	16647138	150570	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF receptors are linked to G-proteins and activate a variety of	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115530	16647138	150571	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF receptors have been cloned from a number of sources including	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115531	16647138	150572	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF activates a wide variety of cells including neutrophils eosinophils monocytes	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115532	16647138	150573	11001	28961	KIAA0101	PAF	PAF	4	0.3	The physiological activity of PAF is not limited to its proinflammatory effects	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115533	16647138	150574	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF is also involved in a variety of other settings including	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115534	16647138	150577	11001	28961	KIAA0101	PAF	PAF	7	0.3	Mammalian tissues have three different pathways for PAF synthesis ( Honda et al. 2002 and Snyder 1995	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115535	16647138	150582	11001	28961	KIAA0101	PAF	PAF	9	0.3	This reaction provides the inter-relationship between the synthesis of PAF and eicosanoids	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115536	16647138	150583	11001	28961	KIAA0101	PAF	PAF	4	0.3	The second step of PAF production requires the conversion of lyso-PAF to PAF by the	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115537	16647138	150583	11001	28961	KIAA0101	PAF	PAF	12	0.3	step of PAF production requires the conversion of lyso-PAF to PAF by the enzyme acetyl CoA lyso-PAF acetyltransferase	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115538	16647138	150586	11001	28961	KIAA0101	PAF	PAF	5	0.3	The synthesis de novo of PAF requires three steps	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115539	16647138	150590	11001	28961	KIAA0101	PAF	PAF	7	0.3	The third pathway for the synthesis of PAF is the oxidative fragmentation of phosphatidylcholines	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115540	16647138	150592	11001	28961	KIAA0101	PAF	PAF	7	0.3	These 1-O -alkyl phospholipids interact with PAF receptors and induce a variety of biological effects ( Stafforini	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115541	16647138	150595	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF is hydrolyzed by PAF acetylhydrolases found in all mammalian tissues	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115542	16647138	150595	11001	28961	KIAA0101	PAF	PAF	4	0.3	PAF is hydrolyzed by PAF acetylhydrolases found in all mammalian tissues ( Snyder 1995	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115543	16647138	150596	11001	28961	KIAA0101	PAF	PAF	13	0.3	human plasma LDL-PLA 2 and the other is bovine brain PAF acetylhydrolase ( Arai 2002 and Tjoelker and Stafforini 2000	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115544	16647138	150597	11001	28961	KIAA0101	PAF	PAF	9	0.3	Although both are serine-dependent enzymes their ability to hydrolyze PAF is quite different	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115545	16647138	150599	11001	28961	KIAA0101	PAF	PAF	3	0.3	In addition to PAF acetylhydrolase activity plasma LDL-PLA 2 also has a high PLA	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115546	16647138	150600	11001	28961	KIAA0101	PAF	PAF	1	0.3	Plasma PAF acetylhydrolase has a dual role in metabolism	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115547	16647138	150601	11001	28961	KIAA0101	PAF	PAF	4	0.3	It not only inactivates PAF released from inflammatory cells but it also eliminates oxidized fatty	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115548	16647138	150602	11001	28961	KIAA0101	PAF	PAF	2	0.3	Bovine brain PAF acetylhydrolase is an _amp_#x3b1 _amp_#x3b2 and _amp_#x3b3 heterotrimer (Mr Mr	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115549	16647138	150603	11001	28961	KIAA0101	PAF	PAF	5	0.3	Mammalian tissues have two other PAF acetylhydrolases	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115550	16647138	150608	11001	28961	KIAA0101	PAF	PAF	3	0.3	The binding of PAF to PAF receptors results in the activation of diverse intracellular	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115551	16647138	150608	11001	28961	KIAA0101	PAF	PAF	5	0.3	The binding of PAF to PAF receptors results in the activation of diverse intracellular signal transduction	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115552	16647138	150610	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF receptor antagonists block all these processes	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115553	16647138	150611	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF stimulates phosphatidylinositol 3-kinase and mitogen-activated protein (MAP) MAP kinase and	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115555	16647138	150612	11001	28961	KIAA0101	PAF	PAF	1	0.3	Moreover PAF also acts as an intracellular mediator ( Marcheselli and Bazan	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115556	16647138	150613	11001	28961	KIAA0101	PAF	PAF	3	0.3	The binding of PAF to intracellular sites elicits gene expression in neuronal and glial	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115557	16647138	150614	11001	28961	KIAA0101	PAF	PAF	1	0.3	Furthermore PAF receptors are also involved in the release of prostaglandin E	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115558	16647138	150616	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF also stimulates the inducible isoform of COX-2 ( Bazan et	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115561	16647138	150618	11001	28961	KIAA0101	PAF	PAF	4	0.3	Preincubation of cells with PAF antagonist BN 50730 blocks stimulation of the immediate early gene	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115563	16647138	150619	11001	28961	KIAA0101	PAF	PAF	1	0.3	Thus PAF is associated with short- and long-term responses of cells to	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115564	16647138	150623	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF antagonists block the development of long-term potentiation ( Del Cerro	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115565	16647138	150623	11001	28961	KIAA0101	PAF	PAF	32	0.3	and Zorumski 1996 and Kornecki et al. 1996 indicating that PAF modulates long-term potentiation	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115566	16647138	150624	11001	28961	KIAA0101	PAF	PAF	5	0.3	In rats the administration of PAF antagonists impairs spatial learning and inhibitory avoidance tests while treatment	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115567	16647138	150624	11001	28961	KIAA0101	PAF	PAF	22	0.3	avoidance tests while treatment with a synthetic non-hydrolyzable analog of PAF 1-O -hexadecyl-2-methylcarbamoyl-sn -glycerol-3-phosphocholine enhances memory ( Packard et al. 1996	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115568	16647138	150625	11001	28961	KIAA0101	PAF	PAF	3	0.3	Intracarotid infusion of PAF decreases cerebral blood flow with a concomitant increase in the	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115569	16647138	150626	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF administration causes a dose-dependent decrease in spinal cord blood flow	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115570	16647138	150627	11001	28961	KIAA0101	PAF	PAF	1	0.3	A PAF receptor antagonist can block this decrease in blood flow (	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115571	16647138	150628	11001	28961	KIAA0101	PAF	PAF	1	0.3	Although PAF does not cross the blood_amp_#x2013 brain barrier itself it induces	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115572	16647138	150629	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF is also an essential component of the intricate mechanisms by	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115573	16647138	150631	11001	28961	KIAA0101	PAF	PAF	2	0.3	Involvement of PAF in neurological disorders	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115574	16647138	150632	11001	28961	KIAA0101	PAF	PAF	10	0.3	Several pathological processes including allergy inflammation shock and trauma involve PAF ( Ishii et al. 1997 Ishii et al. 1998 Nagase	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115575	16647138	150634	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF was identified as a pathological mediator by injecting it into	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115576	16647138	150634	11001	28961	KIAA0101	PAF	PAF	23	0.3	measuring the intensity of inflammation and by the ability of PAF antagonists to block PAF-mediated responses ( Maclennan et al. 1996	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115577	16647138	150634	11001	28961	KIAA0101	PAF	PAF-mediated	27	0.0	inflammation and by the ability of PAF antagonists to block PAF-mediated responses ( Maclennan et al. 1996	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115578	16647138	150635	11001	28961	KIAA0101	PAF	PAF	3	0.3	Excessive levels of PAF are associated with neuronal injury in brain tissue and are	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115579	16647138	150636	11001	28961	KIAA0101	PAF	PAF	2	0.3	Administration of PAF antagonists has beneficial effects in various models of cerebral ischemia	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115580	16647138	150637	11001	28961	KIAA0101	PAF	PAF	0	0.3	PAF activates inflammatory cells and increases vasopermeability a role it may	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115581	16647138	150638	11001	28961	KIAA0101	PAF	PAF	2	0.3	Administration of PAF antagonists improves the neurological score of patients with multiple sclerosis	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115587	16647138	150644	11001	28961	KIAA0101	PAF	PAF	6	0.3	In models of lissencephaly in vitro PAF agonists and antagonists can alter migration of cerebral granule and	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115588	16647138	150644	11001	28961	KIAA0101	PAF	PAF	21	0.3	alter migration of cerebral granule and hippocampal cells indicating that PAF may act as a neuronal migration stop signal ( Adachi	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115589	16647138	150645	11001	28961	KIAA0101	PAF	PAF-mediated	4	0.0	Collective evidence suggests that PAF-mediated processes are involved in the pathogenesis of many neurological conditions	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115590	16647138	150652	16457	8891	PGD	PGD	PGD	0	0.3	PGD 2 and PGI 2 are generally vasorelaxants	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115591	16647138	150652	8612	4458	GPI	PGI	PGI	3	0.6	PGD 2 and PGI 2 are generally vasorelaxants	1		JUMiner_v2.2	1	2	prostacyclin	0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.000317087492660012<>ScoreDetail__1044|BGN|0.000317087492660012__4458|GPI|0.000299625468164794__	0	0	0	0		0
115593	16647138	150656	8612	4458	GPI	PGI	PGI	13	0.6	in systemic blood pressure cause the release of PGE 2 PGI 2 and PGF 2_amp_#x3b1 from brain ( Chemtob et al.	1		JUMiner_v2.2	1	2	prostacyclin	0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.000317087492660012<>ScoreDetail__1044|BGN|0.000317087492660012__4458|GPI|0.000299625468164794__	0	0	0	0		0
115595	16647138	150657	8612	4458	GPI	PGI	PGI	0	0.6	PGI 2 which is released in response to hypercapnia hypotension and	1		JUMiner_v2.2	1	2	prostacyclin	0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.000317087492660012<>ScoreDetail__1044|BGN|0.000317087492660012__4458|GPI|0.000299625468164794__	0	0	0	0		0
115620	16647138	150751	16457	8891	PGD	PGD	PGD	21	0.3	specific target of PGE 2 but not of PGF 2_amp_#x3b1 PGD 2 or PGI 2 which reduced inhibitory glycinergic synaptic transmission	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115621	16647138	150751	8612	4458	GPI	PGI	PGI	25	0.6	PGE 2 but not of PGF 2_amp_#x3b1 PGD 2 or PGI 2 which reduced inhibitory glycinergic synaptic transmission at low nanomolar	1		JUMiner_v2.2	1	2	prostacyclin	0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.000317087492660012<>ScoreDetail__1044|BGN|0.000317087492660012__4458|GPI|0.000299625468164794__	0	0	0	0		0
115633	16647138	150766	16457	8891	PGD	PGD	PGD	8	0.3	Exogenous application of PGE 2 but not PGD 2 or PGF 2_amp_#x3b1 effectively reversed all of these actions	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115638	16647138	150771	3353	1368	CA1	CA1	CA1	19	0.0	PGE 2 reduced somatic and dendritic membrane excitability in hippocampal CA1 pyramidal neurons in brain slices	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115640	16647138	150778	3353	1368	CA1	CA1	CA1	17	0.0	turn triggered Ca 2 elevations in adjacent neurons in the CA1 hippocampus	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115662	16647138	150803	3353	1368	CA1	CA1	CA1	9	0.0	The 12-LOX inhibitor baicalein totally blocked LTD in the CA1 region of hippocampal slices	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115665	16647138	150806	3353	1368	CA1	CA1	CA1	22	0.0	12-LOX metabolites in metabotropic-glutamate receptor-dependent long-term depression at hippocampal CA3_amp_#x2013 CA1 synapses	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115679	16647138	150834	8612	4458	GPI	PGI	PGI	6	0.6	(1997) 1997 using mice lacking prostacyclin (PGI PGI 2 receptors (IP), IP suggested that these receptors play a	1		JUMiner_v2.2	1	2	prostacyclin	0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.000317087492660012<>ScoreDetail__1044|BGN|0.000317087492660012__4458|GPI|0.000299625468164794__	0	0	0	0		0
115691	16647138	150839	16457	8891	PGD	PGD	PGD	7	0.3	When small amounts of PGE 2 PGD 2 PGF 2_amp_#x3b1 or PGI 2 were injected intrathecally into	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115693	16647138	150839	8612	4458	GPI	PGI	PGI	14	0.6	small amounts of PGE 2 PGD 2 PGF 2_amp_#x3b1 or PGI 2 were injected intrathecally into the spinal canal in WT	1		JUMiner_v2.2	1	2	prostacyclin	0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.000317087492660012<>ScoreDetail__1044|BGN|0.000317087492660012__4458|GPI|0.000299625468164794__	0	0	0	0		0
115696	16647138	150844	16457	8891	PGD	PGD	PGD	6	0.3	(2001) 2001 employing wild-type and DP (PGD PGD 2 -receptor-deficient mice demonstrated that PGD 2 infusions into the	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115697	16647138	150844	16457	8891	PGD	PGD	PGD	12	0.3	wild-type and DP (PGD PGD 2 -receptor-deficient mice demonstrated that PGD 2 infusions into the lateral ventricles increased non-rapid eye movement	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115698	16647138	150844	18182	15922	REM1	REM	REM	28	0.0	increased non-rapid eye movement (NREM), NREM with a decrease in REM sleep	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115699	16647138	150845	16457	8891	PGD	PGD	PGD	14	0.3	the amounts of NREM and REM sleep were unchanged by PGD 2 infusions demonstrating an involvement of DP receptors in PGD	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115700	16647138	150845	16457	8891	PGD	PGD	PGD	24	0.3	PGD 2 infusions demonstrating an involvement of DP receptors in PGD 2 -induced NREM sleep	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115701	16647138	150845	18182	15922	REM1	REM	REM	9	0.0	In DP-deficient mice however the amounts of NREM and REM sleep were unchanged by PGD 2 infusions demonstrating an involvement	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115722	16647138	150862	10676	6121	IRF6	LPS	LPS	11	0.3	enhanced in the brain after peripheral (intraperitoneal) intraperitoneal lipopolysaccharide (LPS) LPS or intravenous and intracerebral IL-1_amp_#x3b2 administration whereas COX-2 inhibitors suppress	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
115724	16647138	150864	10676	6121	IRF6	LPS	LPS	9	0.3	(1999) 1999 assessed the febrile response to injection of intraperitoneal LPS in COX-1 and COX-2-deficient mice	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
115728	16647138	150865	10676	6121	IRF6	LPS	LPS	8	0.3	The wild-type and COX-1 _amp_#x2212;/_amp_#x2212; _amp_#x2212 _amp_#x2212 mice responded to LPS with a 1_amp_#xb0 C rise in temperature whereas the COX-2	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
115731	16647138	150865	10676	6121	IRF6	LPS	LPS-induced	31	0.3	no increase in temperature indicating that COX-2 is necessary for LPS-induced fever production	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
115740	16647138	150885	12201	13731	MAEA	MAEA	MAEA	5	0.3	Incubation with R (+) -methanandamide (MAEA), MAEA which is not a substrate for fatty acid amidohydrolase (FAAH),	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115742	16647138	150886	12201	13731	MAEA	MAEA	MAEA	12	0.3	inhibited the PGE 2 production induced by either AEA or MAEA a selective COX-2 inhibitor indicating induction of COX-2	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115745	16647138	150887	12201	13731	MAEA	MAEA	MAEA	2	0.3	AEA and MAEA increased the expression of COX-2 protein an action that AM-251	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115750	16647138	150893	6111	19199	DPPA3	Stella	Stella	28	1.6	which are generated during robust stimulation of hippocampal slices ( Stella et al. 1997 tonically decrease basal excitatory transmission by modulating	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115751	16647138	150894	3353	1368	CA1	CA1	CA1	18	0.0	would have a disinhibitory effect enhancing transmission with depolarization of CA1 pyramidal neurons	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115756	16647138	150904	19891	29546	SH3YL1	Ray	Ray	58	0.9	can contribute to restoration of some function following TBI ( Ray et al. 2002	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115760	16647138	150909	11629	6493	LAMC2	CSF	CSF	6	0.0	In a subsequent study increased plasma CSF and brain levels of PGE 2 6-keto-PGF 1_amp_#x3b1 thromboxane B	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115762	16647138	150913	16457	8891	PGD	PGD	PGD	10	0.3	Azelastine an agent that inhibits the release of leukotrienes and PGD 2 from cultured human mast cells ( Shichijo et al.	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115763	16647138	150913	3353	1368	CA1	CA1	CA1	24	0.0	cultured human mast cells ( Shichijo et al. 1998 protected CA1 neurons in hippocampal slices from injury elicited by fluid percussion	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115775	16647138	150931	12110	6711	LTB	LTB	LTB	18	0.0	changes in leukotrienes LTC 4 LTD 4 LTE 4 and LTB 4 in rat cerebrospinal fluid from 10 min to 7	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115776	16647138	150934	12110	6711	LTB	LTB	LTB	0	0.0	LTB 4 levels were lower and peaked with a two-fold increase	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115779	16647138	150948	12110	6711	LTB	LTB	LTB	12	0.0	of this enzyme is associated with the defective degradation of LTB 4	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115781	16647138	150949	12110	6711	LTB	LTB	LTB	7	0.0	This results in elevated urinary concentrations of LTB 4 LTC 4 and 20-OH-LTB 4 in SLS patients (	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115787	16647138	150953	12110	6711	LTB	LTB	LTB	17	0.0	5-LOX inhibitor (Zileuton) Zileuton blocks peripheral SLS symptoms and inhibits LTB 4 synthesis it does not improve CNS symptoms ( Willemsen	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115788	16647138	150955	203	10522	ACSM3	SAH	SAH	5	0.0	Cerebral ischemia and subarachnoid hemorrhage (SAH) SAH	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115798	16647138	150962	8612	4458	GPI	PGI	PGI	31	0.6	been attributed to blockade of the vasoprotective effects of COX-2-derived PGI 2 ( FitzGerald 2003	1		JUMiner_v2.2	1	2	prostacyclin	0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.000317087492660012<>ScoreDetail__1044|BGN|0.000317087492660012__4458|GPI|0.000299625468164794__	0	0	0	0		0
115829	16647138	151019	3353	1368	CA1	CA1	CA1	25	0.0	the generation of the irreversible depolarization induced in hippocampal slice CA1 pyramidal neurons by oxygen/glucose oxygen glucose deprivation	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115835	16647138	151027	3353	1368	CA1	CA1	CA1	11	0.0	observed the formation of small blebs on the surface of CA1 pyramidal neurons within 30 s of the rapid depolarization induced	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115840	16647138	151031	3353	1368	CA1	CA1	CA1	27	0.0	reperfusion in rats ( Buccellati et al. 1998 reduced ischemia-evoked CA1 hippocampal injury in a gerbil model ( Sasaki et al.	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115845	16647138	151034	3353	1368	CA1	CA1	CA1	18	0.0	ameliorated delayed (7 7 days neuronal deaths in the gerbil CA1 hippocampus	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115846	16647138	151035	3353	1368	CA1	CA1	CA1	13	0.0	study two lipoxygenase inhibitors AA-861 and BW-755C failed to protect CA1 neurons ( Nakagomi et al. 1989	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115856	16647138	151045	3353	1368	CA1	CA1	CA1	11	0.0	inhibitors significantly increased the number of healthy neurons in the CA1 hippocampus even when treatment was initiated 6 h after ischemia	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115865	16647138	151068	3353	1368	CA1	CA1	CA1	10	0.0	The lipoxygenase inhibitors AA-861 and BW-755C failed to protect gerbil CA1 hippocampal neurons from 5 min forebrain ischemia whereas the cyclooxygenase	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115869	16647138	151071	3353	1368	CA1	CA1	CA1	5	0.0	(2001) 2001 demonstrated significant protection of CA1 pyramidal cells following the application of two non-selective LOX inhibitors	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115878	16647138	151088	11629	6493	LAMC2	CSF	CSF	10	0.0	The levels of 20-HETE a potent vasoconstrictor increase in the CSF of rats ( Kehl et al. 2002 and man (	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115879	16647138	151088	203	10522	ACSM3	SAH	SAH	33	0.0	Hacein-Bey et al. 2004 and Poloyac et al. 2005 following SAH	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115880	16647138	151090	11629	6493	LAMC2	CSF	CSF	42	0.0	rats as well as reversing the increase in 20-HETE in CSF of rats after SAH ( Miyata et al. 2005	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115881	16647138	151090	203	10522	ACSM3	SAH	SAH	46	0.0	reversing the increase in 20-HETE in CSF of rats after SAH ( Miyata et al. 2005	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115886	16647138	151095	18187	17922	REPIN1	AP4	AP4	16	0.0	_amp_#x3b1 -amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), AMPA kainate l -2-amino-4-phosphonobutanoate ( l -AP4 and trans -1-amino-cyclopentyl-1 3-dicarboxylate ( trans -ACPD receptors	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
115920	16647138	151116	10676	6121	IRF6	LPS	LPS-induced	15	0.3	2 protects hippocampal and cortical neuronal cultures against glutamate-mediated or LPS-induced cytotoxicity ( Akaike et al. 1994	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
115928	16647138	151128	16457	8891	PGD	PGD	PGD	9	0.3	Spontaneous seizures in gerbils are associated with increases in PGD 2 concentrations in the cerebral cortex hippocampus and striatum and	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
115955	16647138	151157	7708	3811	FOXG1	QIN	Qin	39	0.3	2002 Ho et al. 1999 Manev et al. 2000a and Qin et al. 2003	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
115959	16647138	151158	7708	3811	FOXG1	QIN	Qin	43	0.3	2 found in AD ( Pasinetti and Aisen 1998 and Qin et al. 2003	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
115971	16647138	151161	7708	3811	FOXG1	QIN	Qin	14	0.3	peptide generation through mechanisms that involve _amp_#x3b3 -secretase activity ( Qin et al. 2003	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
115989	16647138	151175	20996	11179	SOD1	ALS	ALS	3	2.9	Amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
115990	16647138	151176	20996	11179	SOD1	ALS	ALS	0	2.9	ALS is a neurological disease that damages motor neurons in the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
115991	16647138	151177	20996	11179	SOD1	ALS	ALS	5	2.9	Although the primary cause of ALS is unknown excitotoxic and oxidative cross talk between motor neurons	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
115992	16647138	151177	20996	11179	SOD1	ALS	ALS	27	2.9	surrounding glial cells may be involved in the pathogenesis of ALS ( Rao and Weiss 2004	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
115993	16647138	151177	832	549	AOC2	RAO	Rao	29	0.3	cells may be involved in the pathogenesis of ALS ( Rao and Weiss 2004	2		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
115994	16647138	151182	20996	11179	SOD1	ALS	ALS	3	2.9	Most cases of ALS are sporadic but 10% are familial	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
115997	16647138	151184	20996	11179	SOD1	ALS	ALS	16	2.9	gene have been reported to occur in familial form of ALS ( Beal 1998a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
116000	16647138	151185	20996	11179	SOD1	ALS	ALS	14	2.9	also occurs in SOD1 transgenic mice at the onset of ALS ( Almer et al. 2001	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
116002	16647138	151186	20996	11179	SOD1	ALS	ALS	17	2.9	SOD1 are related to the antioxidant activity that leads to ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
116003	16647138	151187	20996	11179	SOD1	ALS	ALS	7	2.9	In an organotypic cell culture model of ALS the addition of a selective COX-2 inhibitor SC236 blocked the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
116006	16647138	151187	20996	11179	SOD1	ALS	ALS	40	2.9	COX-2 may play an important role in inflammatory processes in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
116009	16647138	151188	20996	11179	SOD1	ALS	ALS	18	2.9	the survival of neurons in the SOD1 mouse model of ALS ( Drachman et al. 2002	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
116011	16647138	151189	20996	11179	SOD1	ALS	ALS	15	2.9	PGE 2 levels may not be the root cause of ALS alterations in these parameters may be responsible for the induction	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
116012	16647138	151189	20996	11179	SOD1	ALS	ALS	34	2.9	the induction and maintenance of inflammation during the progression of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
116015	16647138	151190	20996	11179	SOD1	ALS	ALS	16	2.9	EPOX expression and their activities is not available for the ALS brain and spinal cord	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
116035	16647138	151211	17345	9449	PRNP	CJD	CJD	2	1.1	Creutzfeldt_amp_#x2013 Jakob disease (CJD) CJD	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
116036	16647138	151212	17345	9449	PRNP	CJD	CJD	0	1.1	CJD is the most prevalent form of prion disease in humans	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
116038	16647138	151213	17345	9449	PRNP	CJD	CJD	16	1.1	extracellular _amp_#x3b2 -helix rich prion protein (PrP PrP sc characterize CJD	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
116043	16647138	151218	17345	9449	PRNP	CJD	CJD	17	1.1	oxidative stress may be closely associated with the pathogenesis of CJD ( Capellari et al. 1999	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
116047	16647138	151219	17345	9449	PRNP	CJD	CJD	15	1.1	both COX-1 and COX-2 are significantly increased in brains from CJD patients compared to age-matched controls implicating both enzymes in the	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
116048	16647138	151219	17345	9449	PRNP	CJD	CJD	28	1.1	to age-matched controls implicating both enzymes in the pathogenesis of CJD ( Deininger et al. 2003	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
116049	16647138	151220	17345	9449	PRNP	CJD	CJD	6	1.1	In CSF from sporadic and familial CJD and in brain homogenates of scrapie-infected mice the upregulation of	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
116053	16647138	151220	11629	6493	LAMC2	CSF	CSF	1	0.0	In CSF from sporadic and familial CJD and in brain homogenates of	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
116054	16647138	151221	17345	9449	PRNP	CJD	CJD	12	1.1	on PGE 2 levels have been obtained in CSF of CJD variants ( Minghetti et al. 2002	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
116055	16647138	151221	11629	6493	LAMC2	CSF	CSF	10	0.1	Similar results on PGE 2 levels have been obtained in CSF of CJD variants ( Minghetti et al. 2002	6		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
116056	16647138	151222	17345	9449	PRNP	CJD	CJD	17	1.1	participate in the inflammatory process and have a role in CJD pathogenesis	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
116057	16647138	151223	17345	9449	PRNP	CJD	CJD	17	1.1	death or is itself a consequence of neuronal disturbance in CJD remains to be defined	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
116066	16647138	151233	17345	9449	PRNP	CJD	CJD	8	1.1	These observations implicate 5-LOX in the pathophysiology of CJD	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
116068	16647138	151234	17345	9449	PRNP	CJD	CJD	7	1.1	Information on the involvement of EPOX in CJD is not available	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
116140	16647138	151272	20996	11179	SOD1	ALS	ALS	11	2.9	pathological situations such as acute neural trauma ischemia AD PD ALS and CJD stimulation and upregulation of COX LOX and EPOX	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00148225451265134<>ScoreDetail__5468|IGFALS|0.0003272086584445__11179|SOD1|0.00148225451265134__	0	0	0	0		0
116141	16647138	151272	17345	9449	PRNP	CJD	CJD	13	1.1	such as acute neural trauma ischemia AD PD ALS and CJD stimulation and upregulation of COX LOX and EPOX isozyme activities	1		JUMiner_v2.2	1	2	creutzfeldt	0	0	0		0	0	0	0		0
105594	16737688	136276	20996	11179	SOD1	ALS	ALS	3	3.2	Amyotrophic lateral sclerosis (ALS) ALS is a rapidly progressive invariably fatal neurological disease of largely	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105595	16737688	136277	20996	11179	SOD1	ALS	ALS	1	3.2	In ALS both the upper (UMN) UMN and the lower motor neurons	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105596	16737688	136277	11901	6637	LMNB1	LMN	LMN	11	0.0	the upper (UMN) UMN and the lower motor neurons (LMN) LMN degenerate leading to progressive muscle weakness atrophy and finally complete	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
105597	16737688	136278	20996	11179	SOD1	ALS	ALS	0	3.2	ALS occurs in sporadic (SALS) SALS and familial forms (FALS) FALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105602	16737688	136283	20996	11179	SOD1	ALS	ALS	19	3.2	causes a phenotype that closely mimics the neuropathological features of ALS ( Doble and Kennel 2000 Gurney et al. 1994 and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105603	16737688	136285	11901	6637	LMNB1	LMN	LMNs	49	0.0	the neurodegenerative changes in SOD1-G93A transgenics are not confined to LMNs	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
105604	16737688	136286	21920	11646	TCFL5	CHA	Cha	45	0.0	while deleterious metabolic changes were shown in the hippocampus ( Cha et al. 2000 the red nucleus ( Chung et al.	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
105605	16737688	136286	21920	11646	TCFL5	CHA	Cha	62	0.0	red nucleus ( Chung et al. 2003b the cerebellum ( Cha et al. 2000 Chung et al. 2003b and Chung et	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
105606	16737688	136288	20996	11179	SOD1	ALS	ALS	12	3.2	latter issue would provide insights in the ongoing debate if ALS is due to anterograde (_amp_#x201c;dying-forward_amp_#x201d;) _amp_#x201c dying-forward_amp_#x201d or retrograde (_amp_#x201c;dying-back_amp_#x201d;)	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105607	16737688	136289	20996	11179	SOD1	ALS	ALS	32	3.2	might be crucial for the progression of cell death in ALS ( Allan and Rothwell 2003 Czlonkowska et al. 2001 McGeer	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105608	16737688	136290	20996	11179	SOD1	ALS	ALS	2	3.2	In fact ALS patients exhibit severe inflammatory reactions in the spinal cord (	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105609	16737688	136292	20996	11179	SOD1	ALS	ALS	38	3.2	and inflammatory changes in the CNS of the SOD1-G93A transgenic ALS model	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105610	16737688	136293	20996	11179	SOD1	ALS	ALS	28	3.2	for the development of more effective even curative therapies for ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105619	16737688	136355	18175	9954	REL	REL	Rel	20	0.0	to a computer equipped with an image program (KS100 KS100 Rel 3.0	2		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		1	nf
105646	16737688	136445	10734	6152	ITGAX	CD11c	CD11c-positive	1	1.9	Likewise CD11c-positive cells emerged first in the spinal cord ( Fig 6	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
105647	16737688	136450	20996	11179	SOD1	ALS	ALS	24	3.2	reactions in the brain of a transgenic animal model of ALS the SOD1-G93A mouse	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105648	16737688	136470	20996	11179	SOD1	ALS	ALS	50	3.2	Gurney 1994 and strikingly similar to those seen in human ALS ( Okamoto et al. 1990 and Takahashi et al. 1997	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105649	16737688	136479	20996	11179	SOD1	ALS	ALS	14	3.2	animal model substantial degenerative changes in the cerebral cortex of ALS patients are well known ( Kiernan and Hudson 1991 Lloyd	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105651	16737688	136480	20996	11179	SOD1	ALS	ALS	12	3.2	close similarities between the histopathology of transgenic SOD1 mice and ALS the experimental model departs from the human disease in an	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105652	16737688	136484	20996	11179	SOD1	ALS	ALS	27	3.2	(_amp_#x201c;dying-back_amp_#x201d;) _amp_#x201c dying-back_amp_#x201d degeneration ( Eisen and Weber 2001 in ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105653	16737688	136491	20996	11179	SOD1	ALS	ALS-affected	20	3.2	and astrocyte activation in the brain as described for the ALS-affected spinal cord ( Alexianu et al. 2001	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105654	16737688	136495	10734	6152	ITGAX	CD11c	CD11c	13	1.9	our study was the infiltration of single T-lymphocytes and CD11c(+) CD11c cells in brain regions that were most heavily degenerated like	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
105657	16737688	136498	10734	6152	ITGAX	CD11c	CD11c	2	1.9	Since the CD11c(+) CD11c cells that appeared in late-stage SOD1-G93A transgenics (i) i were	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
105658	16737688	136501	20996	11179	SOD1	ALS	ALS	6	3.2	(2004) 2004 in the spinal cord of ALS patients and that of Henkel et al	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105659	16737688	136506	20996	11179	SOD1	ALS	ALS	38	3.2	and Reichmann 2001 and Serafini et al. 2000 in the ALS transgenics we found some dendritic cells and single T-lymphocytes after	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105660	16737688	136509	20996	11179	SOD1	ALS	ALS	15	3.2	specify the role of inflammatory reactions in the neurodegeneration in ALS the strong immune activation in the brain suggests that inflammatory	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105661	16737688	136509	20996	11179	SOD1	ALS	ALS	40	3.2	an important role in spinal cord but also in brain ALS pathology	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00069434132908573<>ScoreDetail__5468|IGFALS|0.000360161352285824__11179|SOD1|0.00069434132908573__	0	0	0	0		0
105852	16753239	137026	20996	11179	SOD1	ALS	ALS	34	0.9	(AD), AD Parkinson's disease (PD), PD amyotrophic lateral sclerosis (ALS), ALS and stroke	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000580796516805404<>ScoreDetail__5468|IGFALS|0.000384737206593143__11179|SOD1|0.000580796516805404__	0	0	0	0		0
105897	16753239	137090	16440	8884	PGA	PGA	PGA	1	0.3	Interestingly PGA 2 which like 15d-PGJ 2 is a cyclopentenone prostaglandin but	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
105985	16753239	137152	22088	15934	TH1L	TH1	Th1	29	0.0	and passive EAE presumably by suppressing IL-12 expression and associated Th1 cell differentiation	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
105995	16753239	137165	22088	15934	TH1L	TH1	Th1	27	0.0	differentiation of T lymphocytes toward the T helper 1 (Th1) Th1 phenotype	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
105997	16753239	137168	22088	15934	TH1L	TH1	Th1	19	0.0	progression by inhibiting IL-12 production by microglia which may inhibit Th1 cell differentiation	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
106002	16753239	137169	872	583	APC	APC	APCs	5	0.0	In addition antigen presenting cells (APCs) APCs including microglia can produce co-stimulatory molecules including CD40 CD80 and	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
106009	16753239	137170	872	583	APC	APC	APCs	5	0.0	Interaction of co-stimulatory molecules on APCs with their cognate receptors plays a critical role in the	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
106021	16753239	137187	16343	17468	PDLIM5	LIM	Lim	21	0.3	in animal models of AD ( Heneka et al. 2005 Lim et al. 2000 and Yan et al. 2003	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
106022	16753239	137188	16343	17468	PDLIM5	LIM	Lim	0	0.3	Lim et al	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
106026	16753239	137190	16343	17468	PDLIM5	LIM	Lim	15	0.3	animal model of AD corroborated the in vivo observations of Lim et al	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
106031	16753239	137204	20996	11179	SOD1	ALS	ALS	0	0.9	ALS is a fatal neurodegenerative disorder characterized by loss of motor	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000580796516805404<>ScoreDetail__5468|IGFALS|0.000384737206593143__11179|SOD1|0.000580796516805404__	0	0	0	0		0
106033	16753239	137206	20996	11179	SOD1	ALS	ALS	28	0.9	of superoxide dismutase-1 G93A transgenic mice an animal model of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000580796516805404<>ScoreDetail__5468|IGFALS|0.000384737206593143__11179|SOD1|0.000580796516805404__	0	0	0	0		0
106046	16753239	137232	20996	11179	SOD1	ALS	ALS	26	0.9	neuroinflammatory and neurodegenerative disorders including MS Alzheimer's disease Parkinson's disease ALS and stroke	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000580796516805404<>ScoreDetail__5468|IGFALS|0.000384737206593143__11179|SOD1|0.000580796516805404__	0	0	0	0		0
106631	16766086	138231	9947	5468	IGFALS	ALS	ALS	34	0.3	stroke multiple sclerosis Parkinson's disease and amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131806371756415<>ScoreDetail__5468|IGFALS|0.000444303395747382__11179|SOD1|0.00131806371756415__	0	0	0	0		0
106639	16766086	138260	8569	16769	GORASP1	p65	p65	10	0.0	PPAR_amp_#x3b3 has also been shown to physically interact with the p65 subunit of NF_amp_#x3ba B blocking its ability to interact with	1		JUMiner_v2.2	1	0		0	2	16769	TotalCon:2<>16769|GORASP1|64689|Complete__11509|SYT1|6857|Complete__<>AvaiableGeneRif=2<>BEST:16769|GORASP1|0.000319481375234203<>ScoreDetail__16769|GORASP1|0.000319481375234203__11509|SYT1|0.000190114660956994__	0	0	0	0		0
106646	16766086	138301	16343	17468	PDLIM5	LIM	Lim	19	0.3	burden and reduce inflammation in animal models of AD ( Lim et al. 2000 and Lim et al. 2001	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
106647	16766086	138301	16343	17468	PDLIM5	LIM	Lim	24	0.3	animal models of AD ( Lim et al. 2000 and Lim et al. 2001	2		JUMiner_v2.2	1	2	34	0	0	0		0	0	0	0		0
106662	16766086	138415	9947	5468	IGFALS	ALS	ALS	3	0.3	Amyotrophic lateral sclerosis (ALS) ALS is a fatal late onset and progressive neurodegenerative disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131806371756415<>ScoreDetail__5468|IGFALS|0.000444303395747382__11179|SOD1|0.00131806371756415__	0	0	0	0		0
106663	16766086	138418	9947	5468	IGFALS	ALS	ALS	3	0.3	Animal models of ALS recapitulate the neuronal loss and glial activation that are central	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131806371756415<>ScoreDetail__5468|IGFALS|0.000444303395747382__11179|SOD1|0.00131806371756415__	0	0	0	0		0
106664	16766086	138419	9947	5468	IGFALS	ALS	ALS	18	0.3	the PPAR_amp_#x3b3 agonist pioglitazone in two different murine models of ALS ( Kiaei et al. 2005 and Schutz et al. 2005	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131806371756415<>ScoreDetail__5468|IGFALS|0.000444303395747382__11179|SOD1|0.00131806371756415__	0	0	0	0		0
106665	16766086	138421	9947	5468	IGFALS	ALS	ALS	6	0.3	Oral administration of pioglitazone to transgenic ALS mice resulted in a significant delay in loss of motor	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00131806371756415<>ScoreDetail__5468|IGFALS|0.000444303395747382__11179|SOD1|0.00131806371756415__	0	0	0	0		0
107876	16781706	139905	20996	11179	SOD1	ALS	ALS	6	2.4	Effective treatment for amyotrophic lateral sclerosis (ALS) ALS remains elusive	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107877	16781706	139906	20996	11179	SOD1	ALS	ALS	8	2.4	Motor neuron degeneration is the primary pathology in ALS however non-neuronal cells contribute to the disease process	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107878	16781706	139909	20996	11179	SOD1	ALS	ALS	23	2.4	disease progression when administered after onset of signs in an ALS mouse model (hSOD1 hSOD1 G93A transgenic mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107880	16781706	139911	20996	11179	SOD1	ALS	ALS	3	2.4	Three conditions of ALS the loss of motor function paralysis scoring and weight loss	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107881	16781706	139916	20996	11179	SOD1	ALS	ALS	25	2.4	the basis for developing new drugs for the treatment of ALS and other chronic neurodegenerative diseases	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107882	16781706	139919	20996	11179	SOD1	ALS	ALS	3	2.4	Amyotrophic lateral sclerosis (ALS) ALS is the third most common neurodegenerative cause of adult death	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107883	16781706	139920	20996	11179	SOD1	ALS	ALS	0	2.4	ALS results in the degeneration of motor neurons in the cortex	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107884	16781706	139921	20996	11179	SOD1	ALS	ALS	3	2.4	Most causes of ALS are presently unknown and several mechanisms of insult to motor	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107885	16781706	139923	6111	19199	DPPA3	Stella	Stella	27	1.3	and neuroinflammation ( Carter and Rosen 2001 Pertwee 1999 and Stella 2004 ( Panikashvili et al. 2001	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
107886	16781706	139924	20996	11179	SOD1	ALS	ALS	43	2.4	_amp_#x394 9 -THC slows progression and improves survival in the ALS mouse model ( hSOD1 G93A transgenic mice even when administered	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107888	16781706	139924	24058	12731	WAS	THC	THC	9	0.0	We have previously shown that the cannabinoid _amp_#x394 9 -THC (delta-9-tetrahydrocannabinol, delta-9-tetrahydrocannabinol which acts on cannabinoid CB 1 and CB	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
107889	16781706	139924	24058	12731	WAS	THC	THC	35	0.0	oxidative damage in spinal cord cultures and that _amp_#x394 9 -THC slows progression and improves survival in the ALS mouse model	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
107892	16781706	139928	20996	11179	SOD1	ALS	ALS	16	2.4	are the primary cause of up to 20% of familial ALS cases ( Rosen et al. 1993	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107895	16781706	139930	20996	11179	SOD1	ALS	ALS	21	2.4	similar to patients with familial and some forms of sporadic ALS ( Bruijn et al. 1997 Gurney et al. 1994 and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107897	16781706	139931	20996	11179	SOD1	ALS	ALS	13	2.4	mice are used for preclinical testing of compounds for treating ALS since the disease in these animals follows a consistent onset	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107898	16781706	139931	20996	11179	SOD1	ALS	ALS	30	2.4	follows a consistent onset progression and outcome that mimics human ALS ( Gurney et al. 1996 Klivenyi et al. 1999 and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107904	16781706	139972	12428	6923	MBNL1	EXP	exp	0	0.0	Time=7(1+exp((Age_amp_#x2212; Time=7 1 exp Age_amp_#x2212 A )/ B _amp_#x2212 1	14		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
107907	16781706	139997	20996	11179	SOD1	ALS	ALS	25	2.4	reversing the sexual dimorphism normally seen in this strain of ALS mice ( Trieu and Uckun 1999	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00123539212442415<>ScoreDetail__5468|IGFALS|0.000334317713266841__11179|SOD1|0.00123539212442415__	0	0	0	0		0
107909	16781706	140000	24058	12731	WAS	THC	THC	19	0.0	AM1241 may extend survival as was observed with _amp_#x394 9 -THC treatment where treatment with 5_amp_#xa0;mg/kg 5_amp_#xa0 mg kg did not	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
108709	16793728	140884	13686	7321	MSC	MSC	MSC	7	0.3	On the other hand mesenchymal stem cells (MSC) MSC from adult BM implanted in injured areas recover the morphology	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>7321|MSC|9242|Complete__29786|SLC25A37|51312|No_GeneRif__<>AvaiableGeneRif=1<>	1	1	0	0		0
108710	16793728	140885	13686	7321	MSC	MSC	MSC	20	0.3	is a direct relationship between anti-nervous tissue T cells and MSC reparatory properties	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>7321|MSC|9242|Complete__29786|SLC25A37|51312|No_GeneRif__<>AvaiableGeneRif=1<>	1	1	0	0		0
108711	16793728	140887	13686	7321	MSC	MSC	MSC	6	0.3	These cells were cocultured with autologous MSC for 2-15 days	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>7321|MSC|9242|Complete__29786|SLC25A37|51312|No_GeneRif__<>AvaiableGeneRif=1<>	1	1	0	0		0
108712	16793728	140889	13686	7321	MSC	MSC	MSC	6	0.3	RESULTS After 48 h of coculture MSC adopted a spindle shape with polarization of the cytoplasm that	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>7321|MSC|9242|Complete__29786|SLC25A37|51312|No_GeneRif__<>AvaiableGeneRif=1<>	1	1	0	0		0
108714	16793728	140895	13686	7321	MSC	MSC	MSC	11	0.3	We observed that autoreactive cells may induce the transdifferentiation of MSC to neural stem cells	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>7321|MSC|9242|Complete__29786|SLC25A37|51312|No_GeneRif__<>AvaiableGeneRif=1<>	1	1	0	0		0
100194	16877542	128986	18723	10261	ROS1	ROS	ROS	4	0.0	In Situ Visualization of ROS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100195	16877542	128991	6327	15531	EBNA1BP2	P40	P-40	9	0.3	Supernatants of mouse spinal cord tissue homogenized in Nonidet P-40 buffer containing 50 mM DTT were collected and incubated (at	11		JUMiner_v2.2	1	2	nonidet	0	2	6871	TotalCon:9<>682|ARHGEF2|9181|Complete__15531|EBNA1BP2|10969|Complete__9565|PSMD7|5713|Complete__6029|IL9|3578|Complete__6508|LANCL1|10314|No_GeneRif__6502|RPSA|3921|Complete__6871|MAPK1|5594|Complete__16896|RABEPK|10244|Complete__15979|TP63|8626|Complete__<>AvaiableGeneRif=8<>BEST:6871|MAPK1|0.000752624094504684<>ScoreDetail__15979|TP63|0.000496127774993406__16896|RABEPK|0.000101282916948008__6502|RPSA|0.000521222028738287__15531|EBNA1BP2|0.000738701616486897__682|ARHGEF2|0.000595108664553268__9565|PSMD7|0.000248157574288567__6029|IL9|0.000644004922037618__6871|MAPK1|0.000752624094504684__	0	0	0	0		0
100207	16877542	129018	3884	1659	CD33	p67	p67	4	0.0	The levels of the p67 phox subunit that contains the NADPH-binding site of the NADPH	1		JUMiner_v2.2	1	0		0	2	1659	TotalCon:2<>1659|CD33|945|Complete__16672|METAP2|10988|Complete__<>AvaiableGeneRif=2<>BEST:1659|CD33|0.000776415125613499<>ScoreDetail__1659|CD33|0.000776415125613499__16672|METAP2|0.000718318559914951__	0	0	0	0		0
100211	16877542	129024	18723	10261	ROS1	ROS	ROS	20	0.0	in transgenic SOD1 G93A mice by probing for formation of ROS and evidence of protein oxidation	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100212	16877542	129025	18723	10261	ROS1	ROS	ROS	7	0.0	In nontransgenic mice spinal cord production of ROS evidenced by the fluorescence emitted by ethidium the oxidation product	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100272	16877542	129061	18723	10261	ROS1	ROS	ROS	1	0.0	Microglial-Derived ROS Recapitulate the IGF1/Akt IGF1 Akt Pathway Defect in Vitro	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100275	16877542	129062	18723	10261	ROS1	ROS	ROS	7	0.0	To test the idea that NADPH oxidase-derived ROS could impair IGF1 pathway function an in vitro cell system	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100295	16877542	129074	18723	10261	ROS1	ROS	ROS	40	0.0	morphology of resting microglia and did not seem to produce ROS ( Figs 1 and 6	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100306	16877542	129079	18723	10261	ROS1	ROS	ROS	24	0.0	in transgenic SOD1 G93A mice eliminates the production of microglial-derived ROS ( Fig 1 M and importantly prolongs survival and retards	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100317	16877542	129085	18723	10261	ROS1	ROS	ROS	28	0.0	their plasma membrane proteins and lipids damaged by NADPH oxidase-derived ROS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100321	16877542	129088	18723	10261	ROS1	ROS	ROS	6	0.0	First at that lower level of ROS production oxidative stress may not kill cells but instead may	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100332	16877542	129095	18723	10261	ROS1	ROS	ROS	39	0.0	receptor including autophosphorylation and Akt phosphorylation were indeed abated by ROS in a microglial NADPH oxidase-dependent manner	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100357	16877542	129124	18723	10261	ROS1	ROS	ROS	8	0.0	Modulation of the IGF1/Akt IGF1 Akt pathway by NADPH oxidase-derived ROS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100361	16877542	129128	18723	10261	ROS1	ROS	ROS	4	0.0	Glucose oxidase- and microglial-derived ROS impair the IGF1 Akt pathway in vitro	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100367	16877542	129130	18723	10261	ROS1	ROS	ROS	0	0.0	ROS reactive oxygen species SOD1 superoxide dismutase 1 IGF1 insulin-like growth	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100376	16877542	129138	18723	10261	ROS1	ROS	ROS	12	0.0	mediators that could promote neurodegeneration are reactive oxygen species (ROS) ROS produced by the enzyme NADPH oxidase complex ( 7	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100377	16877542	129139	18723	10261	ROS1	ROS	ROS-generating	2	0.0	Although this ROS-generating multimeric oxidase is indispensable for protecting the host against invading	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
100380	16877542	129143	18723	10261	ROS1	ROS	ROS-generating	29	0.0	provide compelling evidence that supports the concept that this microglial ROS-generating enzymatic complex promotes spinal cord motor neuron degeneration by a	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
101191	16883679	129641	9947	5468	IGFALS	ALS	ALS	3	0.3	Amyotrophic lateral sclerosis (ALS) ALS and asthma are inflammatory diseases	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000996190392783641<>ScoreDetail__5468|IGFALS|0.000133523233042549__11179|SOD1|0.000996190392783641__	0	0	0	0		0
101192	16883679	129642	9947	5468	IGFALS	ALS	ALS	0	0.3	ALS is a fatal progressive neurodegenerative disease with inflammation around the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000996190392783641<>ScoreDetail__5468|IGFALS|0.000133523233042549__11179|SOD1|0.000996190392783641__	0	0	0	0		0
101193	16883679	129645	9947	5468	IGFALS	ALS	ALS	6	0.3	While there is no cure for ALS asthma is managed according to its symptoms and severity to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000996190392783641<>ScoreDetail__5468|IGFALS|0.000133523233042549__11179|SOD1|0.000996190392783641__	0	0	0	0		0
101194	16883679	129646	9947	5468	IGFALS	ALS	ALS	14	0.3	asthma may provide insights into how to clinically deal with ALS the authors examined the etiologies of ALS and asthma and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000996190392783641<>ScoreDetail__5468|IGFALS|0.000133523233042549__11179|SOD1|0.000996190392783641__	0	0	0	0		0
101195	16883679	129646	9947	5468	IGFALS	ALS	ALS	21	0.3	clinically deal with ALS the authors examined the etiologies of ALS and asthma and the factors that exacerbate the symptoms	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000996190392783641<>ScoreDetail__5468|IGFALS|0.000133523233042549__11179|SOD1|0.000996190392783641__	0	0	0	0		0
101966	16909005	130926	20996	11179	SOD1	ALS	ALS	29	1.7	G93A SOD1 transgenic mouse model of amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00156629799558186<>ScoreDetail__5468|IGFALS|0.000360457781382356__11179|SOD1|0.00156629799558186__	0	0	0	0		0
101969	16909005	130930	20996	11179	SOD1	ALS	ALS	13	1.7	improved weight loss motor performance and delayed the onset of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00156629799558186<>ScoreDetail__5468|IGFALS|0.000360457781382356__11179|SOD1|0.00156629799558186__	0	0	0	0		0
101977	16909005	130936	20996	11179	SOD1	ALS	ALS	28	1.7	be a promising therapeutic candidate for the treatment of human ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00156629799558186<>ScoreDetail__5468|IGFALS|0.000360457781382356__11179|SOD1|0.00156629799558186__	0	0	0	0		0
102045	16909020	130991	9947	5468	IGFALS	ALS	ALS	21	0.3	of selective motor neuron degeneration in amyotrophic lateral sclerosis (ALS) ALS remains unsolved	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000907283918953578<>ScoreDetail__5468|IGFALS|0__11179|SOD1|0.000907283918953578__	0	0	0	0		0
102046	16909020	130994	9947	5468	IGFALS	ALS	ALS	7	0.3	This multitude of contributing factors indicates that ALS is a complex disease and also suggests that ALS is	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000907283918953578<>ScoreDetail__5468|IGFALS|0__11179|SOD1|0.000907283918953578__	0	0	0	0		0
102047	16909020	130994	9947	5468	IGFALS	ALS	ALS	16	0.3	that ALS is a complex disease and also suggests that ALS is a multifactorial disorder	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000907283918953578<>ScoreDetail__5468|IGFALS|0__11179|SOD1|0.000907283918953578__	0	0	0	0		0
102048	16909020	130995	9947	5468	IGFALS	ALS	ALS	11	0.3	is not the newest and most spectacular hypothesis in the ALS field but it is undoubtedly one of the most robust	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000907283918953578<>ScoreDetail__5468|IGFALS|0__11179|SOD1|0.000907283918953578__	0	0	0	0		0
102049	16909020	130996	9947	5468	IGFALS	ALS	ALS	15	0.3	riluzole the only drug proven to slow disease progression in ALS is most likely related to its anti-excitotoxic properties	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000907283918953578<>ScoreDetail__5468|IGFALS|0__11179|SOD1|0.000907283918953578__	0	0	0	0		0
102050	16909020	130997	9947	5468	IGFALS	ALS	ALS	19	0.3	the arguments in favor of the involvement of excitotoxicity in ALS and of the possible mechanisms leading to motor neuron death	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000907283918953578<>ScoreDetail__5468|IGFALS|0__11179|SOD1|0.000907283918953578__	0	0	0	0		0
102051	16909020	130998	9947	5468	IGFALS	ALS	ALS	28	0.3	and could explain the selective vulnerability of motor neurons in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000907283918953578<>ScoreDetail__5468|IGFALS|0__11179|SOD1|0.000907283918953578__	0	0	0	0		0
102064	16909022	131018	20996	11179	SOD1	ALS	ALS	4	1.2	In amyotrophic lateral sclerosis (ALS) ALS degeneration of motor neurons is associated with a chronic and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00121547330976728<>ScoreDetail__5468|IGFALS|0.000714059028879721__11179|SOD1|0.00121547330976728__	0	0	0	0		0
102065	16909022	131019	20996	11179	SOD1	ALS	ALS	10	1.2	There is emerging evidence that the KP is important in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00121547330976728<>ScoreDetail__5468|IGFALS|0.000714059028879721__11179|SOD1|0.00121547330976728__	0	0	0	0		0
102066	16909022	131020	20996	11179	SOD1	ALS	ALS	13	1.2	that QUIN is significantly increased in serum and CSF of ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00121547330976728<>ScoreDetail__5468|IGFALS|0.000714059028879721__11179|SOD1|0.00121547330976728__	0	0	0	0		0
102067	16909022	131020	11629	6493	LAMC2	CSF	CSF	11	0.1	we demonstrated that QUIN is significantly increased in serum and CSF of ALS patients	6		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
102068	16909022	131021	20996	11179	SOD1	ALS	ALS	12	1.2	of the factors associated with QUIN toxicity are found in ALS implying that QUIN may play a substantial role in the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00121547330976728<>ScoreDetail__5468|IGFALS|0.000714059028879721__11179|SOD1|0.00121547330976728__	0	0	0	0		0
102069	16909022	131021	20996	11179	SOD1	ALS	ALS	25	1.2	QUIN may play a substantial role in the neuropathogenesis of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00121547330976728<>ScoreDetail__5468|IGFALS|0.000714059028879721__11179|SOD1|0.00121547330976728__	0	0	0	0		0
102070	16909022	131022	20996	11179	SOD1	ALS	ALS	10	1.2	This review details the potential role the KP has in ALS and advances a testable hypothetical model	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00121547330976728<>ScoreDetail__5468|IGFALS|0.000714059028879721__11179|SOD1|0.00121547330976728__	0	0	0	0		0
93459	16983747	120732	20996	11179	SOD1	ALS	ALS	17	0.0	destruction Parkinson's disease (PD), PD one of dopaminergic neuron depletion ALS a disease of motor neuron death and Alzheimer's a disease	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000898762119587972<>ScoreDetail__5468|IGFALS|0.000187160771102377__11179|SOD1|0.000898762119587972__	0	0	0	0		0
94200	17008387	122180	20996	11179	SOD1	ALS	ALS	12	2.2	oxidative damage are also hallmarks of amyotrophic lateral sclerosis (ALS), ALS we studied the effect of oral PDTC treatment on G93A-superoxide	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94202	17008387	122180	20996	11179	SOD1	ALS	ALS	32	2.2	1 (SOD1) SOD1 transgenic (TG) TG rat model of human ALS and observed that PDTC treatment significantly decreases the survival	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94207	17008387	122189	20996	11179	SOD1	ALS	ALS	3	2.2	Amyotrophic lateral sclerosis (ALS) ALS is a late-onset motor neuron degenerative disease of the spinal	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94208	17008387	122190	20996	11179	SOD1	ALS	ALS	3	2.2	The patients with ALS typically become progressively paralyzed and respiratory failure eventually leads to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94209	17008387	122190	20996	11179	SOD1	ALS	ALS	31	2.2	et al. 1986 kappaB accompany motor neuron degeneration either in ALS or SOD1 mutant mice (Migheli Migheli et al. 1997 Tortarolo	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94211	17008387	122191	20996	11179	SOD1	ALS	ALS	10	2.2	Moreover expression of several proinflammatory mediators is increased both in ALS and SOD1 mutant mice (Alexianu Alexianu et al. 2001 Elliott	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94215	17008387	122192	20996	11179	SOD1	ALS	ALS	51	2.2	interplay between glia and motor neurons is required for the ALS pathogenesis	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94216	17008387	122193	20996	11179	SOD1	ALS	ALS	14	2.2	and even apoptosis play major roles in the pathology of ALS we decided to test the effect of PDTC treatment on	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94217	17008387	122195	20996	11179	SOD1	ALS	ALS	25	2.2	of immunoproteasome suggesting that immunoproteasome is a beneficial response in ALS to cope with accumulating protein aggregates	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94218	17008387	122197	20996	11179	SOD1	ALS	ALS	3	2.2	PDTC Treatment of ALS Rats	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94219	17008387	122224	19573	10691	SDS	SDS	SDS-polyacrylamide	8	0.0	Cytosolic proteins were separated by 10% or 12% SDS-polyacrylamide gel electrophoresis on Mini-Protean III electrophoresis device (Bio-Rad) Bio-Rad	11		JUMiner_v2.2	1	0		0	2	19440	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:19440|SBDS|0.000221988138576096<>ScoreDetail__10691|SDS|7.57747973024172e-05__19440|SBDS|0.000221988138576096__	0	0	0	0		0
94221	17008387	122229	20996	11179	SOD1	ALS	ALS	70	2.2	_amp_#177 4 days and vehicle-treated (11 11 _amp_#177 3 days ALS rats ( Fig 1 C and D	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94228	17008387	122238	20996	11179	SOD1	ALS	ALS	23	2.2	a potential therapeutic target verified in numerous animal studies of ALS (Gurney Gurney et al. 1996 Howland et al. 2002 and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94229	17008387	122239	20996	11179	SOD1	ALS	ALS	8	2.2	In agreement with the previous studies on mouse ALS models (Cheroni Cheroni et al. 2005 beta1 beta2 and beta5	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94234	17008387	122242	20996	11179	SOD1	ALS	ALS	43	2.2	which have been reported to be neuroprotective in models of ALS by increasing expression of glutamate transporter GLT-1 (Rothstein Rothstein et	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94238	17008387	122242	20996	11179	SOD1	ALS	ALS	107	2.2	induction of immunoproteasome may be a rather selective characteristic for ALS (models) models compared with models of ischemia trauma and amyloid-accumulating	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94239	17008387	122242	20996	11179	SOD1	ALS	ALS	123	2.2	ischemia trauma and amyloid-accumulating diseases inhibition of immunoproteasome alone in ALS models could increase the accumulation of ubiquitinated proteins including ubiquitinated	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94245	17008387	122244	20996	11179	SOD1	ALS	ALS	80	2.2	It is possible that in a long-term disease such as ALS NF-kappaB activity even though being induced is not maintained at	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94250	17008387	122245	20996	11179	SOD1	ALS	ALS	15	2.2	not provide evidence for a central role of NF-kappaB in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94252	17008387	122246	20996	11179	SOD1	ALS	ALS	35	2.2	be at least directly involved in neuronal survival in TG ALS models	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94256	17008387	122250	20996	11179	SOD1	ALS	ALS	38	2.2	mg kg is not beneficial in a TG model of ALS (L L van den Bosch T Ahtoniemi J Kolstinaho unpublished	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94258	17008387	122251	20996	11179	SOD1	ALS	ALS	17	2.2	the toxic consequences of mutant SOD1 in tissues affected by ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94259	17008387	122253	20996	11179	SOD1	ALS	ALS	3	2.2	PDTC treatment of ALS rats resulted in decreased survival	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
94286	17008387	122318	20996	11179	SOD1	ALS	ALS	4	2.2	ABBREVIATIONS PDTC pyrrolidine dithiocarbamate ALS amyotrophic lateral sclerosis EMSA electrophoretic mobility shift assay NF-kappaB nuclear	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00109824346808189<>ScoreDetail__5468|IGFALS|0.000396780834737039__11179|SOD1|0.00109824346808189__	0	0	0	0		0
81744	17015226	105755	20996	11179	SOD1	ALS	ALS	32	4.8	the progressive late-onset motor neuron disease Amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81745	17015226	105758	20996	11179	SOD1	ALS	ALS	29	4.8	4_amp_#x2013 6 per 100 000 respectively understates the impact of ALS with the lifetime risk at about 1 in 1000 (	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81746	17015226	105759	20996	11179	SOD1	ALS	ALS	4	4.8	Most incidences (90%) 90% of ALS are sporadic that is without an obvious genetic component	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81747	17015226	105760	20996	11179	SOD1	ALS	ALS	13	4.8	in a dominant manner (and and referred to as familial ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81748	17015226	105761	20996	11179	SOD1	ALS	ALS	3	4.8	Sporadic and familial ALS produce similar pathological hallmarks including progressive muscle weakness atrophy and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81749	17015226	105765	20996	11179	SOD1	ALS	ALS	2	4.8	Genetics of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81750	17015226	105766	20996	11179	SOD1	ALS	ALS	3	4.8	Most incidences of ALS are sporadic but 10% of patients have a familial history	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81751	17015226	105767	20996	11179	SOD1	ALS	ALS-like	9	4.2	The identified chromosomal loci containing the mutations leading to ALS-like human motor neuron diseases ( Table 1 have been defined	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81754	17015226	105767	20996	11179	SOD1	ALS	ALS	28	4.8	have been defined as ALS1 through ALS8 as well as ALS with frontotemporal dementia (ALS-FTD) ALS-FTD and ALS-FTD coupled with Parkinson's	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81762	17015226	105770	20996	11179	SOD1	ALS	ALS	10	4.8	ALS-FTD and ALS-FTDP are likely appropriately classified as bona fide ALS but patients have additional disease features including dementia and dystonia	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81769	17015226	105774	20996	11179	SOD1	ALS	ALS	12	4.8	the SOD1 gene are the most common form of inherited ALS accounting for 20% of all the familial ALS forms and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81770	17015226	105774	20996	11179	SOD1	ALS	ALS	20	4.8	of inherited ALS accounting for 20% of all the familial ALS forms and corresponding to 1%_amp_#x2013 2% of all ALS cases	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81771	17015226	105774	20996	11179	SOD1	ALS	ALS	28	4.8	familial ALS forms and corresponding to 1%_amp_#x2013 2% of all ALS cases	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81775	17015226	105778	20996	11179	SOD1	ALS	ALS	5	4.8	Sporadic and SOD1 mutant-mediated familial ALS are clinically indistinguishable and affect the same neurons but even	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81779	17015226	105780	20996	11179	SOD1	ALS	ALS	65	4.8	of our knowledge on mechanisms of motor neuron pathology in ALS is from studies using these models (see see below	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81782	17015226	105782	20996	11179	SOD1	ALS	ALS	20	4.8	hypoxia-induced and tumor-induced angiogenesis gained interest as a contributor to ALS when deletion of the hypoxia response element (HRE) HRE in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81784	17015226	105782	20996	11179	SOD1	ALS	ALS-like	36	4.2	element (HRE) HRE in the murine VEGF promoter resulted in ALS-like disease in mice ( Oosthuyse et_amp_#xa0 al. 2001	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81786	17015226	105784	20996	11179	SOD1	ALS	ALS	2	4.8	Screening of ALS patient DNAs in promoter regions of the VEGF gene including	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81789	17015226	105785	20996	11179	SOD1	ALS	ALS	15	4.8	of the promoter however showed an increased risk of developing ALS in a Belgian Swedish and a British/Birmingham British Birmingham population	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81792	17015226	105787	20996	11179	SOD1	ALS	ALS	8	4.8	Mutations in ANG have also been linked to ALS emphasizing a potential link between altered angiogenesis and motor neuron	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81793	17015226	105788	20996	11179	SOD1	ALS	ALS	10	4.8	Seven missense mutations were identified in 15 patients with familial ALS and 11 apparently sporadic ALS patients ( Greenway et_amp_#xa0 al.	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81794	17015226	105788	20996	11179	SOD1	ALS	ALS	15	4.8	in 15 patients with familial ALS and 11 apparently sporadic ALS patients ( Greenway et_amp_#xa0 al. 2006	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81795	17015226	105789	20996	11179	SOD1	ALS	ALS-linked	26	4.2	English Swedish and North American populations and therefore suggest that ALS-linked ANG mutations are rare	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81797	17015226	105792	20996	11179	SOD1	ALS	ALS	8	4.8	Interestingly the majority of the mutations found in ALS patients are located within the catalytic core and one of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81800	17015226	105795	20996	11179	SOD1	ALS	ALS	29	4.8	disease course with most instances of disease representing an atypical ALS that is accompanied by an unusual tremor ( Nishimura et_amp_#xa0	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81801	17015226	105796	20996	11179	SOD1	ALS	ALS	25	4.8	and a small proportion of patients develop symptoms of classic ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81805	17015226	105800	20996	11179	SOD1	ALS	ALS	14	4.8	three neurofilament subunits have long been suspected as causative for ALS because of their link with motor neuron pathology in mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81806	17015226	105801	20996	11179	SOD1	ALS	ALS	21	4.8	accumulations are a pathological hallmark of both familial and sporadic ALS ( Hirano 1991 Hirano et_amp_#xa0 al. 1984a and Hirano et_amp_#xa0	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81807	17015226	105801	20996	11179	SOD1	ALS	ALS	39	4.8	and Hirano et_amp_#xa0 al. 1984b and are also seen in ALS mice expressing mutant SOD1 ( Bruijn et_amp_#xa0 al. 1997 and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81812	17015226	105803	20996	11179	SOD1	ALS	ALS	24	4.8	failed to yield conclusive linkage to either sporadic or familial ALS patients ( Garcia et_amp_#xa0 al. 2006 although dominant point mutations	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81815	17015226	105804	20996	11179	SOD1	ALS	ALS	30	4.8	the NF-H subunit have been reported in 1% of sporadic ALS patients ( Al-Chalabi et_amp_#xa0 al. 1999 Figlewicz et_amp_#xa0 al. 1994	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81816	17015226	105805	20996	11179	SOD1	ALS	ALS	12	4.8	is likely that these neurofilament variants are risk factors for ALS and/or and or a primary event with low penetrance	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81817	17015226	105806	20996	11179	SOD1	ALS	ALS	7	4.8	A final potential contribution of neurofilaments to ALS comes from errors in the expression of an additional intermediate	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81818	17015226	105807	20996	11179	SOD1	ALS	ALS	10	4.8	An assembly-disrupting frameshift mutation has been reported in one sporadic ALS case ( Gros-Louis et_amp_#xa0 al. 2004	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81819	17015226	105808	20996	11179	SOD1	ALS	ALS-causing	53	4.2	has no affect on disease course in mice having an ALS-causing SOD1 mutation ( Lariviere et_amp_#xa0 al. 2003	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81850	17015226	105823	20996	11179	SOD1	ALS	ALS-like	22	4.2	hSOD1 Quad resulting in dismutase inactive SOD1 still develop typical ALS-like motor neuron disease ( Wang et_amp_#xa0 al. 2003	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81854	17015226	105825	20996	11179	SOD1	ALS	ALS-Causing	7	4.2	Misfolded SOD1 as a Common Feature of ALS-Causing Mutations	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81855	17015226	105826	20996	11179	SOD1	ALS	ALS	17	4.8	different neurodegenerative disorders including Alzheimer's Parkinson's and Huntington's diseases and ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81856	17015226	105827	20996	11179	SOD1	ALS	ALS	10	4.8	Cytoplasmic protein aggregates are observed in both sporadic and familial ALS cases as well as in mutant SOD1 transgenic mice (	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81864	17015226	105834	20996	11179	SOD1	ALS	ALS-like	34	4.2	very aggressive disease course in humans neither induces aggregates nor ALS-like disease in mice except in the context of high levels	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81874	17015226	105842	20996	11179	SOD1	ALS	ALS	3	4.8	Aggregates found in ALS patients as well as mouse models contain ubiquitin ( Ince	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81879	17015226	105850	20996	11179	SOD1	ALS	ALS	6	4.8	In spinal cord extracts of presymptomatic ALS mice an overall decrease of chaperone activity has been reported	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81890	17015226	105853	20996	11179	SOD1	ALS	ALS	29	4.8	al. 2003 which may contribute to their selective vulnerability in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81908	17015226	105861	20996	11179	SOD1	ALS	ALS	10	4.8	Mitochondria were implicated as a possible target for toxicity in ALS by histopathological observations of vacuolated and dilated mitochondria with disorganized	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81909	17015226	105861	20996	11179	SOD1	ALS	ALS	35	4.8	motor neurons (and and muscle of both sporadic and familial ALS patients ( Afifi et_amp_#xa0 al. 1966 Hirano et_amp_#xa0 al. 1984a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81910	17015226	105862	18111	5724	RBPJ	SUH	Suh	30	0.6	respiration and increased levels of uncoupling proteins ( Chung and Suh 2002 Dupuis et_amp_#xa0 al. 2003 Echaniz-Laguna et_amp_#xa0 al. 2002 Vielhaber	2		JUMiner_v2.2	1	2	UserEdit	0	2	5724	TotalCon:2<>5724|RBPJ|3516|Complete__13761|RBPJL|11317|Complete__<>AvaiableGeneRif=2<>BEST:5724|RBPJ|0.00027587698614083<>ScoreDetail__5724|RBPJ|0.00027587698614083__13761|RBPJL|0.000145008887641501__	1	1	0	0		0
81938	17015226	105895	20996	11179	SOD1	ALS	ALS	52	4.8	Bcl-2 have been reported in spinal cord motor neurons of ALS patients ( Ekegren et_amp_#xa0 al. 1999 and Mu et_amp_#xa0 al.	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81950	17015226	105902	20996	11179	SOD1	ALS	ALS	11	4.8	of the Neuromuscular Synapse as the First Cellular Phenotype in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81951	17015226	105904	20996	11179	SOD1	ALS	ALS	11	4.8	to the muscle at the neuromuscular junction is lost in ALS mouse models long before motor neuron degeneration or death and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81952	17015226	105905	20996	11179	SOD1	ALS	ALS	43	4.8	5 _amp_#x3bc m myelinated axons that are selectively vulnerable in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81959	17015226	105912	20996	11179	SOD1	ALS	ALS	8	4.8	Damage within the Axon Compromised Axonal Transport in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
81984	17015226	105930	20996	11179	SOD1	ALS	ALS	4	4.8	Although progressive paralysis in ALS arises from degeneration and death of motor neurons evidence from	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82008	17015226	105955	20996	11179	SOD1	ALS	ALS	1	4.8	In ALS microglial activation has been described in the brain and spinal	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82010	17015226	105957	20996	11179	SOD1	ALS	ALS	22	4.8	the immune response have been reported in spinal cords of ALS patients and hSOD1 G93A mice during the disease course (	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82012	17015226	105959	20996	11179	SOD1	ALS	ALS	7	4.8	Minocycline was potent in increasing survival of ALS mice and reduced microglial activation ( Kriz et_amp_#xa0 al. 2002	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82013	17015226	105963	20996	11179	SOD1	ALS	ALS	8	4.8	Either way supported by its beneficial effect in ALS mice minocycline has been proposed for clinical trial ( Gordon	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82016	17015226	105964	20996	11179	SOD1	ALS	ALS	36	4.8	cytokines and COX-2 expression is induced in spinal cords of ALS patients ( Yasojima et_amp_#xa0 al. 2001 and Yiangou et_amp_#xa0 al.	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82018	17015226	105966	20996	11179	SOD1	ALS	ALS	14	4.8	in a human trial failed to provide a benefit in ALS ( Cudkowicz et_amp_#xa0 al. 2006	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82019	17015226	105967	20996	11179	SOD1	ALS	ALS	7	4.8	Additional evidence implicating microglia in pathogenesis of ALS arose from forcing activation of the immune system using chronic	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82025	17015226	105971	11629	6493	LAMC2	CSF	CSF	2	0.3	Cerebrospinal fluid (CSF) CSF and serum of ALS patients also contain increased levels of	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
82026	17015226	105971	20996	11179	SOD1	ALS	ALS	6	4.8	Cerebrospinal fluid (CSF) CSF and serum of ALS patients also contain increased levels of inflammation related factors including	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82044	17015226	105983	20996	11179	SOD1	ALS	ALS	24	4.8	of this pathway which is apparently also activated in presymptomatic ALS mice ( Raoul et_amp_#xa0 al. 2002 Raoul et_amp_#xa0 al. 2006	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82046	17015226	105985	20996	11179	SOD1	ALS	ALS	2	4.8	Astrocytes in ALS Gatekeepers of Synaptic Glutamate and Excitoxicity	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82053	17015226	105992	20996	11179	SOD1	ALS	ALS	19	4.8	editing is reduced in the spinal cord motor neurons of ALS patients compared to controls ( Kawahara et_amp_#xa0 al. 2004 and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82057	17015226	105996	20996	11179	SOD1	ALS	ALS	8	4.8	Astrocyte activation is seen in spinal cords of ALS patients and SOD1 mutant mice ( Hall et_amp_#xa0 al. 1998	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82062	17015226	105998	20996	11179	SOD1	ALS	ALS	16	4.8	the few firm mechanistic links between sporadic and SOD1 mutant-caused ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82063	17015226	105999	20996	11179	SOD1	ALS	ALS	14	4.8	been reported in synaptosomes obtained from affected CNS tissues of ALS patients ( Rothstein et_amp_#xa0 al. 1992 and levels of EAAT2	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82065	17015226	105999	20996	11179	SOD1	ALS	ALS	35	4.8	are reduced in the motor cortex and spinal cord of ALS patients ( Fray et_amp_#xa0 al. 1998 Maragakis et_amp_#xa0 al. 2004	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82067	17015226	106000	20996	11179	SOD1	ALS	ALS	7	4.8	This is functionally of consequence for familial ALS in that hSOD1 G93A mice heterozygous for EAAT2 develop earlier-onset	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82073	17015226	106002	20996	11179	SOD1	ALS	ALS	20	4.8	to underlie the mild slowing of disease course in human ALS from the only FDA-approved treatment (riluzole; riluzole Doble 1996	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82074	17015226	106003	20996	11179	SOD1	ALS	ALS	7	4.8	Additional implication for an astrocytic contribution in ALS is demonstration in cell culture that activated astrocytes induce embryonic	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82080	17015226	106005	20996	11179	SOD1	ALS	ALS	3	4.8	Muscle Involvement in ALS Targets for Therapy	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82081	17015226	106006	20996	11179	SOD1	ALS	ALS-	7	4.2	Among the earliest events in the human ALS- and SOD1-mediated disease is withdrawal of the motor axons from	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82083	17015226	106007	20996	11179	SOD1	ALS	ALS	6	4.8	This denervation generates the progressive paralysis of_amp_#xa0 ALS a consequence of which is muscle atrophy ( Cifuentes-Diaz et_amp_#xa0	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82085	17015226	106009	20996	11179	SOD1	ALS	ALS	15	4.8	muscle mass and strength per se can be beneficial in ALS has been attempted by repetitive injection into hSOD1 G93A mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82088	17015226	106011	20996	11179	SOD1	ALS	ALS	38	4.8	et_amp_#xa0 al. 2005 has led to significant life extensions in ALS transgenic mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82092	17015226	106015	20996	11179	SOD1	ALS	ALS	14	4.8	number of studies have shown that exercise is beneficial in ALS transgenic animals ( Kirkinezos et_amp_#xa0 al. 2003 and Veldink et_amp_#xa0	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82094	17015226	106016	20996	11179	SOD1	ALS	ALS	13	4.8	this synergism is not known and the relevance for human ALS unclear as no consensus has emerged from several efforts to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82095	17015226	106017	20996	11179	SOD1	ALS	ALS	9	4.8	A Model for Selective Vulnerability of Motor Neurons in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82096	17015226	106018	20996	11179	SOD1	ALS	ALS	14	4.8	multiple animal models used a determine pathogenic mechanisms in inherited ALS the central insight is that although motor neuron degeneration and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82107	17015226	106038	20996	11179	SOD1	ALS	ALS	10	4.8	these mechanisms (which which have also been invoked in sporadic ALS are right and all combine to underlie selective vulnerability	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82108	17015226	106040	20996	11179	SOD1	ALS	ALS	4	4.8	Growth Factor Therapies in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82109	17015226	106041	20996	11179	SOD1	ALS	ALS	12	4.8	trophic factors has dominated recent efforts in clinical trials in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82114	17015226	106043	20996	11179	SOD1	ALS	ALS	37	4.8	for BDNF ( BDNF Study Group 1999 or CNTF ( ALS CNTF Treatment Study Group 1996	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82116	17015226	106044	20996	11179	SOD1	ALS	ALS	12	4.8	the absence of evidence that growth factors were limiting in ALS the weakness of these approaches was insuring adequate delivery to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82119	17015226	106048	38	22	AAVS1	AAV	AAV	15	0.3	A an IGF-1-encoding gene was inserted into adenoassociated virus (AAV), AAV a small replication-defective virus that is episomally maintained within the	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
82121	17015226	106052	38	22	AAVS1	AAV	AAV	2	0.3	The same AAV producing GDNF used in the same manner provided only a	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
82124	17015226	106052	38	22	AAVS1	AAV	AAV	36	0.3	GDNF encoded by adenovirus ( Acsadi et_amp_#xa0 al. 2002 or AAV ( Wang et_amp_#xa0 al. 2002 delivered intramuscularly	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
82126	17015226	106053	20996	11179	SOD1	ALS	ALS	14	4.8	variants in the VEGF gene contribute to some examples of ALS ( Table 1 delivery of an integrating lentivirus encoding VEGF	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82130	17015226	106054	11629	6493	LAMC2	CSF	CSF	12	0.3	did continuous ICV infusion of recombinant VEGF protein into the CSF ( Figure_amp_#xa0 4 B disease onset was delayed and survival	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
82137	17015226	106059	20996	11179	SOD1	ALS	ALS	3	4.8	Gene Therapies in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82138	17015226	106060	20996	11179	SOD1	ALS	ALS	6	4.8	With recognition that the instances of ALS caused by dominant mutation in SOD1 derive from a toxic	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82143	17015226	106066	38	22	AAVS1	AAV	AAV	13	0.3	disease onset was seen by retrograde delivery of an siRNA-encoding AAV ( Miller et_amp_#xa0 al. 2005	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
82146	17015226	106075	20996	11179	SOD1	ALS	ALS	20	4.8	be an effective dosage-regulatable means of treating neurodegenerative diseases including ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82147	17015226	106077	20996	11179	SOD1	ALS	ALS	4	4.8	Stem Cell Therapies in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82148	17015226	106078	20996	11179	SOD1	ALS	ALS	9	4.8	The selective age-dependent killing of motor neurons has made ALS one of the poster diseases for cell replacement using stem	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82150	17015226	106089	20996	11179	SOD1	ALS	ALS	16	4.8	in a model of chronic motor neuron degeneration such as ALS remains to be determined	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82156	17015226	106098	20996	11179	SOD1	ALS	ALS-Causing	3	4.2	Figure_amp_#xa0 1._amp_#xa0 Proposed Toxicities of ALS-Causing SOD1 Protein Aggregates	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82160	17015226	106100	20996	11179	SOD1	ALS	ALS	17	4.8	Degeneration and Glial Activation during the Course of SOD1 Mutant-Initiated ALS Disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82161	17015226	106101	20996	11179	SOD1	ALS	ALS	5	4.8	Figure_amp_#xa0 4._amp_#xa0 New Directions for Therapies in ALS Using Viral Delivery or Direct Infusion into the Brain or	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000885320172874395<>ScoreDetail__5468|IGFALS|0.000464705082286802__11179|SOD1|0.000885320172874395__	0	0	0	0		0
82230	17018025	106132	20996	11179	SOD1	ALS	ALS	23	1.3	progression of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), ALS Parkinson's disease and Alzheimer's disease (for for review see Block	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000526036006401261<>ScoreDetail__5468|IGFALS|0.000526036006401261__11179|SOD1|0.000515829408284609__	0	0	0	0		0
82231	17018025	106135	20996	11179	SOD1	ALS	ALS	15	1.3	to reduce neuronal injury in disease models of Parkinson's disease ALS and Alzheimer's disease ( Town et al 2002 Angelov et	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000526036006401261<>ScoreDetail__5468|IGFALS|0.000526036006401261__11179|SOD1|0.000515829408284609__	0	0	0	0		0
82249	17018025	106149	1759	1102	BRD1	BRL	BRL	9	0.3	Culture media sera and antibiotics were purchased from Gibco BRL (Rockville, Rockville MD USA and all other reagents were from	1		JUMiner_v2.2	1	2	gibco brl	0	0	0		0	0	0	0		0
82251	17018025	106161	7361	20442	FBRS	FBS	FBS	16	0.0	in SATO's medium supplemented with 10% fetal bovine serum (FBS) FBS and seeded in 150 cm 2 flasks at a density	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>20442|FBRS|64319|Complete__13587|FBXO8|26269|No_GeneRif__<>AvaiableGeneRif=1<>	0	0	0	0		0
82262	17018025	106198	3778	10620	CCL21	ECL	ECL	1	0.0	The ECL plus detection system (Amersham Amersham Pharmacia Biotech Piscataway NJ USA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
82264	17018025	106202	7572	17371	FHL5	ACT	ACT	16	0.3	follows for IL-4R the primers 5'-CCT GTT CCC AGC CAG ACT AC-3' and 5'-AGC ACA GAC CTC AGC AAC AA-3' T	1		JUMiner_v2.2	1	2	35	0	2	17371	TotalCon:6<>24157|ACOT7|11332|Complete__17371|FHL5|9457|Complete__16|SERPINA3|12|Complete__17780|ACTBL2|345651|No_GeneRif__144|ACTG1|71|Complete__145|ACTG2|72|Complete__<>AvaiableGeneRif=5<>BEST:17371|FHL5|0.000663206860248865<>ScoreDetail__17371|FHL5|0.000663206860248865__145|ACTG2|0.000493896671877277__24157|ACOT7|0.000449445971408322__144|ACTG1|0.000317923116934336__16|SERPINA3|0.000530363016633887__	0	0	0	0		0
82265	17018025	106202	22079	11778	TGM2	TGC	TGC	38	0.0	59.6_amp_deg C for B-actin the primers 5'-TTG CTG ACA GGA TGC AGA AG-3' and 5'-CAG TGA GGC CAG GAT AGA GC-3'	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
82266	17018025	106202	426	318	AGA	AGA	AGA	39	0.0	C for B-actin the primers 5'-TTG CTG ACA GGA TGC AGA AG-3' and 5'-CAG TGA GGC CAG GAT AGA GC-3' T	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
82267	17018025	106202	21860	11592	TBX1	TGA	TGA	43	0.0	primers 5'-TTG CTG ACA GGA TGC AGA AG-3' and 5'-CAG TGA GGC CAG GAT AGA GC-3' T m = 59.6_amp_deg C	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
82268	17018025	106202	8451	13734	GLYAT	GAT	GAT	46	0.0	ACA GGA TGC AGA AG-3' and 5'-CAG TGA GGC CAG GAT AGA GC-3' T m = 59.6_amp_deg C	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
82269	17018025	106202	426	318	AGA	AGA	AGA	47	0.0	GGA TGC AGA AG-3' and 5'-CAG TGA GGC CAG GAT AGA GC-3' T m = 59.6_amp_deg C	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
82351	17018025	106262	18723	10261	ROS1	ROS	ROS	31	0.0	several substances implicated in neurotoxicity including reactive oxygen species (ROS), ROS such as nitric oxide and superoxide ( pro-inflammatory neurotoxic cytokines	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
82378	17018025	106282	20996	11179	SOD1	ALS	ALS	18	1.3	been postulated to play a role in the pathogenesis of ALS Alzheimer's disease and Parkinson's disease ( Le et al 2001	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000526036006401261<>ScoreDetail__5468|IGFALS|0.000526036006401261__11179|SOD1|0.000515829408284609__	0	0	0	0		0
82449	17018025	106329	20996	11179	SOD1	ALS	ALS	25	1.3	self-reactive T cells was neuroprotective in a transgenic model of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000526036006401261<>ScoreDetail__5468|IGFALS|0.000526036006401261__11179|SOD1|0.000515829408284609__	0	0	0	0		0
83587	17034351	107852	20996	11179	SOD1	ALS	ALS	7	1.4	Mouse models of familial amyotrophic lateral sclerosis (ALS) ALS based on overexpressed mutant human Cu Zn-superoxide dismutase (SOD1) SOD1	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00163377962594661<>ScoreDetail__5468|IGFALS|0.000363664701145544__11179|SOD1|0.00163377962594661__	0	0	0	0		0
79604	17114826	102824	3852	1634	CD1A	CD1	CD-1	3	0.0	Young male colony CD-1 mice were injected with the adjuvants at doses equivalent to	11		JUMiner_v2.2	1	0		0	2	1636	TotalCon:3<>1634|CD1A|909|Complete__1635|CD1B|910|Complete__1636|CD1C|911|Complete__<>AvaiableGeneRif=3<>BEST:1636|CD1C|0.000411584225099154<>ScoreDetail__1634|CD1A|0.000380054727880815__1636|CD1C|0.000411584225099154__1635|CD1B|0.000340028108990343__	0	0	0	0		0
79966	17127558	103267	9947	5468	IGFALS	ALS	ALS	4	0.3	The possible causes of ALS are unknown and multiple biological systems have been implicated	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000976662897090573<>ScoreDetail__5468|IGFALS|0.000976662897090573__11179|SOD1|0.000839868655379314__	0	0	0	0		0
79967	17127558	103268	9947	5468	IGFALS	ALS	ALS	19	0.3	expression profiling to evaluate a broad spectrum of systems in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000976662897090573<>ScoreDetail__5468|IGFALS|0.000976662897090573__11179|SOD1|0.000839868655379314__	0	0	0	0		0
79968	17127558	103269	9947	5468	IGFALS	ALS	ALS	21	0.3	and adjacent sensory cortex were collected at autopsy from five ALS patients and three normal individuals	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000976662897090573<>ScoreDetail__5468|IGFALS|0.000976662897090573__11179|SOD1|0.000839868655379314__	0	0	0	0		0
79969	17127558	103271	9947	5468	IGFALS	ALS	ALS	12	0.3	difference in expression of 275 genes was found in the ALS motor cortex of the genes whose expression was changed 10	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000976662897090573<>ScoreDetail__5468|IGFALS|0.000976662897090573__11179|SOD1|0.000839868655379314__	0	0	0	0		0
79970	17127558	103272	9947	5468	IGFALS	ALS	ALS	30	0.3	consistent with the idea of excitotoxicity contributing to neurodegeneration in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000976662897090573<>ScoreDetail__5468|IGFALS|0.000976662897090573__11179|SOD1|0.000839868655379314__	0	0	0	0		0
79971	17127558	103274	9947	5468	IGFALS	ALS	ALS	17	0.3	expression patterns between the sensory and motor cortex in the ALS brains	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000976662897090573<>ScoreDetail__5468|IGFALS|0.000976662897090573__11179|SOD1|0.000839868655379314__	0	0	0	0		0
79972	17127558	103276	9947	5468	IGFALS	ALS	ALS	18	0.3	gene array data newly acquired motor and sensory cortex of ALS and control cases (n n = 4 each were used	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000976662897090573<>ScoreDetail__5468|IGFALS|0.000976662897090573__11179|SOD1|0.000839868655379314__	0	0	0	0		0
79973	17127558	103278	9947	5468	IGFALS	ALS	ALS	12	0.3	profile data reported here are consistent with evidence that the ALS brain is characterized by an environment that is permissive for	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000976662897090573<>ScoreDetail__5468|IGFALS|0.000976662897090573__11179|SOD1|0.000839868655379314__	0	0	0	0		0
79974	17127558	103279	9947	5468	IGFALS	ALS	ALS	16	0.3	that a metal imbalance particularly for zinc could exist in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000976662897090573<>ScoreDetail__5468|IGFALS|0.000976662897090573__11179|SOD1|0.000839868655379314__	0	0	0	0		0
79975	17127558	103280	9947	5468	IGFALS	ALS	ALS	17	0.3	that is thought to be part of the pathogenesis in ALS there was a notable lack of increase in genes required	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000976662897090573<>ScoreDetail__5468|IGFALS|0.000976662897090573__11179|SOD1|0.000839868655379314__	0	0	0	0		0
79976	17127558	103281	9947	5468	IGFALS	ALS	ALS	14	0.3	a conceptual framework in which to consider the possibility that ALS could result from a failure to mount adequate protective responses	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000976662897090573<>ScoreDetail__5468|IGFALS|0.000976662897090573__11179|SOD1|0.000839868655379314__	0	0	0	0		0
80156	17128115	103759	9947	5468	IGFALS	ALS	ALS	6	0.3	Other compounds have been tried in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000932157670843983<>ScoreDetail__5468|IGFALS|0.000302038761641077__11179|SOD1|0.000932157670843983__	0	0	0	0		0
74827	17190960	95976	20996	11179	SOD1	ALS	ALS	18	0.0	rare idiosyncratic reaction that can occur with the riluzole in ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000339500933627567<>ScoreDetail__5468|IGFALS|0.000339500933627567__11179|SOD1|0.000247529181602915__	0	0	0	0		0
74828	17190960	95988	6981	22140	FAM20C	RNS	RNS	9	0.0	var oas='URL' var RN = new String (Math.random()); Math.random var RNS = RN.substring (2, 2 11 function DisplayAds (position, position sitepage	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
74829	17190960	95988	6981	22140	FAM20C	RNS	RNS	27	0.0	position sitepage width height var oaspage= sitepage '/1' ' 1' RNS '@' position if (_version _version ' else document.write (' '	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
74830	17190960	95996	20996	11179	SOD1	ALS	ALS	10	0.0	Riluzole is the only Food and Drug Administration-approved treatment of ALS that has been shown to modestly prolong survival	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000339500933627567<>ScoreDetail__5468|IGFALS|0.000339500933627567__11179|SOD1|0.000247529181602915__	0	0	0	0		0
74831	17190960	96002	20996	11179	SOD1	ALS	ALS	14	0.0	life-threatening systemic inflammatory reaction to riluzole in a patient with ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000339500933627567<>ScoreDetail__5468|IGFALS|0.000339500933627567__11179|SOD1|0.000247529181602915__	0	0	0	0		0
74832	17190960	96003	20996	11179	SOD1	ALS	ALS	7	0.0	A healthy 50-year-old man was diagnosed with ALS after presenting with 1 year of progressive asymmetrical hand weakness	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000339500933627567<>ScoreDetail__5468|IGFALS|0.000339500933627567__11179|SOD1|0.000247529181602915__	0	0	0	0		0
74833	17190960	96004	20996	11179	SOD1	ALS	ALS	9	0.0	He fulfilled the El Escorial Criteria for clinically definite ALS at the time of his presentation	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000339500933627567<>ScoreDetail__5468|IGFALS|0.000339500933627567__11179|SOD1|0.000247529181602915__	0	0	0	0		0
74834	17190960	96008	20172	10933	SLC17A5	AST	AST	10	0.0	His liver enzymes at that time demonstrated a modest elevation AST of 92 (normal, normal 12 to 31 alanine aminotransferase of	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
74863	17191135	96081	18723	10261	ROS1	ROS	ROS	6	0.6	However while excess reactive oxygen species (ROS) ROS are toxic regulated ROS play an important role in cell	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
74864	17191135	96081	18723	10261	ROS1	ROS	ROS	10	0.6	while excess reactive oxygen species (ROS) ROS are toxic regulated ROS play an important role in cell signaling	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
74865	17191135	96082	6554	3309	ELA2	HNE	HNE	20	0.0	of the product of polyunsaturated fatty acid peroxidation (hydroxynonenals, hydroxynonenals HNE or cholesterol oxidation can disrupt redox homeostasis	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
74866	17191135	96085	18723	10261	ROS1	ROS	ROS	18	0.6	is generally associated with metabolic derangements and excessive production of ROS	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
74869	17191135	96101	18723	10261	ROS1	ROS	ROS	16	0.6	uptake by cells is converted into reactive oxygen species (ROS) ROS 1	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
74870	17191135	96103	18723	10261	ROS1	ROS	ROS	9	0.6	In contrast to this physiological role pathological actions of ROS occur at an order of magnitude higher concentrations	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
74871	17191135	96106	18723	10261	ROS1	ROS	ROS	5	0.6	Indeed continuous low concentrations of ROS induce expression of antioxidant enzymes and related defense mechanisms	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
74872	17191135	96107	20996	11179	SOD1	ALS	ALS	13	1.9	s diseases (HD), HD but also amyotrophic lateral scelrosis (ALS) ALS and Friedreich_amp_#8217 s ataxia (FRDA) FRDA belong to the so-called	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000570340949044605<>ScoreDetail__5468|IGFALS|0.000429859285933318__11179|SOD1|0.000570340949044605__	0	0	0	0		0
74874	17191135	96111	18723	10261	ROS1	ROS	ROS	20	0.6	stress which leads to mitochondrial dysfunction and excessive production of ROS thus inducing oxidative stress	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
74875	17191135	96112	18723	10261	ROS1	ROS	ROS	9	0.6	The ability of a cell to deal with excessive ROS as well as excessive reactive nitrogen species (RNS) RNS requires	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
74876	17191135	96112	6981	22140	FAM20C	RNS	RNS	17	0.6	excessive ROS as well as excessive reactive nitrogen species (RNS) RNS requires the activation of pro-survival pathways as well as the	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
74879	17191135	96115	6981	22140	FAM20C	RNS	RNS	21	0.6	stress through its properties to bind and inactivate NO and RNS 11 -14	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
74898	17191135	96135	18723	10261	ROS1	ROS	ROS	6	0.6	As a consequence of this aggregation ROS formation increases and a pro-oxidant environment takes place	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
74900	17191135	96140	18723	10261	ROS1	ROS	ROS	13	0.6	heme oxygenase could _amp_#8220 sense_amp_#8221 NO and thus protect against ROS and RNS insults is supported by the following findings (a)	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
74901	17191135	96140	6981	22140	FAM20C	RNS	RNS	15	0.6	could _amp_#8220 sense_amp_#8221 NO and thus protect against ROS and RNS insults is supported by the following findings (a) a NO	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
74903	17191135	96141	6981	22140	FAM20C	RNS	RNS	5	0.6	The conception that NO and RNS can be directly involved in the modulation of HO-1 expression	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
74907	17191135	96142	10676	6121	IRF6	LPS	LPS	7	0.6	In rat glial cells treatment with lipopolysaccaride (LPS) LPS and interferon-G (IFN-G) IFN-G promotes a rapid increase in both	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
74913	17191135	96142	10676	6121	IRF6	LPS	LPS	45	0.6	of HO-1 mRNA expression by iNOS-derived NO following stimulation with LPS has also been reported in different brain regions particularly in	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
74939	17191135	96162	10463	6018	IL6	HSF	HSFs	7	0.3	These denaturated proteins activate heat shock factors (HSFs) HSFs within the cytosol (or or ER by dissociating other Hsps	13		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
74940	17191135	96162	10463	6018	IL6	HSF	HSF	20	0.3	(or or ER by dissociating other Hsps normally bound to HSF 34	13		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
74941	17191135	96163	10463	6018	IL6	HSF	HSF	1	0.3	Freed HSF is phosphorylated and forms trimers which enter the nucleus and	13		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
74942	17191135	96163	9652	23316	HSD17B6	HSE	HSE	17	0.0	enter the nucleus and bind to heat shock elements (HSE) HSE within the promoters of different heat shock genes leading to	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
74959	17191135	96177	11717	6530	LCT	LAC	LAC	28	0.0	up-regulation of Hsp60 may be a fundamental site targeted by LAC action with consequent restoration of complex IV function under conditions	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
74965	17191135	96184	18723	10261	ROS1	ROS	ROS	8	0.6	Heme oxygenase-1 is induced by various stimuli including ROS RNS ischemia heat shock LPS hemin and the neuroprotective agent	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
74966	17191135	96184	6981	22140	FAM20C	RNS	RNS	9	0.6	Heme oxygenase-1 is induced by various stimuli including ROS RNS ischemia heat shock LPS hemin and the neuroprotective agent Neotrofin	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
74967	17191135	96184	10676	6121	IRF6	LPS	LPS	13	0.6	induced by various stimuli including ROS RNS ischemia heat shock LPS hemin and the neuroprotective agent Neotrofin 41 44 -46	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
74999	17191135	96199	10676	6121	IRF6	LPS	LPS	19	0.6	recent data showed that the reductase can be induced by LPS and bromobenzene at a post-transcriptional level whereas heat shock has	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
75025	17191135	96223	1755	1101	BRCA2	FAD	FAD	14	0.3	which each monomer includes two prosthetic flavin adenine dinucleotide (FAD) FAD groups and a NADPH binding site	1		JUMiner_v2.2	1	2	nadph	0	2	3585	TotalCon:3<>1101|BRCA2|675|Complete__3585|FANCD2|2177|Complete__9508|PSEN1|5663|Complete__<>AvaiableGeneRif=3<>BEST:3585|FANCD2|0.000616414966919063<>ScoreDetail__1101|BRCA2|0.000291740765865872__9508|PSEN1|0.000550124664860037__3585|FANCD2|0.000616414966919063__	0	0	0	0		0
75026	17191135	96224	1755	1101	BRCA2	FAD	FAD	18	0.3	consisting of two cysteines adjacent to the flavin ring of FAD in the N-terminal part of the protein	1		JUMiner_v2.2	1	2	nadph	0	2	3585	TotalCon:3<>1101|BRCA2|675|Complete__3585|FANCD2|2177|Complete__9508|PSEN1|5663|Complete__<>AvaiableGeneRif=3<>BEST:3585|FANCD2|0.000616414966919063<>ScoreDetail__1101|BRCA2|0.000291740765865872__9508|PSEN1|0.000550124664860037__3585|FANCD2|0.000616414966919063__	0	0	0	0		0
75066	17191135	96251	18723	10261	ROS1	ROS	ROS	16	0.6	of reducing equivalents Trx by itself acts as antioxidant or ROS scavenger	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
75084	17191135	96261	22000	11730	TERT	TERT	tert	29	0.3	embryo kidney cells to cell death induced by etopoxide or tert -butylhydroperoxide 82	14		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
75088	17191135	96264	18723	10261	ROS1	ROS	ROS	16	0.6	to be associated with brain regions producing high levels of ROS 83	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
75090	17191135	96269	12369	6893	MAPT	tau	tau	42	1.8	ubiquitination clearing misfolded proteins to the proteasome and segregation of tau aggregates from the cellular machinery and recruitment of chaperone pairs	1		JUMiner_v2.2	1	2	35	0	0	0		0	0	0	0		0
75095	17191135	96270	7962	4012	FUT1	HSC	Hsc	23	0.5	for the E3 ligase carboxyl terminus of heat-shock cognate (Hsc)70-interacting Hsc 70-interacting protein (CHIP) CHIP 86 -88	2		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
75140	17191135	96305	18723	10261	ROS1	ROS	ROS	16	0.6	to inhibit lipid peroxidation and to effectively intercept and neutralize ROS and RNS 23	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
75141	17191135	96305	6981	22140	FAM20C	RNS	RNS	18	0.6	lipid peroxidation and to effectively intercept and neutralize ROS and RNS 23	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
75144	17191135	96307	18723	10261	ROS1	ROS	ROS	32	0.6	that HO-1-derived BR has the ability to efficiently scavenge both ROS and RNS 8 11 -13 99	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
75145	17191135	96307	6981	22140	FAM20C	RNS	RNS	34	0.6	BR has the ability to efficiently scavenge both ROS and RNS 8 11 -13 99	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
75146	17191135	96309	16343	17468	PDLIM5	LIM	Lim	4	0.3	Based on these findings Lim and colleagues have provided convincing evidence that dietary curcumin given	2		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
75147	17191135	96314	11717	6530	LCT	LAC	LAC	3	0.0	Acetyl-l -carnitine (LAC), LAC is a compound of great interest for its wide clinical	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
75149	17191135	96322	11717	6530	LCT	LAC	LAC	29	0.0	often obscured by more abundant ones it has reported that LAC modulates specific genes in the rat CNS such as the	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
75154	17191135	96329	20996	11179	SOD1	ALS	ALS	7	1.9	Protein conformational diseases such as AD PD ALS HD and MS affect a large portion of our aging	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000570340949044605<>ScoreDetail__5468|IGFALS|0.000429859285933318__11179|SOD1|0.000570340949044605__	0	0	0	0		0
75155	17191135	96334	18723	10261	ROS1	ROS	ROS	24	0.6	(mal)folding mal folding cycles and oxidative damage cycles sustaining excessive ROS production and oxidative stress 125 126 (Figs Figs 3 4	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
75156	17191135	96335	18723	10261	ROS1	ROS	ROS	1	0.6	These ROS set in motion a lot of redox reactions which can	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
75157	17191135	96336	18723	10261	ROS1	ROS	ROS	8	0.6	The ability of a cell to deal with ROS and oxidative stress requires functional chaperones antioxidant production protein degradation	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
75158	17191135	96337	18723	10261	ROS1	ROS	ROS	20	0.6	susceptible to perturbations in the quality control system and that ROS play an important role in the development and/or and or	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
75162	17191135	96349	18723	10261	ROS1	ROS	ROS	24	0.6	the altered membrane permeability results in Ca 2 leakage and ROS formation	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
75163	17191135	96351	18723	10261	ROS1	ROS	ROS	0	0.6	ROS generated during and as a consequence of protein misfolding cause	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
75164	17191135	96352	18723	10261	ROS1	ROS	ROS-induced	10	0.3	In these conditions chaperone proteins themselves can be target of ROS-induced alterations	1		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
76076	17214440	97706	20996	11179	SOD1	ALS	ALS	6	1.7	In most cases the cause of ALS is unknown although in a number of familial ALS cases	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014093227737752<>ScoreDetail__5468|IGFALS|0.000540686672073533__11179|SOD1|0.0014093227737752__	0	0	0	0		0
76077	17214440	97706	20996	11179	SOD1	ALS	ALS	15	1.7	of ALS is unknown although in a number of familial ALS cases mutations in the superoxide dismutase 1 (SOD1) SOD1 gene	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014093227737752<>ScoreDetail__5468|IGFALS|0.000540686672073533__11179|SOD1|0.0014093227737752__	0	0	0	0		0
76079	17214440	97711	20996	11179	SOD1	ALS	ALS	10	1.7	Despite the fact that only the motor neurons die during ALS it is clear that also other cell types play an	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014093227737752<>ScoreDetail__5468|IGFALS|0.000540686672073533__11179|SOD1|0.0014093227737752__	0	0	0	0		0
76080	17214440	97714	20996	11179	SOD1	ALS	ALS	31	1.7	disease and on the survival of a mouse model for ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014093227737752<>ScoreDetail__5468|IGFALS|0.000540686672073533__11179|SOD1|0.0014093227737752__	0	0	0	0		0
76081	17214440	97716	20996	11179	SOD1	ALS	ALS	20	1.7	the mechanisms responsible for the selective motor neuron death during ALS and we hope that this information can help in the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014093227737752<>ScoreDetail__5468|IGFALS|0.000540686672073533__11179|SOD1|0.0014093227737752__	0	0	0	0		0
76082	17214440	97716	20996	11179	SOD1	ALS	ALS	48	1.7	incurable disease 3000 Leuven motorneurondood bij Amyotrofische Lateraal Sclerose (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.0014093227737752<>ScoreDetail__5468|IGFALS|0.000540686672073533__11179|SOD1|0.0014093227737752__	0	0	0	0		0
76740	17241118	98804	20996	11179	SOD1	ALS	ALS	3	1.7	Amyotrophic lateral sclerosis (ALS) ALS is a neurodegenerative disease characterized by progressive motor neuron loss	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00113214309859518<>ScoreDetail__5468|IGFALS|0.00054973582139694__11179|SOD1|0.00113214309859518__	0	0	0	0		0
76741	17241118	98806	20996	11179	SOD1	ALS	ALS	6	1.7	Neuroinflammation may accelerate the progression of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00113214309859518<>ScoreDetail__5468|IGFALS|0.00054973582139694__11179|SOD1|0.00113214309859518__	0	0	0	0		0
76745	17241118	98809	20996	11179	SOD1	ALS	ALS	10	1.7	In G93A-SOD1 mutant mice the most well-characterized animal model of ALS endogenous cannabinoids are elevated in spinal cords of symptomatic mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00113214309859518<>ScoreDetail__5468|IGFALS|0.00054973582139694__11179|SOD1|0.00113214309859518__	0	0	0	0		0
76750	17241118	98813	20996	11179	SOD1	ALS	ALS	21	1.7	function and represent a novel therapeutic modality for treatment of ALS of Arkansas for Medical Sciences Little Rock Arkansas 72205 USA	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00113214309859518<>ScoreDetail__5468|IGFALS|0.00054973582139694__11179|SOD1|0.00113214309859518__	0	0	0	0		0
67241	17305588	84702	20996	11179	SOD1	ALS	ALS	3	0.0	Amyotrophic lateral sclerosis (ALS) ALS is a clinically severe and fatal neurodegenerative disease characterized by	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000905901536738425<>ScoreDetail__5468|IGFALS|0.000267863121944686__11179|SOD1|0.000905901536738425__	0	0	0	0		0
67242	17305588	84703	20996	11179	SOD1	ALS	ALS	8	0.0	While the exact cause of neuronal death in ALS remains unknown it is proposed that multiple molecular defects trigger	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000905901536738425<>ScoreDetail__5468|IGFALS|0.000267863121944686__11179|SOD1|0.000905901536738425__	0	0	0	0		0
67243	17305588	84705	20996	11179	SOD1	ALS	ALS	27	0.0	a pharmacotherapy and in the design of clinical trials in ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000905901536738425<>ScoreDetail__5468|IGFALS|0.000267863121944686__11179|SOD1|0.000905901536738425__	0	0	0	0		0
67244	17305588	84707	20996	11179	SOD1	ALS	ALS	4	0.0	In the context of ALS we review some of the salient issues related to the	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000905901536738425<>ScoreDetail__5468|IGFALS|0.000267863121944686__11179|SOD1|0.000905901536738425__	0	0	0	0		0
67245	17305588	84707	20996	11179	SOD1	ALS	ALS	33	0.0	to assessing studies in translating therapeutic strategies to patients with ALS and discuss therapeutic targets and pharmacological approaches to slowing disease	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000905901536738425<>ScoreDetail__5468|IGFALS|0.000267863121944686__11179|SOD1|0.000905901536738425__	0	0	0	0		0
67325	17306794	84920	20996	11179	SOD1	ALS	ALS	55	1.9	mouse models of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) ALS and Alzheimer's disease (AD) AD	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000516590229165011<>ScoreDetail__5468|IGFALS|0.00031808959679112__11179|SOD1|0.000516590229165011__	0	0	0	0		0
67335	17306794	84957	19573	10691	SDS	SDS	SDS	10	0.0	Proteins were electrophoretically separated on a 10% polyacrylamide gel containing SDS and transferred onto a PVDF-membrane (Carl Carl Roth Karlsruhe Germany	1		JUMiner_v2.2	1	0		0	2	19440	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:19440|SBDS|0.00036058737944172<>ScoreDetail__10691|SDS|0.000149094781682641__19440|SBDS|0.00036058737944172__	0	0	0	0		0
67336	17306794	84958	19329	10524	SALL1	TBS	TBS	15	0.0	1% BSA in TBS_amp_#x2013 Tween (0.1% 0.1% Tween 20_amp_#xa0 mM TBS at RT for 1_amp_#xa0 h	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
67337	17306794	84961	7329	16460	FARP2	FRG	FRG	32	0.0	with mouse anti-chick -tubulin (1:400,000; 1 400 000 Sigma Deisenhofen FRG HRP-coupled anti-mouse (1:50,000 1 50 000 in 1.5% milk powder	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
67352	17306794	85075	20996	11179	SOD1	ALS	ALS	12	1.9	the expression pattern and activity profile during the pathogenesis of ALS and AD in transgenic mouse models and patient material of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000516590229165011<>ScoreDetail__5468|IGFALS|0.00031808959679112__11179|SOD1|0.000516590229165011__	0	0	0	0		0
67365	17306794	85133	20996	11179	SOD1	ALS	ALS	16	1.9	upregulated in these cells in degenerating brain regions of the ALS transgenic mouse model SOD1-G93A and around senile plaques of APP/PS1	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000516590229165011<>ScoreDetail__5468|IGFALS|0.00031808959679112__11179|SOD1|0.000516590229165011__	0	0	0	0		0
67373	17306794	85154	20996	11179	SOD1	ALS	ALS	29	1.9	et al. 2001 and Deng et al. 2001 and in ALS ( Wootz et al. 2006 and could thereby modulate or	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000516590229165011<>ScoreDetail__5468|IGFALS|0.00031808959679112__11179|SOD1|0.000516590229165011__	0	0	0	0		0
67617	17311555	85701	20996	11179	SOD1	ALS	ALS	38	0.0	rheumatoid arthritis traumatic brain injury and amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000826422729474794<>ScoreDetail__5468|IGFALS|0.000270343336036767__11179|SOD1|0.000826422729474794__	0	0	0	0		0
69184	17350694	88332	20996	11179	SOD1	ALS	ALS	10	0.5	AD Parkinson's disease (PD) PD and amyotrophic lateral sclerosis (ALS) ALS are among the best examples of neurodegenerative disorders associated with	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000948068072053173<>ScoreDetail__5468|IGFALS|0.000363147764825507__11179|SOD1|0.000948068072053173__	0	0	0	0		0
69185	17350694	88351	20996	11179	SOD1	ALS	ALS	20	0.5	or cerebrospinal fluid of individuals affected with AD PD and ALS 3 and 9	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000948068072053173<>ScoreDetail__5468|IGFALS|0.000363147764825507__11179|SOD1|0.000948068072053173__	0	0	0	0		0
69188	17350694	88366	20996	11179	SOD1	ALS	ALS	13	0.5	process has been described in the brains of individuals with ALS and a correlation between the intensity of inflammation and progression	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000948068072053173<>ScoreDetail__5468|IGFALS|0.000363147764825507__11179|SOD1|0.000948068072053173__	0	0	0	0		0
69189	17350694	88367	20996	11179	SOD1	ALS	ALS	19	0.5	the number of activated microglia is greater in individuals with ALS than in controls 17	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000948068072053173<>ScoreDetail__5468|IGFALS|0.000363147764825507__11179|SOD1|0.000948068072053173__	0	0	0	0		0
69190	17350694	88368	20996	11179	SOD1	ALS	ALS	6	0.5	Further evidence of microglial involvement in ALS pathology has come from studies showing pro-survival effects of the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000948068072053173<>ScoreDetail__5468|IGFALS|0.000363147764825507__11179|SOD1|0.000948068072053173__	0	0	0	0		0
69191	17350694	88368	20996	11179	SOD1	ALS	ALS	34	0.5	spinal cord neurons exposed to cerebrospinal fluid from individuals with ALS 18	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000948068072053173<>ScoreDetail__5468|IGFALS|0.000363147764825507__11179|SOD1|0.000948068072053173__	0	0	0	0		0
69193	17350694	88369	20996	11179	SOD1	ALS	ALS	22	0.5	a G93A mutation (hSOD1G93A), hSOD1G93A an animal model of familial ALS 19 and a clinical trial exploring the effect of a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000948068072053173<>ScoreDetail__5468|IGFALS|0.000363147764825507__11179|SOD1|0.000948068072053173__	0	0	0	0		0
69194	17350694	88369	20996	11179	SOD1	ALS	ALS	39	0.5	exploring the effect of a immunomodulatory agent in individuals with ALS is currently ongoing 20	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000948068072053173<>ScoreDetail__5468|IGFALS|0.000363147764825507__11179|SOD1|0.000948068072053173__	0	0	0	0		0
69201	17350694	88419	673	473	AMT	AMT	AMT	24	0.0	uptake of AEA (by by compounds that we term _amp_#x2018 AMT inhibitors_amp_#x2019 35 ( Table 1	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
69205	17350694	88430	673	473	AMT	AMT	AMT	13	0.0	also been reported in experimental MS in response to pharmacological AMT inhibitors which can increase levels of AEA 45 and 46	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
69206	17350694	88437	673	473	AMT	AMT	AMT	6	0.0	Promising results have been reported with AMT inhibitors such as AM404 (see see Chemical names VDM11 and	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
69208	17350694	88438	673	473	AMT	AMT	AMT	36	0.0	the direct activation of TRPV1 by AM404 rather than to AMT inhibition	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
69209	17350694	88442	673	473	AMT	AMT	AMT	2	0.0	Notably another AMT inhibitor UCM707 significantly protects mice against the excitotoxin kainic acid	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
69229	17350694	88486	1760	1103	BRD2	NAT	NAT	37	0.0	a Ca 2 -dependent N -acyltransferase or trans -acylase (NAT) NAT	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
69231	17350694	88488	673	473	AMT	AMT	AMT	29	0.0	occurs through cellular uptake by a purported high-affinity transporter (AMT) AMT	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
69232	17350694	88489	673	473	AMT	AMT	AMT	7	0.0	As yet the existence of a true AMT is a matter of debate and it is possible that	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
69234	17350694	88493	673	473	AMT	AMT	AMT	24	0.0	purported 2-AG membrane transporter that might be the same as AMT	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
60779	17418957	76946	20996	11179	SOD1	ALS	ALS	29	0.5	been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60780	17418957	76947	20996	11179	SOD1	ALS	ALS	6	0.5	The mechanism of neuron death in ALS remains unclear along with the contributions of mitochondrial dysfunction and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60783	17418957	76951	20996	11179	SOD1	ALS	ALS	15	0.5	precede and in fact cause the mitochondrial changes observed in ALS tissue	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60784	17418957	76952	20996	11179	SOD1	ALS	ALS	3	0.5	Amyotrophic lateral sclerosis (ALS) ALS is a common fatal neurodegenerative disease which involves the degeneration	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60785	17418957	76953	20996	11179	SOD1	ALS	ALS	3	0.5	The pathogenesis of ALS most likely reflects a multifaceted interaction of genetic factors (	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60786	17418957	76954	20996	11179	SOD1	ALS	ALS	9	0.5	Mitochondrial dysfunction is involved in the cellular pathology of ALS ( Orrell and Schapira 2002 and Hervias et al 2005	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60787	17418957	76955	20996	11179	SOD1	ALS	ALS	2	0.5	Mitochondria in ALS have been shown to have impaired electron transport increased free	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60789	17418957	76958	20996	11179	SOD1	ALS	ALS	13	0.5	ultrastructurally abnormal mitochondria occur at the synapses of MN from ALS patients ( Sasaki and Iwata 1999	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60790	17418957	76959	20996	11179	SOD1	ALS	ALS	9	0.5	In addition ultrastructural studies of anterior horn cells of ALS patients and SOD1 mouse model show accumulation of mitochondria in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60793	17418957	76960	20996	11179	SOD1	ALS	ALS	20	0.5	its soluble receptors have been reported to be elevated in ALS patients as compared with healthy controls ( Poloni et al	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60798	17418957	76962	7708	3811	FOXG1	QIN	Qin	60	0.0	2001 Brabers and Nottet 2006 and Nakazawa et al 2006 Qin et al. 2007	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
60801	17418957	76964	20996	11179	SOD1	ALS	ALS	27	0.5	observation that mimics the in vivo histological findings in human ALS and mouse models of the disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60803	17418957	76965	20996	11179	SOD1	ALS	ALS	28	0.5	et al 2002 and Strong 2003 in the setting of ALS and the known positive effects of the TNF-_amp_#x3b1 blocker thalidomide	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60805	17418957	76965	20996	11179	SOD1	ALS	ALS	43	0.5	effects of the TNF-_amp_#x3b1 blocker thalidomide on the progression of ALS in the SOD1 mouse model ( Wong et al 2004	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60809	17418957	76966	20996	11179	SOD1	ALS	ALS	34	0.5	migration and have well-documented histological characteristics in the setting of ALS ( Sasaki and Iwata 1996 and Sasaki et al 2005	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60811	17418957	76969	14565	7896	NPAT	E14	E14	21	0.0	Sasco Sprague_amp_#x2013 Dawley rat embryos at gestation day 14 (E14) E14 as described previously ( Hanson et al 1998 and Ullian	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
60814	17418957	76973	7361	20442	FBRS	FBS	FBS	21	0.0	spun down at 1000 r.p.m in the presence of 30% FBS and brought up in serum-free growth medium	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>20442|FBRS|64319|Complete__13587|FBXO8|26269|No_GeneRif__<>AvaiableGeneRif=1<>	0	0	0	0		0
60816	17418957	76974	13439	1304	MRAP	B27	B27	10	0.0	base media (Invitrogen, Invitrogen Carlsbad CA USA was supplemented with B27 (Invitrogen), Invitrogen 10 ng/ml ng ml each of BDNF CNTF	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
60817	17418957	76974	1624	1033	BDNF	BDNF	BDNF	16	0.0	with B27 (Invitrogen), Invitrogen 10 ng/ml ng ml each of BDNF CNTF and GDNF (Peprotech, Peprotech Rocky Hill NJ USA 100	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
60823	17418957	77000	19254	10472	RUNX2	CCD	CCD	38	0.0	objective lens and recorded with a Cooke Sensicam QE digital CCD camera (Applied Applied Scientific Instrumentation Eugene OR USA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
60846	17418957	77051	20996	11179	SOD1	ALS	ALS	38	0.5	h representing a typical pattern seen in the histopathology of ALS ( Sasaki and Iwata 1996 and Sasaki et al 2005	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60856	17418957	77074	7708	3811	FOXG1	QIN	Qin	60	0.0	2001 Brabers and Nottet 2006 and Nakazawa et al 2006 Qin et al. 2007	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
60858	17418957	77075	20996	11179	SOD1	ALS	ALS	31	0.5	that associates with axonal spheroid inclusions in degenerating MN of ALS patients ( Robertson et al. 2001	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60860	17418957	77076	20996	11179	SOD1	ALS	ALS	18	0.5	thalidomide is effective in increasing survival and delaying progression of ALS phenotypes in the SOD1 G93A mouse model ( Wong et	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60870	17418957	77078	20996	11179	SOD1	ALS	ALS	29	0.5	TNF-_amp_#x3b1 and its receptors may connect inflammation to apoptosis in ALS ( Hensley et al. 2002	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60876	17418957	77082	20996	11179	SOD1	ALS	ALS	5	0.5	There is increasing evidence that ALS is not just a disease of MN and that neighboring	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60881	17418957	77087	20996	11179	SOD1	ALS	ALS	18	0.5	TNF-_amp_#x3b1 is similar to that observed in the MN of ALS patients a disease which has been shown to have elevated	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
60885	17418957	77090	20996	11179	SOD1	ALS	ALS	19	0.5	glia and secreted cytokines is involved in MN degeneration and ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000611016399378423<>ScoreDetail__5468|IGFALS|0.000375697724345213__11179|SOD1|0.000611016399378423__	0	0	0	0		0
63131	17439481	80138	20996	11179	SOD1	ALS	ALS	13	1.7	suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00147096540591102<>ScoreDetail__5468|IGFALS|0.00078717618434235__11179|SOD1|0.00147096540591102__	0	0	0	0		0
63132	17439481	80139	20996	11179	SOD1	ALS	ALS	18	1.7	enhanced death signals are involved in amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00147096540591102<>ScoreDetail__5468|IGFALS|0.00078717618434235__11179|SOD1|0.00147096540591102__	0	0	0	0		0
63135	17439481	80141	20996	11179	SOD1	ALS	ALS	14	1.7	evaluate the effect of recombinant human EPO (rhEPO) rhEPO on ALS model mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00147096540591102<>ScoreDetail__5468|IGFALS|0.00078717618434235__11179|SOD1|0.00147096540591102__	0	0	0	0		0
63136	17439481	80142	20996	11179	SOD1	ALS	ALS	3	1.7	We treated 96 ALS model mice with vehicle only or 1 2.5 or 5	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00147096540591102<>ScoreDetail__5468|IGFALS|0.00078717618434235__11179|SOD1|0.00147096540591102__	0	0	0	0		0
63137	17439481	80144	20996	11179	SOD1	ALS	ALS	13	1.7	that treatment with rhEPO represents a potential therapeutic strategy for ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00147096540591102<>ScoreDetail__5468|IGFALS|0.00078717618434235__11179|SOD1|0.00147096540591102__	0	0	0	0		0
57141	17555556	72116	20996	11179	SOD1	ALS	ALS	3	1.9	Amyotrophic lateral sclerosis (ALS) ALS is a progressive neurodegenerative disease characterized by the selective loss	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00146837970366485<>ScoreDetail__5468|IGFALS|0.000620334567109861__11179|SOD1|0.00146837970366485__	0	0	0	0		0
57142	17555556	72118	20996	11179	SOD1	ALS	ALS	21	1.9	recently been considered as important contributors to the pathogenesis of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00146837970366485<>ScoreDetail__5468|IGFALS|0.000620334567109861__11179|SOD1|0.00146837970366485__	0	0	0	0		0
57143	17555556	72119	20996	11179	SOD1	ALS	ALS	18	1.9	have been demonstrated in the affected areas of tissue from ALS patients ( Engelhardt et al 1993 Henkel et al 2004	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00146837970366485<>ScoreDetail__5468|IGFALS|0.000620334567109861__11179|SOD1|0.00146837970366485__	0	0	0	0		0
57145	17555556	72120	20996	11179	SOD1	ALS	ALS	18	1.9	2 superoxide dismutase (mSOD1), mSOD1 an animal model of familial ALS immune/inflammatory immune inflammatory changes have been observed at early symptomatic	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00146837970366485<>ScoreDetail__5468|IGFALS|0.000620334567109861__11179|SOD1|0.00146837970366485__	0	0	0	0		0
57146	17555556	72120	20996	11179	SOD1	ALS	ALS	55	1.9	suggesting a role for these factors in the pathogenesis of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00146837970366485<>ScoreDetail__5468|IGFALS|0.000620334567109861__11179|SOD1|0.00146837970366485__	0	0	0	0		0
57158	17555556	72130	20996	11179	SOD1	ALS	ALS	24	1.9	microglia also resulted in longer disease duration and survival in ALS mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00146837970366485<>ScoreDetail__5468|IGFALS|0.000620334567109861__11179|SOD1|0.00146837970366485__	0	0	0	0		0
57165	17555556	72135	1759	1102	BRD1	BRL	BRL	9	0.3	Culture media sera and antibiotics were purchased from Gibco BRL (Rockville, Rockville MD USA and all other reagents were from	1		JUMiner_v2.2	1	2	gibco brl	0	0	0		0	0	0	0		0
57181	17555556	72183	3778	10620	CCL21	ECL	ECL	1	0.0	The ECL system (Amersham Amersham Biosciences Piscataway NJ USA was used to	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
57297	17555556	72262	20996	11179	SOD1	ALS	ALS	49	1.9	to be up-regulated in a transgenic mouse model of familial ALS both in early symptomatic stages and at the end-stage of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00146837970366485<>ScoreDetail__5468|IGFALS|0.000620334567109861__11179|SOD1|0.00146837970366485__	0	0	0	0		0
57299	17555556	72263	20996	11179	SOD1	ALS	ALS	19	1.9	production which plays a deleterious role in the pathogenesis of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00146837970366485<>ScoreDetail__5468|IGFALS|0.000620334567109861__11179|SOD1|0.00146837970366485__	0	0	0	0		0
57321	17555556	72282	20996	11179	SOD1	ALS	ALS	6	1.9	In contrast free IGF-1 levels in ALS patients_amp_#8217 spinal cords and serum were shown to be significantly	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00146837970366485<>ScoreDetail__5468|IGFALS|0.000620334567109861__11179|SOD1|0.00146837970366485__	0	0	0	0		0
57324	17555556	72285	20996	11179	SOD1	ALS	ALS	10	1.9	2003 successfully prolonged life and delayed disease progression in transgenic ALS mice by enhancing IGF-1 expression in motoneurons	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00146837970366485<>ScoreDetail__5468|IGFALS|0.000620334567109861__11179|SOD1|0.00146837970366485__	0	0	0	0		0
57379	17555556	72324	20996	11179	SOD1	ALS	ALS	9	1.9	A recent study showed a novel pathogenic mechanism for ALS based on chromogranin-mediated secretion of misfolded mutant SOD1 but not	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00146837970366485<>ScoreDetail__5468|IGFALS|0.000620334567109861__11179|SOD1|0.00146837970366485__	0	0	0	0		0
58392	17569578	73548	8612	4458	GPI	PGI	PGI	5	0.3	PPAR_amp_#x3b2;/_amp_#x3b4; PPAR_amp_#x3b2 _amp_#x3b4 agonists include the prostacyclin PGI 2 and synthetic agents including GW0742 GW501516 and GW7842	1		JUMiner_v2.2	1	2	prostacyclin	0	2	1044	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:1044|BGN|0.000683936789173194<>ScoreDetail__1044|BGN|0.000683936789173194__4458|GPI|0.000553558943116586__	0	0	0	0		0
58419	17569578	73617	22088	15934	TH1L	TH1	Th1	31	0.0	cord sections and an increase in T cell proliferation and Th1 response upon MOG peptide stimulation when compared to PPAR_amp_#x3b3 wild	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58428	17569578	73639	11668	6518	LBR	PHA	PHA	24	0.0	on human T-leukemia cells (Jurkat Jurkat cells and phytohemagglutinin (PHA)-stimulated PHA -stimulated PBMCs derived from 21 MS patients and 12 healthy	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58429	17569578	73640	11668	6518	LBR	PHA	PHA-induced	6	0.0	In this study all drugs suppressed PHA-induced T-cell proliferation by 40_amp_#x2013 50% and secretion of IFN_amp_#x3b3 and	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58430	17569578	73648	11668	6518	LBR	PHA	PHA-induced	7	0.0	Importantly long-term oral pioglitazone treatment prevented the PHA-induced loss of PPAR_amp_#x3b3 expression in PBMCs from diabetic patients demonstrating	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58453	17569578	73737	14535	7873	NOS2A	iNOS	iNOS-positive	11	1.0	decreased microglial and astrocyte activation and reduced the number of iNOS-positive cells in both the striatum and SNpc 19 and 47	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
58455	17569578	73742	13434	7225	MPZ	MPP	MPP	10	0.3	colleagues demonstrated that PPAR_amp_#x3b2;/_amp_#x3b4;_amp_#xa0;agonist PPAR_amp_#x3b2 _amp_#x3b4 _amp_#xa0 agonist treatment of MPP stimulated neuroblastoma cells exerted neuroprotective effects 85	1		JUMiner_v2.2	1	2	UserEdit	0	2	7214	TotalCon:2<>7214|MPHOSPH6|10200|Complete__7225|MPZ|4359|Complete__<>AvaiableGeneRif=2<>BEST:7214|MPHOSPH6|0.000624256837098692<>ScoreDetail__7214|MPHOSPH6|0.000624256837098692__7225|MPZ|0.000474578928800094__	1	1	0	0		0
58456	17569578	73748	20996	11179	SOD1	ALS	ALS	3	0.5	Amyotrophic lateral sclerosis (ALS) ALS represents a fatal neurodegenerative disorder characterized by progressive death of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000909962863677726<>ScoreDetail__5468|IGFALS|0.00074992500749925__11179|SOD1|0.000909962863677726__	0	0	0	0		0
58457	17569578	73749	20996	11179	SOD1	ALS	ALS	28	0.5	treatment strategies are being evaluated in transgenic mouse models of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000909962863677726<>ScoreDetail__5468|IGFALS|0.00074992500749925__11179|SOD1|0.000909962863677726__	0	0	0	0		0
58458	17569578	73750	20996	11179	SOD1	ALS	ALS	27	0.5	tested whether SOD1-G93A transgenic mice an established mouse model of ALS benefit from oral treatment with the PPAR_amp_#x3b3 agonist pioglitazone 92	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000909962863677726<>ScoreDetail__5468|IGFALS|0.00074992500749925__11179|SOD1|0.000909962863677726__	0	0	0	0		0
58463	17569578	73759	20996	11179	SOD1	ALS	ALS	12	0.5	underlying mechanisms are not fully understood both studies suggest that ALS patients may benefit from treatment with this PPAR_amp_#x3b3 agonist	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000909962863677726<>ScoreDetail__5468|IGFALS|0.00074992500749925__11179|SOD1|0.000909962863677726__	0	0	0	0		0
58464	17569578	73760	20996	11179	SOD1	ALS	ALS	25	0.5	a first clinical trial (GERPALS, GERPALS German pioglitazone study in ALS which will start to enroll patients late 2007	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000909962863677726<>ScoreDetail__5468|IGFALS|0.00074992500749925__11179|SOD1|0.000909962863677726__	0	0	0	0		0
58477	17569578	73804	19623	10722	SELPLG	CLA	CLA	5	0.3	Treatment with conjugated linoleic acid (CLA) CLA inhibited growth in human ADF glioblastoma cells 33 and 114	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
58478	17569578	73804	6176	15750	DSTN	ADF	ADF	10	0.0	with conjugated linoleic acid (CLA) CLA inhibited growth in human ADF glioblastoma cells 33 and 114 and this was associated with	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58479	17569578	73805	19623	10722	SELPLG	CLA	CLA	7	0.3	Cimini and others 33 also found that CLA and the PPAR_amp_#x3b3 agonist GW347845X induced apoptosis in ADF cells	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
58480	17569578	73805	6176	15750	DSTN	ADF	ADF	16	0.0	that CLA and the PPAR_amp_#x3b3 agonist GW347845X induced apoptosis in ADF cells suggesting that this effect was mediated by PPAR_amp_#x3b3 activation	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58481	17569578	73806	19623	10722	SELPLG	CLA	CLA	16	0.3	finding that the PPAR_amp_#x3b3 antagonist GW259662 completely prevented both the CLA and GW347854X-induced effects on cell growth and apoptosis	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
58483	17569578	73809	18723	10261	ROS1	ROS	ROS	10	0.0	and co-workers reported that generation of reactive oxygen species (ROS) ROS was likely to be responsible for glitazone-induced glial cell death	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58498	17569578	73851	11940	6667	LPA	LPA	LPA	14	0.0	cell death type II or autophagy and the serum lysolipid LPA is responsible for modulating this cellular response	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58500	17569578	73853	17264	9353	PRDX2	TSA	TSA	14	0.0	PGJ 2 and the histone deacetylase inhibitor trichostatin A (TSA) TSA enhanced the growth inhibition effects and is therefore proposed as	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58783	17574754	74304	8612	4458	GPI	PGI	PGI	6	0.6	We find that PGD 2 PGI 2 and PGF 2_amp_#x3b1 receptors protect motor neurons in an	1		JUMiner_v2.2	1	2	prostacyclin	0	2	4458	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:4458|GPI|0.000430668045800177<>ScoreDetail__1044|BGN|0.000352631672412787__4458|GPI|0.000430668045800177__	0	0	0	0		0
58784	17574754	74304	16457	8891	PGD	PGD	PGD	3	0.0	We find that PGD 2 PGI 2 and PGF 2_amp_#x3b1 receptors protect motor neurons	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
58785	17574754	74304	16459	8893	PGF	PGF	PGF	10	0.0	We find that PGD 2 PGI 2 and PGF 2_amp_#x3b1 receptors protect motor neurons in an organotypic spinal cord	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58786	17574754	74304	20996	11179	SOD1	ALS	ALS	26	0.0	an organotypic spinal cord model of amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00135542706503777<>ScoreDetail__5468|IGFALS|0.000184791647417537__11179|SOD1|0.00135542706503777__	0	0	0	0		0
58787	17574754	74305	8612	4458	GPI	PGI	PGI	2	0.6	In addition PGI 2 and TXA 2 receptors rescue CA1 neurons in an	1		JUMiner_v2.2	1	2	prostacyclin	0	2	4458	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:4458|GPI|0.000430668045800177<>ScoreDetail__1044|BGN|0.000352631672412787__4458|GPI|0.000430668045800177__	0	0	0	0		0
58788	17574754	74305	3353	1368	CA1	CA1	CA1	9	0.0	In addition PGI 2 and TXA 2 receptors rescue CA1 neurons in an organotypic hippocampal model of N -methyl-d	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58792	17574754	74308	20996	11179	SOD1	ALS	ALS	43	0.0	of chronic neurodegeneration that model human amyotrophic lateral sclerosis (ALS), ALS Parkinson's disease (PD), PD and Alzheimer's disease (AD; AD reviewed	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00135542706503777<>ScoreDetail__5468|IGFALS|0.000184791647417537__11179|SOD1|0.00135542706503777__	0	0	0	0		0
58794	17574754	74309	20996	11179	SOD1	ALS	ALS	12	0.0	increased COX-2 and prostaglandin production have been observed in AD ALS multiple sclerosis and PD 1 10 22 and 24	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00135542706503777<>ScoreDetail__5468|IGFALS|0.000184791647417537__11179|SOD1|0.00135542706503777__	0	0	0	0		0
58801	17574754	74314	8612	4458	GPI	PGI	PGI	12	0.6	The five prostaglandins PGE 2 PGF 2_amp_#x3b1 PGD 2 PGI 2 (prostacyclin), prostacyclin and TXA 2 (thromboxane) thromboxane bind to	1		JUMiner_v2.2	1	2	prostacyclin	0	2	4458	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:4458|GPI|0.000430668045800177<>ScoreDetail__1044|BGN|0.000352631672412787__4458|GPI|0.000430668045800177__	0	0	0	0		0
58802	17574754	74314	16459	8893	PGF	PGF	PGF	6	0.0	The five prostaglandins PGE 2 PGF 2_amp_#x3b1 PGD 2 PGI 2 (prostacyclin), prostacyclin and TXA 2	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58803	17574754	74314	16457	8891	PGD	PGD	PGD	9	0.0	The five prostaglandins PGE 2 PGF 2_amp_#x3b1 PGD 2 PGI 2 (prostacyclin), prostacyclin and TXA 2 (thromboxane) thromboxane	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
58811	17574754	74315	16457	8891	PGD	PGD	PGD	28	0.0	subtypes (EP1, EP1 EP2 EP3 and EP4 and for the PGD 2 DP family where there are two receptors DP1 and	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
58821	17574754	74320	3353	1368	CA1	CA1	CA1	11	0.0	have previously reported that the PGE 2 EP2 receptor rescues CA1 pyramidal neurons in organotypic hippocampal cultures treated with NMDA or	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58824	17574754	74322	16457	8891	PGD	PGD	PGD	0	0.0	PGD 2 signaling via its DP1 receptor similarly rescues CA1 and	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
58825	17574754	74322	3353	1368	CA1	CA1	CA1	10	0.0	PGD 2 signaling via its DP1 receptor similarly rescues CA1 and CA3 neurons in organotypic hippocampal slices treated with NMDA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58826	17574754	74322	3355	1374	CA3	CA3	CA3	10	0.0	PGD 2 signaling via its DP1 receptor similarly rescues CA1 and CA3 neurons in organotypic hippocampal slices treated with NMDA	15		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58827	17574754	74322	3355	1374	CA3	CA3	CA3	12	0.0	2 signaling via its DP1 receptor similarly rescues CA1 and CA3 neurons in organotypic hippocampal slices treated with NMDA 14 and	15		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58836	17574754	74334	16457	8891	PGD	PGD	PGD	32	0.0	(THA; THA Tocris Elisville MO propidium idodide (PI, PI Sigma PGD 2 BW245C fluprostenol 13 14-dehydro-15-cyclohexyl carbaprostacyclin U-46619 and 13 14-dihydro-15-keto-PGD	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
58837	17574754	74337	20996	11179	SOD1	ALS	ALS	12	0.0	d l -threohydroxyaspartate (THA), THA a glutamate transport inhibitor models ALS with motor neuron loss resulting from chronic glutamate toxicity	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00135542706503777<>ScoreDetail__5468|IGFALS|0.000184791647417537__11179|SOD1|0.00135542706503777__	0	0	0	0		0
58839	17574754	74339	16457	8891	PGD	PGD	PGD	0	0.0	PGD 2 and DP1 DP2 IP TP and FP receptor agonists	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
58843	17574754	74347	3353	1368	CA1	CA1	CA1	23	0.0	M NMDA and PI and incubated overnight to induce maximum CA1 neuronal loss and imaged 24 h later ( t max	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58844	17574754	74348	3353	1368	CA1	CA1	CA1	12	0.0	was assayed by quantification of mean PI fluorescence in the CA1 subregion of each hippocampal slice for t b t 24h	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58850	17574754	74357	16457	8891	PGD	PGD	PGD	4	0.0	Co-administration of THA and PGD 2 protected motor neurons at nM doses selective agonists of	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
58853	17574754	74358	8612	4458	GPI	PGI	PGI	18	0.6	agonist fluprostenol ( Fig 1 D and the prostacyclin (PGI PGI 2 IP receptor agonist carbaprostacyclin ( Fig 1 E significantly	1		JUMiner_v2.2	1	2	prostacyclin	0	2	4458	TotalCon:2<>1044|BGN|633|Complete__4458|GPI|2821|Complete__<>AvaiableGeneRif=2<>BEST:4458|GPI|0.000430668045800177<>ScoreDetail__1044|BGN|0.000352631672412787__4458|GPI|0.000430668045800177__	0	0	0	0		0
58854	17574754	74358	16459	8893	PGF	PGF	PGF	5	0.0	In addition co-administration of the PGF 2_amp_#x3b1 FP receptor agonist fluprostenol ( Fig 1 D and	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58856	17574754	74360	16457	8891	PGD	PGD	PGD	2	0.0	Administration of PGD 2 DP1 DP2 FP IP and TP agonists alone had	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
58860	17574754	74361	16457	8891	PGD	PGD	PGD	14	0.1	that activation of the PGE 2 EP2 receptor and the PGD 2 DP1 receptor protect CA1 neurons in organotypic hippocampal slices	6		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
58861	17574754	74361	3353	1368	CA1	CA1	CA1	19	0.0	2 EP2 receptor and the PGD 2 DP1 receptor protect CA1 neurons in organotypic hippocampal slices treated with NMDA 15 and	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58862	17574754	74362	3353	1368	CA1	CA1	CA1	9	0.0	Here we examined effects of additional prostaglandin receptors on CA1 neuronal survival in hippocampal slices treated acutely with NMDA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58865	17574754	74366	3353	1368	CA1	CA1	CA1	13	0.0	FP IP and TP agonists alone had no effect on CA1 neuronal survival (data data not shown	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58873	17574754	74370	3353	1368	CA1	CA1	CA1	13	0.0	LPS (0.1_amp_#x2013;5 0.1_amp_#x2013 5 _amp_#x3bc;g/ml) _amp_#x3bc g ml leads to CA1 pyramidal death as measured by PI fluorescence	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58879	17574754	74372	3353	1368	CA1	CA1	CA1	11	0.0	activation of the EP2 and EP3 receptors also increased LPS-mediated CA1 neurotoxicity ( Fig 3 B and C	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58881	17574754	74375	16457	8891	PGD	PGD	PGD	15	0.0	models have identified paradoxical neuroprotective effects of PGE 2 and PGD 2 receptors that have been confirmed in vivo in models	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
58882	17574754	74377	16457	8891	PGD	PGD	PGD	13	0.0	slices that are chronically exposed to glutamate reuptake inhibitors both PGD 2 DP receptors as well as the PGF 2_amp_#x3b1 FP	1		JUMiner_v2.2	1	0		0	1	0	TotalCon:2<>8891|PGD|5226|No_GeneRif__8923|PHGDH|26227|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
58883	17574754	74377	16459	8893	PGF	PGF	PGF	21	0.0	inhibitors both PGD 2 DP receptors as well as the PGF 2_amp_#x3b1 FP and prostacyclin IP receptors rescued motor neurons	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58885	17574754	74378	20996	11179	SOD1	ALS	ALS	22	0.0	model as well as in the transgenic model of Familial ALS 3 7 and 8	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00135542706503777<>ScoreDetail__5468|IGFALS|0.000184791647417537__11179|SOD1|0.00135542706503777__	0	0	0	0		0
58891	17574754	74381	3353	1368	CA1	CA1	CA1	17	0.0	with picomolar concentrations of agonist resulted in significant rescue of CA1 pyramidal neurons	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58897	17574754	74386	16459	8893	PGF	PGF	PGF	9	0.0	A similar divergence of effect was found for the PGF 2_amp_#x3b1 FP receptor which had no effect on CA1 neuronal	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58898	17574754	74386	3353	1368	CA1	CA1	CA1	18	0.0	the PGF 2_amp_#x3b1 FP receptor which had no effect on CA1 neuronal survival unlike its significant protective effect in the spinal	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58901	17574754	74389	3353	1368	CA1	CA1	CA1	18	0.0	15 and 16 and EP3 ( Fig 2 receptor rescues CA1 neurons stimulated with NMDA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58906	17574754	74390	3353	1368	CA1	CA1	CA1	30	0.0	stimulation of the EP2 or EP3 receptor now increases LPS-mediated CA1 toxicity	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58910	17574754	74391	3353	1368	CA1	CA1	CA1	13	0.0	not find a consistent dose response of LPS and increasing CA1 toxicity in this paradigm the addition of either PGE 2	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
58912	17574754	74391	3353	1368	CA1	CA1	CA1	42	0.0	the EP3 agonist sulprostone (10 10 nM consistently enhanced LPS-induced CA1 PI fluorescence	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
59187	17582695	74872	8595	19680	GPBAR1	GPCR	GPCRs	8	0.6	VN receptors are class II G protein-coupled receptors (GPCRs) GPCRs which couple primarily to the adenylate cyclase (AC)-cyclic AC -cyclic	13		JUMiner_v2.2	1	2	g protein-coupled receptor	0	2	14298	TotalCon:15<>19680|GPBAR1|151306|Complete__24884|OXER1|165140|Complete__18274|CYSLTR2|57105|Complete__4042|FZD4|8322|Complete__23624|GPR151|134391|Complete__23626|GPR166P|442206|No_GeneRif__30224|GPR172A|79581|No_GeneRif__30225|GPR172B|55065|No_GeneRif__18510|GPRC6A|222545|Complete__19719|LGR6|59352|No_GeneRif__14298|LPAR3|23566|Complete__17962|MRGPRX1|259249|No_GeneRif__17980|MRGPRX3|117195|Complete__17617|MRGPRX4|117196|No_GeneRif__13300|GPR61|83873|Complete__<>AvaiableGeneRif=9<>BEST:14298|LPAR3|0.00104185486299307<>ScoreDetail__23624|GPR151|0.000317073170731707__17980|MRGPRX3|0.00021680216802168__19680|GPBAR1|0.000982292014700969__18510|GPRC6A|0.0004516711833785__13300|GPR61|0.000670731707317073__18274|CYSLTR2|0.000692855601122383__14298|LPAR3|0.00104185486299307__4042|FZD4|0.000587427001030574__24884|OXER1|0.00061617458279846__	0	0	0	0		0
59188	17582695	74873	20996	11179	SOD1	ALS	ALS	12	0.5	in multiple sclerosis (MS) MS and amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59189	17582695	74876	20996	11179	SOD1	ALS	ALS	15	0.5	that autoimmune dysfunction of VNs may contribute to MS and ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59190	17582695	74877	20996	11179	SOD1	ALS	ALS	3	0.5	While MS and ALS differ in important respects they have common pathogenic features including	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59191	17582695	74879	20996	11179	SOD1	ALS	ALS	5	0.5	Diseases such as MS and ALS may represent related conditions resulting from variation in expression of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59194	17582695	74887	8595	19680	GPBAR1	GPCR	GPCRs	8	0.6	VN receptors are class II G protein-coupled receptors (GPCRs) GPCRs which couple primarily to the adenylate cyclase (AC)-cyclic AC -cyclic	13		JUMiner_v2.2	1	2	g protein-coupled receptor	0	2	14298	TotalCon:15<>19680|GPBAR1|151306|Complete__24884|OXER1|165140|Complete__18274|CYSLTR2|57105|Complete__4042|FZD4|8322|Complete__23624|GPR151|134391|Complete__23626|GPR166P|442206|No_GeneRif__30224|GPR172A|79581|No_GeneRif__30225|GPR172B|55065|No_GeneRif__18510|GPRC6A|222545|Complete__19719|LGR6|59352|No_GeneRif__14298|LPAR3|23566|Complete__17962|MRGPRX1|259249|No_GeneRif__17980|MRGPRX3|117195|Complete__17617|MRGPRX4|117196|No_GeneRif__13300|GPR61|83873|Complete__<>AvaiableGeneRif=9<>BEST:14298|LPAR3|0.00104185486299307<>ScoreDetail__23624|GPR151|0.000317073170731707__17980|MRGPRX3|0.00021680216802168__19680|GPBAR1|0.000982292014700969__18510|GPRC6A|0.0004516711833785__13300|GPR61|0.000670731707317073__18274|CYSLTR2|0.000692855601122383__14298|LPAR3|0.00104185486299307__4042|FZD4|0.000587427001030574__24884|OXER1|0.00061617458279846__	0	0	0	0		0
59195	17582695	74890	567	877	ALDH7A1	PDE	PDE	7	0.0	Importantly cAMP effects are maintained by phosphodiesterase (PDE) PDE inhibitors which may have implications for treatment of postulated cAMP	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
59196	17582695	74892	20996	11179	SOD1	ALS	ALS	12	0.5	in multiple sclerosis (MS) MS and amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59197	17582695	74896	20996	11179	SOD1	ALS	ALS	15	0.5	that autoimmune dysfunction of VNs may contribute to MS and ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59198	17582695	74897	20996	11179	SOD1	ALS	ALS	4	0.5	Aetiology of MS and ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59199	17582695	74898	20996	11179	SOD1	ALS	ALS	5	0.5	The causes of MS and ALS are unknown	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59200	17582695	74899	20996	11179	SOD1	ALS	ALS	7	0.5	While complex diseases such as MS and ALS are thought likely to demonstrate multiple genetic and environmental factors	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59201	17582695	74900	20996	11179	SOD1	ALS	ALS	8	0.5	Exposure to environmental chemicals increases risk of sporadic ALS particularly industrial herbicide/pesticide herbicide pesticide exposure 4 and military service	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59202	17582695	74900	20996	11179	SOD1	ALS	ALS	29	0.5	possibly Gulf War service may also hold an association for ALS 5	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59203	17582695	74901	20996	11179	SOD1	ALS	ALS	16	0.5	s disease (PD) PD dementia complex (PDC) PDC and atypical ALS which may have been attributed to Rotenone a natural toxin	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59204	17582695	74901	16271	8759	PDC	PDC	PDC	13	0.0	have experienced Parkinson_amp_#x2019 s disease (PD) PD dementia complex (PDC) PDC and atypical ALS which may have been attributed to Rotenone	1		JUMiner_v2.2	1	0		0	2	9153	TotalCon:2<>8759|PDC|5132|Complete__9153|PNKD|25953|Complete__<>AvaiableGeneRif=2<>BEST:9153|PNKD|0.00048780487804878<>ScoreDetail__8759|PDC|0.000154043645699615__9153|PNKD|0.00048780487804878__	0	0	0	0		0
59207	17582695	74902	20996	11179	SOD1	ALS	ALS	24	0.5	may have predisposed to neuronal pathology of Parkinson_amp_#x2019 s or ALS type because of its specific anatomical distribution	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59209	17582695	74905	20996	11179	SOD1	ALS	ALS	6	0.5	As noted above clinical presentation of ALS is not confined to motor neuron abnormality	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59210	17582695	74907	20996	11179	SOD1	ALS	ALS	9	0.5	Behavioural changes such as apathy occur at onset of ALS suggesting this link with fronto-temporal dementia 15	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59211	17582695	74908	20996	11179	SOD1	ALS	ALS	17	0.5	volume and correlates with psychopathological findings in later stages of ALS 16	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59212	17582695	74909	20996	11179	SOD1	ALS	ALS	5	0.5	Alterations in cortical functions in ALS suggest upper motor neuron pathology 17	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59213	17582695	74910	20996	11179	SOD1	ALS	ALS	9	0.5	Moreover cerebral degeneration is predictive of reduced survival in ALS 18	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59214	17582695	74914	20996	11179	SOD1	ALS	ALS	19	0.5	may be early and significant events in both MS and ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59219	17582695	74917	20996	11179	SOD1	ALS	ALS	5	0.5	Serum VEGF is higher in ALS in human samples than controls 23 as it is in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59222	17582695	74918	20996	11179	SOD1	ALS	ALS	21	0.5	spinal cord of transgenic SOD1 (G93A) G93A mice models of ALS 25	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59224	17582695	74919	11629	6493	LAMC2	CSF	CSF	6	0.3	High erythropoietin and low VEGF in CSF from hypoxemic ALS patients suggest an abnormal response to hypoxia	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
59225	17582695	74919	20996	11179	SOD1	ALS	ALS	9	0.5	High erythropoietin and low VEGF in CSF from hypoxemic ALS patients suggest an abnormal response to hypoxia compared with hypoxic	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59227	17582695	74920	11629	6493	LAMC2	CSF	CSF	6	0.3	Moreover low concentrations of EPO in CSF point to a rapid progression of disease that may be	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
59228	17582695	74923	20996	11179	SOD1	ALS	ALS	3	0.5	While MS and ALS differ in important respects they have common pathogenic features including	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59229	17582695	74924	20996	11179	SOD1	ALS	ALS	15	0.5	are modulated by certain cytokines in neurodegenerative disorders such as ALS and PD e.g. IL-1beta and IL-6 32	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59232	17582695	74925	20996	11179	SOD1	ALS	ALS	30	0.5	is suggested associated with oxidative stress and glial activation in ALS 33	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59233	17582695	74927	20996	11179	SOD1	ALS	ALS	15	0.5	stages of disease play causative roles in the pathogenesis of ALS in rodent models 35	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59235	17582695	74930	20996	11179	SOD1	ALS	ALS	16	0.5	to the development and progression of motor neuron pathology in ALS 36	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59240	17582695	74932	20996	11179	SOD1	ALS	ALS	22	0.5	in the spinal motor neurons of mouse models of familial ALS 38	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59242	17582695	74933	20996	11179	SOD1	ALS	ALS	12	0.5	alpha signalling is postulated to have a key role in ALS 39	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59247	17582695	74936	20996	11179	SOD1	ALS	ALS	16	0.5	and proinflammatory cytokines are implicated in a lipopolysaccharide model of ALS suggesting that environmental factors and innate immunity are linked 42	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59248	17582695	74937	20996	11179	SOD1	ALS	ALS	11	0.5	and inflammatory responses appear to magnify motor neuron degeneration in ALS 43	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59250	17582695	74939	20996	11179	SOD1	ALS	ALS	8	0.5	Moreover TGFbeta1 is significantly higher in long duration ALS than short duration ALS possibly indicating severity and duration of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59251	17582695	74939	20996	11179	SOD1	ALS	ALS	12	0.5	is significantly higher in long duration ALS than short duration ALS possibly indicating severity and duration of the disease 45 and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59252	17582695	74944	20996	11179	SOD1	ALS	ALS	7	0.5	Also neurodegenerative disorders such as PD and ALS have been termed protein misfolding disorders because of their association	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59255	17582695	74946	20996	11179	SOD1	ALS	ALS	6	0.5	Vasoactive neuropeptide dysfunction in MS and ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59256	17582695	74947	20996	11179	SOD1	ALS	ALS	13	0.5	critical role in neuronal survival however in a series of ALS patients CSF levels of VIP were found to be significantly	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59257	17582695	74947	11629	6493	LAMC2	CSF	CSF	15	0.3	in neuronal survival however in a series of ALS patients CSF levels of VIP were found to be significantly lower compared	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
59260	17582695	74948	20996	11179	SOD1	ALS	ALS	18	0.5	in spinal cord cultures suggesting its use in treatment of ALS 53	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59265	17582695	74954	8595	19680	GPBAR1	GPCR	GPCRs	3	0.6	As noted above GPCRs transduce signals promoting cellular survival and neurotrophic activity	13		JUMiner_v2.2	1	2	g protein-coupled receptor	0	2	14298	TotalCon:15<>19680|GPBAR1|151306|Complete__24884|OXER1|165140|Complete__18274|CYSLTR2|57105|Complete__4042|FZD4|8322|Complete__23624|GPR151|134391|Complete__23626|GPR166P|442206|No_GeneRif__30224|GPR172A|79581|No_GeneRif__30225|GPR172B|55065|No_GeneRif__18510|GPRC6A|222545|Complete__19719|LGR6|59352|No_GeneRif__14298|LPAR3|23566|Complete__17962|MRGPRX1|259249|No_GeneRif__17980|MRGPRX3|117195|Complete__17617|MRGPRX4|117196|No_GeneRif__13300|GPR61|83873|Complete__<>AvaiableGeneRif=9<>BEST:14298|LPAR3|0.00104185486299307<>ScoreDetail__23624|GPR151|0.000317073170731707__17980|MRGPRX3|0.00021680216802168__19680|GPBAR1|0.000982292014700969__18510|GPRC6A|0.0004516711833785__13300|GPR61|0.000670731707317073__18274|CYSLTR2|0.000692855601122383__14298|LPAR3|0.00104185486299307__4042|FZD4|0.000587427001030574__24884|OXER1|0.00061617458279846__	0	0	0	0		0
59269	17582695	74958	20996	11179	SOD1	ALS	ALS	18	0.5	in cultured spinal motor neurons indicating a possible role in ALS treatment 59	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
59270	17582695	74958	567	877	ALDH7A1	PDE	PDE	0	0.0	PDE inhibitors have been found to be neuroprotective in cultured spinal	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
59271	17582695	74959	567	877	ALDH7A1	PDE	PDE	0	0.0	PDE inhibitors are also being considered as novel therapies for MS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
59273	17582695	74966	20996	11179	SOD1	ALS	ALS	5	0.5	Diseases such as MS and ALS may represent related conditions resulting from variation in expression of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000778010267622989<>ScoreDetail__5468|IGFALS|0.000516679348796137__11179|SOD1|0.000778010267622989__	0	0	0	0		0
46960	17597167	59385	872	583	APC	APC	APCs	15	0.0	of immunocompetent cells such as lymphocytes and antigen-presenting cells (APCs), APCs that includes stimulation of their production of cytokines chemotactic agents	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
46975	17597167	59396	9590	5164	HPSE	HPA	HPA	8	0.0	such as IL-1 also activate the hypothalamo_amp_#x2013 pituitary_amp_#x2013 adrenal (HPA)-axis HPA -axis (see see 3 resulting in the release of corticotrophin-releasing	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
46977	17597167	59398	10676	6121	IRF6	LPS	LPS	20	0.3	adrenal gland constitutively as well as inducible by lipopolysaccharides (LPS) LPS 4 provides another source of agonists as well as antagonists	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
46981	17597167	59407	9947	5468	IGFALS	ALS	ALS	28	0.3	as Alzheimer's disease (AD), AD epilepsy amyotrophic lateral sclerosis (ALS) ALS and Parkinson's disease as well as diseases with autoimmune characteristics	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000450260721008533<>ScoreDetail__5468|IGFALS|0.000337695077597634__11179|SOD1|0.000450260721008533__	0	0	0	0		0
46982	17597167	59408	18723	10261	ROS1	ROS	ROS	28	0.0	such as nitric oxide (NO), NO reactive oxygen species (ROS), ROS glutamate quinolinic acid and proteolytic enzymes are thus common features	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
47003	17597167	59436	11629	6493	LAMC2	CSF	CSF	20	0.0	factors in post mortem brain tissue and cerebrospinal fluid (CSF) CSF samples from AD patients represent evidence for an inflammatory reaction	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
47014	17597167	59442	353	245	ADD3	ADDL	ADDLs	15	0.0	indicate that A_amp_#x3b2 oligomers or A_amp_#x3b2 -derived diffusible ligands (ADDLs), ADDLs may interfere with synaptic transmission and cause neurotoxicity 33 34	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
47015	17597167	59443	9905	5438	IFNG	IFN	IFN-G	19	0.0	1_amp_#x2013 42 stimulated an increased release of the inflammatory cytokines IFN-_amp_#x3b3 IL-1_amp_#x3b1 and IL-1_amp_#x3b2 30 may support the involvement of these	11		JUMiner_v2.2	1	0		0	2	5417	TotalCon:2<>5438|IFNG|3458|Complete__5417|IFNA1|3439|Complete__<>AvaiableGeneRif=2<>BEST:5417|IFNA1|0.00050621058468952<>ScoreDetail__5438|IFNG|0.000402004662223399__5417|IFNA1|0.00050621058468952__	0	0	0	0		0
47017	17597167	59444	11629	6493	LAMC2	CSF	CSF	5	0.0	The levels of sIL-1RII in CSF were increased in AD patients with moderate cognitive dysfunction 37	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
47026	17597167	59461	9659	18646	HSD17B12	KAR	KA-receptor	18	0.0	systemic administration of KA is mediated not only by the KA-receptor subtype of glutamate receptors but also indirectly by the release	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
47028	17597167	59462	4877	2322	CPP	CPP	CPP	8	0.0	fact the NMDA-receptor antagonists MK-801 (dizocilpine) dizocilpine and (R)-CPP R -CPP reduced KA-induced expression of IL-1_amp_#x3b2 and IL-1ra 47 indicating that	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
47048	17597167	59484	3353	1368	CA1	CA1	CA1	21	0.0	a 75% larger number of viable neurons in the hippocampal CA1 pyramidal cell layer as compared to saline-treated rats 62 (	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
47052	17597167	59487	3353	1368	CA1	CA1	CA1	21	0.0	and the rescuing effect seen by stereological analysis of the CA1 pyramidal cell layer 65 was accompanied by a reduction in	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
47060	17597167	59506	3353	1368	CA1	CA1	CA1	14	0.0	violet-stained sections of the rat hippocampus showing part of the CA1 pyramidal cell layer after (A) A sham surgery (B) B	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
51654	17678953	64372	18723	10261	ROS1	ROS	ROS	14	0.0	as nitric oxide (NO) NO and reactive oxygen species (ROS), ROS can contribute to neurodegenerative diseases in part by triggering protein	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
51655	17678953	64374	20996	11179	SOD1	ALS	ALS	39	0.0	ranging from Parkinson's disease (PD), PD amyotrophic lateral sclerosis (ALS), ALS multiple sclerosis and Alzheimer's disease (AD) AD to stroke and	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000568982184781108<>ScoreDetail__5468|IGFALS|0.000370578326782706__11179|SOD1|0.000568982184781108__	0	0	0	0		0
51656	17678953	64375	18723	10261	ROS1	ROS	ROS	36	0.0	ion channel and subsequent free radical production including NO and ROS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
51659	17678953	64388	1442	905	AXL	UFO	UFO	9	0.0	these Uncompetitive/Fast Uncompetitive Fast Off-rate therapeutics we use the term UFO drugs because like Unidentified Flying Objects they leave very quickly	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
51661	17678953	64396	1442	905	AXL	UFO	UFO	16	0.0	can be achieved by coupling NO to memantine yielding second-generation UFO drugs known as NitroMemantines	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
43599	17852013	55125	20996	11179	SOD1	ALS	ALS	12	0.0	been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00124340580038119<>ScoreDetail__5468|IGFALS|0.0011449835408616__11179|SOD1|0.00124340580038119__	0	0	0	0		0
43601	17852013	55127	10471	6026	IL8RA	C-C	C-C	11	0.0	activation normal T-cell expressed and secreted (RANTES) RANTES is a C-C beta-chemokine with strong chemo-attractant activity for T-lymphocytes and monocytes	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
43605	17852013	55128	20996	11179	SOD1	ALS	ALS	13	0.0	of RANTES in 20 patients with amyotrophic lateral sclerosis (ALS), ALS 14 patients with non-inflammatory neurological disorders (NIND) NIND and 13	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00124340580038119<>ScoreDetail__5468|IGFALS|0.0011449835408616__11179|SOD1|0.00124340580038119__	0	0	0	0		0
43606	17852013	55128	5131	2524	CTRL	CTRL	CTRL	25	0.0	non-inflammatory neurological disorders (NIND) NIND and 13 control subjects (CTRL) CTRL and cerebrospinal fluid (CSF) CSF levels of RANTES in ALS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
43607	17852013	55128	11629	6493	LAMC2	CSF	CSF	29	0.0	and 13 control subjects (CTRL) CTRL and cerebrospinal fluid (CSF) CSF levels of RANTES in ALS and NIND group patients in	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
43608	17852013	55128	20996	11179	SOD1	ALS	ALS	34	0.1	CTRL and cerebrospinal fluid (CSF) CSF levels of RANTES in ALS and NIND group patients in order to investigate whether RANTES	6		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00124340580038119<>ScoreDetail__5468|IGFALS|0.0011449835408616__11179|SOD1|0.00124340580038119__	0	0	0	0		0
43609	17852013	55128	20996	11179	SOD1	ALS	ALS	53	0.0	whether RANTES as index of immune activation is present in ALS patients	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00124340580038119<>ScoreDetail__5468|IGFALS|0.0011449835408616__11179|SOD1|0.00124340580038119__	0	0	0	0		0
43611	17852013	55129	20996	11179	SOD1	ALS	ALS	2	0.0	Patients with ALS had higher RANTES levels compared with the NIND patients and	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00124340580038119<>ScoreDetail__5468|IGFALS|0.0011449835408616__11179|SOD1|0.00124340580038119__	0	0	0	0		0
43612	17852013	55129	5131	2524	CTRL	CTRL	CTRL	13	0.0	had higher RANTES levels compared with the NIND patients and CTRL subjects (p p = 0.005 and p = 0.02 respectively	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
43614	17852013	55130	11629	6493	LAMC2	CSF	CSF	0	0.2	CSF RANTES levels were also higher compared with the NIND patients	5		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
43616	17852013	55131	11629	6493	LAMC2	CSF	CSF	5	0.2	No correlation of serum and CSF RANTES levels with disease duration was found	5		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
43617	17852013	55132	20996	11179	SOD1	ALS	ALS	18	0.0	recruitment of peripheral inflammatory cells to sites of inflammation in ALS patients	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00124340580038119<>ScoreDetail__5468|IGFALS|0.0011449835408616__11179|SOD1|0.00124340580038119__	0	0	0	0		0
43674	17853944	55213	20996	11179	SOD1	ALS	ALS	4	2.2	Abstract Amyotrophic lateral sclerosis (ALS), ALS one of the most common adult-onset neurodegenerative diseases has no	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43675	17853944	55214	20996	11179	SOD1	ALS	ALS	12	2.2	stress and inflammation have been associated with the pathoprogression of ALS through a poorly defined mechanism	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43676	17853944	55215	20996	11179	SOD1	ALS	ALS	8	2.2	Here we determined that dysregulated redox stress in ALS mice caused by NADPH oxidases Nox1 and Nox2 significantly influenced	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43683	17853944	55218	20996	11179	SOD1	ALS	ALS	2	2.2	Interestingly female ALS mice containing only 1 active X-linked Nox1 or Nox2 gene	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43687	17853944	55219	20996	11179	SOD1	ALS	ALS	9	2.2	Nox activity in spinal cords from Nox2 heterozygous female ALS mice was approximately 50% that of WT female ALS mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43688	17853944	55219	20996	11179	SOD1	ALS	ALS	18	2.2	female ALS mice was approximately 50% that of WT female ALS mice suggesting that random X-inactivation was not influenced by Nox2	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43690	17853944	55220	20996	11179	SOD1	ALS	ALS	19	2.2	spinal cord significantly delayed onset of motor neuron disease in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43691	17853944	55221	20996	11179	SOD1	ALS	ALS	15	2.2	believe to be new modifier gene targets for treatment of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43692	17853944	55223	20996	11179	SOD1	ALS	ALS	3	2.2	Amyotrophic lateral sclerosis (ALS) ALS is a fatal neurodegenerative disease that can be caused by	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43694	17853944	55224	20996	11179	SOD1	ALS	ALS	13	2.2	as to the precise mechanism of motor neuron death in ALS although oxidative stress and inflammation are both believed to be	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43696	17853944	55225	20996	11179	SOD1	ALS	ALS	10	2.2	Transgenic mice overexpressing a mutant form of SOD1 found in ALS patients (SOD1 SOD1 G93A develop motor neuron disease similar to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43698	17853944	55225	20996	11179	SOD1	ALS	ALS	28	2.2	disease similar to that seen clinically in familial forms of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43702	17853944	55229	20996	11179	SOD1	ALS	ALS	13	2.2	thought to be an important component of disease progression in ALS ( 3 7	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43704	17853944	55230	20996	11179	SOD1	ALS	ALS	8	2.2	Indeed recent studies have shown that SOD1 G93A ALS transgenic mice produce elevated levels of Nox2 gp91phox and superoxide	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43719	17853944	55234	20996	11179	SOD1	ALS	ALS	15	2.2	other Nox genes may more significantly influence redox stress in ALS disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43728	17853944	55236	20996	11179	SOD1	ALS	ALS	22	2.2	Nox1 deletion on disease progression in mixed hybrid SOD1 G93A ALS mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43729	17853944	55237	20202	10964	SLC22A18	HET	HET	32	0.6	Y and female (WT, WT Nox X+/X+ X X heterozygous HET Nox X+/X_amp_#x02013; X X_amp_#x02013 and KO Nox X_amp_#x02013;/X_amp_#x02013; X_amp_#x02013 X_amp_#x02013	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43734	17853944	55239	20996	11179	SOD1	ALS	ALS	32	2.2	neuron disease in a SOD1 G93A transgenic mouse model of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43735	17853944	55240	20996	11179	SOD1	ALS	ALS	2	2.2	Interestingly female ALS mice lacking a single copy of the X-chromosomal Nox1 or	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43740	17853944	55241	20996	11179	SOD1	ALS	ALS	26	2.2	or Nox2 -expressing cells has a substantial therapeutic benefit in ALS mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43741	17853944	55242	20996	11179	SOD1	ALS	ALS	14	2.2	multiple Nox genes appear to contribute to the pathoprogression of ALS and expand potential therapeutic targets for this disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43743	17853944	55246	20996	11179	SOD1	ALS	ALS	18	2.2	G93A mutant ( 22 were used as a model of ALS strain name B6SJL-Tg( B6SJL-Tg SOD1 G93A )1Gur/J; 1Gur J stock	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43754	17853944	55253	20202	10964	SLC22A18	HET	HET	27	0.6	to obtain all possible genotypes in each sex ( Nox -HET males were the only genotype not attainable	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43758	17853944	55255	20202	10964	SLC22A18	HET	HET	1	0.6	Nox -HET females were used for the next round of breeding against	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43766	17853944	55255	20202	10964	SLC22A18	HET	HET	50	0.6	mixed litters containing Nox -KO (male male and female Nox -HET (female female only and Nox -WT (male male only genotypes	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43768	17853944	55256	20202	10964	SLC22A18	HET	HET	2	0.6	Similarly Nox -HET females were also bred against SOD1 G93A hemizygous Nox -WT	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43776	17853944	55256	20202	10964	SLC22A18	HET	HET	45	0.6	to mixed litters containing Nox -KO (male male only Nox -HET (female female only and Nox -WT (male male and female	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43790	17853944	55269	10452	6001	IL2	IL2	IL2	15	0.0	the difference between the human SOD1 CT and the mouse IL2 CT for all mice in the Nox2 F2 generation	10		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
43797	17853944	55276	20202	10964	SLC22A18	HET	HET	19	0.6	presymptomatic weight exceeded 40 g 2 Nox2 -WT 1 Nox2 -HET and 1 Nox2 -KO	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43805	17853944	55285	20202	10964	SLC22A18	HET	HET	4	0.6	Eye infection in Nox2 -HET females hemizygous for the SOD1 G93A transgene was only observed	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43809	17853944	55312	15877	8512	OTC	OTC	OTC	4	0.0	Segments were embedded in OTC freezing medium and sectioned axially at 20 _amp_#x003bc m at	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
43818	17853944	55332	20996	11179	SOD1	ALS	ALS	12	2.2	enhanced redox stress has been associated with disease progression in ALS mouse models we sought to evaluate 2 potential Nox genes	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43819	17853944	55332	18723	10261	ROS1	ROS	ROS	25	0.3	we sought to evaluate 2 potential Nox genes responsible for ROS generation in hemizygous SOD1 G93A transgenic mice and their affect	3		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
43824	17853944	55333	20996	11179	SOD1	ALS	ALS	14	2.2	-KO and Nox2 -KO mice to hemizygous male SOD1 G93A ALS mice (Supplemental Supplemental Figures 1 and 2 supplemental material available	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43840	17853944	55338	20996	11179	SOD1	ALS	ALS	15	2.2	or Nox2 significantly delayed the death of hemizygous SOD1 G93A ALS mice (Figure Figure 1 A	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43854	17853944	55344	20996	11179	SOD1	ALS	ALS	3	2.2	Enhanced survival of ALS Nox2 -KO mice correlated with higher motor neuron counts in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43865	17853944	55349	20996	11179	SOD1	ALS	ALS	21	2.2	decreased motor neuron disease in male and female Nox2 -KO ALS mice (Figure Figure 3 B_amp_#x02013 D	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43866	17853944	55350	20996	11179	SOD1	ALS	ALS	20	2.2	by hind-limb muscle atrophy a hallmark of disease progression in ALS mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43882	17853944	55358	20996	11179	SOD1	ALS	ALS	14	2.2	C57BL/6 C57BL 6 modifier genes can slow disease progression in ALS mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43911	17853944	55368	20202	10964	SLC22A18	HET	HET	2	0.6	Interestingly Nox2 -HET female ALS mice also demonstrated significant increases in survival (	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43912	17853944	55368	20996	11179	SOD1	ALS	ALS	4	2.2	Interestingly Nox2 -HET female ALS mice also demonstrated significant increases in survival ( Nox2 -WT	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43915	17853944	55368	20202	10964	SLC22A18	HET	HET	18	0.6	significant increases in survival ( Nox2 -WT 132 days Nox2 -HET 186 days Figure 1 A and Figure 3 A although	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43917	17853944	55369	20202	10964	SLC22A18	HET	HET	14	0.6	limited but significant heterozygous effect on increased survival in Nox1 -HET female ALS mice (Figure Figure 1 A	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43918	17853944	55369	20996	11179	SOD1	ALS	ALS	16	2.2	significant heterozygous effect on increased survival in Nox1 -HET female ALS mice (Figure Figure 1 A	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43920	17853944	55370	20202	10964	SLC22A18	HET	HET	21	0.6	the finding of decreased motor neuron disease in female Nox2 -HET ALS mice (Figure Figure 3 B_amp_#x02013 D	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43921	17853944	55370	20996	11179	SOD1	ALS	ALS	22	2.2	finding of decreased motor neuron disease in female Nox2 -HET ALS mice (Figure Figure 3 B_amp_#x02013 D	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43927	17853944	55375	20202	10964	SLC22A18	HET	HET	8	0.6	Given the significant protective effect seen in Nox2 -HET female mice we sought to determine how dosage of Nox2	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43929	17853944	55375	20996	11179	SOD1	ALS	ALS	29	2.2	activity in the spinal cord might influence disease progression in ALS mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43931	17853944	55376	20202	10964	SLC22A18	HET	HET	14	0.6	disease Nox activity in the spinal cords of female Nox2 -HET SOD1 G93A mice fell between that of female Nox2 -KO	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43937	17853944	55377	20202	10964	SLC22A18	HET	HET	10	0.6	This suggests that X-inactivation likely occurs randomly in female Nox2 -HET SOD1 G93A mice with about 50% of the microglia and	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
43941	17853944	55378	20996	11179	SOD1	ALS	ALS	21	2.2	the spinal cord has a significant impact on survival of ALS mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43948	17853944	55382	20996	11179	SOD1	ALS	ALS	6	2.2	It has been postulated that the ALS phenotype is at least partially dictated by an altered redox-balance	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43951	17853944	55384	20996	11179	SOD1	ALS	ALS	16	2.2	findings our current data demonstrating significantly enhanced survival in female ALS mice with chimeric Nox2 expression suggest that SOD1 G93A expression	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43961	17853944	55390	20996	11179	SOD1	ALS	ALS	5	2.2	Importantly antibiotic treatment of control ALS mice on the WT Nox2 background did not alter either	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43984	17853944	55407	20996	11179	SOD1	ALS	ALS	13	2.2	cannot explain why the infection was only present in the ALS Nox2 -KO mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43986	17853944	55411	18723	10261	ROS1	ROS	ROS	13	0.3	microglia can lead to the production of proinflammatory cytokines and ROS which have been associated with neuroinflammation that can further perpetuate	3		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
43987	17853944	55412	18723	10261	ROS1	ROS	ROS	7	0.3	Among the factors produced by activated microglia ROS could potentially enhance neurodegeneration by at least 2 mechanisms	3		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
43988	17853944	55413	18723	10261	ROS1	ROS	ROS	1	0.3	First ROS can cause direct damage to neurons	3		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
43989	17853944	55414	18723	10261	ROS1	ROS	ROS	7	0.3	Second increases in the intracellular concentrations of ROS may activate pro-inflammatory signaling cascades that result in the activation	3		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
43990	17853944	55415	20996	11179	SOD1	ALS	ALS	15	2.2	there is an upregulation of microglia during the progression of ALS disease and that in Nox2 -KO mice there is a	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
43992	17853944	55415	10676	6121	IRF6	LPS	LPS	35	0.3	a marked decrease in the number of activated microglia following LPS treatment ( 21	1		JUMiner_v2.2	1	2	UserEdit	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	1	1	0	0		0
43993	17853944	55416	18723	10261	ROS1	ROS	ROS	3	0.3	This suggests that ROS generated from NADPH oxidases play a role in signaling events	3		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
43994	17853944	55417	20996	11179	SOD1	ALS	ALS	15	2.2	to determine the effect of NADPH oxidase_amp_#x02013 derived superoxide in ALS disease progression in transgenic mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44000	17853944	55420	5281	2578	CYBB	NOX2	Nox2-inactive	19	2.0	heterozygous for the Nox2 X-linked gene and hence containing 50% Nox2-inactive cells suggest that the interplay between Nox-activated microglia and neuronal	15		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
44001	17853944	55420	20996	11179	SOD1	ALS	ALS	33	2.2	the interplay between Nox-activated microglia and neuronal cell types in ALS may be more complex than previously thought	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44004	17853944	55424	20996	11179	SOD1	ALS	ALS	11	2.2	genetic background has previously been shown to influence survival of ALS mice ( 13 and this could have accounted for the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44007	17853944	55425	20996	11179	SOD1	ALS	ALS	17	2.2	seen in the Nox1 -KO compared with the Nox2 -KO ALS mice would suggest that modifier genes must act in concert	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44010	17853944	55426	20996	11179	SOD1	ALS	ALS	13	2.2	of additional modifier genes that may influence Nox2 function in ALS would be particularly relevant to human ALS disease which manifests	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44011	17853944	55426	20996	11179	SOD1	ALS	ALS	20	2.2	Nox2 function in ALS would be particularly relevant to human ALS disease which manifests considerable phenotypic variability	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44012	17853944	55428	20996	11179	SOD1	ALS	ALS	9	2.2	First we believe the demonstrated increase in survival of ALS mice is the largest ever reported as a consequence of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44017	17853944	55429	20996	11179	SOD1	ALS	ALS	21	2.2	gene ( Nox1 and Nox2 can influence disease progression in ALS mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44018	17853944	55430	20996	11179	SOD1	ALS	ALS	19	2.2	deletions have been shown to significantly delay disease progression in ALS mice (i.e., i.e. survival index	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44019	17853944	55431	20996	11179	SOD1	ALS	ALS	5	2.2	Finally our findings in female ALS mice suggest that a 50% reduction in Nox2 activity can	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44022	17853944	55431	20996	11179	SOD1	ALS	ALS	29	2.2	progression of disease in this SOD1 G93A transgenic model of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44023	17853944	55432	20996	11179	SOD1	ALS	ALS	17	2.2	Nox pathways using pharmacologic-based approaches could provide significant benefits for ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44024	17853944	55437	20996	11179	SOD1	ALS	ALS	4	2.2	Footnotes Nonstandard abbreviations used ALS amyotrophic lateral sclerosis CT threshold cycle HET heterozygous SOD superoxide	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44025	17853944	55437	20202	10964	SLC22A18	HET	HET	11	0.6	Nonstandard abbreviations used ALS amyotrophic lateral sclerosis CT threshold cycle HET heterozygous SOD superoxide dismutase	1		JUMiner_v2.2	1	2	UserEdit	0	2	10520	TotalCon:2<>10520|SAFB|6294|Complete__10964|SLC22A18|5002|Complete__<>AvaiableGeneRif=2<>BEST:10520|SAFB|0.000455539358600583<>ScoreDetail__10520|SAFB|0.000455539358600583__10964|SLC22A18|0.000385868633167553__	1	1	0	0		0
44029	17853944	55441	20996	11179	SOD1	ALS	ALS	18	2.2	( Nox1 or Nox2 enhances survival and survival index in ALS mice and significantly reduces superoxide production in spinal cords of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
44035	17853944	55443	20996	11179	SOD1	ALS	ALS	11	2.2	3 Disease phenotyping of Nox2 genotypes on the SOD1 G93A ALS background	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00177027188415898<>ScoreDetail__5468|IGFALS|0.0008079344737282__11179|SOD1|0.00177027188415898__	0	0	0	0		0
45275	17896980	57308	9947	5468	IGFALS	ALS	ALS	23	0.3	and the immune system such as amyotrophic lateral sclerosis (ALS), ALS Alzheimer's disease (AD), AD neuropathy pain allergic bronchial asthma (BA)	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00061616799804828<>ScoreDetail__5468|IGFALS|0.000489585187822681__11179|SOD1|0.00061616799804828__	0	0	0	0		0
46161	17908040	58285	20996	11179	SOD1	ALS	ALS	24	0.0	cell death in AD PD and amyotrophic lateral sclerosis (ALS) ALS as well as several other CNS complications	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000555587013653184<>ScoreDetail__5468|IGFALS|0.00026542800265428__11179|SOD1|0.000555587013653184__	0	0	0	0		0
38593	17969353	48250	9947	5468	IGFALS	ALS	ALS	8	0.3	Gene expression profile of spinal ventral horn in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00103931458879183<>ScoreDetail__5468|IGFALS|0.00073946853680645__11179|SOD1|0.00103931458879183__	0	0	0	0		0
38594	17969353	48251	9947	5468	IGFALS	ALS	ALS	8	0.3	The causative pathomechanism of sporadic amyotrophic lateral sclerosis (ALS) ALS is not clearly understood	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00103931458879183<>ScoreDetail__5468|IGFALS|0.00073946853680645__11179|SOD1|0.00103931458879183__	0	0	0	0		0
38595	17969353	48252	9947	5468	IGFALS	ALS	ALS	26	0.3	well as spinal ventral horn from autopsied patients with sporadic ALS were examined	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00103931458879183<>ScoreDetail__5468|IGFALS|0.00073946853680645__11179|SOD1|0.00103931458879183__	0	0	0	0		0
38603	17969353	48258	22568	11905	TNFRSF10B	DR5	DR5	8	0.0	Promoters for cell death pathway death receptor 5 (DR5), DR5 cyclins C (CCNC) CCNC and A1 (CCNA), CCNA and caspases	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
38604	17969353	48258	3793	1581	CCNC	CCNC	CCNC	11	0.0	death pathway death receptor 5 (DR5), DR5 cyclins C (CCNC) CCNC and A1 (CCNA), CCNA and caspases were upregulated whereas cell	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
38605	17969353	48259	13346	7178	MMRN1	ECM	ECM	18	0.0	cell surface antigens/receptors, antigens receptors transcription and cell adhesion/ECM adhesion ECM were increased	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
38607	17969353	48262	9947	5468	IGFALS	ALS	ALS	18	0.3	from early DCTN1 downregulation to late CCNC upregulation in sporadic ALS can provide direct information on the genes leading to neurodegeneration	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00103931458879183<>ScoreDetail__5468|IGFALS|0.00073946853680645__11179|SOD1|0.00103931458879183__	0	0	0	0		0
38608	17969353	48262	3793	1581	CCNC	CCNC	CCNC	14	0.0	neuron-specific gene expression changes from early DCTN1 downregulation to late CCNC upregulation in sporadic ALS can provide direct information on the	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27677	17997855	32892	20996	11179	SOD1	ALS	ALS	13	1.9	the course of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27679	17997855	32893	20996	11179	SOD1	ALS	ALS	15	1.9	superoxide dismutase (EC EC 1.15.1.1 SOD1 are associated with familial ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27681	17997855	32895	20996	11179	SOD1	ALS	ALS	14	1.9	transfected with the G93A mutant of SOD1 typical for familial ALS (G93A-SOD1) G93A-SOD1 and SH-SY5Y neuroblastoma cells transfected with wildtype SOD1	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27683	17997855	32895	5021	2444	CSK	CSK	CSK	50	0.0	S -lysyl- S -lysine _amp_#x000d7 3 HCl (Pam Pam 3 CSK 4	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27685	17997855	32899	20996	11179	SOD1	ALS	ALS	14	1.9	transfected with the G93A mutant of SOD1 typical for familial ALS (G93A-SOD1) G93A-SOD1 were more vulnerable to the neurotoxic action of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27687	17997855	32899	5021	2444	CSK	CSK	CSK	35	0.0	and to the attack of monocytes stimulated by Pam 3 CSK 4 than SH-SY5Y cells transfected with wild-type human SOD1	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27688	17997855	32903	20996	11179	SOD1	ALS	ALS	21	1.9	inflammation may be partly responsible for the clinical deterioration of ALS patients during infections	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27689	17997855	32904	20996	11179	SOD1	ALS	ALS	16	1.9	neuron disease and suggest early treatment of respiratory infections in ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27690	17997855	32906	20996	11179	SOD1	ALS	ALS	23	1.9	Alzheimer's disease Parkinson's disease stroke and amyotrophic lateral sclerosis (ALS) ALS 1 2	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27691	17997855	32908	20996	11179	SOD1	ALS	ALS	8	1.9	In support of the link between infections and ALS an epidemiological study found evidence for infection with Mycoplasma spp	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27692	17997855	32908	20996	11179	SOD1	ALS	ALS	30	1.9	the blood of more than 80% of patients suffering from ALS and in less than 10% of age-matched control subjects 3	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27693	17997855	32908	9401	16435	HM13	SPP	spp	18	0.0	ALS an epidemiological study found evidence for infection with Mycoplasma spp in the blood of more than 80% of patients suffering	14		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27694	17997855	32909	20996	11179	SOD1	ALS	ALS	0	1.9	ALS is an ultimately lethal disease with a high inter-subject variation	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27695	17997855	32911	20996	11179	SOD1	ALS	ALS	0	1.9	ALS appears to be a multifactorial disease where motor neuron degradation	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27697	17997855	32913	20996	11179	SOD1	ALS	ALS	1	1.9	Clinically ALS occurs both sporadically and as a familial form	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27698	17997855	32914	20996	11179	SOD1	ALS	ALS	2	1.9	In 5_amp_#x02013 10% ALS is a familial disease and approximately 20% of the familial	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27699	17997855	32914	20996	11179	SOD1	ALS	ALS	13	1.9	is a familial disease and approximately 20% of the familial ALS cases are caused by a mutation in the gene encoding	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27702	17997855	32917	20996	11179	SOD1	ALS	ALS	9	1.9	Families with the G93A-SOD1 mutation are indistinguishable from sporadic ALS by clinical and pathologic criteria 5	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27705	17997855	32920	20996	11179	SOD1	ALS	ALS	9	1.9	A significant inflammatory component contributes to the pathology of ALS 7 8	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27706	17997855	32921	20996	11179	SOD1	ALS	ALS	17	1.9	and various cytokines and chemokines in the CNS tissue of ALS patients and mouse models 7 9 10 and the presence	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27707	17997855	32921	20996	11179	SOD1	ALS	ALS	45	1.9	cells as demonstrated in post mortem spinal cord tissue of ALS patients 10 11 and by positron emission tomography using 11	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27708	17997855	32921	20996	11179	SOD1	ALS	ALS	63	1.9	emission tomography using 11 C](R)-PK11195 C R -PK11195 in living ALS patients 12	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27709	17997855	32922	20996	11179	SOD1	ALS	ALS	13	1.9	activated microglial cells in the vicinity of neuronal death in ALS suggests that stimulants of microglial activation are produced by stressed	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27712	17997855	32942	19573	10691	SDS	SDS	SDS-polyacrylamide	5	0.0	Toxin purity was assessed by SDS-polyacrylamide gel electrophoresis followed by Coomassie-blue staining which showed a single	11		JUMiner_v2.2	1	0		0	2	19440	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:19440|SBDS|0.000386094610941903<>ScoreDetail__10691|SDS|0.000132749236691889__19440|SBDS|0.000386094610941903__	0	0	0	0		0
27717	17997855	32956	5021	2444	CSK	CSK	CSK	24	0.0	Cys-SKKKK _amp_#x000d7 3 HCl EMC Microcollections Tuebingen Germany Pam 3 CSK 4 22 in concentrations of 10 _amp_#x003bc;g/ml _amp_#x003bc g ml	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27718	17997855	32957	23484	12446	TYRO3	BYK	Byk	26	0.0	enzyme immunoassay (LIA) LIA using the Liaison _amp_#x000ae Analyser from Byk Sangtec and reagents from Diasorin (Dietzenbach, Dietzenbach Germany	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27719	17997855	32963	19254	10472	RUNX2	CCD	CCD	10	0.0	Changes in Ca 2 i were measured using a CCD camera system (TILL TILL Photonics Martinsried Germany 23 24	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27720	17997855	32965	19254	10472	RUNX2	CCD	CCD	1	0.0	The CCD camera displayed 12-bit dynamics and an A/D A D converter	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27721	17997855	32973	20247	20116	SLC25A29	CACL	CaCl	12	1.0	either RPMI-1640 or (in in mM NaCl 140 KCl 2 CaCl 2 2.5 MgCl 2 1 HEPES 10 glucose 40 and	14		JUMiner_v2.2	1	2	cacl	0	0	0		0	0	0	0		0
27722	17997855	32974	20247	20116	SLC25A29	CACL	CaCl	11	1.0	nominally Ca 2 -free solutions MgCl 2 was substituted for CaCl 2 without adding EGTA	14		JUMiner_v2.2	1	2	cacl	0	0	0		0	0	0	0		0
27725	17997855	32977	20996	11179	SOD1	SOD1	SOD1	38	3.2	activated caspase-3 was used to detect apoptosis in pneumolysin-treated G93A SOD1 cells fixated cells were permeabilised with Triton X (0.1% 0.1%	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
27728	17997855	32979	20996	11179	SOD1	SOD1	SOD1	34	3.2	staining of the somata of macrophages (CD68)/apoptotic CD68 apoptotic G93A SOD1 cells (Caspase Caspase 3	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
27745	17997855	33017	5021	2444	CSK	CSK	CSK	22	0.0	of monocytes stimulated with the Toll-like receptor-2 agonist Pam 3 CSK 4 After stimulation of human neuroblastoma and macrophage co-cultures with	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27746	17997855	33017	5021	2444	CSK	CSK	CSK	38	0.0	neuroblastoma and macrophage co-cultures with the TLR2 agonist Pam 3 CSK 4 for a period of 72 hours the release of	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27748	17997855	33018	5021	2444	CSK	CSK	CSK	26	0.0	co-cultures with Wt-SOD1 SH-SY5Y cells after stimulation with Pam 3 CSK 4 (27.8 27.8 _amp_#x000b1 2.4% vs 19.0 _amp_#x000b1 3.3% p	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27750	17997855	33026	20996	11179	SOD1	ALS	ALS	24	1.9	transfected with the G93A mutant of SOD1 typical for familial ALS (G93A-SOD1) G93A-SOD1 are more vulnerable to infectious stimuli than neuroblastoma	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27758	17997855	33050	20996	11179	SOD1	ALS	ALS	10	1.9	Mitochondrial damage contributes to neuronal death both in inflammation and ALS 46 47	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27764	17997855	33053	5021	2444	CSK	CSK	CSK	13	0.0	that activation of macrophages by the TLR2 agonist Pam 3 CSK 4 can also cause neuronal death and that neuroblastoma cells	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27765	17997855	33057	20996	11179	SOD1	ALS	ALS	2	1.9	In inherited ALS after an initial phase of the disease predominated by motor	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00179627854242123<>ScoreDetail__5468|IGFALS|0.000471355078514289__11179|SOD1|0.00179627854242123__	0	0	0	0		0
27773	17997855	33088	20996	11179	SOD1	SOD1	SOD1	15	3.2	influx into G 93A-SOD1 neuroblastoma cells in comparison to wild-type SOD1 cells	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
27774	17997855	33090	20996	11179	SOD1	SOD1	SOD1	15	3.2	influx into G 93A-SOD1 neuroblastoma cells in comparison to wild-type SOD1 cells	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
27775	17997855	33092	20996	11179	SOD1	SOD1	SOD1	15	3.2	influx into G 93A-SOD1 neuroblastoma cells in comparison to wild-type SOD1 cells	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
27779	17997855	33097	5021	2444	CSK	CSK	CSK	19	0.0	cells to the attack of monocytes stimulated with Pam 3 CSK 4	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27782	17997855	33100	5021	2444	CSK	CSK	CSK	19	0.0	cells to the attack of monocytes stimulated with Pam 3 CSK 4	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27783	17997855	33101	5021	2444	CSK	CSK	CSK	5	0.0	After staining of Pam 3 CSK 4 -stimulated co-cultures with light green and macrophage staining with	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
27784	17997855	33102	5021	2444	CSK	CSK	CSK	16	0.0	cells to the attack of monocytes stimulated with Pam 3 CSK 4	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29808	18040778	35397	11629	6493	LAMC2	CSF	CSF	18	0.0	the blood-brain barrier (BBB) BBB and blood-cerebral spinal fluid (CSF) CSF barrier as well as the presence of drug-specific transporters in	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29809	18040778	35411	9006	4799	HADH	HAD	HAD	4	0.0	HIV infection HIV-associated dementia (HAD) HAD is typically a late manifestation of HIV infection and is	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29810	18040778	35412	9006	4799	HADH	HAD	HAD	7	0.0	A key element in the development of HAD appears to be infection of microglia which are the only	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29811	18040778	35413	9006	4799	HADH	HAD	HAD	18	0.0	and macrophages in the CNS is a better correlate with HAD than the presence and amount of HIV-1-infected cells in the	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29812	18040778	35416	9006	4799	HADH	HAD	HAD	26	0.0	limited compared to the diffuse CNS abnormalities that occur in HAD (Lipton Lipton and Gendelman 1995 which suggests that diffusible factors	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29815	18040778	35419	450	330	AGRP	ART	ART	3	0.0	Although antiretroviral therapy (ART) ART is extremely important in the control of HIV infection its	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29816	18040778	35419	9006	4799	HADH	HAD	HAD	16	0.0	important in the control of HIV infection its role in HAD is less clear	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29817	18040778	35420	450	330	AGRP	ART	ARTs	1	0.0	Specific ARTs such as efavirenz have been shown to inhibit HIV replication	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29818	18040778	35421	10676	6121	IRF6	LPS	LPS	11	0.3	indinavir and zidovudine have been shown to inhibit lipopolysaccharide (LPS)-stimulated LPS -stimulated microglial production of matrix metalloproteinase (MMP)-9, MMP -9 thereby	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
29819	18040778	35422	9006	4799	HADH	HAD	HAD	11	0.0	with activity against HIV may not be enough to impact HAD	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29820	18040778	35423	9006	4799	HADH	HAD	HAD	13	0.0	microglia release neurotoxins which may ultimately be more important in HAD than viral replication per se	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29821	18040778	35424	450	330	AGRP	ART	ART	6	0.0	Also there is some evidence that ART itself may contribute to overall neuroinflammation	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29822	18040778	35427	9006	4799	HADH	HAD	HAD	10	0.0	For these reasons ideal therapeutic agents for the treatment of HAD would attenuate HIV-1 neuropathogenesis through both direct inhibition of viral	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29823	18040778	35430	10676	6121	IRF6	LPS	LPS-induced	16	0.3	the benzodiazepines which cross the CNS bind to microglia inhibit LPS-induced TNF-A production suppress HIV-1 Tat protein-induced chemotaxis and also inhibit	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
29825	18040778	35431	9006	4799	HADH	HAD	HAD	10	0.0	These agents may yet prove to be useful in controlling HAD by targeting microglia as the central player in this process	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29826	18040778	35433	5693	2770	DES	DES	Des	32	0.0	subarachnoid space from an adjacent parenchymal tubercle (Leonard Leonard and Des Prez 1990	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
29841	18040778	35462	9947	5468	IGFALS	ALS	ALS	54	0.3	(Cagnin Cagnin et al. 2001 and amyotrophic lateral sclerosis (ALS) ALS (Turner Turner et al. 2004	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00072716234739917<>ScoreDetail__5468|IGFALS|0.000246042811449192__11179|SOD1|0.00072716234739917__	0	0	0	0		0
29842	18040778	35466	9947	5468	IGFALS	ALS	ALS	37	0.3	neurodegenerative processes in MS AD Parkinson's disease (PD), PD and ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00072716234739917<>ScoreDetail__5468|IGFALS|0.000246042811449192__11179|SOD1|0.00072716234739917__	0	0	0	0		0
29844	18040778	35471	10676	6121	IRF6	LPS	LPS	1	0.3	Lipopolysaccharide (LPS), LPS tumor necrosis factor (TNF)-A, TNF -A reactive oxygen intermediates (ROI),	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
29846	18040778	35471	9947	5468	IGFALS	ALS	ALS	29	0.3	(AD), AD Parkinson's disease (PD), PD amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00072716234739917<>ScoreDetail__5468|IGFALS|0.000246042811449192__11179|SOD1|0.00072716234739917__	0	0	0	0		0
29850	18040778	35499	9947	5468	IGFALS	ALS	ALS	13	0.3	E 2 are elevated in the CNS of patients with ALS and recent studies have implicated activated microglia in this _amp_#8220	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00072716234739917<>ScoreDetail__5468|IGFALS|0.000246042811449192__11179|SOD1|0.00072716234739917__	0	0	0	0		0
29852	18040778	35501	9947	5468	IGFALS	ALS	ALS	61	0.3	in development of new treatments of AD PD MS and ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00072716234739917<>ScoreDetail__5468|IGFALS|0.000246042811449192__11179|SOD1|0.00072716234739917__	0	0	0	0		0
29859	18040778	35510	10676	6121	IRF6	LPS	LPS	30	0.3	as well as to suppress the production of TNF-A by LPS and AB peptide-stimulated microglia (Dheen Dheen et al. 2005 moreover	1		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
29860	18040778	35514	9947	5468	IGFALS	ALS	ALS	3	0.3	Of relevance to ALS a drug screening program recently revealed that ceftriaxone modulates glutamate	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00072716234739917<>ScoreDetail__5468|IGFALS|0.000246042811449192__11179|SOD1|0.00072716234739917__	0	0	0	0		0
29861	18040778	35514	9947	5468	IGFALS	ALS	ALS	27	0.3	neurons both in vitro and in an animal model of ALS (Rothstein Rothstein et al. 2005	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00072716234739917<>ScoreDetail__5468|IGFALS|0.000246042811449192__11179|SOD1|0.00072716234739917__	0	0	0	0		0
24978	18246426	29675	20996	11179	SOD1	ALS	ALS	12	0.0	of cytokines in the pathophysiology of amyotrophic lateral sclerosis (ALS) ALS and its relation to clinical outcome has not been clearly	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
24981	18246426	29676	20996	11179	SOD1	ALS	ALS	18	0.0	nitric oxide (NO) NO levels in the serum of 22 ALS patients and 20 controls	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
24984	18246426	29677	20996	11179	SOD1	ALS	ALS	14	0.0	IFN-G levels were significantly ( P _lt_ 0.001 elevated in ALS patients	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
24985	18246426	29679	20996	11179	SOD1	ALS	ALS	9	0.0	We further noticed positive correlation between the duration of ALS and these proinflammatory molecule levels	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
24986	18246426	29680	20996	11179	SOD1	ALS	ALS	16	0.0	to play a crucial role in the neurodegeneration observed in ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
24988	18246426	29681	20996	11179	SOD1	ALS	ALS	30	0.0	may be one of the factors underlying the progression of ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
24989	18246426	29682	20996	11179	SOD1	ALS	ALS	8	0.0	This study confirms the involvement of inflammation in ALS and the need to develop surrogate markers to check the	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
24990	18246426	29684	20996	11179	SOD1	ALS	ALS	4	0.0	Introduction Amyotrophic lateral sclerosis (ALS), ALS which is progressive and usually runs a fatal course within	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
24991	18246426	29685	20996	11179	SOD1	ALS	ALS	4	0.0	The underlying cause of ALS is not well known but familial environmental viral metabolic and	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
24992	18246426	29689	20996	11179	SOD1	ALS	ALS	16	0.0	levels were significantly higher in a group of northern indian ALS patients 9	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25013	18246426	29703	20996	11179	SOD1	ALS	ALS	18	0.0	the systemic inflammatory markers TNF-A IFN-G and nitric oxide in ALS patients and evaluate their role in the prognosis of this	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25014	18246426	29705	20996	11179	SOD1	ALS	ALS	0	0.0	ALS patients and control subjects This is a tertiary referral-hospital based	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25015	18246426	29706	20996	11179	SOD1	ALS	ALS	0	0.0	ALS patients were recruited from outpatients using El Escorial diagnostic criteria	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25016	18246426	29708	20996	11179	SOD1	ALS	ALS	3	0.0	Patients diagnosed with ALS also met an extensive list of exclusionary criteria including sensory	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25017	18246426	29708	20996	11179	SOD1	ALS	ALS	28	0.0	bladder changes and metabolic or toxic disorder that could mimic ALS e.g. myelopathy lead intoxication endocrine abnormalities or peripheral neuropathy	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25018	18246426	29709	20996	11179	SOD1	ALS	ALS	7	0.0	Twenty-two patients were diagnosed as having sporadic ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25019	18246426	29715	12527	9234	MED1	PBP	PBP	11	0.6	these patients were diagnosed as having progressive bulbar palsy (PBP), PBP which results from exclusive lower motor neuron involvement in bulbar	1		JUMiner_v2.2	1	2	UserEdit	0	2	9240	TotalCon:5<>8630|PEBP1|5037|Complete__2989|DOCK3|1795|Complete__9234|MED1|5469|Complete__9008|PKD1|5310|Complete__9240|PPBP|5473|Complete__<>AvaiableGeneRif=5<>BEST:9240|PPBP|0.000751566220115642<>ScoreDetail__9234|MED1|0.000574762661096727__9008|PKD1|0.000448804005918725__8630|PEBP1|0.000596132816928709__2989|DOCK3|0.000427899015832264__9240|PPBP|0.000751566220115642__	1	1	0	0		0
25020	18246426	29716	12527	9234	MED1	PBP	PBP	1	0.6	These PBP patients were having tongue fasciculations and swallowing difficulty but their	1		JUMiner_v2.2	1	2	UserEdit	0	2	9240	TotalCon:5<>8630|PEBP1|5037|Complete__2989|DOCK3|1795|Complete__9234|MED1|5469|Complete__9008|PKD1|5310|Complete__9240|PPBP|5473|Complete__<>AvaiableGeneRif=5<>BEST:9240|PPBP|0.000751566220115642<>ScoreDetail__9234|MED1|0.000574762661096727__9008|PKD1|0.000448804005918725__8630|PEBP1|0.000596132816928709__2989|DOCK3|0.000427899015832264__9240|PPBP|0.000751566220115642__	1	1	0	0		0
25021	18246426	29721	20996	11179	SOD1	ALS	ALS	9	0.0	We were interested in testing the immunologic pathogenesis for ALS as has been recently proposed hence we only included 20	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25026	18246426	29729	11629	6493	LAMC2	CSF	CSF	4	0.0	We have not obtained CSF from patients and controls due to ethical considerations	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
25029	18246426	29742	20996	11179	SOD1	ALS	ALS	24	0.0	values of these cytokines in control subjects and patients with ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25031	18246426	29746	20996	11179	SOD1	ALS	ALS	9	0.0	It may be noted that serum TNF-A levels in ALS patients were significantly higher ( P _lt_ 0.001 with respect	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25033	18246426	29747	20996	11179	SOD1	ALS	ALS	17	0.0	( P _lt_ 0.001 in serum IFN-G NO levels in ALS patients versus controls (Figs Figs 2 3	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25035	18246426	29748	20996	11179	SOD1	ALS	ALS	9	0.0	1 Serum mean TNF-A (pg/ml pg ml SEM levels in ALS patients ( n = 22 and controls ( n =	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25037	18246426	29749	20996	11179	SOD1	ALS	ALS	9	0.0	2 Serum mean IFN-G (pg/ml pg ml SEM levels in ALS patients ( n = 22 and controls ( n =	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25038	18246426	29750	20996	11179	SOD1	ALS	ALS	11	0.0	NO (_amp_#956;Mol/ml _amp_#956 Mol ml of blood SEM levels in ALS patients ( n = 22 and controls ( n =	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25041	18246426	29751	20996	11179	SOD1	ALS	ALS	7	0.0	Furthermore it can be seen that in ALS patients serum TNF-A IFN-G and NO levels (Figs Figs 4	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25043	18246426	29753	20996	11179	SOD1	ALS	ALS	22	0.0	SEM levels versus duration of illness in the patients of ALS ( n = 12 at 6 months 5 at 12	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25045	18246426	29755	20996	11179	SOD1	ALS	ALS	20	0.0	ml SEM versus duration of illness in the patients of ALS ( n = 12 at 6 months 5 at 12	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25046	18246426	29757	20996	11179	SOD1	ALS	ALS	22	0.0	blood SEM versus duration of illness in the patients of ALS ( n = 12 at 6 months 5 at 12	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25047	18246426	29760	20996	11179	SOD1	ALS	ALS	0	0.0	ALS occurs more commonly in men than in women and women	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25048	18246426	29761	20996	11179	SOD1	ALS	ALS	20	0.0	to whether estrogen may be neuroprotective in delaying or preventing ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25052	18246426	29763	20996	11179	SOD1	ALS	ALS	15	0.0	observed significant elevation in serum TNF-A and IFN-G levels in ALS patients and also this increase was most prominent at 24	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25055	18246426	29765	20996	11179	SOD1	ALS	ALS	13	0.0	et al 29 measured IL-6 and TNF-A in patients with ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25056	18246426	29766	20996	11179	SOD1	ALS	ALS	13	0.0	elevated levels to a normal response to hypoxemia rather than ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25058	18246426	29768	20996	11179	SOD1	ALS	ALS	17	0.0	five patients died around 25 months from the onset of ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25062	18246426	29770	20996	11179	SOD1	ALS	ALS	25	0.0	between blood TNF-A levels and duration of the disease in ALS patients	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25065	18246426	29771	11629	6493	LAMC2	CSF	CSF	16	0.0	31 could not detect TNF-A and IFN-G levels in the CSF of ALS patients using a cytometric bead assay	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
25066	18246426	29771	20996	11179	SOD1	ALS	ALS	18	0.0	not detect TNF-A and IFN-G levels in the CSF of ALS patients using a cytometric bead assay	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25067	18246426	29772	20996	11179	SOD1	ALS	ALS	15	0.0	could be due to several factors including geographical pattern of ALS methodology antigenic versus biological response etc	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25069	18246426	29774	20996	11179	SOD1	ALS	ALS	21	0.0	of NOS in brain 34 the pronounced increases found in ALS patients may also suggest a role for NO in the	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25070	18246426	29776	20996	11179	SOD1	ALS	ALS	28	0.0	the patients due to significant morbidity and mortality associated with ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25073	18246426	29777	20996	11179	SOD1	ALS	ALS	16	0.0	levels peaked around 24 months from the onset in these ALS patients and it may be that systemic inflammation noticed could	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
25074	18246426	29778	20996	11179	SOD1	ALS	ALS	11	0.0	the exact role of this observation in the pathogenesis of ALS and its correlation to neuroinflammation and neurodegeneration needs a rigorous	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.00103658273225932<>ScoreDetail__5468|IGFALS|0.00103658273225932__11179|SOD1|0.000659654298654437__	0	0	0	0		0
15943	18312546	18853	20996	11179	SOD1	ALS	ALS	15	1.4	programmed cell death and inflammation in amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00122970320456855<>ScoreDetail__5468|IGFALS|0.000393226670598933__11179|SOD1|0.00122970320456855__	0	0	0	0		0
15945	18312546	18854	20996	11179	SOD1	ALS	ALS	15	1.4	the anti-inflammatory peroxisome proliferator-activated receptor-gamma (PPARgamma) PPARgamma agonist pioglitazone in ALS we verified changes in the population of neurons astrocytes and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00122970320456855<>ScoreDetail__5468|IGFALS|0.000393226670598933__11179|SOD1|0.00122970320456855__	0	0	0	0		0
15947	18312546	18854	20996	11179	SOD1	ALS	ALS	54	1.4	transgene for G93A mutant human superoxide dismutase-1 (SOD1) SOD1 (ALS ALS mice and non-transgenic littermates (control control mice performed immunohistochemical and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00122970320456855<>ScoreDetail__5468|IGFALS|0.000393226670598933__11179|SOD1|0.00122970320456855__	0	0	0	0		0
15951	18312546	18855	20996	11179	SOD1	ALS	ALS	20	1.4	significantly lower in the non-treated groups of presymptomatic and advanced ALS mice than in the non-treated groups of age-matched control mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00122970320456855<>ScoreDetail__5468|IGFALS|0.000393226670598933__11179|SOD1|0.00122970320456855__	0	0	0	0		0
15954	18312546	18855	20996	11179	SOD1	ALS	ALS	56	1.4	microglia were significantly higher in the non-treated group of advanced ALS mice than in the non-treated group of control mice and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00122970320456855<>ScoreDetail__5468|IGFALS|0.000393226670598933__11179|SOD1|0.00122970320456855__	0	0	0	0		0
19002	18370853	22358	20996	11179	SOD1	ALS	ALS	3	2.4	Amyotrophic lateral sclerosis (ALS) ALS is a late-onset progressive degeneration of motor neurons occurring both	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00227846138246539<>ScoreDetail__5468|IGFALS|0.000577151587166865__11179|SOD1|0.00227846138246539__	0	0	0	0		0
19003	18370853	22359	20996	11179	SOD1	ALS	ALS	3	2.4	The etiology of ALS remains unknown but one fifth of instances are due to	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00227846138246539<>ScoreDetail__5468|IGFALS|0.000577151587166865__11179|SOD1|0.00227846138246539__	0	0	0	0		0
19005	18370853	22360	20996	11179	SOD1	ALS	ALS	4	2.4	Because sporadic and familial ALS affect the same neurons with similar pathology it is hoped	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00227846138246539<>ScoreDetail__5468|IGFALS|0.000577151587166865__11179|SOD1|0.00227846138246539__	0	0	0	0		0
19007	18370853	22361	20996	11179	SOD1	ALS	ALS	22	2.4	mutant SOD1 which represent the best available models for familial ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00227846138246539<>ScoreDetail__5468|IGFALS|0.000577151587166865__11179|SOD1|0.00227846138246539__	0	0	0	0		0
20052	18397603	23527	20996	11179	SOD1	ALS	ALS	15	0.5	ubiquitin caspase and CDK5 expression in skeletal muscle of an ALS mouse model	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00116148231049488<>ScoreDetail__5468|IGFALS|0.0005161100051611__11179|SOD1|0.00116148231049488__	0	0	0	0		0
20053	18397603	23528	20996	11179	SOD1	ALS	ALS	19	0.5	altered in several neuromuscular diseases including amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00116148231049488<>ScoreDetail__5468|IGFALS|0.0005161100051611__11179|SOD1|0.00116148231049488__	0	0	0	0		0
20055	18397603	23530	9939	5464	IGF1	IGF1	Igf-1	9	0.0	We previously reported that muscle-restricted expression of a localized Igf-1 isoform maintained muscle integrity stabilized neuromuscular junctions reduced inflammation in	11		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
20066	18397603	23537	20996	11179	SOD1	ALS	ALS	22	0.5	the attenuation of muscle wasting in the mouse model of ALS disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00116148231049488<>ScoreDetail__5468|IGFALS|0.0005161100051611__11179|SOD1|0.00116148231049488__	0	0	0	0		0
10356	18425621	11987	20996	11179	SOD1	ALS	ALS	8	0.0	Objective Neuroinflammation contributes to motor neuron degeneration in ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000723351088314592<>ScoreDetail__5468|IGFALS|0.000723351088314592__11179|SOD1|0.000577648692549949__	0	0	0	0		0
10357	18425621	11988	21921	11791	TCHH	THL	THL	1	0.0	Thalidomide (THL) THL shows potent anti-inflammatory properties and increased the lifespan in ALS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
10358	18425621	11988	20996	11179	SOD1	ALS	ALS	11	0.0	THL shows potent anti-inflammatory properties and increased the lifespan in ALS transgenic mice	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000723351088314592<>ScoreDetail__5468|IGFALS|0.000723351088314592__11179|SOD1|0.000577648692549949__	0	0	0	0		0
10359	18425621	11989	21921	11791	TCHH	THL	THL	19	0.0	treatment of ALS.We conducted a pilot randomized clinical trial of THL in patients with ALS to assess safety feasibility and preliminary	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
10360	18425621	11989	20996	11179	SOD1	ALS	ALS	23	0.0	a pilot randomized clinical trial of THL in patients with ALS to assess safety feasibility and preliminary estimates of treatment efficacy	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000723351088314592<>ScoreDetail__5468|IGFALS|0.000723351088314592__11179|SOD1|0.000577648692549949__	0	0	0	0		0
10361	18425621	11990	21921	11791	TCHH	THL	THL	5	0.0	Methods Patients were randomized to THL in combination with riluzole (n n = 18 or riluzole	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
10362	18425621	11991	21921	11791	TCHH	THL	THL	0	0.0	THL was initiated at 100 mg per day for 6 weeks	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
10363	18425621	11993	21921	11791	TCHH	THL	THL	5	0.0	Results Within 12 weeks of THL treatment nine THL patients (50%) 50% developed bradycardia defined as	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
10364	18425621	11993	21921	11791	TCHH	THL	THL	8	0.0	Results Within 12 weeks of THL treatment nine THL patients (50%) 50% developed bradycardia defined as a heart rate	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
10365	18425621	11994	21921	11791	TCHH	THL	THL	8	0.0	Mean heart rate dropped by 17 bpm with THL treatment	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
10366	18425621	11999	21921	11791	TCHH	THL	THL	9	0.0	Conclusion Bradycardia was the most common adverse event of THL treatment in ALS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
10367	18425621	11999	20996	11179	SOD1	ALS	ALS	12	0.0	was the most common adverse event of THL treatment in ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000723351088314592<>ScoreDetail__5468|IGFALS|0.000723351088314592__11179|SOD1|0.000577648692549949__	0	0	0	0		0
10368	18425621	12000	21921	11791	TCHH	THL	THL-related	0	0.0	THL-related bradycardia does not appear to be ALS-specific	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
10369	18425621	12000	20996	11179	SOD1	ALS	ALS-specific	7	0.0	THL-related bradycardia does not appear to be ALS-specific	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000723351088314592<>ScoreDetail__5468|IGFALS|0.000723351088314592__11179|SOD1|0.000577648692549949__	0	0	0	0		0
10370	18425621	12001	21921	11791	TCHH	THL	THL-induced	11	0.0	is conceivable however that the unexpected frequency and severity of THL-induced bradycardia may be related to subclinical involvement of the autonomic	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
10371	18425621	12001	20996	11179	SOD1	ALS	ALS	25	0.0	related to subclinical involvement of the autonomic nervous system in ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000723351088314592<>ScoreDetail__5468|IGFALS|0.000723351088314592__11179|SOD1|0.000577648692549949__	0	0	0	0		0
10372	18425621	12002	21921	11791	TCHH	THL	THL	11	0.0	cardiac toxicity discourages further clinical trials and compassionate use of THL in ALS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
10373	18425621	12002	20996	11179	SOD1	ALS	ALS	13	0.0	discourages further clinical trials and compassionate use of THL in ALS	1		JUMiner_v2.2	1	0		0	2	5468	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:5468|IGFALS|0.000723351088314592<>ScoreDetail__5468|IGFALS|0.000723351088314592__11179|SOD1|0.000577648692549949__	0	0	0	0		0
10983	18436268	12688	20996	11179	SOD1	ALS	ALS	3	2.4	Amyotrophic lateral sclerosis (ALS) ALS is a neurodegenerative disease caused by selective degeneration of motor	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
10985	18436268	12689	20996	11179	SOD1	ALS	ALS	12	2.4	superoxide dismutase (SOD1) SOD1 account for 20% cases of familial ALS (fALS), fALS but the underlying pathogenetic mechanisms are largely unknown	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
10987	18436268	12690	20996	11179	SOD1	ALS	ALS	6	2.4	Using SOD1 G93A mice model of ALS we demonstrated that mutation in SOD1 caused a significant increase	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
10994	18436268	12694	24185	29175	WDTC1	ADP	ADP-ribose	14	0.2	treatment decreased the levels of cleaved caspase-3 and poly(ADP-ribose)polymerase poly ADP-ribose polymerase (PARP) PARP but up-regulated the level of anti-apoptotic protein	5		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
10995	18436268	12699	20996	11179	SOD1	ALS	ALS	3	2.4	Amyotrophic lateral sclerosis (ALS) ALS is the most frequently diagnosed form of adult-onset motor neuron	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
10996	18436268	12700	20996	11179	SOD1	ALS	ALS	0	2.4	ALS is characterized by the selective degeneration of lower and upper	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
10997	18436268	12701	20996	11179	SOD1	ALS	ALS	4	2.4	Around 10% cases of ALS patients are autosomal dominant referred as fALS and 20% patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11000	18436268	12702	20996	11179	SOD1	ALS	ALS	21	2.4	neuron disease resembling the most clinical features of the human ALS which make them suitable for studying the pathogenesis of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11001	18436268	12702	20996	11179	SOD1	ALS	ALS	31	2.4	ALS which make them suitable for studying the pathogenesis of ALS ( Gurney et_amp_#xa0 al. 1994	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11003	18436268	12703	20996	11179	SOD1	ALS	ALS	20	2.4	the association of homocysteine (Hcy) Hcy and the development of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11006	18436268	12707	20996	11179	SOD1	ALS	ALS	46	2.4	Hcy may play an important role in the pathogenesis of ALS ( Chung et_amp_#xa0 al. 2003 and Sung et_amp_#xa0 al. 2002	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11008	18436268	12708	18723	10261	ROS1	ROS	ROS	20	0.0	factors such as TNF-_amp_#x3b1 and promoted reactive oxygen species (ROS) ROS as well as activated NMDA subtype of the glutamate receptors	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
11009	18436268	12709	20996	11179	SOD1	ALS	ALS	15	2.4	hypothesize that Hcy may be involved in the pathogenesis of ALS and lowering Hcy may be beneficial to this disease	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11011	18436268	12716	20996	11179	SOD1	ALS	ALS	24	2.4	and B12 treatment has clinical value for the treatment of ALS patients in the future	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11013	18436268	12722	22055	11764	TG	TGN	TgN	4	0.2	The colony of well-characterized TgN (SOD1 SOD1 G93A Gur transgenic males which resemble most clinical	5		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
11019	18436268	12759	19728	9075	SERPINF2	API	API	9	0.0	MS/MS MS MS system was a triple quadrupole mass spectrometer API 3000 instrument (ABI-SCIEX, ABI-SCIEX Toronto Canada equipped with Turbo Ionspray	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
11028	18436268	12788	19573	10691	SDS	SDS	SDS	10	0.0	40 _amp_#x3bc g of each sample was separated in 8% SDS gel transferred onto 0.45 _amp_#x3bc m PVDF membrane incubated with	1		JUMiner_v2.2	1	0		0	2	10691	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:10691|SDS|0.000488963397597094<>ScoreDetail__10691|SDS|0.000488963397597094__19440|SBDS|0.000312857868080233__	0	0	0	0		0
11029	18436268	12789	3778	10620	CCL21	ECL	ECL	35	0.0	Pierce IL USA and then protein bands were visualized using ECL (Pierce, Pierce IL USA	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
11034	18436268	12802	20996	11179	SOD1	ALS	ALS	9	2.4	SOD1 G93A mice usually recapitulated the clinical progression of ALS by displaying overt hind-limb disability at the age about 100	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11046	18436268	12822	20996	11179	SOD1	ALS	ALS	9	2.4	Inflammation plays an important role in the pathogenesis of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11072	18436268	12842	20996	11179	SOD1	ALS	ALS	29	2.4	prolong the lifespan by protecting motor neurons against apoptosis in ALS transgenic mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11073	18436268	12843	20996	11179	SOD1	ALS	ALS	11	2.4	The neuroprotective effects of FA or FA B12 treatment in ALS transgenic model may be related to their biological role in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11079	18436268	12846	20996	11179	SOD1	ALS	ALS	13	2.4	have showed that there might be association between Hcy and ALS the role of Hcy in ALS development is not well	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11080	18436268	12846	20996	11179	SOD1	ALS	ALS	19	2.4	association between Hcy and ALS the role of Hcy in ALS development is not well defined	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11081	18436268	12847	20996	11179	SOD1	ALS	ALS	21	2.4	level of cytokine which may contribute to the progression of ALS ( Holven et_amp_#xa0 al. 2006	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11090	18436268	12852	20996	11179	SOD1	ALS	ALS	42	2.4	which suggest that iNOS may contribute to the pathology of ALS and represent a valuable therapeutic target for the disease (	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11095	18436268	12855	20996	11179	SOD1	ALS	ALS	12	2.4	supports that the eventual process of motor neuron death in ALS may result from the activation of apoptotic pathways especially the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11099	18436268	12857	20996	11179	SOD1	ALS	ALS	6	2.4	Bcl-2 plays a prominent role in ALS pathogenesis which is involved in the oxidative stress and in	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11113	18436268	12865	20996	11179	SOD1	ALS	ALS	28	2.4	FA or FA B12 could provide anti-apoptotic effect in the ALS transgenic mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11116	18436268	12868	20996	11179	SOD1	ALS	ALS	29	2.4	lifespan accompanied by the attenuation of motor neuron loss in ALS transgenic mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11121	18436268	12871	20996	11179	SOD1	ALS	ALS	17	2.4	potential of FA or FA B12 for the treatment of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00180359344307603<>ScoreDetail__5468|IGFALS|0.000929775250879012__11179|SOD1|0.00180359344307603__	0	0	0	0		0
11940	18464922	14213	20996	11179	SOD1	ALS	ALS	4	1.1	Abstract Amyotrophic lateral sclerosis (ALS) ALS is a debilitating and one of the most common adult-onset	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
11941	18464922	14215	20996	11179	SOD1	ALS	ALS	0	1.1	ALS has an obscure cause and currently no effective treatment exists	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
11943	18464922	14216	20996	11179	SOD1	ALS	ALS	35	1.1	ability to block the neuropathological damage caused by inflammation in ALS and possibly in other neudegenerative diseases like Huntington's disease (HD)	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
11945	18464922	14218	20996	11179	SOD1	ALS	ALS	10	1.1	Therefore PPAR-_amp_#x003b3 agonists are thought to be neuroprotective in ALS and HD	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
11948	18464922	14219	20996	11179	SOD1	ALS	ALS	22	1.1	a PPAR-_amp_#x003b3 agonist in G93A SOD1 transgenic mouse model of ALS and found significant increase in survival of G93A SOD1 mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
11951	18464922	14220	20996	11179	SOD1	ALS	ALS	25	1.1	a new target for the development of therapeutic strategies for ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
11957	18464922	14223	20996	11179	SOD1	ALS	ALS	8	1.1	Therefore PPAR-_amp_#x003b3 is a possible target for ALS and HD as it functions as transcription factor that interacts	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
11960	18464922	14224	20996	11179	SOD1	ALS	ALS	9	1.1	In this review the role of PPAR-_amp_#x003b3 in ALS and HD is discussed based on the current literature and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
11985	18464922	14246	20996	11179	SOD1	ALS	ALS	16	1.1	be neurotoxic in models of neurodegenerative diseases for example in ALS 28 _amp_#x02013 30	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
11993	18464922	14255	20996	11179	SOD1	ALS	ALS	17	1.1	b schematic diagrams linking mechanisms of neuronal cell death in ALS and a representation of PPAR-_amp_#x003b3 activation	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
11995	18464922	14256	20996	11179	SOD1	ALS	ALS	9	1.1	The mechanisms and pathways implicated in the pathogenesis of ALS that lead to the demise of motor (more more ...	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
11997	18464922	14259	20996	11179	SOD1	ALS	ALS	3	1.1	Amyotrophic lateral sclerosis (ALS) ALS is a devastating fatal neurodegenerative disorder characterized by a loss	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
11998	18464922	14260	20996	11179	SOD1	ALS	ALS	10	1.1	Oxidative stress mitochondrial dysfunction and neuroinflammation have been implicated in ALS pathogenesis ( Figure 1(b) 1 b	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12001	18464922	14261	20996	11179	SOD1	ALS	ALS	16	1.1	may be a major signaling pathway involved in neuroinflammation in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12003	18464922	14262	20996	11179	SOD1	ALS	ALS	21	1.1	and promising approach to understand the mechanism of neuroinflammation in ALS ( Figure 1(b) 1 b	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12004	18464922	14263	20996	11179	SOD1	ALS	ALS	10	1.1	Since neuroinflammatory pathway has become one of the hallmarks of ALS 29 33 34 therefore blockage of neuroinflammation is of great	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12005	18464922	14263	20996	11179	SOD1	ALS	ALS	32	1.1	is of great interest because of the potential efficacy in ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12012	18464922	14265	20996	11179	SOD1	ALS	ALS	31	1.1	and are indispensable to study the role of PPAR-_amp_#x003b3 in ALS which may potentially lead to beneficial effects in ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12013	18464922	14265	20996	11179	SOD1	ALS	ALS	40	1.1	in ALS which may potentially lead to beneficial effects in ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12016	18464922	14269	20996	11179	SOD1	ALS	ALS	4	1.1	PIOGLITAZONE IS NEUROPROTECTIVE IN ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12018	18464922	14270	20996	11179	SOD1	ALS	ALS	15	1.1	effect of pioglitazone in transgenic G93A SOD1 mouse model of ALS and showed that pioglitazone treatment improved motor performance delayed weight	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12019	18464922	14270	20996	11179	SOD1	ALS	ALS	40	1.1	loss and significantly increased survival by delaying the onset of ALS 38	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12024	18464922	14273	20996	11179	SOD1	ALS	ALS	21	1.1	of pioglitazone treatment in G93A SOD1 transgenic mouse model of ALS 39	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12026	18464922	14274	20996	11179	SOD1	ALS	ALS	15	1.1	agonist treatment improved survival muscle strength and weight loss in ALS mice	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12042	18464922	14287	20996	11179	SOD1	ALS	ALS	16	1.1	neuroprotective role of PPAR-_amp_#x003b3 agonist in transgenic mouse model of ALS and other experimental animal models could potentially be a foundation	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12044	18464922	14287	20996	11179	SOD1	ALS	ALS	52	1.1	their role in protecting motor neurons from inflammatory damages in ALS ( Figure 1(b) 1 b	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12048	18464922	14288	20996	11179	SOD1	ALS	ALS	40	1.1	will provide crucial insights on the role of PPAR-_amp_#x003b3 in ALS and other neurodegenerative diseases	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12049	18464922	14290	20996	11179	SOD1	ALS	ALS	3	1.1	MITOCHONDRIAL DYSFUNCTION IN ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12050	18464922	14291	20996	11179	SOD1	ALS	ALS	3	1.1	Mitochondrial compromise in ALS is substantiated by reports of changes in their structure number	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12051	18464922	14291	20996	11179	SOD1	ALS	ALS	26	1.1	in motor neurons and skeletal muscle in familial and sporadic ALS patients 42	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12052	18464922	14292	20996	11179	SOD1	ALS	ALS	12	1.1	reported the potential involvement of mitochondria in the pathogenesis of ALS as mitochondrial abnormalities were found in proximal axons anterior horn	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12053	18464922	14292	20996	11179	SOD1	ALS	ALS	24	1.1	mitochondrial abnormalities were found in proximal axons anterior horn of ALS spinal cords 43	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12054	18464922	14293	20996	11179	SOD1	ALS	ALS	16	1.1	have been detected in postmortem muscle and spinal cord of ALS patients	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12057	18464922	14295	20996	11179	SOD1	ALS	ALS	16	1.1	mice overexpressing human G93A SOD1 that display most of the ALS symptoms and pathologies have mitochondrial dysfunction	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12058	18464922	14298	20996	11179	SOD1	ALS	ALS	11	1.1	observations suggest that mitochondrial abnormalities may trigger the onset of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12070	18464922	14305	20996	11179	SOD1	ALS	ALS	27	1.1	predict that PGC-1 _amp_#x003b1 could play an important role in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12072	18464922	14306	20996	11179	SOD1	ALS	ALS	10	1.1	Impairment of PGC-1 _amp_#x003b1 could contribute to mitochondrial dysfunction in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12074	18464922	14307	20996	11179	SOD1	ALS	ALS	22	1.1	_amp_#x003b1 or its expression in the transgenic mouse model of ALS or human ALS postmortem tissues	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12075	18464922	14307	20996	11179	SOD1	ALS	ALS	25	1.1	expression in the transgenic mouse model of ALS or human ALS postmortem tissues	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12076	18464922	14308	20996	11179	SOD1	ALS	ALS	13	1.1	reports on the altered or impaired expression of genes in ALS that some of them fit in the PGC-1 _amp_#x003b1 target	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12079	18464922	14308	20996	11179	SOD1	ALS	ALS	45	1.1	be a prominent role for PGC-1 _amp_#x003b1 translational machinery in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12088	18464922	14310	20996	11179	SOD1	ALS	ALS	32	1.1	impair PGC-1 _amp_#x003b1 and expression of its target genes in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12093	18464922	14312	20996	11179	SOD1	ALS	ALS	9	1.1	Future studies on PGC-1 _amp_#x003b1 and PPAR-_amp_#x003b3 in ALS patients and transgenic mice will shed some lights on these	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12108	18464922	14323	1489	932	BAAT	BAT	BAT	24	0.0	found to be disrupted in the brown adipose tissue (BAT) BAT of HD transgenic mice	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
12109	18464922	14326	1489	932	BAAT	BAT	BAT	2	0.0	In rodents BAT is the tissue that responds to cold	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
12156	18464922	14373	20996	11179	SOD1	ALS	ALS	6	1.1	The role of PPAR-_amp_#x003b3 in ALS AD and Parkinson's disease are backed with evidence 19 20	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12171	18464922	14383	20996	11179	SOD1	ALS	ALS	20	1.1	in neurodegenerative diseases in particular in a mouse model of ALS and HD	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12172	18464922	14384	20996	11179	SOD1	ALS	ALS	9	1.1	The utilization of pioglitazone in a mouse model of ALS by two independent studies provides strong indication for the involvement	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12174	18464922	14384	20996	11179	SOD1	ALS	ALS	24	1.1	studies provides strong indication for the involvement of PPAR-_amp_#x003b3 in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12178	18464922	14386	20996	11179	SOD1	ALS	ALS	20	1.1	which PPAR-_amp_#x003b3 agonists produce neuroprotection in a mouse model of ALS and test whether PPAR-_amp_#x003b3 has a role in HD	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12182	18464922	14388	20996	11179	SOD1	ALS	ALS	18	1.1	to determine the effect of PPAR-_amp_#x003b3 agonist on muscles in ALS and HD mouse models	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12184	18464922	14389	20996	11179	SOD1	ALS	ALS	20	1.1	studies are necessary in determining the role of PPAR-_amp_#x003b3 in ALS and HD	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12190	18464922	14393	20996	11179	SOD1	ALS	ALS	11	1.1	lack of report on the role of PGC-1 _amp_#x003b1 in ALS is a limiting step on the hypothesis that PGC-1 _amp_#x003b1	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12192	18464922	14393	20996	11179	SOD1	ALS	ALS	31	1.1	_amp_#x003b1 could be a target of investigation or therapeutic for ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12193	18464922	14394	20996	11179	SOD1	ALS	ALS	5	1.1	Mitochondria have been implicated in ALS and PGC-1 _amp_#x003b1 has possible role in mitochondrial biogenesis therefore	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12196	18464922	14394	20996	11179	SOD1	ALS	ALS	28	1.1	be informative to examine mitochondrial abnormalities and PGC-1 _amp_#x003b1 in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12201	18464922	14395	20996	11179	SOD1	ALS	ALS	30	1.1	_amp_#x003b1 in connection with PPAR-_amp_#x003b3 could play some role in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000878787222981725<>ScoreDetail__5468|IGFALS|0.000465213801779607__11179|SOD1|0.000878787222981725__	0	0	0	0		0
12287	18464925	14411	9947	5468	IGFALS	ALS	ALS	4	0.3	In amyotrophic lateral sclerosis (ALS) ALS and Parkinson's disease animal models the TZD pioglitazone ameliorated the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00050067446478045<>ScoreDetail__5468|IGFALS|0.000328025032588574__11179|SOD1|0.00050067446478045__	0	0	0	0		0
12361	18464925	14498	14639	7968	NR1I2	PRR	PRRs	20	0.6	they express several_amp_#x02014 though fewer than microglia_amp_#x02014 pattern-recognition receptors (PRRs) PRRs such as for example the Toll-like receptors and release cytokines	13		JUMiner_v2.2	1	2	UserEdit	0	2	7968	TotalCon:2<>9706|PVRL1|5818|Complete__7968|NR1I2|8856|Complete__<>AvaiableGeneRif=2<>BEST:7968|NR1I2|0.000541958385455212<>ScoreDetail__7968|NR1I2|0.000541958385455212__9706|PVRL1|0.000392674626390011__	1	1	0	0		0
12383	18464925	14519	10676	6121	IRF6	LPS	LPS-stimulated	34	0.3	expression of the inducible enzymes iNOS and COX2 induced in LPS-stimulated astrocyte and microglial cultures 58	11		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
12394	18464925	14523	18723	10261	ROS1	ROS	ROS	37	0.0	by a PPAR-_amp_#x003b3 independent mechanism which required the presence of ROS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
12401	18464925	14526	10676	6121	IRF6	LPS	LPS	6	0.3	They found that in primary astrocytes LPS induced the production of IL-12p40 IL-23 and IL-27p28 proteins which	11		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
12408	18464925	14528	22088	15934	TH1L	TH1	Th1	38	0.0	Th2 type cytokine which plays an important role in controlling Th1 cell responses and resolution of inflammation	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
12431	18464925	14552	10676	6121	IRF6	LPS	LPS	67	0.3	accumulation in the murine BV-2 microglial cell line stimulated by LPS	11		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
12438	18464925	14555	10676	6121	IRF6	LPS	LPS	44	0.3	is reduced in the presence of microglial activators such as LPS and IFN-_amp_#x003b3	11		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
12441	18464925	14557	10676	6121	IRF6	LPS	LPS-induced	12	0.3	BV-2 cell line in primary microglial cultures 15d-PGJ 2 prevented LPS-induced iNOS expression and TNF-_amp_#x003b1 production as well as IFN-_amp_#x003b3 -induced	11		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
12449	18464925	14557	10676	6121	IRF6	LPS	LPS	57	0.3	and NF-_amp_#x003ba B which are known to mediate IFN-_amp_#x003b3 and LPS signaling 76	11		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
12452	18464925	14559	10676	6121	IRF6	LPS	LPS	22	0.3	primary microglia and mouse cell line N9 activated either by LPS alone or in combination with IFN-_amp_#x003b3 or TNF-_amp_#x003b1 63 77	11		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
12456	18464925	14560	10676	6121	IRF6	LPS	LPS-induced	12	0.3	cortical mixed neuron-glial cultures 15d-PGJ 2 ciglitazone and troglitazone prevented LPS-induced neuronal death suggesting a PPAR-_amp_#x003b3 mediated mechanism of neuroprotection 79	11		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
12463	18464925	14564	22227	5057	TLX2	NCX	NCX	1	0.0	Interestingly NCX 2216 after an initial activation induced PPAR-_amp_#x003b3 nitration and inactivation	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
12466	18464925	14565	22227	5057	TLX2	NCX	NCX	37	0.0	dynamic regulation of the functional state of activated microglia by NCX 2216	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
12468	18464925	14566	22227	5057	TLX2	NCX	NCX	3	0.0	Long treatment with NCX 2216 could therefore lead after an initial activation of PPAR-_amp_#x003b3	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
12470	18464925	14567	22227	5057	TLX2	NCX	NCX	28	0.0	by 81 only in the case of protracted administration of NCX 2216 in an AD animal model the reduction of cerebral	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
12473	18464925	14569	10676	6121	IRF6	LPS	LPS-stimulated	29	0.3	lower than those required for PPAR-_amp_#x003b3 activation effectively reduced the LPS-stimulated production of PGJ 2 by directly preventing the enzymatic activity	11		JUMiner_v2.2	1	2	lipopolysaccharide	0	1	0	TotalCon:2<>12728|VWS||No_GeneRif__6121|IRF6|3664|Complete__<>AvaiableGeneRif=1<>	0	0	0	0		0
12484	18464925	14584	1184	746	ASL	ASL	ASL	10	0.0	The clinical use of PPAR-_amp_#x003b3 agonists in MS and ASL remains poorly investigated	1		JUMiner_v2.2	1	0		0	2	291	TotalCon:2<>746|ASL|435|Complete__291|ADSL|158|Complete__<>AvaiableGeneRif=2<>BEST:291|ADSL|0.000516212447956619<>ScoreDetail__291|ADSL|0.000516212447956619__746|ASL|0.000364373752415956__	0	0	0	0		0
12485	18464925	14586	9947	5468	IGFALS	ALS	ALS	10	0.3	A first clinical trial for the use of pioglitazone in ALS started in Germany in late 2007	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.00050067446478045<>ScoreDetail__5468|IGFALS|0.000328025032588574__11179|SOD1|0.00050067446478045__	0	0	0	0		0
2523	18513389	3474	20996	11179	SOD1	ALS	ALS	13	2.5	predisposing to the sporadic form of amyotrophic lateral sclerosis (ALS) ALS have been identified but the pathology itself seems to be	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2524	18513389	3476	20996	11179	SOD1	ALS	ALS	37	2.5	coagulation inflammation cellular adhesion and matrix integrity in 54 sporadic ALS patients and 208 controls	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2525	18513389	3481	20996	11179	SOD1	ALS	ALS	10	2.5	An unexpected discovery of a strong genetic background in sporadic ALS using a DNA multiarray panel and analytical processing of the	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2526	18513389	3486	20996	11179	SOD1	ALS	ALS	18	2.5	method offers a new insight into genetic markers of sporadic ALS pointing out the existence of a strong genetic background	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2527	18513389	3488	20996	11179	SOD1	ALS	ALS	3	2.5	Amyotrophic lateral sclerosis (ALS), ALS the most common form of motoneuron disease is a relatively	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2529	18513389	3491	20996	11179	SOD1	ALS	ALS	4	2.5	Genetic risk factors for ALS have been extensively studied and some major genes in addition	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2531	18513389	3492	20996	11179	SOD1	ALS	ALS	10	2.5	There are now at least six dominant inherited adult onset ALS genes of which only three have been identified so far	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2532	18513389	3493	20996	11179	SOD1	ALS	ALS	2	2.5	However most ALS cases seem to be a typical multifactorial disease deriving from	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2533	18513389	3496	20996	11179	SOD1	ALS	ALS	9	2.5	Among the genetic factors that may predispose to sporadic ALS neurofilaments apolipoprotein epsilon 4 genotype excitotoxicity genes ciliary neurotrophic factor	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2538	18513389	3499	20996	11179	SOD1	ALS	ALS	27	2.5	have identified SNPs (single single nucleotide polymorphisms potentially associated with ALS 13 -16	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2539	18513389	3502	20996	11179	SOD1	ALS	ALS	11	2.5	so far no microarrays panel has been specifically developed for ALS and the aetiology of the disease still remains to be	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2540	18513389	3509	20996	11179	SOD1	ALS	ALS	36	2.5	disease prompted us to employ the same approach also in ALS hoping to discover specific genetic patterns underlying the sporadic form	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2541	18513389	3510	20996	11179	SOD1	ALS	ALS	18	2.5	in genes that could be involved in the pathogenesis of ALS disease since it has been demonstrated that inflammation cellular adhesion	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2542	18513389	3511	20996	11179	SOD1	ALS	ALS	24	2.5	homocysteine metabolism and matrix integrity pathways are directly linked to ALS even though they could be indirectly	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2543	18513389	3512	20996	11179	SOD1	ALS	ALS	2	2.5	Genotyping of ALS cases and controls was performed	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2544	18513389	3516	20996	11179	SOD1	ALS	ALS	19	2.5	origin belonging to Italian ancestry and consisted of 54 sporadic ALS (SALS) SALS patients and 208 control subjects	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2545	18513389	3517	20996	11179	SOD1	ALS	ALS	3	2.5	Diagnostic Criteria for ALS disease were based on the World Federation of Neurology El	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2546	18513389	3518	20996	11179	SOD1	ALS	ALS	10	2.5	All patients diagnosed to have Definite Probable or Probably laboratory-supported ALS who gave their informed consent were included in the study	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2547	18513389	3519	20996	11179	SOD1	ALS	ALS	4	2.5	The diagnosis of Possible ALS was also accepted	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2549	18513389	3523	20996	11179	SOD1	ALS	ALS	10	2.5	We checked the absence of personal and familial history of ALS in this group through direct interview	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2577	18513389	3527	19725	8583	SERPINE1	PAI	PAI	102	0.0	FV arg506gln FVII -230 10 bp del/ins, del ins arg353glu PAI -675 G5/G4, G5 G4 11053 G/T, G T FGB -455	1		JUMiner_v2.2	1	0		0	2	8583	TotalCon:2<>8583|SERPINE1|5054|Complete__8584|SERPINB2|5055|Complete__<>AvaiableGeneRif=2<>BEST:8583|SERPINE1|0.000382406265260087<>ScoreDetail__8584|SERPINB2|0.000351017000607165__8583|SERPINE1|0.000382406265260087__	0	0	0	0		0
2578	18513389	3527	10717	6137	ITGA2	ITGA2	ITGA2	110	0.0	G4 11053 G/T, G T FGB -455 G/A, G A ITGA2 873 G/A, G A ITGB3 leu33pro SELE ser128arg leu554phe ICAM	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
2581	18513389	3529	20996	11179	SOD1	ALS	ALS	1	2.5	All ALS subjects were screened for SOD1 mutation through PCR amplification and	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2586	18513389	3533	20996	11179	SOD1	ALS	ALS	6	2.5	The association of these variables with ALS status was tested by ANNs and the results were compared	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2587	18513389	3568	23261	10539	TSPAN31	SAS	SAS	6	0.0	For the analysis of LDA the SAS version 6.04 (SAS SAS Institute Cary NC USA using forward	1		JUMiner_v2.2	1	0		0	2	19237	TotalCon:2<>10539|TSPAN31|6302|Complete__19237|NANS|54187|Complete__<>AvaiableGeneRif=2<>BEST:19237|NANS|0.000559255464480874<>ScoreDetail__10539|TSPAN31|0.000204918032786885__19237|NANS|0.000559255464480874__	0	0	0	0		0
2588	18513389	3568	23261	10539	TSPAN31	SAS	SAS	9	0.0	For the analysis of LDA the SAS version 6.04 (SAS SAS Institute Cary NC USA using forward stepwise procedure was employed	1		JUMiner_v2.2	1	0		0	2	19237	TotalCon:2<>10539|TSPAN31|6302|Complete__19237|NANS|54187|Complete__<>AvaiableGeneRif=2<>BEST:19237|NANS|0.000559255464480874<>ScoreDetail__10539|TSPAN31|0.000204918032786885__19237|NANS|0.000559255464480874__	0	0	0	0		0
2589	18513389	3574	23447	12428	TWIST1	TWIST	TWIST	2	1.0	-Optimized criterion TWIST system The TWIST system is an ensemble of two algorithms	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2590	18513389	3574	23447	12428	TWIST1	TWIST	TWIST	5	1.0	-Optimized criterion TWIST system The TWIST system is an ensemble of two algorithms Training and Testing	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2591	18513389	3617	12382	7142	MARCKSL1	MLP	MLPs	4	0.0	Two independent Multilayers Perceptrons (MLPs) MLPs with 4 hidden units are trained for 100 epochs and	13		JUMiner_v2.2	1	0		0	2	7512	TotalCon:3<>7142|MARCKSL1|65108|Complete__2472|CSRP3|8048|Complete__7512|MUC2|4583|Complete__<>AvaiableGeneRif=3<>BEST:7512|MUC2|0.000283227263687246<>ScoreDetail__2472|CSRP3|0.000157103825136612__7512|MUC2|0.000283227263687246__7142|MARCKSL1|9.31445603576751e-05__	0	0	0	0		0
2592	18513389	3618	12382	7142	MARCKSL1	MLP	MLPs	10	0.0	A function of the testing results of the two independent MLPs defines the fitness of each individual	13		JUMiner_v2.2	1	0		0	2	7512	TotalCon:3<>7142|MARCKSL1|65108|Complete__2472|CSRP3|8048|Complete__7512|MUC2|4583|Complete__<>AvaiableGeneRif=3<>BEST:7512|MUC2|0.000283227263687246<>ScoreDetail__2472|CSRP3|0.000157103825136612__7512|MUC2|0.000283227263687246__7142|MARCKSL1|9.31445603576751e-05__	0	0	0	0		0
2593	18513389	3624	4850	2300	CPB2	CPU	CPU	13	0.0	algorithms in C language and we used a Pentium III CPU to run the system on real data	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
2596	18513389	3645	23447	12428	TWIST1	TWIST	TWIST	2	1.0	With the TWIST approach every experiment was conducted in a blind and independent	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2597	18513389	3645	23447	12428	TWIST1	TWIST	TWIST	46	1.0	sub-sample A The results from the best five applications of TWIST procedures are reported in Table 4	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2598	18513389	3647	23447	12428	TWIST1	TWIST	TWIST	3	1.0	In all the TWIST system experiments the 90% overall accuracy threshold was exceeded whereas	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2599	18513389	3649	23447	12428	TWIST1	TWIST	TWIST	6	1.0	Genetic variants selected by the five TWIST procedures Seven genetic variants were always independently selected by the	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2600	18513389	3649	23447	12428	TWIST1	TWIST	TWIST	18	1.0	Seven genetic variants were always independently selected by the five TWIST procedures apolipoprotein E (APOE) APOE (chromosome chromosome 19q13.2 arg158cys hepatic	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2605	18513389	3649	10717	6137	ITGA2	ITGA2	ITGA2	55	0.0	F7 (chromosome chromosome 13q34 arg353glu glycoprotein Ia/IIa Ia IIa (ITGA2) ITGA2 (chromosome chromosome 5q23-q31 873 G/A; G A E-selectin (SELE) SELE	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
2606	18513389	3652	23447	12428	TWIST1	TWIST	TWIST	6	1.0	Genetic variants independently selected by four TWIST procedures The number of genetic variants selected four times over	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2619	18513389	3654	23447	12428	TWIST1	TWIST	TWIST	6	1.0	First it was selected by four TWIST systems and later since the information linked to such a	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2620	18513389	3654	23447	12428	TWIST1	TWIST	TWIST	24	1.0	to such a variation was already recruited none of the TWIST systems selected this SNP	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2621	18513389	3655	23447	12428	TWIST1	TWIST	TWIST	6	1.0	Genetic variants never selected by any TWIST procedures The following gene/genetic gene genetic variants were never selected	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2622	18513389	3655	23447	12428	TWIST1	TWIST	TWIST	18	1.0	gene/genetic gene genetic variants were never selected by the five TWIST procedures apolipoprotein A4 (APOA4) APOA4 (chromosome chromosome 11q23 thr347ser apolipoprotein	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2635	18513389	3657	20996	11179	SOD1	ALS	ALS	5	2.5	The mechanism of neurodegeneration in ALS remains an enigma	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2636	18513389	3661	20996	11179	SOD1	ALS	ALS	24	2.5	these new analytical tools shows that even in so-called sporadic ALS the genetic background plays a fundamental role	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2637	18513389	3662	20996	11179	SOD1	ALS	ALS	13	2.5	in approaching the molecular basis of a rare disease like ALS in a conventional manner is related to the difficulty of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2638	18513389	3669	20996	11179	SOD1	ALS	ALS	18	2.5	allelic variants that are likely to produce accurate predictions of ALS for a single individual regardless of some possible limitations such	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2639	18513389	3670	20996	11179	SOD1	ALS	ALS	13	2.5	more than 50 medical cases with an accurate diagnosis of ALS and we were able to test them for 69 SNPs	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2640	18513389	3672	20996	11179	SOD1	ALS	ALS	2	2.5	Besides all ALS patients were previously screened for SOD1 gene mutations with negative	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2644	18513389	3676	23447	12428	TWIST1	TWIST	TWISTs	9	1.0	Indeed ApoE arg158cys was selected by all the five TWISTs while the ApoE cys112arg was selected only once	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2647	18513389	3677	23447	12428	TWIST1	TWIST	TWISTs	37	1.0	in position 698 were both selected by all the five TWISTs	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2651	18513389	3679	20996	11179	SOD1	ALS	ALS	8	2.5	The role of the paroxonase in predisposing to ALS disease appears to be confirmed PON1 met 55leu and PON2	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2655	18513389	3680	20996	11179	SOD1	ALS	ALS	16	2.5	we can assume a generic role of this receptor on ALS disease since PPAR_amp_#x003b3 is at the crossroads between lipid metabolism	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2658	18513389	3681	20996	11179	SOD1	ALS	ALS	28	2.5	for hemocromatosis and the peripherin gene both previously involved in ALS disease 35	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2659	18513389	3682	23447	12428	TWIST1	TWIST	TWIST	10	1.0	Few genetic variants were never selected by any of the TWIST procedures	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2665	18513389	3685	20996	11179	SOD1	ALS	ALS	10	2.5	Indeed a very recent paper on genome wide genotyping in ALS 13 found no SNPs associated with the disease on chromosome	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2671	18513389	3689	20996	11179	SOD1	ALS	ALS	21	2.5	the misfolding protein aggregations in several neurodegenerative diseases including familial ALS 36	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2672	18513389	3693	20996	11179	SOD1	ALS	ALS	10	2.5	We analysed genetic variables within genes possibly involved in the ALS disease and thanks to artificial intelligence agents such as those	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2673	18513389	3693	20996	11179	SOD1	ALS	ALS	42	2.5	genetic data only we were are able to conveniently differentiate ALS cases from control subjects	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2674	18513389	3695	20996	11179	SOD1	ALS	ALS	33	2.5	this study offers new insight into genetic markers of sporadic ALS pointing out the existence of a strong genetic background	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2675	18513389	3696	20996	11179	SOD1	ALS	ALS	17	2.5	future research on the complexity of the genetic profile of ALS subjects	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000764651968728075<>ScoreDetail__5468|IGFALS|0.00070002310755889__11179|SOD1|0.000764651968728075__	0	0	0	0		0
2676	18513389	3706	23447	12428	TWIST1	TWIST	TWIST	8	1.0	Table 4 Results of ten experiment obtained applying TWIST procedure in an independent manner to the whole dataset	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
2677	18513389	3707	23447	12428	TWIST1	TWIST	TWIST	14	1.0	with ANNs using only the seven genetic variants selected by TWIST procedure	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5026	18539342	5531	11629	6493	LAMC2	CSF	CSF	12	0.3	CPs could represent a site for lymphocyte entry in the CSF and for CSF antigens presentation	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5027	18539342	5531	11629	6493	LAMC2	CSF	CSF	15	0.3	a site for lymphocyte entry in the CSF and for CSF antigens presentation	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5028	18539342	5534	11629	6493	LAMC2	CSF	CSF	23	0.3	parenchyma such as the leptomeninges and the cerebrospinal fluid (CSF), CSF in the pathogenetic process of multiple sclerosis (MS) MS and	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5029	18539342	5535	11629	6493	LAMC2	CSF	CSF	33	0.3	CNS and as a link for antigen trafficking between the CSF and the peripheral blood ( Nathanson and Chun 1989 Kivis_amp_#xe4	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5030	18539342	5539	11629	6493	LAMC2	CSF	CSF	8	0.3	The CP is in close contact with the CSF the CP epithelial cells (constituting constituting the blood_amp_#x2013 CSF barrier	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5031	18539342	5539	11629	6493	LAMC2	CSF	CSF	15	0.3	the CSF the CP epithelial cells (constituting constituting the blood_amp_#x2013 CSF barrier form an interface between CSF and periphery since their	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5032	18539342	5539	11629	6493	LAMC2	CSF	CSF	21	0.3	(constituting constituting the blood_amp_#x2013 CSF barrier form an interface between CSF and periphery since their apical side faces the CSF and	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5033	18539342	5539	11629	6493	LAMC2	CSF	CSF	30	0.3	between CSF and periphery since their apical side faces the CSF and their basal side facing fenestrated capillaries has access to	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5034	18539342	5540	11629	6493	LAMC2	CSF	CSF	17	0.3	of the main routes of entry of lymphocytes in the CSF for routine immune surveillance in the normal brain ( Kivis_amp_#xe4	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5035	18539342	5541	11629	6493	LAMC2	CSF	CSF	18	0.3	of the CP could be to scavenge antigens from the CSF acting as an immunological link between CSF and blood (	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5036	18539342	5541	11629	6493	LAMC2	CSF	CSF	25	0.3	antigens from the CSF acting as an immunological link between CSF and blood ( Nathanson and Chun 1989	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5037	18539342	5546	20996	11179	SOD1	ALS	ALS	65	0.0	6 brains from patients affected by amyotrophic lateral sclerosis (ALS), ALS a non-inflammatory neurological disease	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5038	18539342	5548	20996	11179	SOD1	ALS	ALS	22	0.0	in control cases 59.4_amp_#xa0 years (range range 52_amp_#x2013 68 in ALS cases	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5047	18539342	5566	19329	10524	SALL1	TBS	TBS	3	0.0	After washing with TBS the sections were incubated at room temperature for 30_amp_#xa0 min	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
5050	18539342	5571	23936	12693	VIP	VIP	VIP	29	0.0	normal serum and peroxidase labeling for HLA-DR was visualized with VIP red (Vector Vector Laboratories Burlingame USA	1		JUMiner_v2.2	1	0		0	2	23228	TotalCon:2<>12693|VIP|7432|Complete__23228|CPAMD8|27151|Complete__<>AvaiableGeneRif=2<>BEST:23228|CPAMD8|0.000974870017331023<>ScoreDetail__23228|CPAMD8|0.000974870017331023__12693|VIP|0.000559874556408352__	0	0	0	0		0
5056	18539342	5583	20996	11179	SOD1	ALS	ALS	11	0.0	the number of epiplexus cells between MS brains and ALS/control ALS control brains were assessed with a two-tailed T test using	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5057	18539342	5596	20996	11179	SOD1	ALS	ALS	21	0.0	on routine hematoxylin_amp_#x2013 eosin staining if compared to viral encephalitis ALS or control brains	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5058	18539342	5600	20996	11179	SOD1	ALS	ALS	18	0.0	0.71 cells/field, cells field range 0.2_amp_#x2013 1.4 if compared to ALS and control brains (mean mean 0.06 cells/field, cells field range	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5059	18539342	5610	11629	6493	LAMC2	CSF	CSF	12	0.3	staining was also observed on epiplexus cells apposed to the CSF side of the CP epithelium ( Fig 1 E	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5060	18539342	5612	20996	11179	SOD1	ALS	ALS	1	0.0	In ALS brains and in normal controls only extremely rare HLA-DR positive	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5066	18539342	5618	20996	11179	SOD1	ALS	ALS	12	0.0	rare CD68 stained cells were observed in the CP in ALS or control brains these were mainly round cells in the	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5075	18539342	5629	20996	11179	SOD1	ALS	ALS	11	0.0	CD3 positive T cell was detected in the CP in ALS brains and in normal controls	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5082	18539342	5638	20996	11179	SOD1	ALS	ALS	9	0.0	No VCAM-1 immunostaining was detected in the CP in ALS brains and in normal controls ( Fig 3 G	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5086	18539342	5642	20996	11179	SOD1	ALS	ALS	8	0.0	No CD138 stained cells were observed in encephalitis ALS and control brains	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5087	18539342	5646	20996	11179	SOD1	ALS	ALS	37	0.0	of patients affected by other neurological diseases either non-inflammatory (ALS) ALS or due to direct viral etiology (acute acute viral encephalitis	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5093	18539342	5658	11629	6493	LAMC2	CSF	CSF	14	0.3	are known to actively gather proteins and metabolites from the CSF and remove them in the peripheral blood ( Nathanson and	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5094	18539342	5658	11629	6493	LAMC2	CSF	CSF	42	0.3	in the CP stroma could be therefore well-suited to detect CSF antigens and to present them to peripheral lymphocytes	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5095	18539342	5659	872	583	APC	APC	APCs	21	0.0	express the necessary costimulatory molecules to act as fully capable APCs	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
5096	18539342	5660	872	583	APC	APC	APCs	6	0.0	It has been hypothesized that the APCs present in the CP after antigen uptake might migrate in	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
5100	18539342	5665	11629	6493	LAMC2	CSF	CSF	12	0.3	might be involved in the scavenging of antigens from the CSF and in the production of cytokines chemokines and nitric oxide	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5101	18539342	5665	11629	6493	LAMC2	CSF	CSF	24	0.3	in the production of cytokines chemokines and nitric oxide whose CSF levels are increased in MS patients ( Eng-Ang et al.	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5104	18539342	5667	11629	6493	LAMC2	CSF	CSF	19	0.3	monocytes on the route from the peripheral blood to the CSF or intraventricular macrophages on the route from the CSF to	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5105	18539342	5667	11629	6493	LAMC2	CSF	CSF	28	0.3	the CSF or intraventricular macrophages on the route from the CSF to the peripheral blood ( Eng-Ang et al. 1998	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5107	18539342	5668	20996	11179	SOD1	ALS	ALS	26	0.0	the MS brains while these were not observed in encephalitis ALS and control brains	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5112	18539342	5673	11629	6493	LAMC2	CSF	CSF	35	0.3	of the CP for the passage of lymphocyte in the CSF in MS The cellular composition of the CSF in MS	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5113	18539342	5673	11629	6493	LAMC2	CSF	CSF	43	0.3	in the CSF in MS The cellular composition of the CSF in MS does not correspond to that of the peripheral	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5114	18539342	5673	11629	6493	LAMC2	CSF	CSF	64	0.3	blood suggesting an active regulation of leukocyte trafficking in the CSF ( Engelhardt and Ransohoff 2005	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5115	18539342	5674	11629	6493	LAMC2	CSF	CSF	4	0.3	Abnormalities found in MS CSF include increased percentage of T cells higher CD4/CD8 CD4 CD8	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5118	18539342	5674	11629	6493	LAMC2	CSF	CSF	52	0.3	B cells and antibody-secreting cells can be found in the CSF of MS patients ( Corcione et al. 2005 Pedemonte et	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5120	18539342	5675	11629	6493	LAMC2	CSF	CSF	12	0.3	of VCAM-1 in this route of lymphocyte entry in the CSF is underscored by the recent observations that therapy with natalizumab	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5122	18539342	5675	11629	6493	LAMC2	CSF	CSF	42	0.3	a considerable reduction of the number of lymphocytes in the CSF ( St_amp_#xfc ve et al. 2006	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5123	18539342	5676	11629	6493	LAMC2	CSF	CSF	16	0.3	important role of the CP for lymphocyte recruitment in MS CSF other routes of lymphocyte entry might exist such as through	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5124	18539342	5678	20996	11179	SOD1	ALS	ALS	27	0.0	was always absent in the control brains and in the ALS brains (in in most of the latter the cause of	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5125	18539342	5679	11629	6493	LAMC2	CSF	CSF	22	0.3	entry of lymphocytes in the CNS and for presentation of CSF antigens by APCs in the CP stroma	1		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
5126	18539342	5679	872	583	APC	APC	APCs	25	0.0	in the CNS and for presentation of CSF antigens by APCs in the CP stroma	13		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
5127	18539342	5687	20996	11179	SOD1	ALS	ALS	4	0.0	H HLA-DR immunostaining in ALS CP (40X, 40X scale bar = 25_amp_#xa0 _amp_#x3bc m epiplexus	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5131	18539342	5691	20996	11179	SOD1	ALS	ALS	7	0.0	D Epiplexus cell showing CD68 immunostaining in ALS CP (100X, 100X scale bar = 10_amp_#xa0 _amp_#x3bc m	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
5144	18539342	5699	20996	11179	SOD1	ALS	ALS	4	0.0	G VCAM-1 immunostaining in ALS CP no endothelial staining is observed (40X, 40X scale bar	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000548204718954395<>ScoreDetail__5468|IGFALS|0.000378049844417949__11179|SOD1|0.000548204718954395__	0	0	0	0		0
7909	18598679	9075	20996	11179	SOD1	ALS	ALS	13	0.8	neuroinflammation is a key event in amyotrophic lateral sclerosis (ALS) ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
7913	18598679	9083	20996	11179	SOD1	ALS	ALS	3	0.8	Amyotrophic lateral sclerosis (ALS) ALS is a neurodegenerative disease characterized by the selective degeneration of	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
7915	18598679	9085	20996	11179	SOD1	ALS	ALS-like	11	0.8	of mutant human SOD1 selectively in neurons failed to cause ALS-like disease in mice ( Pramatarova et al. 2001 and Lino	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
7916	18598679	9086	20996	11179	SOD1	SOD1	SOD1-expressing	11	0.8	of chimeric mice composed of mixture of wild-type or mutant SOD1-expressing cells suggested that nonneuronal cells influence the fate of spinal	1		JUMiner_v2.2	1	2	32	0	0	0		0	0	0	0		0
7919	18598679	9088	20996	11179	SOD1	ALS	ALS	15	0.8	cells other than motor neurons play an important role in ALS development	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
7920	18598679	9089	20996	11179	SOD1	ALS	ALS	28	0.8	dendritic cells cytokines and chemokines in the spinal cord of ALS patients and mouse models ( Henkel et al. 2004 Alexianu	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
7922	18598679	9091	20996	11179	SOD1	ALS	ALS	7	0.8	Analyses of serum skin and muscle from ALS patients indicate widespread inflammatory responses ( Baron et al. 2005	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
7926	18598679	9093	20996	11179	SOD1	ALS	ALS	15	0.8	an anti-inflammatory compound conferred protection in a mouse model of ALS ( Kriz et al. 2002	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
7927	18598679	9094	20996	11179	SOD1	ALS	ALS	14	0.8	that inflammation is a key event in the pathogenesis of ALS and may mediate motor neuron injury	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
7928	18598679	9099	18723	10261	ROS1	ROS	ROS	10	0.3	nervous system is particularly vulnerable to reactive oxygen species (ROS) ROS due to its high metabolic rate its deficient oxidant defense	3		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
7929	18598679	9100	20996	11179	SOD1	ALS	ALS	13	0.8	was hold as a common denominator in the pathogenesis of ALS ( Simpson et al. 2003	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
7930	18598679	9101	18723	10261	ROS1	ROS	ROS	3	0.3	The source of ROS has generally been attributed to accidental leakage from the electron	3		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
7931	18598679	9102	18723	10261	ROS1	ROS	ROS	5	0.3	However another major source of ROS in the central nervous system is the respiratory burst system	3		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
7932	18598679	9103	18723	10261	ROS1	ROS	ROS	12	0.3	acting as the functional enzyme in the respiratory burst generates ROS not as a byproduct but rather as the primary function	3		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
7933	18598679	9104	18723	10261	ROS1	ROS	ROS	4	0.3	Recent studies indicate that ROS produced by NADPH oxidase could promote neurodegeneration ( Block and	3		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
7934	18598679	9104	20996	11179	SOD1	ALS	ALS	30	0.8	et al. 2005 but the role of NADPH oxidase in ALS remains largely unexplored	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
7936	18598679	9107	20996	11179	SOD1	ALS	ALS	22	0.8	to interneurons which is similar to the pathological change in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
7941	18598679	9130	19329	10524	SALL1	TBS	TBS	37	0.0	and then rinsed 3 times with Tris buffered saline (TBS) TBS	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
7942	18598679	9131	19329	10524	SALL1	TBS	TBS	5	0.0	After blocking for 1_amp_#xa0 h in TBS with 10% horse serum cultures were stained overnight at 4_amp_#xa0	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
7943	18598679	9131	19329	10524	SALL1	TBS	TBS	38	0.0	against calretinin (1:60, 1 60 Santa Cruz CA diluted in TBS containing 0.5% Triton X-100	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
7944	18598679	9132	19329	10524	SALL1	TBS	TBS	4	0.0	After several washings with TBS containing 0.3% Triton X-100 the cultures were incubated with biotinylated	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
7945	18598679	9132	19329	10524	SALL1	TBS	TBS	25	0.0	1 1000 or 1 200 Vector Laboratories Burlingame CA in TBS containing 0.3% Triton X-100 for 1_amp_#xa0 h at RT and	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
7946	18598679	9132	19329	10524	SALL1	TBS	TBS	46	0.0	complex reagents (1:200, 1 200 Vector Laboratories Burlingame CA in TBS for 1_amp_#xa0 h at RT	1		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
7950	18598679	9152	19573	10691	SDS	SDS	SDS-polyacrylamide	5	0.0	The samples were electrophoresed on SDS-polyacrylamide gel and the resolved proteins were transferred to polyvinylidene difluoride	11		JUMiner_v2.2	1	0		0	2	10691	TotalCon:2<>10691|SDS|10993|Complete__19440|SBDS|51119|Complete__<>AvaiableGeneRif=2<>BEST:10691|SDS|0.000257997936016512<>ScoreDetail__10691|SDS|0.000257997936016512__19440|SBDS|0.000218026424802686__	0	0	0	0		0
8011	18598679	9256	20996	11179	SOD1	ALS	ALS	57	0.8	partially responsible for the selective vulnerability of motor neurons in ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
8028	18598679	9273	3884	1659	CD33	p67	p67	37	0.0	phox and several cytosolic components including p47 phox p40 phox p67 phox and rac1/2 rac1 2 ( Babior et al. 2002	1		JUMiner_v2.2	1	0		0	2	1659	TotalCon:2<>1659|CD33|945|Complete__16672|METAP2|10988|Complete__<>AvaiableGeneRif=2<>BEST:1659|CD33|0.000604495164038688<>ScoreDetail__1659|CD33|0.000604495164038688__16672|METAP2|0.000526974507608194__	0	0	0	0		0
8052	18598679	9298	20996	11179	SOD1	ALS	ALS	33	0.8	showed little change which is similar to the pathology of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
8054	18598679	9308	18723	10261	ROS1	ROS	ROS	3	0.3	High concentrations of ROS can exert direct toxicity on mitochondria and impair neurons	3		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
8055	18598679	9309	18723	10261	ROS1	ROS	ROS	4	0.3	In addition NADPH oxidase-derived ROS can mediate proinflammatory gene expression and lead to the production	3		JUMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
8056	18598679	9309	7708	3811	FOXG1	QIN	Qin	19	0.0	expression and lead to the production of inflammatory cytokines ( Qin et al. 2004	2		JUMiner_v2.2	1	0		0	0	0		0	0	0	0		0
8057	18598679	9310	20996	11179	SOD1	ALS	ALS	23	0.8	processes both of which are implicated in the pathogenesis of ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
8058	18598679	9312	20996	11179	SOD1	ALS	ALS	18	0.8	that NADPH oxidase is up-regulated in the spinal cords of ALS patients and SOD1 G93A transgenic mice ( Wu et al.	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
8062	18598679	9312	20996	11179	SOD1	ALS	ALS	47	0.8	Nox2 gene significantly slowed disease progression and improved survival of ALS mice ( Marden et al. 2007	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
8081	18598679	9335	20996	11179	SOD1	ALS	ALS	23	0.8	and may lead to development of strategies of treatment for ALS	1		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000910039911268296<>ScoreDetail__5468|IGFALS|0.000512229478806505__11179|SOD1|0.000910039911268296__	0	0	0	0		0
1567	18691039	2340	11629	6493	LAMC2	CSF	CSF	3	0.5	Biochemical Markers in CSF of ALS Patients	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
1568	18691039	2340	20996	11179	SOD1	ALS	ALS	5	0.1	Biochemical Markers in CSF of ALS Patients	6		JUMiner_v2.2	1	2	amyotrophic lateral sclerosis	0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000787252646703788<>ScoreDetail__5468|IGFALS|0.000366372629146352__11179|SOD1|0.000787252646703788__	0	0	0	0		0
1569	18691039	2341	20996	11179	SOD1	ALS	ALS	3	0.0	Amyotrophic lateral sclerosis (ALS) ALS is the most common form of motor neuron diseases (MND)	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000787252646703788<>ScoreDetail__5468|IGFALS|0.000366372629146352__11179|SOD1|0.000787252646703788__	0	0	0	0		0
1570	18691039	2342	20996	11179	SOD1	ALS	ALS	8	0.0	Although several mutations underlying rare cases of familial ALS were identified during the last decade the pathogenesis of ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000787252646703788<>ScoreDetail__5468|IGFALS|0.000366372629146352__11179|SOD1|0.000787252646703788__	0	0	0	0		0
1571	18691039	2342	20996	11179	SOD1	ALS	ALS	18	0.0	ALS were identified during the last decade the pathogenesis of ALS remains poorly understood	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000787252646703788<>ScoreDetail__5468|IGFALS|0.000366372629146352__11179|SOD1|0.000787252646703788__	0	0	0	0		0
1572	18691039	2344	11629	6493	LAMC2	CSF	CSF	14	0.5	related to these pathomechanisms were investigated in cerebrospinal fluid (CSF) CSF	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
1573	18691039	2345	11629	6493	LAMC2	CSF	CSF	10	0.5	Although none of these markers gained clinical importance so far CSF might reflect pathophysiological alterations in the course of the disease	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
1574	18691039	2346	11629	6493	LAMC2	CSF	CSF	13	0.5	that cellular and proteinchemical processes are better reflected in the CSF than in other body fluids such as blood or urine	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
1575	18691039	2346	11629	6493	LAMC2	CSF	CSF	35	0.5	to the proximity of the affected motor neurons to the CSF compartment	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
1576	18691039	2347	11629	6493	LAMC2	CSF	CSF	24	0.5	central nervous system may be mirrored in corresponding changes in CSF protein content	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
1577	18691039	2348	11629	6493	LAMC2	CSF	CSF	4	0.5	Research on biomarkers in CSF using novel discovery technologies such as proteomics allows to search	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
1578	18691039	2349	11629	6493	LAMC2	CSF	CSF	9	0.5	In this review an updated overview is given on CSF biomarkers related to the pathomechanisms supposed to be participating in	3		JUMiner_v2.2	1	2	UserEdit	0	0	0		1	1	0	0		0
1579	18691039	2349	20996	11179	SOD1	ALS	ALS	25	0.0	supposed to be participating in the complex disease process of ALS	1		JUMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000787252646703788<>ScoreDetail__5468|IGFALS|0.000366372629146352__11179|SOD1|0.000787252646703788__	0	0	0	0		0
1888	18715147	2783	18723	10261	ROS1	ROS	ROS	6	0.3	The generation of reactive oxygen species (ROS) ROS and reactive nitrogen species (RNS) RNS leads to oxidative and/or	3		SciMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
1889	18715147	2783	6981	22140	FAM20C	RNS	RNS	11	0.0	reactive oxygen species (ROS) ROS and reactive nitrogen species (RNS) RNS leads to oxidative and/or and or nitrosative damage to cellular	1		SciMiner_v2.2	1	0		0	0	0		0	0	0	0		0
1890	18715147	2784	18723	10261	ROS1	ROS	ROS	11	0.3	oxidative stress increases due to an aberrant generation of ROS/RNS ROS RNS and a gradual decline in cellular antioxidant defense mechanisms	3		SciMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
1891	18715147	2784	6981	22140	FAM20C	RNS	RNS	11	0.3	stress increases due to an aberrant generation of ROS/RNS ROS RNS and a gradual decline in cellular antioxidant defense mechanisms	4		SciMiner_v2.2	1	2	reactive nitrogen species	0	0	0		0	0	0	0		0
1892	18715147	2788	18723	10261	ROS1	ROS	ROS	5	0.3	However additional intracellular sources of ROS and RNS exist as well as extracellular sources such as	3		SciMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
1893	18715147	2788	6981	22140	FAM20C	RNS	RNS	7	0.1	However additional intracellular sources of ROS and RNS exist as well as extracellular sources such as those resulting	6		SciMiner_v2.2	1	2	reactive nitrogen species	0	0	0		0	0	0	0		0
1894	18715147	2789	18723	10261	ROS1	ROS	ROS	7	0.3	A significant body of literature indicates that ROS and/or and or RNS resulting from mitochondrial dysfunction neuroinflammation or	3		SciMiner_v2.2	1	2	ros	0	0	0		0	0	0	0		0
1895	18715147	2789	6981	22140	FAM20C	RNS	RNS	9	0.1	significant body of literature indicates that ROS and/or and or RNS resulting from mitochondrial dysfunction neuroinflammation or toxicants are major factors	6		SciMiner_v2.2	1	2	reactive nitrogen species	0	0	0		0	0	0	0		0
1896	18715147	2789	20996	11179	SOD1	ALS	ALS	44	0.0	(AD), AD Huntingtons disease (HD), HD amyotrophic lateral sclerosis (ALS), ALS and many others (1, 1 8 9 16 18	1		SciMiner_v2.2	1	0		0	2	11179	TotalCon:2<>11179|SOD1|6647|Complete__5468|IGFALS|3483|Complete__<>AvaiableGeneRif=2<>BEST:11179|SOD1|0.000707286291639221<>ScoreDetail__5468|IGFALS|6.43107495417859e-05__11179|SOD1|0.000707286291639221__	0	0	0	0		0
#sen2geneID	pmid	senID	geneID	hgncID	approvedSymbol	matchString	actualString	startPos	score	flankingText	matchCodeID	tag	SciMinerVersion	SciMinerMethod	inExClude	inExCludeCond	phenotypeOnly	conflictCode	hgncIDbyNR	NRText	editTag	editUser	oldGeneID	oldHgncID	oldApprovedSymbol	oldInExClude	oldInExCludeCond
305252	3772394	443573	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	significant increase in immunosuppressive acidic protein iap in serum of patients with multiple sclerosis and other inflammatory neurological disorders. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
305254	3772394	443577	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	in multiple sclerosis patients however iap increased during exacerbation 630 +/ 191 and decreased during the inactive stage 433 +/ 170 . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
297407	8605177	424637	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	human mitochondrial manganese superoxide dismutase polymorphic variant ile58thr reduces activity by destabilizing the tetrameric interface. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
297409	8605177	424638	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	human manganese superoxide dismutase mnsod is a homotetrameric enzyme which protects mitochondria against oxygen mediated free radical damage. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
296756	9086508	423597	1133	727	ARTN	neurotrophic factor	neurotrophic factor	0	0.0	neurotrophic factors ntfs such as nerve growth factor ngf brain derived neurotrophic factor bdnf and ciliary neurotrophic factor cntf are currently being explored as novel therapeutics in a range of neurodegenerative disorders such as amyotrophic lateral sclerosis als and alzheimer's disease. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
296760	9086508	423606	1133	727	ARTN	neurotrophic factor	neurotrophic factor	0	0.0	brain derived neurotrophic factor|ciliary neurotrophic factor|nerve growth factors|nerve tissue proteins| 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
296076	9125377	422219	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	ad vectors may not be easily used either in diseases displaying major immune dysfunction e.g multiple sclerosis . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
288507	9562310	408248	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	ted in experimental allergic encephalomyelitis csf gijbels et al. 1990 and systemic lupus erythematosus with central nervous system involvement hirohata and miyamoto 1990 but il 6 was not detected in multiple sclerosis ms houssiau et al. 1988 ; frei et al. 1988 and araga et al. 1991 or detected no more frequently than in neurological disease controls hauser et al. 1990 . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
288508	9562310	408248	20402	18176	SLEV1	systemic lupus erythematosus	systemic lupus erythematosus	0	1.0	il 6 was detected in experimental allergic encephalomyelitis csf gijbels et al. 1990 and systemic lupus erythematosus with central nervous system involvement hirohata and miyamoto 1990 but il 6 was not detected in multiple sclerosis ms houssiau et al. 1988 ; frei et al. 1988 and araga et al. 1991 or detected no more	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
288523	9562310	408278	551	399	ALB	albumin	albumin	0	0.0	igg index was determined by the quotient csf igg/serum igg divided by the quotient csf albumin/serum albumin. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
288546	9562310	408324	20402	18176	SLEV1	systemic lupus erythematosus	systemic lupus erythematosus	0	1.0	serum il 6 was not measured in als but prior studies have shown that il 6 can concentrate in the csf compartment e.g during active cns systemic lupus erythematosus hirohata and miyamoto 1990 . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
273831	10417811	383073	16700	9030	PLA2G1B	phospholipase a2	phospholipase a2	0	0.0	cytosolic phospholipase a2 is induced in reactive glia following different forms of neurodegeneration. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
275737	10525172	386981	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	inflammatory reaction is thought to be an important contributor to neuronal damage in neurodegenerative disorders such as alzheimer's disease ad parkinson's disease pd multiple sclerosis ms amyotrophic lateral sclerosis als and the parkinsonism dementia complex of guam. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
275738	10525172	386988	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	 many proteins known to be involved in inflammatory processes with senile plaques and microfibrillary tangles in chronic neurodegenerative disorders like alzheimer's disease ad parkinson's disease pd multiple sclerosis ms amyotrophic lateral sclerosis als and the parkinsonism dementia complex of guam is consistent with the autotoxic loop hypothesis developed by mcgeer and mcgeer [ 56 57 ] fig 1 . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
275743	10525172	387026	5284	19986	CYCS	cytochrome c	cytochrome c	0	0.0	moreover excess no may also promote an increase of o 2 _amp_#x2212; production by binding to the heme moiety of the cytochrome c oxidase the complex iv of the electron transport chain in the mitochondrial membrane. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
275749	10525172	387085	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	multiple sclerosis 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
253054	11173059	346482	1133	727	ARTN	neurotrophic factor	neurotrophic factor	0	0.0	neurotrophic factors such as brain derived neurotrophic factor bdnf ciliary neurotrophic factor cntf and insulin like growth factor 1 igf 1 enhance motor neuron survival in vitro and can also exert beneficial effects in mouse models of amyotrophic lateral sclerosis reviewed in yuen and mobley 1	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253056	11173059	346482	10601	6081	INS	insulin	insulin	0	0.0	neurotrophic factors such as brain derived neurotrophic factor bdnf ciliary neurotrophic factor cntf and insulin like growth factor 1 igf 1 enhance motor neuron survival in vitro and can also exert beneficial effects in mouse models of amyotrophic lateral sclerosis reviewed in yuen and mobley 1996 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253057	11173059	346482	9939	5464	IGF1	insulin like growth factor	insulin like growth factor	0	0.0	neurotrophic factors such as brain derived neurotrophic factor bdnf ciliary neurotrophic factor cntf and insulin like growth factor 1 igf 1 enhance motor neuron survival in vitro and can also exert beneficial effects in mouse models of amyotrophic lateral sclerosis reviewed in yuen and mobley 1996 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253075	11173059	346527	11942	21210	LPAL2	apolipoprotein	apolipoprotein	0	1.0	rkinson's disease have revealed that allele polymorphism of the promoter sequence nac rep1 is significantly associated with an increased risk of disease development especially in combination with the apolipoprotein apo allele 4 kruger et al. 1999 . 	7		JUMiner_v2.2	2	2	UserEdit	0	0	0		1	1	0	0		0
253093	11173059	346605	1133	727	ARTN	neurotrophic factor	neurotrophic factor	0	0.0	a number of neurotrophic factors show protective effects on dopaminergic neurons in vivo including glial cell line derived neurotrophic factor gdnf basic fibroblast growth factor bfgf brain derived neurotrophic factor neurotrophin 3 neurotrophin 4/5 ciliary neurotrophic factor and transforming growth factor tgf _amp_#x3b2; dunnett and bj_amp_#xf6;rklund 1999 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253094	11173059	346605	1133	727	ARTN	neurotrophic factor	neurotrophic factor	0	0.0	 neurotrophin 3 neurotrophin 4/5 ciliary neurotrophic factor and transforming growth factor tgf _amp_#x3b2; dunnett and bj_amp_#xf6;rklund 1999 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253095	11173059	346605	1624	1033	BDNF	neurotrophin	neurotrophin	0	0.0	rophic factors show protective effects on dopaminergic neurons in vivo including glial cell line derived neurotrophic factor gdnf basic fibroblast growth factor bfgf brain derived neurotrophic factor neurotrophin 3 neurotrophin 4/5 ciliary neurotrophic factor and transforming growth factor tgf _amp_#x3b2; dunnett and bj_amp_#xf6;rklund 1999 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253096	11173059	346605	1624	1033	BDNF	neurotrophin	neurotrophin	0	0.0	 3 neurotrophin 4/5 ciliary neurotrophic factor and transforming growth factor tgf _amp_#x3b2; dunnett and bj_amp_#xf6;rklund 1999 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253100	11173059	346605	7522	3676	FGF2	basic fibroblast growth factor	basic fibroblast growth factor	0	0.0	a number of neurotrophic factors show protective effects on dopaminergic neurons in vivo including glial cell line derived neurotrophic factor gdnf basic fibroblast growth factor bfgf brain derived neurotrophic factor neurotrophin 3 neurotrophin 4/5 ciliary neurotrophic factor and transforming growth factor tgf _amp_#x3b2; dunnett and bj_amp_#xf6;rklund 1999 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253112	11173059	346635	24393	12854	YWHAQ	protein tau	protein tau	0	1.0	they are composed of hyperphosphorylated insoluble forms of microtubule associated protein tau often conjugated with ubiquitin selkoe 1999 . 	7		JUMiner_v2.2	2	2	UserEdit	0	0	0		1	1	0	0		0
253117	11173059	346674	11942	21210	LPAL2	apolipoprotein	apolipoprotein	0	0.0	at present the most important genetic information in patients with late onset alzheimer disease comes from the analysis of allele polymorphism of the apolipoprotein e apoe gene. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253123	11173059	346688	10436	5991	IL1A	interleukin 1	interleukin 1	0	0.0	therefore polymorphism analysis of the 1 antichymotrypsin gene especially in conjunction with that of the interleukin 1 gene may provide further indications for the use of anti inflammatory drugs or interleukin 1 receptor antagonist in alzheimer disease table 4 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253124	11173059	346688	10444	5993	IL1R1	interleukin 1 receptor	interleukin 1 receptor	0	0.0	therefore polymorphism analysis of the 1 antichymotrypsin gene especially in conjunction with that of the interleukin 1 gene may provide further indications for the use of anti inflammatory drugs or interleukin 1 receptor antagonist in alzheimer disease table 4 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253135	11173059	346710	10601	6081	INS	insulin	insulin	0	0.0	brain derived neurotrophic factor levels are decreased in alzheimer disease hippocampi ferrer et al. 1999 and insulin like growth factor 1 shows protective effects against _amp_#x3b2; amyloid protein neurotoxicity dore et al. 1999 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253136	11173059	346710	9939	5464	IGF1	insulin like growth factor	insulin like growth factor	0	0.0	brain derived neurotrophic factor levels are decreased in alzheimer disease hippocampi ferrer et al. 1999 and insulin like growth factor 1 shows protective effects against _amp_#x3b2; amyloid protein neurotoxicity dore et al. 1999 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253145	11173059	346727	10436	5991	IL1A	interleukin 1	interleukin 1	0	0.0	therapeutic trials involving the use of anti inflammatory drugs or interleukin 1 antagonists e.g. interleukin 1 receptor antagonist inhibitors of interleukin 1 converting enzyme are now being planned: results are eagerly awaited as they may lead to substantial changes in treatment protocols for alzheimer disease table 4 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
253146	11173059	346727	10444	5993	IL1R1	interleukin 1 receptor	interleukin 1 receptor	0	0.0	therapeutic trials involving the use of anti inflammatory drugs or interleukin 1 antagonists e.g. interleukin 1 receptor antagonist inhibitors of interleukin 1 converting enzyme are now being planned: results are eagerly awaited as they may lead to substantial changes in treatment protocols for alzheimer disease table 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
247364	11458198	336764	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	this paper reviews the possible mechanisms which may play a role in metal induced autoimmunity with the emphasis on multiple sclerosis ms rheumatoid arthritis ra and amyotrophic lateral sclerosis als . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
234259	11796754	317532	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	e 30 being elevated and seven decreased. cdna microarray analysis to monitor gene expression during neurodegeneration revealed an up regulation of genes related to an inflammatory process such as the tumor necrosis factor alpha tnf alpha gene resulting from glial cell activation together with the change in apoptosis related gene expression such as caspase 1. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
235282	11847479	319132	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	 sufficient to show whether tnf has a pathogenic or a protective role in mnd though anti tnf antibodies have shown protective effects in experimental allergic encephalomyelitis eae an animal model of multiple sclerosis ms . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
235283	11847479	319134	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	antibodies monoclonal|nf kappa b|nerve growth factors|neuroprotective agents|receptors tumor necrosis factor|tumor necrosis factor alpha|superoxide dismutase| 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
227548	12060810	305734	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	familial als accounts for 10_amp_#37; of all cases and mutations of the superoxide dismutase 1 sod1 gene have been identified in about 20_amp_#37; of the familial cases. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
228120	12076984	307182	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	asing evidence has suggested that inflammation in the brain is closely associated with the pathogenesis of several degenerative neurologic disorders including parkinson's disease alzheimer's diseases multiple sclerosis amyotrophic lateral sclerosis and aids dementia. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
229974	12137643	310068	10601	6081	INS	insulin	insulin	0	0.0	recombinant human insulin like growth factor i rhigf i for amyotrophic lateral sclerosis/motor neuron disease. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
229976	12137643	310069	10601	6081	INS	insulin	insulin	0	0.0	background: trophic factors including recombinant human insulin like growth factor i have been postulated as possible disease modifying therapies for amyotrophic lateral sclerosis. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
229978	12137643	310070	10601	6081	INS	insulin	insulin	0	0.0	randomised clinical trials of recombinant human insulin like growth factor i in amyotrophic lateral sclerosis to date have yielded conflicting results. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
229980	12137643	310071	10601	6081	INS	insulin	insulin	0	0.0	objectives: the main objective of this review was to examine the efficacy of recombinant human insulin like growth factor i in amyotrophic lateral sclerosis. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
229982	12137643	310073	10601	6081	INS	insulin	insulin	0	0.0	search strategy: a search was carried out using the cochrane neuromuscular disease group register for randomised clinical trials of recombinant human insulin like growth factor i in amyotrophic lateral sclerosis. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
229984	12137643	310074	10601	6081	INS	insulin	insulin	0	0.0	enquiries were also made of authors of randomised clinical trials as well as the manufacturers of recombinant human insulin like growth factor i regarding any other randomised clinical trials which had not yet been published. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
229986	12137643	310075	10601	6081	INS	insulin	insulin	0	0.0	selection criteria: types of studies: all randomised controlled clinical trials involving recombinant human insulin like growth factor i treatment of amyotrophic lateral sclerosis. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
229988	12137643	310077	10601	6081	INS	insulin	insulin	0	0.0	types of interventions: treatment with recombinant human insulin like growth factor i or placebo. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
229990	12137643	310078	10601	6081	INS	insulin	insulin	0	0.0	types of outcome measures: primary: change in appel amyotrophic lateral sclerosis rating scale aalsrs total score with 0.1mg/kg/day of recombinant human insulin like growth factor i after nine months treatment. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
229992	12137643	310079	10601	6081	INS	insulin	insulin	0	0.0	secondary: change in aalsrs with recombinant human insulin like growth factor i 0.1mg/kg/day and 0.05mg/kg/day at 1 2 3 4 5 6 7 8 9 months change in quality of life sickness impact profile scale survival and adverse events. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
229994	12137643	310084	10601	6081	INS	insulin	insulin	0	0.0	main results: the primary outcome measure was change in disease progression as determined by the appel als rating scale total score with 0.1 mg/kg/day of recombinant human insulin like growth factor i subcutaneously after nine months treatment. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
229996	12137643	310085	10601	6081	INS	insulin	insulin	0	0.0	the level of significance was lower in the european trial which compared 59 patients on placebo with 124 on insulin like growth factor i 0.1 mg/kg/day weighted mean difference 3.30 95%ci 8.68 to 2.08 than in the north american trial which compared 90 patients on placebo with 89 on recombinant human insulin like gr	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
229997	12137643	310085	10601	6081	INS	insulin	insulin	0	0.0	 like growth factor i 0.1 mg/kg/day weighted mean difference 3.30 95%ci 8.68 to 2.08 than in the north american trial which compared 90 patients on placebo with 89 on recombinant human insulin like growth factor i 0.05 mg/kg/day 89 patients and 87 patients on 0.1mg/kg/day weighted mean difference 6.00 95%ci 10.99 to 1.01 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
230000	12137643	310087	10601	6081	INS	insulin	insulin	0	0.0	the secondary outcome measures showed similar trends favouring recombinant human insulin like growth factor i but these did not reach significance at the five per cent level. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
230002	12137643	310088	10601	6081	INS	insulin	insulin	0	0.0	similarly the data with the 0.05mg/kg/day dose showed trends favouring recombinant human insulin like growth factor i at all time points but did not reach significance at the five per cent level at any point. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
230004	12137643	310089	10601	6081	INS	insulin	insulin	0	0.0	evaluation of adverse events showed an increased risk of injection site reactions/inflammation with recombinant human insulin like growth factor i relative risk 2.53 95% ci 1.40 to 4.59 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
230006	12137643	310091	10601	6081	INS	insulin	insulin	0	0.0	reviewer's conclusions: recombinant human insulin like growth factor i may be modestly effective but the evidence currently available is insufficient for a definitive assessment. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
218045	12387699	291553	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	ible for the selective loss of motor neurones are still unknown however several hypotheses have been put forward including oxidative damage and/or toxicity from intracellular aggregates due to mutant superoxide dismutase 1 activity axonal strangulation from cytoskeletal abnormalities loss of trophic factor support and glutamate mediated excitotoxicity. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
220509	12417341	294835	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	approximately 10% of als is familial and 10_amp_#x2013;20% of these familial als fals cases are caused by missense mutations in the cu/zn superoxide dismutase sod1 gene [ 1 ] while others are considered to be sporadic als sals . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
220514	12417341	294930	19134	10417	RPS27A	ubiquitin	ubiquitin	0	0.0	dorfin is a new ring finger type ubiquitin ligase containing two ring finger motifs and an ibr motif at its n terminus. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
215954	12528305	289116	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	superoxide dismutase 1|superoxide dismutase| 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
199268	12843244	266717	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	we show here that the expression of caspase 11 is upregulated in the spinal cord of superoxide dismutase 1 sod1 g93a transgenic mice a mouse model of amyotrophic lateral sclerosis als before the onset of motor dysfunction and remains at the high levels throughout the course of disease. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
199270	12843244	266718	10436	5991	IL1A	interleukin 1	interleukin 1	0	0.0	the caspase 1 and caspase 3 like activities as well as the level of interleukin 1 beta were significantly reduced in the spinal cord of symptomatic caspase 11 / ;sod1 g93a mice compared with that of caspase 11 +/ ; sod1 g93a mice. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
199274	12843244	266723	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	nd lower motor neurons leading to paralysis and death at ~1 5 years after the onset cleveland and rothstein 2001 ~5% of the cases in 1993 rosen et al demonstrated that several mutations in the cu /zn superoxide dismutase sod1 are causally responsible for a subset of familial als fals . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
199297	12843244	266771	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	aspase 11 has been found to be induced under multiple pathological conditions including lps induced septic shock wang et al. 1996 the experimental autoimmune encephalomyelitis eae as a mouse model of multiple sclerosis hisahara et al. 2001 brain ischemia induced by middle cerebral artery occlusion as a mouse model of stroke kang et al. 2000 and g93a transgenic mice this study . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
193546	14511332	258352	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	missense mutations in a gene encoding for the cu/zn superoxide dismutase sod1 account for a familial form of als linked to chromosome 21q rosen et al . 1993 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
195620	14556941	260916	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	recent studies suggest that glutamate neurotoxicity is involved in the pathogenesis of multiple sclerosis ms and that treatment with glutamate receptor ampa/kainate antagonists inhibits experimental autoimmune encephalomyelitis eae the conventional model of ms. therefore we examined whether riluzole an i	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
195622	14556941	260925	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	multiple sclerosis ms is a chronic disabling autoimmune neurological disorder targeting the white matter of the central nervous system cns . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
196866	14597108	262734	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	d immunohistochemically in mature senile plaques and reactive microglia in brain tissues of patients suffering from alzheimer's disease [ ishizuka et al. 1997 ] as well as in demyelinating plaques in multiple sclerosis patients [ mcmanus et al. 1998 ]. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
188368	14661102	251387	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	tion in certain neurodegenerative disorders parkinson s disease alzheimer s disease amyotrophic lateral sclerosis stroke and inflammatory and autoimmune disorders with particular attention devoted to multiple sclerosis . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
188369	14661102	251390	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	the participation of nitrative oxidation to the direct and indirect injury of neurons and other cells of the brain i.e. oligodendrocytes for multiple sclerosis is clear; less evident is their relevance for the development and progression of these disorders. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
190874	14739060	254321	12355	6872	MAPK10	map kinase	map kinase	0	1.0	it is now recognized that redox regulation involving ros is key to the modulation of critical cellular functions notably for neurons astrocytes and microglia such as mitogene activated protein map kinase cascade activation ion transport calcium mobilization and apoptosis program activation. 	7		JUMiner_v2.2	2	2	UserEdit	0	0	0		1	1	0	0		0
190898	14739060	254413	19134	10417	RPS27A	ubiquitin	ubiquitin	0	0.0	parkin is one member of the family of ubiquitin ligase responsible for ubiquination a process tagging proteins for degradation through proteosomal pathway. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
190902	14739060	254448	12580	7008	MELAS	mitochondrial encephalomyopathy	mitochondrial encephalomyopathy	0	0.0	the classic phenotypes of mitochondrial encephalomyopathy has been described as mitochondrial encephalomyopathy lactic acidosis and stroke like episodes syndrome melas . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
190903	14739060	254448	12580	7008	MELAS	mitochondrial encephalomyopathy, lactic acidosis, 	mitochondrial encephalomyopathy lactic acidosis an	0	1.0	the classic phenotypes of mitochondrial encephalomyopathy has been described as mitochondrial encephalomyopathy lactic acidosis and stroke like episodes syndrome melas . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
190904	14739060	254456	12580	7008	MELAS	mitochondrial encephalomyopathy	mitochondrial encephalomyopathy	0	1.0	primary coenzyme q deficiency cause a mitochondrial encephalomyopathy that is responsive to coenzyme q administration [ 44 ]. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
181107	14960605	241508	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	transgenic mice expressing a mutant form of the superoxide dismutase 1 sod1 linked to familial amyotrophic lateral sclerosis were challenged intraperitoneally with a single nontoxic or repeated injections of lps 1 mg/kg . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
181110	14960605	241514	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	key words: innate immunity ; neurodegeneration ; lipopolysaccharide ; microglia ; amyotrophic lateral sclerosis ; superoxide dismutase 1 ; proinflammatory cytokines ; transgenic mice 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
181112	14960605	241519	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	interestingly numerous proinflammatory genes are induced in the cns of presymptomatic mice expressing a mutant form of superoxide dismutase 1 sod1 linked to amyotrophic lateral sclerosis als the most common form of human motor neuron disease nguyen et al. 2001b ~20% cases of familial als rosen et al. 1993 ; cudkowicz et al. 1997 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
181117	14960605	241565	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	n l5 segment and cervical part of the spinal cord are microglial cells see fig 3 laflamme et al. 2001 kappab alpha [inhibitory protein of nuclear factor kappab nf kappab ] index of nf kappab activity tumor necrosis factor alpha tnf alpha and cd14 data not shown . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
176639	15081582	235244	7522	3676	FGF2	basic fibroblast growth factor	basic fibroblast growth factor	0	0.0	astrocytic cox 2 is also induced by lps tnf basic fibroblast growth factor bfgf and phorbol ester o'banion 1999 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
170007	15210305	227155	11942	21210	LPAL2	apolipoprotein	apolipoprotein	0	0.0	no conclusive data have emerged from the analysis of potential risk factors in als such as the neurofilament heavy subunit [ 25 ] the apolipoprotein e allele 4 [ 71 ] the gene survival motor neuron smn and neuronal apoptosis inhibitory protein naip [ 79 ]. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
170009	15210305	227156	1133	727	ARTN	neurotrophic factor	neurotrophic factor	0	0.0	recently ciliary neurotrophic factor cntf has been proposed as a modifier gene since the rare null mutations cause an earlier age of onset of disease in fals cases carrying a sod1 mutation. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
170012	15210305	227223	20339	13448	SLC38A2	amino acid transporter 2	amino acid transporter 2	0	0.0	for this reason the expression of glutamate receptors and of the excitatory amino acid transporter 2 eaat2 which is involved in the removal of glutamate from the synapse in spinal cord have been extensively investigated [ 92 and 107 ]. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
170028	15210305	227268	4437	2004	CLA3	cerebellar ataxia	cerebellar ataxia	0	1.0	epm1 is an autosomal recessive disorder characterized by seizures myoclonus and progression to cerebellar ataxia. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
170055	15210305	227344	78	61	ABCD1	adrenoleukodystrophy	adrenoleukodystrophy	0	1.0	a form of x linked adrenoleukodystrophy x ald which involves the spinal cord adrenomyeloneuropathy amn is another neurodegenerative disease characterized by elevated levels of saturated long chain fatty acids lcfa [ 64 ]. 	7		JUMiner_v2.2	2	2	UserEdit	0	0	0		1	1	0	0		0
170062	15210305	227386	11942	21210	LPAL2	apolipoprotein	apolipoprotein	0	0.0	apolipoprotein e apoe and to a lesser extent apo d gene expression are induced up to fivefold at 120 days of age. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
170070	15210305	227442	17345	9449	PRNP	prion protein	prion protein	0	0.0	inflammatory rna profile of microglia has been recently described which contrasts with that of uninfected microglia exposed to inflammatory stimuli such as lipopolysaccharide and ifn gamma as well as prion protein prp amyloid [ 5 ]. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
170072	15210305	227444	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	 up regulation of a subset of mrnas involved in inflammatory/immune functions have been described in monocyte depleted peripheral blood mononuclear cells from patients affected by relapsing remitting multiple sclerosis compared to age and sex matched controls [ 88 ]. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
175691	15341181	234528	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	evidence is now available to support this scenario for neurological disorders such as alzheimer's disease amyotrophic lateral sclerosis parkinson's disease multiple sclerosis and huntington's disease but also in the brain damage following ischemia and reperfusion down's syndrome and mitochondrial encephalopathies. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
164720	15453089	221240	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	this article will review new data in this area focusing on some major human neurological diseases such as multiple sclerosis amyotrophic lateral sclerosis parkinson disease creutzfeldt jakob disease and alzheimer disease. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
164737	15453089	221281	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	the present article will review new data in this area focusing on some major human neurological diseases such as multiple sclerosis ms amyotrophic lateral sclerosis als parkinson disease pd creutzfeldt jakob disease cjd and alzheimer disease ad . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
164760	15453089	221308	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	multiple sclerosis ms is an inflammatory demyelinating disease of the cns with a typical onset in the early adult life and characterized by perivascular infiltration of lymphocytes and macrophages into the brain parenc	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
164783	15453089	221345	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	missense mutations in the gene encoding for the cu/zn superoxide dismutase sod1 account for a familial form of als linked to chromosome 21q. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
164808	15453089	221395	17345	9449	PRNP	prion protein	prion protein	0	0.0	the characteristic neuropathological signs of the disease are amyloid deposition of the proteinase resistant prion protein prp res or prp sc astrocytosis and spongiform degeneration. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
161133	15571972	216653	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	minocycline could also facilitate recovery after spinal cord injury lee et al. 2003 and wells et al. 2003 attenuate neuropathic pain raghavendra et al. 2003 and display beneficial effect in models of multiple sclerosis brundula et al. 2002 and nelissen et al. 2003 and autoimmune encephalomyelitis popovic et al. 2002 . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
161396	15572176	216888	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	while ngf can signal through activation of the high affinity trka receptor it also can activate the non selective neurotrophin receptor p75 ntr a member of the tumor necrosis factor receptor superfamily. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
161397	15572176	216888	3889	11919	CD40	tumor necrosis factor receptor	tumor necrosis factor receptor	0	0.0	while ngf can signal through activation of the high affinity trka receptor it also can activate the non selective neurotrophin receptor p75 ntr a member of the tumor necrosis factor receptor superfamily. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
161402	15572176	216897	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	expression of ngf receptors in active multiple sclerosis lesions suggests a role for ngf in regulating the autoimmune response at both immune and glial cell levels [ 17 and 135 ]. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
155438	15649489	206205	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	a major advance in understanding its pathogenesis came from the genetics that identified mutations in the gene coding for copper_amp_#x2013;zinc superoxide dismutase 1 sod1 in a subset of patients with autosomal dominant inherited als rosen et al. 1993 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
155448	15649489	206294	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	recently daily treatment with 45 mg po pioglitazone for 3 years induced apparent clinical improvement without adverse events treatment in a patient with secondary multiple sclerosis pershadsingh et al. 2004 . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
156677	15657392	207607	10601	6081	INS	insulin	insulin	0	0.0	here we show that muscle restricted expression of a localized insulin like growth factor igf 1 isoform maintained muscle integrity and enhanced satellite cell activity in sod1 transgenic mice inducing calcineurin mediated regenerative pathways. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
156679	15657392	207610	10601	6081	INS	insulin	insulin	0	0.0	abbreviations used in this paper: achr acetylcholine receptor; als amyotrophic lateral sclerosis; cna calcineurin; gfap glial fibrillary acidic protein; igf insulin like growth factor; migf 1 local isoform of igf 1; myhc myosin heavy chain; sod1 superoxide dismutase1; wt wild type. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
156685	15657392	207618	10601	6081	INS	insulin	insulin	0	0.0	among these insulin like growth factor 1 igf 1 has been implicated in anabolism of muscle and nerve tissues inducing muscle hypertrophy and promoting neuronal survival musar_amp_ograve; and rosenthal 2002 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
156686	15657392	207618	9939	5464	IGF1	insulin like growth factor	insulin like growth factor	0	0.0	among these insulin like growth factor 1 igf 1 has been implicated in anabolism of muscle and nerve tissues inducing muscle hypertrophy and promoting neuronal survival musar_amp_ograve; and rosenthal 2002 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
157144	15668976	208360	1133	727	ARTN	neurotrophic factor	neurotrophic factor	0	0.0	moreover neuroprotective neurotrophic factors such as ciliary neurotrophic factor cntf hepatocyte growth factor hgf and glial cell line derived neurotrophic factor were upregulated. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
157381	15681814	208645	8198	4191	GCG	glucagon-like peptide 1	glucagon like peptide 1	0	0.0	stimulation of the glucagon like peptide 1 receptor glp 1r in brain is associated with neurotrophic functions that additionally can protect cells against excess glutamate and other toxic insults. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
157384	15681814	208647	7568	3701	FHIT	tumor suppressor protein	tumor suppressor protein	0	1.0	neoplasm proteins|receptors glucagon|receptors tumor necrosis factor type ii|tumor necrosis factor decoy receptors|tumor suppressor protein p53|glucagon like peptide receptor| 	7		JUMiner_v2.2	2	2	UserEdit	0	0	0		1	1	0	0		0
157739	15691215	209300	1133	727	ARTN	neurotrophic factor	neurotrophic factor	0	0.0	gene transfer of vegf or glial cell line derived neurotrophic factor anti inflammatory cox 2 inhibitors and minocycline have had particularly promising results in mice. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
150951	15777251	199027	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	these include head injury multiple sclerosis ms stroke and neurodegenerative diseases parkinson's disease pd alzheimer's disease ad or amyotrophic lateral sclerosis als . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
150968	15782606	199052	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	[primary progressive multiple sclerosis as a differential diagnosis of als: a case report] 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
150969	15782606	199057	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	er multiple plaques on the head and spinal mri a prolonged central conduction time of mep and sep a delayed p100 latency of vep and a increased igg index in the csf indicated primary progressive type multiple sclerosis. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
147250	15974901	194272	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	these include alzheimer's ad parkinson's pd and huntington's diseases amyotrophic lateral sclerosis all of the tauopathies multiple sclerosis and many other less common conditions. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
140847	16104843	184943	19134	10417	RPS27A	ubiquitin	ubiquitin	0	0.0	under normal oxygenation conditions hif 1 a is scarcely detectable because it is targeted for rapid destruction by an e3 ubiquitin ligase containing pvhl von hippel lindau tumour suppressor protein . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
140848	16104843	184943	18456	21148	RNF123	ubiquitin ligase	ubiquitin ligase	0	0.0	under normal oxygenation conditions hif 1 a is scarcely detectable because it is targeted for rapid destruction by an e3 ubiquitin ligase containing pvhl von hippel lindau tumour suppressor protein . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
140977	16104843	185181	23910	12680	VEGFA	vascular endothelial growth factor	vascular endothelial growth factor	0	0.0	vascular endothelial growth factor a|receptors vascular endothelial growth factor| 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
142381	16120782	186877	4413	1984	CISH	suppressor of cytokine signaling	suppressor of cytokine signaling	0	0.0	interestingly mrna levels of the suppressor of cytokine signaling 1 and 3 genes were increased by pio whereas both the mrna and protein levels of endogenous mouse sod1 and of transgenic human sod1 remained unaffected. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
142415	16120782	186990	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	our results strongly suggest that pio mediated suppression of inflammation may offer a new therapeutic avenue in als treatment as supported by previous findings in animal models of multiple sclerosis niino et al. 2001 ; feinstein et al. 2002 ; natarajan et al. 2003 parkinson's disease breidert et al. 2002 and stroke sundararajan et al. 2005 . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
131190	16179515	172942	20339	13448	SLC38A2	amino acid transporter 2	amino acid transporter 2	0	0.0	however it did upregulate 3 genes unaffected by the presence of the g93a/sod1 mutation: glial fibrillary acidic protein gfap stroma derived factor 1 sdf 1 and excitatory amino acid transporter 2 eaat2 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
131192	16179515	172945	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	baicalein treatment also downregulated tumor necrosis factor receptor tnfrp55 and upregulated noninducible nitric oxide synthase nnos and glutamine synthase gs . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
128756	16380619	169458	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	the authors compared il 6 and tumor necrosis factor alpha tnf alpha levels in csf and sera from 10 hypoxemics and 10 normoxemics patients with als to those of 10 hypoxemics and 10 normoxemics neurologic controls. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
128761	16380619	169463	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	an excessive production of tumor necrosis factor alpha tnf alpha with lower csf levels of interleukin il 6 was demonstrated in a sod 1 mouse model suggesting an increase cytotoxic potential of microglia. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
128808	16380619	169505	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	csf and sera interleukin 6 levels and tumor necrosis factor alpha sera levels in patients with als according to the condition of hypoxemia or normoxemia pao 2 . *significant difference p _lt_ 0.05 between the hypoxemic and the normoxemic groups. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
128811	16380619	169507	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	csf and sera interleukin 6 levels and tumor necrosis factor alpha sera levels in neurologic controls according to the condition of hypoxemia or normoxemia pao 2 . *significant difference p _lt_ 0.05 between the hypoxemic and the normoxemic groups. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
118656	16436205	154736	551	399	ALB	albumin	albumin	0	0.0	cytokines were predissolved in 4% fatty acid free bovine serum albumin bsa in 0.9% saline at 100 fold working concentration. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
122441	16510725	160990	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	important mediators of inflammation such as the cytokine tumor necrosis factor alpha tnf alpha and its superfamily member fibroblast associated cell surface ligand fasl have been implicated in apoptosis. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
122451	16510725	161004	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	tumor necrosis factor alpha tnf alpha is a major inflammatory cytokine that elicits a wide range of biological responses including neuronal apoptosis tewari and dixit 1996 alpha mediates its biological effects through act	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
122482	16510725	161099	14535	7873	NOS2A	nitric oxide synthase	nitric oxide synthase	0	0.0	fas triggers cell death in embryonic motoneurons by a pathway requiring upregulation of neuronal nitric oxide synthase and involving daxx apoptosis signal regulated kinase 1 and p38 as well as the fadd/caspase 8 pathway raoul et al. 2002 alpha upregulates fasl pinkoski et al. 2002 alpha immunostaining was found in th	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
122527	16510725	161206	6392	3209	EEF1B3	beta 3	beta3	0	1.0	no changes were detected in il 12p35 il 10 il 18 ifn gamma or ifn beta il 6 tgf beta3 and lt alpha or lt beta data not shown . 	7		JUMiner_v2.2	2	2	UserEdit	0	0	0		1	1	0	0		0
109234	16533145	142007	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	with the discovery of mutations in one gene cu/zn superoxide dismutase as a primary cause of some forms of als model systems have been developed that have helped us begin to understand mechanisms involved in motor neuron death and enabled testing of potential new therap	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
113323	16624536	147036	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	superoxide dismutase 1|superoxide dismutase| 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
114313	16637591	148926	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	on the other hand elevations of s100b levels in blood or cerebrospinal fluid have been observed in patients with alzheimer's disease down's syndrome amyotrophic lateral sclerosis multiple sclerosis schizophrenia depression cerebral stroke and traumatic brain injury and the levels have reached micromol/l order at focal regions. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
116213	16647138	150427	14535	7873	NOS2A	nitric oxide synthase	nitric oxide synthase	0	0.0	in endothelial cell cultures the overexpression of epox upregulates both endothelial nitric oxide synthase enos and pi3 kinase/akt pathways. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
116243	16647138	150608	10640	14645	IPPK	inositol 1	inositol 1	0	1.0	ate transcription factors and gene expression and stimulate activities of phospholipases a 2 c and d. the stimulation of these enzymes results in the generation of arachidonic acid diacylglycerol and inositol 1 4 5 trisphosphate. 	7		JUMiner_v2.2	2	2	UserEdit	0	0	0		1	1	0	0		0
116245	16647138	150609	10640	14645	IPPK	inositol 1	inositol 1	0	1.0	arachidonic acid is metabolized to eicosanoids diacylglycerol activates protein kinase c and inositol 1 4 5 trisphosphate mobilizes calcium from intracellular stores ishii and shimizu 2000 and izumi and shimizu 1995 . 	7		JUMiner_v2.2	2	2	UserEdit	0	0	0		1	1	0	0		0
116253	16647138	150635	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	excessive levels of paf are associated with neuronal injury in brain tissue and are involved in ischemic injury spinal cord injury hiv multiple sclerosis and meningitis brochet et al. 1995 and gelbard et al. 1994 table 2 . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
116254	16647138	150637	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	paf activates inflammatory cells and increases vasopermeability a role it may play in acute and chronic inflammatory diseases such as multiple sclerosis and viral and bacterial infections brochet et al. 1995 . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
116255	16647138	150638	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	administration of paf antagonists improves the neurological score of patients with multiple sclerosis. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
116350	16647138	150946	570	412	ALDH9A1	aldehyde dehydrogenase	aldehyde dehydrogenase	0	0.0	it is caused by a deficiency of the microsomal fatty aldehyde dehydrogenase de laurenzi et al. 1996 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
116352	16647138	150951	570	412	ALDH9A1	aldehyde dehydrogenase	aldehyde dehydrogenase	0	0.0	the deficiency of fatty aldehyde dehydrogenase is also accompanied by the accumulation of aldehyde modified lipids or fatty alcohols in sls. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
116453	16647138	151184	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	mutations in cu/zn superoxide dismutase sod1 gene have been reported to occur in familial form of als beal 1998a . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
116466	16647138	151213	17345	9449	PRNP	prion protein	prion protein	0	0.0	neuronal loss gliosis and accumulation of abnormal extracellular _amp_#x3b2; helix rich prion protein prp sc characterize cjd. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
116468	16647138	151214	17345	9449	PRNP	prion protein	prion protein	0	0.0	this abnormal protein is an isoform of a normally occurring _amp_#x3b1; helix rich prion protein prp c whose function has not been clearly elucidated brown 1999 and prusiner 2001 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
105662	16737688	136267	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	transgenic mice expressing a mutated human cu/zn superoxide dismutase sod1 gene develop a motor neuron disease similar to familial amyotrophic lateral sclerosis fals . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
105663	16737688	136279	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	about 15_amp_#x2013;20% of fals has been linked to inheritance in an autosomal dominant fashion of a mutant form of cu/zn superoxide dismutase sod1; rosen 1993 that normally functions in the regulation of oxidative stress. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
106051	16753239	137026	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	under such conditions glia can become chronically activated and may contribute to the neuropathology associated with a variety of neuroinflammatory disorders including multiple sclerosis ms alzheimer's disease ad parkinson's disease pd amyotrophic lateral sclerosis als and stroke. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
106070	16753239	137139	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	multiple sclerosis 3.1.1. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
106076	16753239	137206	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	recent reports demonstrate that the ppar _amp_#x3b3; agonist pioglitazone protected motor neurons improved motor performance and extended the survival of superoxide dismutase 1 g93a transgenic mice an animal model of als. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
106078	16753239	137208	4413	1984	CISH	suppressor of cytokine signaling	suppressor of cytokine signaling	0	0.0	finally these studies demonstrated reduced gliosis decreased nf _amp_#x3ba;b and increased suppressor of cytokine signaling 1 and 3 expression in pioglitazone treated animals kiaei et al. 2005 and sch_amp_#xfc;tz et al. 2005 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
106080	16753239	137221	11942	21210	LPAL2	apolipoprotein	apolipoprotein	0	0.0	the ppar _amp_#x3b1; agonist fenofibrate reduced the susceptibility of apolipoprotein e deficient mice to stroke. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
106668	16766086	138218	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	ppar_amp_#x3b3; agonists have been shown to be efficacious in animal models of alzheimer's disease stroke multiple sclerosis parkinson's disease and amyotrophic lateral sclerosis. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
106670	16766086	138231	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	together these findings inspired a number of studies investigating the utility of these agents in a broad range of disease indications including alzheimer's disease ad stroke multiple sclerosis parkinson's disease and amyotrophic lateral sclerosis als . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
106682	16766086	138377	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	multiple sclerosis 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
106683	16766086	138378	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	multiple sclerosis is a progressive autoimmune neurodegenerative disorder and experimental allergic encephalomyelitis eae is an animal model which recapitulates many aspects of the human disease. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
106684	16766086	138410	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	ite the common belief that ppar_amp_#x3b3; modulates eae by its anti inflammatory activity in t cells microglia and astrocytes it remains possible that it affects other cell types involved in eae and multiple sclerosis including neurons and oligodendrocytes. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
107912	16781706	139928	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	mutations in cu/zn superoxide dismutase sod1 are the primary cause of up to 20% of familial als cases rosen et al. 1993 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
108388	16785600	140295	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	estrogens are thought to play a role in the sex difference observed in many neurological diseases with inflammatory components including stroke alzheimer's and parkinson's diseases multiple sclerosis or amyotrophic lateral sclerosis. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
100383	16877542	128960	10601	6081	INS	insulin	insulin	0	0.0	we also show that nadph oxidase derived oxidant products damage proteins such as insulin like growth factor 1 igf1 receptors which are located on motor neurons. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
100384	16877542	128960	9939	5464	IGF1	insulin like growth factor	insulin like growth factor	0	0.0	we also show that nadph oxidase derived oxidant products damage proteins such as insulin like growth factor 1 igf1 receptors which are located on motor neurons. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
100421	16877542	129047	10601	6081	INS	insulin	insulin	0	0.0	nadph oxidase impairs the insulin like growth factor 1 igf1 /akt pathway in transgenic sod1 g93a mice. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
100422	16877542	129047	9939	5464	IGF1	insulin like growth factor	insulin like growth factor	0	0.0	nadph oxidase impairs the insulin like growth factor 1 igf1 /akt pathway in transgenic sod1 g93a mice. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
100461	16877542	129130	10601	6081	INS	insulin	insulin	0	0.0	ros reactive oxygen species sod1 superoxide dismutase 1 igf1 insulin like growth factor 1 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
100462	16877542	129130	9939	5464	IGF1	insulin like growth factor	insulin like growth factor	0	0.0	ros reactive oxygen species sod1 superoxide dismutase 1 igf1 insulin like growth factor 1 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
100464	16877542	129130	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	ros reactive oxygen species sod1 superoxide dismutase 1 igf1 insulin like growth factor 1 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
100466	16877542	129133	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	insights into its neurodegenerative mechanisms followed the discovery that dominant mutations in the gene for superoxide dismutase 1 sod1 cause familial als 2 3 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
100469	16877542	129140	4848	30998	CPAT1	cerebral palsy	cerebral palsy	0	1.0	such bystander cytotoxicity is thought to lead to the death of developing oligodendrocytes in periventricular leukomalacia 9 one of the most important causes of cerebral palsy. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
101426	16892030	129923	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	superoxide dismutase 1|superoxide dismutase|cre recombinase|integrases| 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
93461	16983747	120731	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
93462	16983747	120732	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	multiple sclerosis is considered a disease of myelin destruction; parkinson's disease pd one of dopaminergic neuron depletion; als a disease of motor neuron death; and alzheimer's a disease of plaques and tangles. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
94289	17008387	122180	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	because inflammation and oxidative damage are also hallmarks of amyotrophic lateral sclerosis als we studied the effect of oral pdtc treatment on g93a superoxide dismutase 1 sod1 transgenic tg rat model of human als and observed that pdtc treatment significantly decreases the survival. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
94291	17008387	122188	10436	5991	IL1A	interleukin 1	interleukin 1	0	0.0	r use in the treatment of aids reisinger et al. 1990 kappa b nf kappab that regulates the expression of several proinflammatory genes and some genes related to apoptosis schreck et al. 1992 alpha and interleukin 1 beta nurmi et al. 2004a beta signaling nurmi et al. 2006 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
94294	17008387	122221	551	399	ALB	albumin	albumin	0	0.0	proteasomal activity was measured in aliquots of 10 microg of protein in 50 microl volume of assay buffer 20 mm tris hcl ph 7.5 1 mm atp 2 mm mgcl 2 and 0.1% bovine serum albumin containing 100 microm n succinyl leu leu val tyr 7 amino 4 methylcoumarin . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
94300	17008387	122237	10436	5991	IL1A	interleukin 1	interleukin 1	0	0.0	ranscription factor nf kappab serving as a strong antioxidant or by activating akt gsk3 beta pathway cuzzocrea et al. 2002 kappab driven genes such as cyclooxygenase 2 tumor necrosis factor alpha and interleukin 1 beta drachman et al. 2002 beta pathway reduced mutant sod1 mediated motor neuron cell death in vitro koh et al. 2005 we found that pdtc treatment does not provide protection but instead significantly	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
94302	17008387	122237	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	y inhibiting the activation of transcription factor nf kappab serving as a strong antioxidant or by activating akt gsk3 beta pathway cuzzocrea et al. 2002 kappab driven genes such as cyclooxygenase 2 tumor necrosis factor alpha and interleukin 1 beta drachman et al. 2002 beta pathway reduced mutant sod1 mediated motor neuron cell death in vitro koh et al. 2005 we found that pdtc treatment does not provide protection b	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82164	17015226	105773	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	the lion's share of work has focused on als1 caused by_amp_#xa0;mutations in cu/zn superoxide dismutase sod1 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82173	17015226	105796	20478	11117	SMN1	spinal muscular atrophy	spinal muscular atrophy	0	1.0	about one fourth of affected individuals in the same families develop a late onset spinal muscular atrophy and a small proportion of patients develop symptoms of classic als. 	7		JUMiner_v2.2	2	2	UserEdit	0	0	0		1	1	0	0		0
82201	17015226	105927	10545	6047	IMMT	motor protein	motor protein	0	0.0	these include loss of the kinesin motor protein kif1b_amp_#x3b2; as causative for cmt type 2a zhao et_amp_#xa0;al. 2001 loss of kif5a in hereditary spastic paraplegia reid et_amp_#xa0;al. 2002 and loss of kif21a in a rare disorder affecting the oc	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82203	17015226	105939	10704	6132	ISL1	islet-1	islet 1	0	1.0	excision of the floxed mutant sod1 gene exclusively within motor neurons by action of cre recombinase expressed under control of the motor neuron specific promoter islet 1 extended survival by slowing onset and an early phase of disease progression. 	7		JUMiner_v2.2	2	2	UserEdit	0	0	0		1	1	0	0		0
82212	17015226	106011	10601	6081	INS	insulin	insulin	0	0.0	on the other hand muscle hypertrophy induced by agents such as insulin like growth factor 1 igf 1 or growth hormone dobrowolny et_amp_#xa0;al. 2005 kaspar et_amp_#xa0;al. 2003 and kaspar et_amp_#xa0;al. 2005 has led to significant life extensions in als transgenic mice.	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82213	17015226	106011	9939	5464	IGF1	insulin like growth factor	insulin like growth factor	0	0.0	on the other hand muscle hypertrophy induced by agents such as insulin like growth factor 1 igf 1 or growth hormone dobrowolny et_amp_#xa0;al. 2005 kaspar et_amp_#xa0;al. 2003 and kaspar et_amp_#xa0;al. 2005 has led to significant life extensions in als transgenic mice. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82215	17015226	106087	1133	727	ARTN	neurotrophic factor	neurotrophic factor	0	0.0	a key improvement seems to be use of dibutyryl camp as an anti myelin repulsion factor and grafting of neural stem cells expressing glial derived neurotrophic factor gdnf into the nerve. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82218	17015226	106102	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	superoxide dismutase 1|superoxide dismutase| 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82454	17018025	106123	10601	6081	INS	insulin	insulin	0	0.0	tivated by lipopolysaccharide as well as to activated microglia cocultured with primary motoneurons. lipopolysaccharide increased nitric oxide and superoxide o 2 _amp_middot;_amp_#8722; and decreased insulin like growth factor 1 igf 1 release from microglial cultures and induced motoneuron injury in microglia motoneuron cocultures. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82455	17018025	106123	9939	5464	IGF1	insulin like growth factor	insulin like growth factor	0	0.0	tivated by lipopolysaccharide as well as to activated microglia cocultured with primary motoneurons. lipopolysaccharide increased nitric oxide and superoxide o 2 _amp_middot;_amp_#8722; and decreased insulin like growth factor 1 igf 1 release from microglial cultures and induced motoneuron injury in microglia motoneuron cocultures. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82466	17018025	106140	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	il 4 has also been shown to reduce the production of pro inflammatory cytokines such as il 6 il 8 tumor necrosis factor alpha tnf a mip 1a and rantes in glial cultures treated with lipopolysaccharide or il 1 ledeboer et al 2000 ; ehrlich et al 1998 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82471	17018025	106141	10601	6081	INS	insulin	insulin	0	0.0	recently it has been documented that protection of il 4 was attributed to down regulation of tnf a and up regulation of insulin like growth factor 1 igf 1 from microglia butovsky et al 2005 2006 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82472	17018025	106141	9939	5464	IGF1	insulin like growth factor	insulin like growth factor	0	0.0	recently it has been documented that protection of il 4 was attributed to down regulation of tnf a and up regulation of insulin like growth factor 1 igf 1 from microglia butovsky et al 2005 2006 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82478	17018025	106154	551	399	ALB	albumin	albumin	0	0.0	after centrifugation at 800 g for 15 min the sharp band on top of the histodenz cushion was collected and centrifuged through a 4% bovine serum albumin bsa cushion at 400 g for 10 min. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82484	17018025	106175	14373	7808	NGF	nerve growth factor	nerve growth factor	0	0.0	as a specific marker for motoneurons p75 the low affinity nerve growth factor receptor immunocytochemistry provides a clear labeling of the motoneurons over microglia layer and simplifies identification and counting under brightfield microscope. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82485	17018025	106175	14374	7809	NGFR	nerve growth factor receptor	nerve growth factor receptor	0	0.0	as a specific marker for motoneurons p75 the low affinity nerve growth factor receptor immunocytochemistry provides a clear labeling of the motoneurons over microglia layer and simplifies identification and counting under brightfield microscope. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
82561	17018025	106319	22058	11765	TGFA	transforming growth factor	transforming growth factor	0	0.0	besides il 4 il 10 and transforming growth factor beta tgf b are two other major anti inflammatory cytokines. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
83595	17034351	107856	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	egulation of proinflammatory genes including arachidonic acid metabolizing enzymes [e.g. cyclooxygenase ii cox ii and 5 lipoxygenase 5lox ]; nitric oxide synthase nos isoforms; cytokines particularly tumor necrosis factor alpha tnf alpha ; chemokines; and immunoglobulin fc receptors fcgammars . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
76083	17214440	97706	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	in most cases the cause of als is unknown although in a number of familial als cases mutations in the superoxide dismutase 1 sod1 gene were discovered. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
69242	17350694	88332	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	alzheimer's disease ad parkinson's disease pd and amyotrophic lateral sclerosis als are among the best examples of neurodegenerative disorders associated with intense inflammation whereas multiple sclerosis ms and hiv associated dementia are inflammatory disorders that lead to diffuse neuronal damage see glossary . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
69243	17350694	88375	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	multiple sclerosis 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
69253	17350694	88427	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	multiple sclerosis 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
60886	17418957	76946	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	motor neuron mn mitochondrial abnormalities and elevation in spinal fluid levels of the inflammatory cytokine tumor necrosis factor alpha tnf _amp_#x3b1; have been implicated in the pathogenesis of amyotrophic lateral sclerosis als . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
60888	17418957	76960	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	serum levels of the cytokine tumor necrosis factor alpha tnf _amp_#x3b1; and its soluble receptors have been reported to be elevated in als patients as compared with healthy controls poloni et al 2000 and strong 2003 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
60892	17418957	76983	551	399	ALB	albumin	albumin	0	0.0	triton x 100 0.1% bovine serum albumin 1% and normal goat serum 1% were used to permeate the cells and limit non specific binding. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
60897	17418957	77109	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	tumor necrosis factor alpha| 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
54654	17497670	67901	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	ative stress neuroinflammation and excitotoxicity are frequently considered distinct but common hallmarks of several neurological disorders including parkinson's disease amyotrophic lateral sclerosis multiple sclerosis and alzheimer's disease. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
57389	17555556	72111	10601	6081	INS	insulin	insulin	0	0.0	following activation with lipopolysaccharide msod1 g93a microglia released more nitric oxide more superoxide and less insulin like growth factor 1 than wild type microglia. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
57390	17555556	72111	9939	5464	IGF1	insulin like growth factor	insulin like growth factor	0	0.0	following activation with lipopolysaccharide msod1 g93a microglia released more nitric oxide more superoxide and less insulin like growth factor 1 than wild type microglia. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
57394	17555556	72133	10601	6081	INS	insulin	insulin	0	0.0	our results demonstrate that msod1 g93a mouse microglia release more nitric oxide more superoxide and less insulin like growth factor 1 igf 1 than wild type microglia. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
57395	17555556	72133	9939	5464	IGF1	insulin like growth factor	insulin like growth factor	0	0.0	our results demonstrate that msod1 g93a mouse microglia release more nitric oxide more superoxide and less insulin like growth factor 1 igf 1 than wild type microglia. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
57397	17555556	72152	551	399	ALB	albumin	albumin	0	0.0	the cells were collected and centrifuged through a 4% bovine serum albumin cushion at 450 g for 10 min. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
57401	17555556	72196	10601	6081	INS	insulin	insulin	0	0.0	elisa for igf 1 insulin like growth factor 1 elisa duoset kit r _amp_ d systems minneapolis mn usa was used to determine the concentrations of igf 1 in cell culture supernatants. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
57402	17555556	72196	9939	5464	IGF1	insulin like growth factor	insulin like growth factor	0	0.0	elisa for igf 1 insulin like growth factor 1 elisa duoset kit r _amp_ d systems minneapolis mn usa was used to determine the concentrations of igf 1 in cell culture supernatants. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
57405	17555556	72219	10601	6081	INS	insulin	insulin	0	0.0	insulin like growth factor 1 is a potent motoneuron trophic and survival factor. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
57406	17555556	72219	9939	5464	IGF1	insulin like growth factor	insulin like growth factor	0	0.0	insulin like growth factor 1 is a potent motoneuron trophic and survival factor. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
57411	17555556	72272	14535	7873	NOS2A	nitric oxide synthase	nitric oxide synthase	0	0.0	although two earlier reports demonstrated that gene deletion of inos or neuronal nitric oxide synthase nnos does not alter motoneuron disease in double transgenic inos _amp_#8722;/_amp_#8722; /msod1 g93a or nnos _amp_#8722;/_amp_#8722; /msod1 g93a mice facchinetti et al 1999 ; son et al 2001 a recent 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
58501	17569578	73494	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	activation of all ppar isoforms but especially of ppar_amp_#x3b3; has been found to be protective in murine in vitro and in vivo models of multiple sclerosis. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
58502	17569578	73495	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	the verification of these findings in human cells prompted the initiation of clinical studies evaluating ppar_amp_#x3b3; activation in multiple sclerosis patients. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
58506	17569578	73593	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	multiple sclerosis and experimental allergic encephalitis 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
58507	17569578	73594	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	multiple sclerosis ms is a chronic autoimmune disorder of the cns that affects most commonly young adults and is characterized pathologically by multiple areas of white matter inflammation demyelination and glial scarr	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
58508	17569578	73596	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	several cytokines including tumor necrosis factor _amp_#x3b1;_amp_#xa0; tnf_amp_#x3b1; interferon _amp_#x3b3;_amp_#xa0; ifn_amp_#x3b3; and interleukin 6 il 6 are regularly found in multiple sclerosis brain lesions and in spinal cord infiltrates of eae mice [124] . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
58521	17569578	73637	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	human multiple sclerosis 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
58536	17569578	73758	4413	1984	CISH	suppressor of cytokine signaling	suppressor of cytokine signaling	0	0.0	interestingly mrna levels of the suppressor of cytokine signaling 1 and 3 genes were increased by pioglitazone whereas both the mrna and protein levels of endogenous mouse sod1 and of transgenic human sod1 remained unaffected [154] . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
58942	17574754	74309	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	in humans increased cox 2 and prostaglandin production have been observed in ad als multiple sclerosis and pd [1] [10] [22] and [24] . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
59274	17582695	74871	348	21285	ADCY10	adenylate cyclase	adenylate cyclase	0	0.0	autoimmune dysfunction of endogenous vasoactive neuropeptides vns such as vasoactive intestinal peptide vip and pituitary adenylate cyclase activating polypeptide pacap has been postulated as a cause for some fatigue related conditions. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
59278	17582695	74873	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	complex clinical signs occur in multiple sclerosis ms and amyotrophic lateral sclerosis als . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
59280	17582695	74884	348	21285	ADCY10	adenylate cyclase	adenylate cyclase	0	0.0	autoimmune dysfunction of endogenous vasoactive neuropeptides vns such as vasoactive intestinal peptide vip and pituitary adenylate cyclase activating polypeptide pacap has been postulated as a cause for some fatigue related conditions. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
59284	17582695	74892	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	complex clinical signs occur in multiple sclerosis ms and amyotrophic lateral sclerosis als . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
59298	17582695	74963	1133	727	ARTN	neurotrophic factor	neurotrophic factor	0	0.0	therapies aimed at haematopoietic stem cells may involve glial cell line derived neurotrophic factor gdnf around host motor neurons produced by grafted cells [68] . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
59300	17582695	74970	348	21285	ADCY10	adenylate cyclase	adenylate cyclase	0	0.0	adcyap1 protein human|neuropeptides|pituitary adenylate cyclase activating polypeptide|receptors g protein coupled|vasoactive intestinal peptide| 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
47078	17597167	59407	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	bi and stroke and for chronic disorders such as alzheimer's disease ad epilepsy amyotrophic lateral sclerosis als and parkinson's disease as well as diseases with autoimmune characteristics including multiple sclerosis ms myasthenia gravis mg and guillain barr_amp_#xe9; syndrome. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
51662	17678953	64374	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	d in a final common pathway contributing to neuronal injury and death in a wide range of acute and chronic neurological disorders ranging from parkinson's disease pd amyotrophic lateral sclerosis als multiple sclerosis and alzheimer's disease ad to stroke and trauma. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
51664	17678953	64378	23469	20652	TXNDC15	disulfide isomerase	disulfide isomerase	0	0.0	one such molecule affected is protein disulfide isomerase pdi an enzyme responsible for normal protein folding in the endoplasmic greticulum er . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
51665	17678953	64382	19134	10417	RPS27A	ubiquitin	ubiquitin	0	0.0	another molecule whose s nitrosylation can lead to abnormal protein accumulation is the e3 ubiquitin ligase parkin which contributes to the pathogenesis of pd. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
51666	17678953	64382	18456	21148	RNF123	ubiquitin ligase	ubiquitin ligase	0	0.0	another molecule whose s nitrosylation can lead to abnormal protein accumulation is the e3 ubiquitin ligase parkin which contributes to the pathogenesis of pd. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
44036	17853944	55223	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	amyotrophic lateral sclerosis als is a fatal neurodegenerative disease that can be caused by dominant mutations in superoxide dismutase 1 sod1 1 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
44045	17853944	55444	14554	14874	NOX5	nadph oxidase	nadph oxidase	0	0.0	membrane glycoproteins|superoxide dismutase 1|superoxide dismutase|nadh nadph oxidoreductases|cybb protein mouse|nadph oxidase|nadph oxidase 1| 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
46167	17908040	58283	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	one strong candidate trigger protein and thus a potential target for therapeutic manipulation is the potent pro inflammatory / pro apoptotic cytokine tumor necrosis factor alpha tnf alpha . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
27790	17997855	32973	551	399	ALB	albumin	albumin	0	0.0	bathing solutions were either rpmi 1640 or in mm nacl 140 kcl 2 cacl 2 2.5 mgcl 2 1 hepes 10 glucose 40 and bovine serum albumin 0.05% at ph 7.3. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
29863	18040778	35370	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	at both serve important defense functions against invading neurotropic pathogens and have been implicated in brain damage in infectious as well as neuroinflammatory/neurodegenerative diseases such as multiple sclerosis alzheimer's disease parkinson's disease and amyotrophic lateral sclerosis. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
29872	18040778	35462	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	ailable such as imaging with [11c]pk 11195 a ligand for peripheral benzodiazepine receptors their presence has been demonstrated in a variety of neuroinflammatory/neurodegenerative diseases including multiple sclerosis ms chen et al. 2004 alzheimer's disease ad cagnin et al. 2001 and amyotrophic lateral sclerosis als turner et al. 2004 . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
29873	18040778	35471	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	lipopolysaccharide lps tumor necrosis factor tnf a reactive oxygen intermediates roi reactive nitrogen intermediates rni quinolinic acid qa multiple sclerosis ms alzheimer's disease ad parkinson's disease pd amyotrophic lateral sclerosis als . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
32207	18077562	39882	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	er perspective and indicates a more active role of neuroinflammation in the pathophysiology of progressive neurodegenerative disorders such as ad parkinson's disease amyotrophic lateral sclerosis and multiple sclerosis. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
25075	18246426	29676	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	we evaluated tumor necrosis factor alpha tnf a interferon g ifn g and nitric oxide no levels in the serum of 22 als patients and 20 controls. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
25081	18246426	29720	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	since there were several reports that neurological disorders such as multiple sclerosis alzheimer_amp_#8217;s disease parkinson_amp_#8217;s disease guillian barre syndrome japanese encephalitis tuberculous meningitis epilepsy stroke migraine and others were having an inflammatory compon	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
15961	18312546	18852	12355	6872	MAPK10	map kinase	map kinase	0	0.0	effects of the ppargamma activator pioglitazone on p38 map kinase and ikappabalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
15965	18312546	18854	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	ulation of neurons astrocytes and microglia in the ventral horns of spinal cord lumbar segments from the pioglitazone treated and non treated groups of mice carrying a transgene for g93a mutant human superoxide dismutase 1 sod1 als mice and non transgenic littermates control mice performed immunohistochemical and immunoblot analyses of ppargamma active form of phosphorylated p38 mitogen activated protein kinase p p38	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
19010	18370853	22359	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	the etiology of als remains unknown but one fifth of instances are due to specific gene defects the best characterized of which is point mutations in the gene coding for cu/zn superoxide dismutase sod1 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
19154	18375019	22638	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	other powerful inflammatory stimulants such as lipopolysaccharide 0.5mug/ml tumor necrosis factor alpha 10ng/ml and interleukin 1beta 10ng/ml alone or in combination were without effect. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
19156	18375019	22644	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	inally using human postmortem material we showed sharp upregulation of the ifngr on activated astrocytes in affected areas in alzheimer's disease parkinson's disease amyotrophic lateral sclerosis and multiple sclerosis. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
19229	18384649	22738	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	rt neuroprotective activity against oxidative damage inflammation and apoptosis in several neurodegenerative disorders including alzheimer's parkinson's huntington's amyotrophic lateral sclerosis and multiple sclerosis. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
9666	18414597	11018	11942	21210	LPAL2	apolipoprotein	apolipoprotein	0	0.0	apolipoprotein e is the principal cholesterol carrier protein in the brain and the gene encoding the variant apolipoprotein e4 is a significant risk factor for alzheimer's disease. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
9669	18414597	11021	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	multiple sclerosis is an autoimmune inflammatory demyelinating condition of the cns. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
9763	18422522	11246	14535	7873	NOS2A	nitric oxide synthase	nitric oxide synthase	0	0.0	endothelial nitric oxide synthase overexpression by neuronal cells in neurodegeneration: a link between inflammation and neuroprotection. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
9765	18422522	11247	14535	7873	NOS2A	nitric oxide synthase	nitric oxide synthase	0	0.0	the roles of neuronal and inducible nitric oxide synthases in neurones have been extensively investigated; by contrast the biological significance of endothelial nitric oxide synthase enos overexpression that occurs in several pathological conditions has not yet been studied. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
11145	18436268	12693	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	t fa or fa + b12 treatment significantly attenuated the plasma hcy level suppressed the activation of microglia and astrocytes and inhibited the expression of inducible nitric oxide synthase inos and tumor necrosis factor alpha tnf _amp_#x3b1; in spinal cord. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
11151	18436268	12701	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	around 10% cases of als patients are autosomal dominant referred as fals and 20% patients with fals have missense mutations in the gene encoding for cu/zn superoxide dismutase sod1 al chalabi and leigh 2000 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
12218	18464922	14278	4413	1984	CISH	suppressor of cytokine signaling	suppressor of cytokine signaling	0	0.0	further evidence in the modulation of proinflammatory markers by pioglitazone were reported by sch_amp_#x000fc;tz et al. which suggests that mrna levels of two cytokine suppressor genes suppressor of cytokine signaling 1 and 3 socs 1 and 3 were increased as assessed by semiquantitative rt pcr [ 39 ]. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
12222	18464922	14282	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	recently xu and drew demonstrated that ppar _amp_#x003b3; agonists suppress cytokines like il 12 family in eae an experimental model of multiple sclerosis when treated with 15 d pgj 2 and rosiglitazone [ 35 ]. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
12490	18464925	14399	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	s and few nonsteroidal anti inflammatory drugs have shown anti inflammatory and protective effects in several experimental models of alzheimer's and parkinson's diseases amyotrophic lateral sclerosis multiple sclerosis and stroke as well as in few clinical studies. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
12492	18464925	14416	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	_#x003b3; could be targeted to control inflammation and treat invalidating diseases such as diabetic retinopathy and optic neuritis a demyelinating disease of the optic nerve frequently associated to multiple sclerosis ms see for review [ 26 ] . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
12494	18464925	14434	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	 janus activated kinases lbd= ligand binding domain lps= lipopolysaccharide mapk= mitogen activated protein kinase mcp 1= monocyte chemoattractrant protein 1 mhc= major histocompatibility complex ms= multiple sclerosis nf _amp_#x003ba; b= nuclear factor _amp_#x003ba; b no= nitric oxide nsaids= nonsteroidal anti inflammatory drugs oxldl= oxidized low density lipoprotein pd= parkinson disease ppar= peroxisome prolife	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
12510	18464925	14523	12355	6872	MAPK10	map kinase	map kinase	0	0.0	similarly lennon and colleagues [ 61 ] showed that ciglitazone and 15d pgj 2 activated the map kinase cascades erk jnk and p38 map kinase in astrocytes by a ppar _amp_#x003b3; independent mechanism which required the presence of ros. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
12514	18464925	14527	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	since these cytokines play critical roles in the differentiation of t helper th 1 and th17 cells and are likely to contribute to the development of multiple sclerosis this observation further support the potential role of ppar _amp_#x003b3; agonists in ms treatment [ 5 64 ]. 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
12532	18464925	14581	11942	21210	LPAL2	apolipoprotein	apolipoprotein	0	0.0	in a second recent trial the improvement in cognition after 6 months of rosiglitazone treatment was significant only in ad patients who did not have the _amp_#x003b5; 4 allele of the apolipoprotein e [ 92 ] a genotype associate with a higher risk to develop ad. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
2678	18513389	3484	11942	21210	LPAL2	apolipoprotein	apolipoprotein	0	0.0	this latter approach allowed the identification of seven genetic variants essential to differentiate cases from controls: apolipoprotein e arg158cys; hepatic lipase 480 c/t; endothelial nitric oxide synthase 690 c/t and glu298asp; vitamin k dependent coagulation factor seven arg353glu glycoprotein ia/iia 873 g/a and e selectin ser128a	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
2681	18513389	3484	14535	7873	NOS2A	nitric oxide synthase	nitric oxide synthase	0	0.0	this latter approach allowed the identification of seven genetic variants essential to differentiate cases from controls: apolipoprotein e arg158cys; hepatic lipase 480 c/t; endothelial nitric oxide synthase 690 c/t and glu298asp; vitamin k dependent coagulation factor seven arg353glu glycoprotein ia/iia 873 g/a and e selectin ser128arg. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
2682	18513389	3490	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	the gene coding for copper/zinc superoxide dismutase 1 sod1 appears to be mutated in 10_amp_#x02013;20% in the familial form [ 1 ]. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
2684	18513389	3496	1133	727	ARTN	neurotrophic factor	neurotrophic factor	0	0.0	among the genetic factors that may predispose to sporadic als neurofilaments apolipoprotein epsilon 4 genotype excitotoxicity genes ciliary neurotrophic factor ctnf cytochrome p450 debrisoquine hydroxylase cyp2d6 apurinic apyrimidinic endonuclease apex mitochondrial manganese superoxide dismutase sod2 monoamine oxidase allele b and paraoxonases have been re	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
2686	18513389	3496	11942	21210	LPAL2	apolipoprotein	apolipoprotein	0	1.0	among the genetic factors that may predispose to sporadic als neurofilaments apolipoprotein epsilon 4 genotype excitotoxicity genes ciliary neurotrophic factor ctnf cytochrome p450 debrisoquine hydroxylase cyp2d6 apurinic apyrimidinic endonuclease apex mitochondrial manganese superoxide dis	7		JUMiner_v2.2	2	2	UserEdit	0	0	0		1	1	0	0		0
2689	18513389	3496	20996	11179	SOD1	superoxide dismutase	superoxide dismutase	0	0.0	apolipoprotein epsilon 4 genotype excitotoxicity genes ciliary neurotrophic factor ctnf cytochrome p450 debrisoquine hydroxylase cyp2d6 apurinic apyrimidinic endonuclease apex mitochondrial manganese superoxide dismutase sod2 monoamine oxidase allele b and paraoxonases have been reported in different studies partly with contradictory results [ 2 4 7 9 ]. 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
2692	18513389	3649	11942	21210	LPAL2	apolipoprotein	apolipoprotein	0	0.0	genetic variants selected by the five twist procedures seven genetic variants were always independently selected by the five twist procedures: apolipoprotein e apoe chromosome 19q13.2 arg158cys; hepatic lipase lipc chromosome 15q21 23 480 c/t; endothelial nitric oxide synthase nos3 chromosome 7q36 690 c/t and glu298asp; vitamin k dependent coagulation fac	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
2695	18513389	3649	14535	7873	NOS2A	nitric oxide synthase	nitric oxide synthase	0	0.0	even genetic variants were always independently selected by the five twist procedures: apolipoprotein e apoe chromosome 19q13.2 arg158cys; hepatic lipase lipc chromosome 15q21 23 480 c/t; endothelial nitric oxide synthase nos3 chromosome 7q36 690 c/t and glu298asp; vitamin k dependent coagulation factor seven f7 chromosome 13q34 arg353glu glycoprotein ia/iia itga2 chromosome 5q23 q31 873 g/a; e selectin sele chromosom	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
2702	18513389	3652	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	some proliferator activated receptor gamma pparg pro12ala chromosome 3p25 lipoprotein lipase lpl asp9asn chromosome 8p22 paraoxonase 1 pon1 met55leu and paraoxonase 2 pon2 ser311cys chromosome 7q21.3 tumor necrosis factor beta tnf beta thr26 asn chrom 6p21.3 methylenetetrahydrofolate reductase mthfr 677 c/t chrom 1p36.3 angiotensin ii receptor type1 agtr1 1166 a/c chromosome 3q21 25 atrial natriuretic peptide nppa 664	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
2703	18513389	3652	22551	11892	TNF	tumor necrosis factor	tumor necrosis factor	0	0.0	 receptor type1 agtr1 1166 a/c chromosome 3q21 25 atrial natriuretic peptide nppa 664 g/a chrom 1p36 21 epithelial na channel subunit scnn1a trp493arg chromosome 12p13 fvii 232 ins/del sele leu554phe tumor necrosis factor alpha tnfalpha 376 g/a and 308 g/a chromosome 6p21.3 . 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
2708	18513389	3652	452	333	AGT	angiotensin ii	angiotensin ii	0	0.0	araoxonase 1 pon1 met55leu and paraoxonase 2 pon2 ser311cys chromosome 7q21.3 tumor necrosis factor beta tnf beta thr26 asn chrom 6p21.3 methylenetetrahydrofolate reductase mthfr 677 c/t chrom 1p36.3 angiotensin ii receptor type1 agtr1 1166 a/c chromosome 3q21 25 atrial natriuretic peptide nppa 664 g/a chrom 1p36 21 epithelial na channel subunit scnn1a trp493arg chromosome 12p13 fvii 232 ins/del sele leu554phe 	7		JUMiner_v2.2	2	0		0	0	0		0	0	0	0		0
2712	18513389	3655	11942	21210	LPAL2	apolipoprotein	apolipoprotein	0	1.0	genetic variants never selected by any twist procedures the following gene/genetic variants were never selected by the five twist procedures: apolipoprotein a4 apoa4 chromosome 11q23 thr347ser; apolipoprotein c3 apoc3 chromosome 11q23.1 q23.2 641 c/a and 482 c/t; beta 3 adrenergic receptor adrb3 trp64arg 8p12 p11.2 ; lpl ser447term; pon1 gln192arg; low density lipoprotein receptor ldlr chromosome 19p13.3 	7		JUMiner_v2.2	2	2	UserEdit	0	0	0		1	1	0	0		0
5146	18539342	5527	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	in multiple sclerosis ms brains cps show immunohistochemistry to hla dr cd3 cd20 cd68 vcam 1 cd138 t lymphocytes in vessels and stroma vcam 1 expression on endothelia intense hla dr immunostaining on cells in cp stroma am	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
5147	18539342	5534	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	recent studies have contributed to characterize the involvement of cns structures outside the brain parenchyma such as the leptomeninges and the cerebrospinal fluid csf in the pathogenetic process of multiple sclerosis ms and experimental allergic encephalomyelitis eae kutzelnigg et al. 2005 ; pedemonte et al. 2006 ; magliozzi et al. 2007 . 	7		JUMiner_v2.2	2	0		1	0	0		0	0	0	0		0
2050	18751914	3068	11942	21210	LPAL2	apolipoprotein	apolipoprotein	0	0.0	apolipoprotein e is the principal cholesterol carrier protein in the brain and the gene encoding the variant apolipoprotein e4 is a significant risk factor for alzheimer's disease. 	7		SciMiner_v2.2	2	0		0	0	0		0	0	0	0		0
2053	18751914	3064	13667	7314	MS	multiple sclerosis	multiple sclerosis	0	1.0	multiple sclerosis is an autoimmune inflammatory demyelinating condition of the cns. 	7		SciMiner_v2.2	2	0		1	0	0		0	0	0	0		0